IMANO Motohiro

    Kindai University Hospital Professor
Last Updated :2024/03/24

Researcher Information

URL

J-Global ID

Research Interests

  • 組織血流障害   グルタチオン   臓器障害   虚血再灌流   循環障害   oxidant stress   nitric oxide   食道癌   酸素ラジカル   apoptosis   benzamide   誤嚥   glutathione   骨微小環境   poly(ADP-riboss)polymerase   磁気ビーズ法   虚血再灌流障害   Ser46   食道切除術   オキシダンストレス   オキシダントストレス   間葉系幹細胞   がんの骨転移   個別化   サブスタンスP   drug delivery system   ATP   咳嗽反射   嚥下機能   高エンドトキシン血症   

Research Areas

  • Life sciences / Digestive surgery
  • Life sciences / General surgery, pediatric surgery
  • Life sciences / Orthopedics

Academic & Professional Experience

  • 2010 - 2012  Kindai UniversityFaculty of Medicine准教授

Published Papers

  • Atsushi Yasuda; Yutaka Kimura; Hiroaki Kato; Tomoya Nakanishi; Masashi Koda; Yoko Hiraki; Takaomi Hagi; Osamu Shiraishi; Masayuki Shinkai; Motohiro Imano; Takushi Yasuda
    Updates in surgery 2024/01 
    Recent reports have described the practicality of laparoscopic intragastric surgery (l-IGS) as an alternative for resecting submucosal tumors (SMTs) near the esophagogastric junction (EGJ), where excision using an exogastric approach would be difficult. However, even using IGS to perform a full-thickness resection of SMTs that are in or extremely close to the EGJ is very difficult to do safely and avoid disrupting or causing stenosis of the EGJ, without advanced experience. This study retrospectively examined the usefulness of l-IGS for gastric SMTs located in or extremely close to the EGJ. Fourteen patients with gastric SMTs < 2 cm of the EGJ and underwent l-IGS were eligible for this study. We examined the tumor location, operative time, intraoperative hemorrhage, degree of deformation, gastroesophageal reflux disease, perioperative complications, and recurrence. Furthermore, we compared patients with tumors in the EGJ with those with tumors near the EGJ and patients in whom three-port l-IGS was performed with those who underwent single-incision laparoscopic surgery. The average tumor size, operative time, intraoperative hemorrhage, and postoperative hospitalization of the 14 patients were 30.9 ± 21.3 mm, 125.2 ± 31.1 min, 30.7 ± 103.3 mL, and 9.2 ± 3.1 d, respectively. No differences in these parameters according to the type of l-IGS or tumor location were observed. All patients underwent l-IGS without complications and were free from EGJ deformation or esophagitis. We believe that l-IGS is useful for gastric SMTs located < 2 cm of the EGJ as it can be safely performed for difficult tumor locations and does not cause deformation of the EGJ.
  • Masayuki Shinkai; Motohiro Imano; Masashi Kohda; Tomoya Nakanishi; Yoko Hiraki; Takaomi Hagi; Hiroaki Kato; Osamu Shiraishi; Atsushi Yasuda; Masanobu Tsubaki; Shozo Nishida; Takushi Yasuda
    Langenbeck's archives of surgery 408 (1) 291 - 291 2023/07 
    PURPOSE: Gastric cancer patients with peritoneal metastasis (PM) are generally treated with systemic chemotherapy. When PM has disappeared because of chemotherapy, radical gastrectomy (so-called conversion surgery) is usually performed. We have previously reported the efficacy of conversion surgery, but there are no reports examining the efficacy of palliative gastrectomy for patients with residual PM after chemotherapy. The purpose of this study was to investigate the efficacy of palliative surgery for gastric cancer patients with PM who still have residual peritoneal dissemination after chemotherapy. METHODS: Twenty-five gastric cancer patients with PM confirmed by laparoscopy and who had received chemotherapy but who still had residual PM were included in this study. Among the 25 patients, palliative surgery was performed in 20 patients (PS group) and chemotherapy was continued in 5 patients (CTx group), and their therapeutic outcomes were compared. RESULTS: In the PS group, total and distal gastrectomies were performed. Clavien-Dindo grade I postoperative complications occurred in two patients (10%). There were no treatment-related deaths. Postoperative chemotherapy was performed all cases. In the PS group, the median survival time (MST) reached 22.5 months, with 1- and 2-year overall survival (OS) rates of 95% and 45%, respectively, whereas in the CTx group, the MST was 15.8 months, and the 1- and 2-year OS rates were 60% and 0%, respectively. The PS group had significantly longer OS than the CTx group (P=0.044). CONCLUSIONS: Palliative surgery is safe and may prolong survival in gastric cancer patients with residual PM after chemotherapy.
  • Atsushi Yasuda; Yutaka Kimura; Osamu Shiraishi; Masayuki Shinkai; Motohiro Imano; Takushi Yasuda
    International journal of surgery case reports 106 108156 - 108156 2023/05 
    INTRODUCTION AND IMPORTANCE: Laparoscopic wedge resection has been widely performed for gastric gastrointestinal stromal tumors (GISTs). However, because GISTs in the esophagogastric junction (EGJ) are prone to deformity and postoperative functional disorders, laparoscopic resection is technically very difficult and rarely reported. Herein, we report a case of a GIST in the EGJ successfully treated by laparoscopic intragastric surgery (IGS). CASE PRESENTATION: A 58-year-old man with a GIST, which was intragastric growth type, 2.5 cm in diameter, located in the EGJ, and confirmed by upper gastrointestinal endoscope and endoscopic ultrasound-guided fine needle aspiration biopsy. We successfully performed IGS and the patient was discharged without complications. CLINICAL DISCUSSION: Using laparoscopic wedge resection by exogastric approach, it is problematic to resect a gastric SMT located at the EGJ because of the difficulty in viewing the surgical field and additional concerns of deformation of the EGJ. We suppose IGS as a suitable method for such tumors. CONCLUSION: Laparoscopic IGS for gastric GIST was useful in terms of safety and convenience even though the tumor was in the ECJ.
  • Osamu Shiraishi; Hiroaki Kato; Kota Momose; Yoko Hiraki; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Takushi Yasuda
    Oncology 101 (3) 203 - 212 2023 
    INTRODUCTION: This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-NAC) for resectable locally advanced esophageal squamous cell carcinoma (ESCC). MATERIALS AND METHODS: To identify the optimal RDI, recurrence-free survival (RFS) and cumulative incidence function (CIF) for recurrence were calculated in low and high RDI groups with any cut-off points. The optimal RDI was defined as the highest RDI administered with a significant increase in either RFS or CIF. The clinicopathological characteristics of the two groups divided by optimal RDI were investigated. The preoperative prognostic factors associated with RFS were confirmed by multivariable Cox proportional hazards model. RESULTS: Among the 150 eligible patients treated with DCF-NAC from 2010 to 2020, 3-year RFS and CIF were 56.3% and 37.8% in 90 patients in the less than 80% RDI group (<80% RDI) and 73.3% and 26.7% in 60 patients in the more than or equal to 80% RDI group (≥80% RDI), respectively. The optimal cut-off RDI was identified as 80%. The <80% RDI group included older individuals, a lower value of creatinine clearance, a higher Charlson Comorbidity Index, reduced RDI at first course, and grade 1-0 in the histopathological tumor response than the ≥80% RDI group. R0 resection and postoperative complication rates were equal in both groups. Cox proportional hazards model identified the response rate and RDI as predictors of RFS. CONCLUSION: An average RDI of more than or equal to 80% improved prognosis in patients receiving DCF-NAC for ESCC.
  • Hikari Teranishi; Atsushi Yasuda; Motohiro Imano; Yoko Hiraki; Kota Momose; Hiroaki Kato; Osamu Shiraishi; Masayuki Shinkai; Yutaka Kimura; Takushi Yasuda
    Gan to kagaku ryoho. Cancer & chemotherapy 49 (13) 1512 - 1514 0385-0684 2022/12 
    Intraperitoneal chemotherapy, in which an anticancer drug is administered directly into the abdominal cavity through an intraperitoneal access port(IP port), is one of the treatment options for advanced gastric cancer with peritoneal metastasis. Herein, we report a case of sheath-like obstruction of the entire catheter of the IP port due to tissue reaction within a short period of time after IP port implantation. The case was a 35-year-old woman with advanced type 4 gastric cancer with peritoneal dissemination. The IP port was placed and intravenous and intraperitoneal chemotherapy using S-1 plus paclitaxel was started. However, in the middle of the second course, the entire catheter was covered with a fibrous capsule and a sheath-like obstruction occurred, so the IP port was removed and a new IP port was reinserted. One of the IP port troubles is obstruction, but such short-term and special obstruction is rare, and the cause is considered to be a foreign body reaction of the catheter.
  • Shota Sasagawa; Hiroaki Kato; Koji Nagaoka; Changbo Sun; Motohiro Imano; Takao Sato; Todd A Johnson; Masashi Fujita; Kazuhiro Maejima; Yuki Okawa; Kazuhiro Kakimi; Takushi Yasuda; Hidewaki Nakagawa
    Cell reports. Medicine 3 (8) 100705 - 100705 2022/08 
    Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive cancers and is primarily treated with platinum-based neoadjuvant chemotherapy (NAC). Some ESCCs respond well to NAC. However, biomarkers to predict NAC sensitivity and their response mechanism in ESCC remain unclear. We perform whole-genome sequencing and RNA sequencing analysis of 141 ESCC biopsy specimens before NAC treatment to generate a machine-learning-based diagnostic model to predict NAC reactivity in ESCC and analyzed the association between immunogenomic features and NAC response. Neutrophil infiltration may play an important role in ESCC response to NAC. We also demonstrate that specific copy-number alterations and copy-number signatures in the ESCC genome are significantly associated with NAC response. The interactions between the tumor genome and immune features of ESCC are likely to be a good indicator of therapeutic capability and a therapeutic target for ESCC, and machine learning prediction for NAC response is useful.
  • Jin Matsuyama; Tetsuji Terazawa; Masahiro Goto; Ryohei Kawabata; Shunji Endo; Motohiro Imano; Shoichiro Fujita; Yusuke Akamaru; Hirokazu Taniguchi; Mitsutoshi Tatsumi; Sang-Woong Lee; Hisato Kawakami; Yukinori Kurokawa; Toshio Shimokawa; Daisuke Sakai; Takeshi Kato; Kazumasa Fujitani; Taroh Satoh
    The oncologist 27 (4) 251-e304  2022/04 
    BACKGROUND: We previously reported the good feasibility and favorable efficacy of perioperative capecitabine plus oxaliplatin (CapeOx) in patients (pts) with clinical T3(SS)/T4a(SE) N1-3 M0 gastric cancer (GC) in a phase II study in which the pathological response rate, the primary endpoint, of 54.1% was demonstrated. Here, we report 3-year follow-up data. METHODS: The eligibility criteria included clinical T3(SS)/T4a(SE) N1-3 M0 GC according to the Japanese Classification of Gastric Carcinoma-3rd English Edition (JCGC). Three cycles of neoadjuvant CapeOx (capecitabine, 2000mg/m2 for 14 days; oxaliplatin, 130mg/m2 on day 1, every 3 weeks) were administered, followed by 5 cycles of adjuvant CapeOx after D2 gastrectomy. Three-year overall survival and relapse-free survival are presented here, and analyzed by cohorts based on pathologic response rate (pRR). RESULTS: Thirty-seven pts were enrolled from July 2016 to May 2017, and fully evaluated for efficacy and toxicity. Thirty-three pts (89.2%) completed the planned three cycles of neoadjuvant CapeOx and underwent gastrectomy, with an R0 resection rate of 78.4% (n = 29). The overall survival (OS) rate and relapse-free survival (RFS) rate at 3 years was 83.8% (95% CI, 72.7-96.5%) and 73.0% (95% CI, 60.0-88.8%), respectively. Further, the 3-year OS rate in pts with pathological response of grade 1a (n = 13) and grade 1b or higher (n = 20) was 69.2% (95% CI: 48.2-99.5%) and 100.0%, respectively, based on JCGC. Pathological response rate was classified according to JCGC as follows: grade 0, the tumor was not affected; grade 1a, less than one-third of the tumor was affected; grade 1b, one to two thirds of the tumor was affected; grade 2, greater than or equal to two thirds was affected; and grade 3, no residual tumor. A pathological response was defined as grade 1b or greater. CONCLUSION: Perioperative CapeOx showed good feasibility and favorable prognosis, especially in pts with pathological response of grade 1b or higher and was found to be useful in predicting prognosis. The data obtained using this novel approach warrant further investigation (Trial ID: UMIN000021641, jRCTs051180109).
  • 切除不能Stage IV胃癌に対するConversion Surgeryを含む集学的治療
    新海 政幸; 今野 元博; 平木 洋子; 百瀬 洸太; 加藤 寛章; 白石 治; 安田 篤; 米田 頼晃; 松井 繁長; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 94回 290 - 290 2022/03
  • Osamu Shiraishi; Takushi Yasuda; Hiroaki Kato; Kota Momose; Yoko Hiraki; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 26 (4) 725 - 732 2022/02 
    BACKGROUND: This study was performed to verify the superiority of a new "non-tensioning method" for avoiding stricture of the cervical esophagogastric anastomosis by circular stapling compared with the conventional method. METHODS: In total, 395 consecutive patients who underwent McKeown esophagectomy with gastric conduit (GC) reconstruction were reviewed. A 4 cm-wide GC was created and pulled up at the cervical site through the retrosternal route. The esophagogastrostomy site of the GC was planned as far caudally as possible on the greater curvature side. In the conventional technique, the stapler was fired while pulling the GC to avoid tissue slack. In the non-tensioning technique, the stapler was fired through the natural thickness of the stomach wall. The length of the blind end was changed from 4 to 2 cm in the non-tensioning technique. Anastomotic leakage and stricture formation were compared between the two techniques, and adjustment was performed using propensity score matching. RESULTS: The conventional group comprised 315 patients, and the non-tensioning group comprised 80 patients. Anastomotic leakage occurred in 22 (7%) and 2 (2.5%) patients, respectively (P = 0.134) [and in 9 (2.9%) and 2 (2.5%) patients, respectively, if leakage at the blind end was excluded]. Anastomotic stricture occurred in 92 (29.2%) and 3 (3.8%) patients, respectively (P < 0.001). The propensity score-matching analysis including 79 pairs of patients confirmed a lower stricture rate in the non-tensioning than conventional group (2.5% vs. 29.1%, P < 0.001). CONCLUSIONS: The non-tensioning technique significantly reduced the incidence of anastomotic stricture compared with the conventional technique.
  • Masayuki Shinkai; Motohiro Imano; Yoko Hiraki; Kota Momose; Hiroaki Kato; Osamu Shiraishi; Atsushi Yasuda; Masanobu Tsubaki; Shozo Nishida; Takushi Yasuda
    Langenbeck's archives of surgery 407 (3) 975 - 983 2022/01 
    PURPOSE: The prognosis of gastric cancer patients with peritoneal metastasis (PM) remains dismal with standard systemic chemotherapy. Intraperitoneal (i.p.) chemotherapy with paclitaxel (PTX) has local effects on intra-abdominal cancer cells. According to this phenomenon, we have developed regimens combining single i.p. PTX administration with systemic chemotherapy. This treatment strategy is very promising; however, the effect of "conversion surgery" in patients responding to this chemotherapy is unclear. Therefore, we performed a retrospective study to evaluate the safety and efficacy of conversion surgery for gastric cancer patients with PM. METHODS: We enrolled 52 gastric cancer patients with PM who were treated with single i.p. PTX plus systemic chemotherapy between 2005 and 2015. Conversion surgery was performed where PM was eliminated by combination chemotherapy. RESULTS: Among 52 gastric cancer patients, the disappearance of PM was confirmed in 33 patients (63.5%). Gastrectomy with D2 lymph node dissection was performed in all these patients. Histological response of grade ≥ 1b was achieved in 13 patients (39%). Clavien-Dindo grade II postoperative complications occurred in three patients (9%). There were no treatment-related deaths. The median survival time and 1-, 3-, and 5-year overall survival rates of the 33 patients who underwent conversion surgery were 30.7 months and 78.8%, 36.3%, and 24.2%, respectively, and those of the 19 patients who did not undergo surgery were 12.5 months and 52.6%, 5.2%, and 0%, respectively. CONCLUSION: Conversion surgery is safe and may prolong survival for gastric cancer patients with PM who have responded to single i.p. PTX plus systemic chemotherapy.
  • Tomoya Takeda; Masanobu Tsubaki; Natsuki Kato; Shuji Genno; Eri Ichimura; Aya Enomoto; Motohiro Imano; Takao Satou; Shozo Nishida
    Oncology letters 22 (6) 827 - 827 2021/12 
    Melanomas are highly malignant tumors that readily metastasize and have poor prognosis. Targeted therapy is a cornerstone of treatment for patients with melanoma. Although c-Kit gene aberration has found in 5-10% of melanoma cases, research on c-Kit inhibitors for melanoma with c-Kit aberration have been disappointing. Sorafenib is a tyrosine kinase inhibitor, whose targets include c-Kit, platelet derived growth factor receptor (PDGFR), VEGFR and RAF. The present study aimed to examine the effect of sorafenib on metastatic melanoma with c-Kit aberration. Cell viability was assessed via trypan blue assay. Migration and invasion were analyzed using cell culture inserts. The anti-metastatic effects and antitumour activity of sorafenib were determined in an in vivo model. Protein expression was detected via western blotting, and the expression of MMP and very late antigen (VLA) was detected via reverse transcription-quantitative PCR. It was identified that sorafenib decreased cell viability, migration and invasion in vitro. Furthermore, sorafenib inhibited metastasis and tumor growth in vivo. Mechanistically, sorafenib inhibited c-Kit, PDGFR, VEGFR, B-Raf and c-Raf phosphorylation both in vitro and in vivo. In addition, sorafenib reduced the expression levels of MMPs and VLA. Importantly, there was a significant effect of sorafenib treatment on overall survival in mice. Collectively, this study suggests that sorafenib may serve as a novel therapeutic option for melanoma with c-Kit dysregulation.
  • Hironori Ishigami; Yasushi Tsuji; Hisashi Shinohara; Yasuhiro Kodera; Mitsuro Kanda; Hiroshi Yabusaki; Seiji Ito; Motohiro Imano; Hiroharu Yamashita; Akio Hidemura; Hironori Yamaguchi; Takeo Fukagawa; Koji Oba; Joji Kitayama; Yasuyuki Seto
    Journal of clinical medicine 10 (23) 2021/11 
    The prognosis of patients with type 4 scirrhous gastric cancer remains poor due to a high risk of peritoneal metastasis. We have previously developed combined chemotherapy regimens of intraperitoneal (IP) paclitaxel (PTX) and systemic chemotherapy, and promising clinical efficacy was reported in gastric cancer with peritoneal metastasis. Herein, a randomized, phase III study is proposed to verify the efficacy of IP PTX to prevent peritoneal recurrence. Gastric cancer patients with type 4 tumors and without apparent distant metastasis, including peritoneal metastasis, will be randomized for standard systemic chemotherapy or combined IP and systemic chemotherapy based on peritoneal lavage cytology findings. Those with negative peritoneal cytology will receive radical gastrectomy and adjuvant chemotherapy of S-1 plus docetaxel (control arm), or S-1 plus intravenous and IP PTX (experimental arm). Those with positive peritoneal cytology will receive three courses of S-1 plus oxaliplatin (control arm), or S-1 plus oxaliplatin and IP PTX (experimental arm). Subsequently, they undergo gastrectomy and receive postoperative chemotherapy of S-1 plus docetaxel (control arm), or S-1 plus intravenous and IP PTX (experimental arm). The primary endpoint is disease free survival after a 3-year follow-up period. Secondary endpoints are overall survival, survival without peritoneal metastasis, safety, completion rate, curative resection rate, and histological response of preoperative chemotherapy. A total of 300 patients are to be enrolled.
  • 【ここが知りたい、表在型Barrett食道腺癌】治療編 表在型Barrett食道腺癌の外科的治療
    安田 篤; 白石 治; 平木 洋子; 百瀬 洸太; 加藤 寛章; 新海 政幸; 今野 元博; 安田 卓司
    消化器内視鏡 (株)東京医学社 33 (11) 1769 - 1774 0915-3217 2021/11
  • Atsushi Yasuda; Yutaka Kimura; Yoko Hiraki; Kota Momose; Hiroaki Kato; Osamu Shiraishi; Masayuki Shinkai; Motohiro Imano; Haruhiko Imamoto; Takushi Yasuda
    Asian journal of endoscopic surgery 14 (3) 658 - 664 2021/07 
    INTRODUCTION: Control of postoperative gastroesophageal reflux (GER) is a critical consideration for patients who undergo proximal gastrectomy. This report describes a new and simple reconstruction method by esophagogastrostomy with placement of the remnant stomach into the lower mediastinum (EG-PRIME). This approach not only suppresses postoperative GER, but it can also be easily performed by total laparoscopy. Detailed herein are the methods for EG-PRIME and the results for three patients with cancer of the upper gastric body. MATERIALS AND SURGICAL TECHNIQUE: At the start of the EG-PRIME surgical procedure, a pseudo-fornix and lozenge-shaped gastric conduit were made by cutting the stomach diagonally. Next, the pseudo-fornix was inserted into the esophageal hiatus to form a new angle of His. Then overlap anastomosis was performed and the entry site was closed longitudinally. The outcomes assessed were operative time, intraoperative blood loss, postoperative complications and GER according to 24-hour pH monitoring. DISCUSSION: The operative times were 339, 288 and 236 minutes; in two patients, intraoperative blood loss was 260 and 343 mL, and in the third, blood loss was minimal. No postoperative complications were observed in any of the three patients. The degree of the GER resulting in fraction time pH<4 was 9.0%, 0.3%, and 2.9%, respectively. No esophagitis by upper gastrointestinal endoscopy was observed in any patient. This EG-PRIME method was technically feasible for reconstruction after proximal gastrectomy by total laparoscopy. This approach may be as simple and useful as esophagogastrostomy for preventing postoperative GER, but more experience with this method is required.
  • Takushi Yasuda; Osamu Shiraishi; Hiroaki Kato; Yoko Hiraki; Kota Momose; Atsushi Yasuda; Masayuki Shinkai; Yutaka Kimura; Motohiro Imano
    Esophagus : official journal of the Japan Esophageal Society 18 (3) 468 - 474 2021/07 
    BACKGROUND: A challenge in esophageal reconstruction after esophagectomy is that the distance from the neck to the abdomen must be replaced with a long segment obtained from the gastrointestinal tract. The success or failure of the reconstruction depends on the blood flow to the reconstructed organ and the tension on the anastomotic site, both of which depend on the reconstruction distance. There are three possible esophageal reconstruction routes: posterior mediastinal, retrosternal, and subcutaneous. However, there is still no consensus as to which route is the shortest. METHODS: The length of each reconstruction route was retrospectively compared using measurements obtained during surgery, where the strategy was to pull up the gastric conduit through the shortest route. The proximal reference point was defined as the left inferior border of the cricoid cartilage and the distal reference point was defined as the superior border of the duodenum arising from the head of the pancreas. RESULTS: This study involved 112 Japanese patients with esophageal cancer (102 men, 10 women). The mean distances of the posterior mediastinal, retrosternal, and subcutaneous routes were 34.7 ± 2.37 cm, 32.4 ± 2.24 cm, and 36.3 ± 2.27 cm, respectively. The retrosternal route was significantly shorter than the other two routes (both p < 0.0001) and shorter by 2.31 cm on average than the posterior mediastinal route. The retrosternal route was longer than the posterior mediastinal route in only 5 patients, with a difference of less than 1 cm. CONCLUSION: The retrosternal route was the shortest for esophageal reconstruction in living Japanese patients.
  • 白石 治; 安田 卓司; 加藤 寛章; 百瀬 洸太; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊
    臨床外科 (株)医学書院 76 (6) 669 - 675 0386-9857 2021/06 
    <文献概要>ポイント ◆郭清の前に周囲組織の授動を十分に行い,郭清組織を衝立化する.◆残すべき神経走行を確認し,切離ラインのデザインを決める.◆残す神経からの枝を鋭的に神経沿いに切離することで,衝立化された郭清組織から神経はスライドするように外れていく.
  • 白石 治; 安田 卓司; 加藤 寛章; 百瀬 洸太; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊
    臨床外科 (株)医学書院 76 (6) 669 - 675 0386-9857 2021/06 
    <文献概要>ポイント ◆郭清の前に周囲組織の授動を十分に行い,郭清組織を衝立化する.◆残すべき神経走行を確認し,切離ラインのデザインを決める.◆残す神経からの枝を鋭的に神経沿いに切離することで,衝立化された郭清組織から神経はスライドするように外れていく.
  • Yusuke Morii; Masanobu Tsubaki; Tomoya Takeda; Rie Otubo; Shiori Seki; Yuta Yamatomo; Motohiro Imano; Takao Satou; Kazunori Shimomura; Shozo Nishida
    European journal of pharmacology 898 173957 - 173957 2021/05 
    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation in colon cancer contributes to the poor prognosis of the disease and chemoresistance of tumors. New therapies are needed; however, the lack of knowledge of the mechanism of chemoresistance has hindered progress. In this study, we investigated the mechanism of the reduced sensitivity of colon cancer cells to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP), and the effects of perifosine, an Akt inhibitor that enhances the cytotoxicity of 5-FU and L-OHP in colon cancer cells harboring the PIK3CA mutation. The use of 5-FU or L-OHP alone or in combination induced significant death of Caco-2 cells (PIK3CA wild type), but only weakly decreased the viability of DLD-1 and SW948 cells harboring the PIK3CA mutation. The use of 5-FU and L-OHP, either alone or in combination, strongly suppressed Akt activation, Survivin, Bcl-2, and Bcl-xL expression, and enhanced Puma, phospho-p53, and p53 expression in Caco-2 cells than in DLD-1 cells. In addition, perifosine enhanced the cytotoxicity of the 5-FU and L-OHP combination, inhibited Akt activation and the expression of Survivin, Bcl-2, and Bcl-xL, and increased the expression of Puma, phospho-p53, and p53 in DLD-1 cells. These results indicate that PIK3CA mutation contributes to reduced sensitivity to 5-FU and L-OHP via Akt activation in colon cancer cells. Perifosine increases the efficacy of 5-FU and L-OHP by suppressing Akt activation. Thus, the use of an Akt inhibitor in combination with 5-FU and L-OHP may be beneficial in colon cancer with cells harboring the PIK3CA mutation.
  • がん腹膜播種に対する治療戦略 腹膜播種を伴う胃癌症例化学療法後non-CR症例に対する外科的治療介入の可能性
    新海 政幸; 今野 元博; 平木 洋子; 百瀬 洸太; 加藤 寛章; 白石 治; 安田 篤; 木村 豊; 安田 卓司
    日本外科系連合学会誌 日本外科系連合学会 46 (3) 341 - 341 0385-7883 2021/05
  • 4型胃癌に対する補助化学療法としての腹腔内・全身併用化学療法の意義を検証する無作為化第III相試験 PHOENIX-GC2 trial
    伊藤 誠二; 石神 浩徳; 山下 裕玄; 小寺 泰弘; 今野 元博; 福島 亮治; 深川 剛生; 藪崎 裕; 北山 丈二; 山口 博紀; 辻 靖; 秀村 晃生; 島田 英昭; 太田 光彦; 廣野 靖夫; 大庭 幸治; 瀬戸 泰之
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 121回 SF - 3 2021/04
  • 胃癌腹膜播種に対する全身・腹腔内投与併用化学療法奏効後のConversion Surgeryの治療成績
    有上 貴明; 石神 浩徳; 大森 健; 小寺 泰弘; 藪崎 裕; 福島 亮治; 今野 元博; 伊藤 誠二; 富田 寿彦; 秀村 晃生; 上之園 芳一; 天貝 賢二; 太田 光彦; 岸 健太郎; 北山 丈二
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 121回 SF - 8 2021/04
  • 4型胃癌に対する補助化学療法としての腹腔内・全身併用化学療法の意義を検証する無作為化第III相試験 PHOENIX-GC2 trial
    伊藤 誠二; 石神 浩徳; 山下 裕玄; 小寺 泰弘; 今野 元博; 福島 亮治; 深川 剛生; 藪崎 裕; 北山 丈二; 山口 博紀; 辻 靖; 秀村 晃生; 島田 英昭; 太田 光彦; 廣野 靖夫; 大庭 幸治; 瀬戸 泰之
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 121回 SF - 3 2021/04
  • 噴門側胃切除後における食道内圧からみた至適な食道残胃吻合法
    安田 篤; 木村 豊; 平木 洋子; 百瀬 光汰; 加藤 寛章; 白石 治; 新海 政幸; 今野 元博; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 121回 SF - 3 2021/04
  • 進行食道癌に対する術前化学療法後のリンパ節における微小転移が再発に及ぼす影響
    平木 洋子; 木村 豊; 今野 元博; 百瀬 洸太; 加藤 寛章; 白石 治; 安田 篤; 新海 政幸; 牧野 知紀; 本告 正明; 山崎 誠; 宮田 博志; 矢野 雅彦; 土岐 祐一郎; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 121回 SF - 3 2021/04
  • 腹膜播種陽性胃癌におけるfirst-line化学療法後、播種遺残例に対する2nd-line治療としての外科治療介入の可能性
    新海 政幸; 今野 元博; 平木 洋子; 百瀬 洸太; 加藤 寛章; 白石 治; 安田 篤; 木村 豊; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 121回 PS - 8 2021/04
  • 高用量CDDの使用が困難な進行食道癌患者に対する術前5-FU+docetaxel+nedaplatin(UDON)療法の治療成績
    木村 豊; 白石 治; 加藤 寛章; 百瀬 洸太; 川上 尚人; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 121回 SF - 6 2021/04
  • Osamu Shiraishi; Takushi Yasuda; Hiroaki Kato; Kota Momose; Yoko Hiraki; Atsushi Yasuda; Masayuki Shinkai; Yutaka Kimura; Motohiro Imano
    Annals of surgical oncology 28 (11) 6366 - 6375 2021/03 
    INTRODUCTION: We compare planned salvage surgery after definitive chemoradiotherapy (SALV) versus neoadjuvant chemoradiotherapy plus surgery (NCRS) for borderline resectable T4 esophageal squamous cell carcinoma. PATIENTS AND METHODS: A total of 37 patients underwent planned SALV, and 20 underwent NCRS from 2004 to 2017. The short-term outcome measures were the R0 resection rate, complications, and treatment-related mortality. The long-term outcome measures were the 5-year overall survival rate and causes of death. RESULTS: R0 resection rate was similar between the SALV and NCRS groups (81% versus 85%). The incidence of postoperative pneumonia (35% versus 18%) and treatment-related mortality rate (9% versus 0%) tended to be higher in the SALV. ypT grade 2-3 (65% versus 30%, p = 0.012) and Clavien-Dindo grade ≥ IIIb complications (32% versus 0%, p = 0.008) were significantly more frequent in the SALV group. The groups had similar 5-year overall survival (26% versus 27%). The causes of death in the SALV and NCRS groups were primary esophageal cancer in 35% and 55% of patients, respectively, and pulmonary-related mortality in 24% and 5%, respectively. Multivariable Cox regression analysis revealed the following significant poor prognostic factors: stable disease as the clinical response, preoperative body mass index (BMI) of < 18.5 kg/m2, ypN stage 1-3, and R1-2 resection. CONCLUSIONS: SALV was associated with a higher incidence of late pulmonary-related mortality but had a stronger antitumor effect than NCRS. Consequently, the survival rate was similar between the groups. Surgery is recommended for patients with a partial response and preoperative BMI of ≥ 18.5 kg/m2.
  • 食道内圧測定と24時間pHモニターからみた噴門側胃切除後食道裂孔挿入食道残胃吻合法の検討
    安田 篤; 木村 豊; 平木 洋子; 百瀬 洸太; 加藤 寛章; 白石 治; 新海 政幸; 今野 元博; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 93回 299 - 299 2021/03
  • 胃癌異時性孤立性脾転移をきたした3例の報告
    平木 洋子; 安田 篤; 百瀬 洸太; 加藤 寛章; 白石 治; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 93回 361 - 361 2021/03
  • 消化器外科術後感染対策 高齢者に対する上部消化管手術における遠隔部位感染の予防対策
    木村 豊; 安田 篤; 白石 治; 平木 洋子; 百瀬 洸太; 加藤 寛章; 新海 政幸; 今野 元博; 安田 卓司
    日本腹部救急医学会雑誌 (一社)日本腹部救急医学会 41 (2) 203 - 203 1340-2242 2021/02
  • RY脚吻合部出血の血腫閉塞により輸入脚閉塞症をきたした2例
    加藤 寛章; 平木 洋子; 百瀬 洸太; 白石 治; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本腹部救急医学会雑誌 (一社)日本腹部救急医学会 41 (2) 228 - 228 1340-2242 2021/02
  • Keisuke Tateishi; Masanobu Tsubaki; Tomoya Takeda; Yuuta Yamatomo; Motohiro Imano; Takao Satou; Shozo Nishida
    Journal of B.U.ON. : official journal of the Balkan Union of Oncology 26 (2) 606 - 612 2021 
    PURPOSE: Head and neck squamous cell carcinoma (HNSCC) is a major malignancy worldwide. Ras overexpression in HNSCC is known to promote tumor cell growth; therefore, inhibition of Ras activation could lead to tumor growth suppression in HNSCC patients. Here, we investigated the effect of FTI-277, a farnesyl transferase inhibitor, and GGTI-287, a geranyltransferase 1 inhibitor, on the Ras signaling pathway in HNSCC cell lines-HEp-2 and HSC-3. METHODS: Cell viability was analyzed using the trypan blue staining exclusion assay. The apoptosis of cells was assessed by flow cytometry and caspase activation analysis. The expression levels of proteins were examined using western blot analysis. RESULTS: FTI-277 and GGTI-287 induced cell death, enhanced caspase 3 activity, and increased the number of annexin V-positive cells in HEp-2 and HSC-3 cells. FTI-277 and GGTI-287 induced apoptosis in HSC-3 cells at much lower concentrations than that in HEp-2 cells. FTI-277 and GGTI-287 decreased the concentration of phosphorylated ERK1/2 and mTOR via membrane localization of Ras and enhanced Bim expression. Furthermore, FTI-277 and GGTI-287 induced cell death in v-H-Ras-transfected NIH3T3 (NW7) cells and not in empty vector-transfected NIH3T3 (NV20) cells. CONCLUSION: FTI-277 and GGTI-287 may be useful as potential therapeutic agents for treating HNSCC patients; moreover, farnesyl transferase and geranylgeranyltransferase 1 inhibitors can be further developed as anticancer agents.
  • Yoko Hiraki; Yutaka Kimura; Motohiro Imano; Hiroaki Kato; Mitsuru Iwama; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Tomoki Makino; Masaaki Motoori; Makoto Yamasaki; Hiroshi Miyata; Takao Satou; Taroh Satoh; Hiroshi Furukawa; Masahiko Yano; Yuichiro Doki; Takushi Yasuda
    Surgery today 51 (1) 118 - 126 2021/01 
    PURPOSE: The purpose of this study is to determine the clinical significance of micrometastases after neoadjuvant chemotherapy (NAC) and the difference in controlling micrometastases using different NAC regimens in resectable advanced esophageal squamous cell carcinoma (ESCC). METHODS: We analyzed patients with ESCC who underwent esophagectomy with lymph node dissection after NAC with Adriamycin + cisplatin + 5-fluorouracil (ACF) or docetaxel + cisplatin + 5-fluorouracil (DCF). Micrometastasis was defined as a single isolated cancer cell or cluster of cancer cells on the cervical, recurrent nerve, or abdominal LNs as shown by immunohistochemical staining with anti-cytokeratin antibody (AE1/AE3). The associations between micrometastases, recurrence, prognosis, and regimen differences were investigated. RESULTS: One hundred and one cases (ACF group: 51 cases; DCF group: 50 cases) were analyzed. Micrometastases occurred in 24 patients (23.8%): 17/51 (33.3%) in the ACF group and 7/50 (13.5%) in the DCF group (p = 0.0403). The 5-year recurrence-free survival (RFS) rates for patients without (n = 77) and with (n = 24) micrometastases were 62 and 32%, respectively, (hazard ratio, 2.158; 95% confidence interval, 1.170-3.980; stratified log-rank test, p = 0.0115). A multivariate analysis showed that stage pN1 or higher and micrometastases were significant risk factors affecting RFS. CONCLUSION: In resectable advanced ESCC, controlling micrometastases in the LNs after NAC varied by regimen and may be associated with preventing ESCC recurrence.
  • [胃]高度進行胃癌に対するConversion surgery 腹膜播種陽性胃癌に対する全身・腹腔内併用化学療法奏効後の胃切除
    竹野 淳; 石神 浩徳; 大森 健; 小寺 泰弘; 藪崎 裕; 福島 亮治; 今野 元博; 伊藤 誠二; 富田 寿彦; 北山 丈二
    日本消化器外科学会総会 (一社)日本消化器外科学会 75回 PD2 - 7 2020/12
  • [食道]進行食道癌に対するConversion surgery cT4食道癌に対するConversion surgeryの治療成績
    白石 治; 平木 洋子; 百瀬 洸太; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 75回 PD1 - 5 2020/12
  • 腹水細胞診陽性(CY1)胃癌に対する腹腔内+全身化学療法奏功例におけるconversion手術
    新海 政幸; 今野 元博; 平木 洋子; 百瀬 洸太; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 75回 RS1 - 6 2020/12
  • 当院で考案した噴門側胃切除後食道残胃吻合法 菱形胃管作成+偽穹窿部食道裂孔挿入法
    安田 篤; 木村 豊; 百瀬 洸太; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 75回 P032 - 5 2020/12
  • 貧血と蛋白漏出症、通過障害を来し、腹腔鏡下胃全摘を施行した非家族性若年性胃ポリポーシスの1症例
    平木 洋子; 木村 豊; 百瀬 洸太; 加藤 寛章; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 75回 P092 - 7 2020/12
  • 初回治療後の病期診断の現況とブレークスルー(領域横断的セッション) 胸部食道扁平上皮癌におけるNAC前後のPET集積変化による予後予測
    白石 治; 平木 洋子; 百瀬 洸太; 加藤 寛章; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 74回 62 - 62 2020/12
  • 再発癌への治療戦略(領域横断的セッション) 再発食道癌における積極的治療対象の検討とその成績
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 木村 豊; 今野 元博
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 74回 70 - 70 2020/12
  • 食道癌における臨床的にネガティブだが病理学的にポジティブなLN(Clinically negative but pathologically positive LNs in esophageal cancer)
    百瀬 洸太; 白石 治; 平木 洋子; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 74回 164 - 164 2020/12
  • 腹部大動脈周囲リンパ節転移Stage IV食道癌に対する導入化学療法+拡大郭清手術
    白石 治; 加藤 寛章; 岩間 密; 平木 洋子; 百瀬 洸太; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 74回 364 - 364 2020/12
  • 高用量CDDPの使用が困難な食道癌患者に対する3剤併用術前化学療法の検討
    木村 豊; 白石 治; 川上 尚人; 岩間 密; 加藤 寛章; 百瀬 洸太; 安田 篤; 新海 政幸; 今野 元博; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 74回 349 - 349 2020/12
  • 白石 治; 安田 卓司; 加藤 寛章; 百瀬 洸太; 平木 洋子; 安田 篤; 新海 政幸; 木村 豊; 今野 元博
    外科 (株)南江堂 82 (13) 1297 - 1302 0016-593X 2020/12 
    <文献概要>食道癌の機能温存縮小手術のめざすところは,生活の質(QOL)と根治性を両立した手術である.頸部食道癌では,舌骨上筋群の温存と下筋群の切離,反回神経麻痺を回避して嚥下能を維持し,輪状咽頭筋切離により最大限に口側切離距離を確保し,喉頭温存手術を可能とする.胸部中下部食道癌では,上縦隔リンパ節転移を認めないことを条件に,嚥下能の低下した高齢者や脳梗塞既往患者を対象に頸部操作を省略できる高位胸腔内胃管再建術を適応する.
  • 食道癌術後患者に対する、安全・簡便・低侵襲な経腸栄養ルートの造設法 内視鏡的経皮経胃管腸瘻造設
    加藤 寛章; 白石 治; 平木 洋子; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    学会誌JSPEN (一社)日本臨床栄養代謝学会 2 (Suppl.1) 452 - 452 2020/11
  • 食道 診断
    木村 豊; 平木 洋子; 今野 元博; 百瀬 洸太; 加藤 寛章; 白石 治; 安田 篤; 新海 政幸; 牧野 知紀; 本告 正明; 山崎 誠; 宮田 博志; 矢野 雅彦; 土岐 祐一郎; 安田 卓司
    日本消化器外科学会雑誌 (一社)日本消化器外科学会 53 (Suppl.2) 358 - 358 0386-9768 2020/11
  • Tomoya Takeda; Masanobu Tsubaki; Shuji Genno; Chisato Nemoto; Yasuka Onishi; Yuuta Yamamoto; Motohiro Imano; Takao Satou; Shozo Nishida
    Oncology reports 44 (5) 2211 - 2218 2020/11 
    Imatinib is the gold standard in the conventional treatment of chronic myeloid leukemia (CML). However, some patients become resistant to imatinib therapy. To overcome this resistance, second‑generation (dasatinib, nilotinib, and bosutinib) and third‑generation (ponatinib) tyrosine kinase inhibitors (TKIs) have been developed and have been shown to be effective against refractory CML. Although these TKIs provide many benefits for patients with CML, advanced patients show resistance even to these TKIs. Therefore, novel therapeutic strategies are urgently needed for the treatment of TKI‑resistant CML patients. AT9283 is a multi‑targeted kinase inhibitor with potent activity against Janus kinase (JAK), Aurora kinases, and Abl. In the present study, we showed that AT9283 significantly decreased the cell viability of both TKI‑sensitive and TKI‑resistant CML cells as determined by trypan blue exclusion assay. In addition, cell cycle analysis, Annexin V assay, and caspase‑3/7 activity assay revealed that AT9283 increased the cell population in the G2/M phase and induced apoptosis. We investigated the molecular mechanisms underlying the decrease in cell viability upon treatment with AT9283 by western blotting. Interestingly, our results showed that AT9283 inhibited the expression of Aurora A, Aurora B, and downstream Histone H3 phosphorylation. In contrast, we observed no changes in the levels of Bcr‑Abl, signal transducer and activator of transcription 3 (STAT3), extracellular signal‑regulated kinase (ERK), and Akt phosphorylation. In addition, we found that AMG900, a selective Aurora A and Aurora B inhibitor, increased the G2/M phase cell population and induced apoptosis via inhibition of Aurora A and Aurora B in both TKI‑sensitive and TKI‑resistant CML cells. Our studies show that Aurora A and Aurora B are promising therapeutic targets for TKI‑sensitive and TKI‑resistant CML, and AT9283 may have potential clinical applications for the treatment of TKI‑resistant CML patients.
  • Osamu Shiraishi; Hiroaki Kato; Mitsuru Iwama; Yoko Hiraki; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Yutaka Kimura; Motohiro Imano; Takushi Yasuda
    Surgical endoscopy 34 (11) 4967 - 4974 2020/11 
    BACKGROUND: Feeding jejunostomy (FJ) is a common treatment to support patients with esophageal cancer after esophagectomy. However, severe FJ-related complications, such as bowel obstruction, occasionally occur. We investigated the ability of our simple, novel FJ technique, the "curtain method," to prevent bowel obstruction. METHODS: In laparoscopic surgery, the main mechanism of bowel obstruction involves torsion of the mesentery accompanied by migration of the intestine across the fixed FJ through the space surrounded by a triangle comprising the ligament of Treitz, fixed FJ, and spleen rather than adhesion. Our "curtain method" involves closure of this triangle zone with omentum, and the appearance of the lifted omentum resembles a curtain. Sixty patients treated with this modified FJ were retrospectively compared with 13 patients treated with conventional FJ in terms of the incidence of bowel obstruction, peritonitis, stoma site infection, and catheter obstruction. RESULTS: From 2013 to 2017, 60 patients underwent esophagectomy and gastric conduit reconstruction accompanied by modified laparoscopic FJ. The median observation period, including the period after tube removal, was 644 days. No FJ-associated bowel obstruction, the prevention of which was the primary aim, occurred in any patient. Likewise, no peritonitis or dislodgement occurred. Eight patients (13%) developed a stoma site infection with granulation. The feeding tube became occluded in 11 patients (18%); however, a new feeding tube was reinserted under fluoroscopy for all of these patients. From 2003 to 2012, 13 patients underwent conventional FJ. The median observation period was 387 days. Three patients (23%) developed bowel obstruction by torsion 71 to 134 days after the first surgery, and all were treated by emergency operations. Other FJ-related complications were not different from those in the modified FJ group. CONCLUSION: Our simple, novel technique, the "curtain method," for prevention of laparoscopic FJ-associated bowel obstruction after esophagectomy is a safe additional surgery.
  • Masanobu Tsubaki; Shiori Seki; Tomoya Takeda; Akiko Chihara; Yuuko Arai; Yuusuke Morii; Motohiro Imano; Takao Satou; Kazunori Shimomura; Shozo Nishida
    International journal of molecular sciences 21 (21) 2020/10 
    Multiple myeloma (MM)-induced bone disease occurs through hyperactivation of osteoclasts by several factors secreted by MM cells. MM cell-secreted factors induce osteoclast differentiation and activation via direct and indirect actions including enhanced expression of receptor activator of nuclear factor κB ligand (RANKL) in osteoblasts and bone marrow stromal cells (BMSCs). Hepatocyte growth factor (HGF) is elevated in MM patients and is associated with MM-induced bone disease, although the mechanism by which HGF promotes bone disease remains unclear. In the present study, we demonstrated that HGF induces RANKL expression in osteoblasts and BMSCs, and investigated the mechanism of induction. We found that HGF and MM cell supernatants induced RANKL expression in ST2 cells, MC3T3-E1 cells, and mouse BMSCs. In addition, HGF increased phosphorylation of Met and nuclear factor κB (NF-κB) in ST2 cells, MC3T3-E1 cells, or mouse BMSCs. Moreover, Met and NF-κB inhibitors suppressed HGF-induced RANKL expression in ST2 cells, MC3T3-E1 cells, and mouse BMSCs. These results indicated that HGF promotes RANKL expression in osteoblasts and BMSCs via the Met/NF-κB signaling pathway, and Met and NF-κB inhibitors suppressed HGF-induced RANKL expression. Our findings suggest that Met and NF-κB inhibitors are potentially useful in mitigating MM-induced bone disease in patients expressing high levels of HGF.
  • 高度進行胃癌、再発胃癌に対する治療戦略-薬物療法と手術との融合- 腹膜播種陽性初発胃癌に対するタキサン系抗癌剤による腹腔内化学療法後の手術加療の意義
    廣野 靖夫; 石神 浩徳; 大森 健; 藪崎 裕; 松木 淳; 今野 元博; 新海 政幸; 富田 寿彦; 有上 貴明; 藤本 大裕; 山下 直行; 松村 卓樹; 北山 丈二
    日本臨床外科学会雑誌 日本臨床外科学会 81 (増刊) 300 - 300 1345-2843 2020/10
  • 食道切除後の消化管再建 食道切除後胸骨後胃管再建における縫合不全対策の変遷と現況
    白石 治; 平木 洋子; 百瀬 洸太; 加藤 寛章; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 81 (増刊) 240 - 240 1345-2843 2020/10
  • 機能温存手術(食道・胃)の現状 頸部・頸胸境界部食道癌に対する喉頭温存、高位吻合術における嚥下機能温存の工夫
    加藤 寛章; 白石 治; 平木 洋子; 百瀬 洸太; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 81 (増刊) 261 - 261 1345-2843 2020/10
  • 高度進行胃癌、再発胃癌に対する治療戦略-薬物療法と手術との融合- 腹膜播種陽性胃癌に対する腹腔内パクリタキセル投与+全身化学療法奏功例に対するconversion手術の有用性
    新海 政幸; 今野 元博; 平木 洋子; 百瀬 洸太; 加藤 寛章; 白石 治; 安田 篤; 木村 豊; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 81 (増刊) 299 - 299 1345-2843 2020/10
  • 木村 豊; 安田 篤; 白石 治; 平木 洋子; 百瀬 洸太; 加藤 寛章; 新海 政幸; 今野 元博; 安田 卓司
    日本外科感染症学会雑誌 (一社)日本外科感染症学会 17 (5) 337 - 337 1349-5755 2020/10
  • 腫瘍免疫病態の多様性とがん治療 術前治療後治癒切除のpN(+)食道癌症例に対するペプチドワクチン術後補助療法に関する探索的単施設第2相臨床試験
    安田 卓司; 錦 耕平; 平木 洋子; 加藤 寛章; 白石 治; 安田 篤; 新海 政幸; 木村 豊; 助川 寧; 千葉 康敬; 今野 元博; 竹田 和由; 佐藤 隆夫; 塩崎 均; 中村 祐輔
    日本癌学会総会記事 (一社)日本癌学会 79回 S15 - 2 0546-0476 2020/10
  • 4型胃癌に対する術後/周術期化学療法としての腹腔内化学療法を検証する第III相試験
    石神 浩徳; 山下 裕玄; 小寺 泰弘; 今野 元博; 福島 亮治; 深川 剛生; 藪崎 裕; 伊藤 誠二; 北山 丈二; 山口 博紀; 瀬戸 泰之
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 58回 PS - 7 2020/10
  • 高度進行胃癌、再発胃癌に対する治療戦略-薬物療法と手術との融合- 腹膜播種陽性初発胃癌に対するタキサン系抗癌剤による腹腔内化学療法後の手術加療の意義
    廣野 靖夫; 石神 浩徳; 大森 健; 藪崎 裕; 松木 淳; 今野 元博; 新海 政幸; 富田 寿彦; 有上 貴明; 藤本 大裕; 山下 直行; 松村 卓樹; 北山 丈二
    日本臨床外科学会雑誌 日本臨床外科学会 81 (増刊) 300 - 300 1345-2843 2020/10
  • Osamu Shiraishi; Takushi Yasuda; Hiroaki Kato; Mitsuru Iwama; Yoko Hiraki; Atsushi Yasuda; Masayuki Shinkai; Yutaka Kimura; Motohiro Imano
    Annals of surgical oncology 27 (11) 4433 - 4440 2020/10 
    PURPOSE: We retrospectively investigated the risk factors for mediastinal lymph node (MLN) metastasis in esophagogastric junction (EGJ) cancer with an epicenter within 2 cm above and below the anatomical cardia, including both adenocarcinoma (AC) and squamous cell carcinoma (SCC). METHODS: Fifty patients who underwent initial surgery for EGJ cancer from January 2002 to December 2013 were included in this study. We defined metastatic lymph nodes as pathological metastases in resected specimens and recurrence within 2 years postoperatively. RESULTS: Thirty-four patients had AC and 16 had SCC; 24 patients underwent transhiatal resection and 26 underwent transthoracic resection. MLN metastasis was observed in 13 patients (26%) regardless of the histological type, 9 of whom had metastasis in the upper and middle mediastinum. Metastasis occurred when the esophageal invasion length (EIL) exceeded 20 mm. In addition, 10/13 patients had stage pN2-3 cancer. Multivariable analysis identified EIL ≥ 20 mm and stage pN2-3 as significant risk factors for MLN metastasis. The 5-year overall survival was 38% and 65% in the MLN-positive and -negative groups, respectively (p = 0.12). Multivariable Cox regression analysis showed that only stage pN2-3, and not the presence of MLN metastasis, was a significantly poor prognostic factor. CONCLUSION: MLN metastasis in EGJ cancer may have a close association with the EIL of the tumor, but the presence of MLN metastasis itself was not a poor prognostic factor. The significance and indications for MLN dissection should be clarified in prospective clinical trials.
  • Tomoya Takeda; Masanobu Tsubaki; Ryota Asano; Tatsuki Itoh; Motohiro Imano; Takao Satou; Shozo Nishida
    Journal of dermatological science 99 (3) 168 - 176 2020/09 
    BACKGROUND: Malignant melanoma is among the deadliest forms of skin cancers, and its incidence has been increasing over the past decades. In malignant melanoma, activation of the nuclear factor kappa B (NF-κB) promotes survival, migration, and invasion of cancer cells. Anti-NF-κB agents for treating metastatic melanoma would be beneficial, but no such drug is approved as either monotherapy or adjuvant therapy. Dimethyl fumarate (DMF) is an approved anti-inflammatory drug already in clinical use for psoriasis and multiple sclerosis. OBJECTIVE: We investigated the anti-tumour effect of DMF treatment in metastatic melanoma in vitro and in vivo. METHODS: The cell viability was assessed via trypan blue exclusion assay. The migration and invasion was analyzed in a Boyden chamber assay. The anti-metastatic effects and anti-tumour activity of DMF was determined in an in-vivo model. The expressions of NF-κB pathway and NF-κB regulatory proteins were detected via western blotting. RESULTS: DMF decreased the cell viability, migration and invasion in vitro. In addition, DMF inhibited spontaneous metastasis and tumour growth. Mechanistically, DMF prevented the nuclear translocation of NF-κB, whereas no changes were observed in the phosphorylation levels of inhibitor of kappa B (IκB). In addition, DMF inhibited the expression of matrix metalloproteinases (MMPs) and very late antigens (VLAs). Furthermore, DMF treatment decreased the expression of Survivin and Bcl-extra large (Bcl-XL) proteins. CONCLUSION: Our results suggest that DMF as a novel inhibitor of NF-κB may be a potential therapeutic agent for metastatic melanoma.
  • Takushi Yasuda; Kohei Nishiki; Yoko Hiraki; Hiroaki Kato; Mitsuru Iwama; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Yutaka Kimura; Yasushi Sukegawa; Yasutaka Chiba; Motohiro Imano; Kazuyoshi Takeda; Takao Satou; Hitoshi Shiozaki; Yusuke Nakamura
    Annals of surgery 275 (1) e155-e162  2020/08 
    OBJECTIVES: To elucidate the efficacy of adjuvant vaccine monotherapy using 3 Human Leukocyte Antigen (HLA)-A24-restricted tumor-specific peptide antigens for ESCC, upregulated lung cancer 10, cell division cycle associated 1, and KH domain-containing protein overexpressed in cancer 1. SUMMARY OF BACKGROUND DATA: ESCC patients with pathologically positive nodes (pN(+)) have a high risk for postoperative recurrence, despite curative resection after preoperative therapy. Subclinical micrometastases are an appropriate target for cancer vaccine. METHODS: This is a non-randomized prospective phase II clinical trial (UMIN000003557). ESCC patients curatively resected after preoperative therapy with pN(+) were allocated into the control and vaccine groups (CG and VG) according to the HLA-A status. One mg each of three epitope peptides was postoperatively injected 10 times weekly followed by 10 times biweekly to the VG. The primary and secondary endpoints were relapse-free survival (RFS) and esophageal cancer-specific survival (ECSS), respectively. RESULTS: Thirty were in the CG and 33 in the VG. No significant difference was observed in RFS between the CG and VG (5-year RFS: 32.5% vs 45.3%), but the recurrence rate significantly decreased with the number of peptides which induced antigen-specific cytotoxic T lymphocytes. The VG showed a significantly higher 5-year ECSS than the CG (60.0% vs 32.4%, P = 0.045) and this difference was more prominent in patients with CD8 and programmed death-ligand 1 double negative tumor (68.0% vs 17.7%, P = 0.010). CONCLUSIONS: Our cancer peptide vaccine might improve the survival of ESCC patients, which is warranted to be verified in the phase III randomized controlled study.
  • T Takeda; M Tsubak; S Genno; T Matsuda; Y Yamamoto; E Ueda; M Imano; T Satou; S Nishida
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 71 (4) 2020/08 
    Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin's B-cell lymphoma. Currently, multi-agent chemotherapy regimens are being used to significantly improve cure rates and achieve complete remissions in BL patients. However, drug resistance can often occur within 6 months in BL patients, contributing to poor prognosis. Mounting evidence suggests that cell adhesion-mediated drug resistance (CAM-DR), caused by the interaction between the bone marrow microenvironment and tumour cells may play an important role in drug resistance to chemotherapy. However, the molecular mechanism underlying CAM-DR in BL has not been identified yet. In this study, we investigated the molecular mechanism responsible for CAM-DR in BL cells. We also examined the therapeutic targets of CAM-DR in BL cells and found CD49d and CD49e to be the important adhesion molecules involved. However, CD49a, CD49b, CD11a, CD29, CD18, and CD61 were not found to be associated with CAM-DR in BL cells. Furthermore, we clarified that CD49d- and CD49e-mediated CAM-DR could be attributed to an increase in the expression of B cell leukemia-xL (Bcl-xL) and survivin proteins, and a decrease in the expression of Bcl-2 associated X (Bax), Bcl-2 interacting mediator (Bim) and p53 upregulated modulator of apoptosis (PUMA) proteins via nuclear factor kappaB (NF-κB) activation. In addition, bortezomib was found to overcome CAM-DR in BL cells by inhibiting NF-κB. Thus, bortezomib may have potential clinical applications in the treatment of CD49d- and CD49e-mediated CAM-DR in BL patients.
  • 腹膜播種陽性胃癌に対する腹腔内+全身化学療法奏功例におけるconversion手術
    新海 政幸; 今野 元博; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 120回 SF - 2 2020/08
  • 75歳以上の根治切除可能な大型3型/4型胃癌に対する術前TS-1併用化学放射線療法の第I相臨床試験(OGSG1303)
    木村 豊; 今野 元博; 古河 洋; 遠藤 俊治; 中川 朋; 足立 真一; 藤田 淳也; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 横川 正樹; 西村 恭昌; 安田 卓司; 坂井 大介; 黒川 幸典; 下川 敏雄; 佐藤 太郎
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 120回 SF - 8:[*] 2020/08
  • 食道胃接合部癌に対するリンパ節転移分布に基づく術式選択
    白石 治; 加藤 寛章; 岩間 密; 平木 洋子; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 120回 DP - 2 2020/08
  • 初診時切除不能胃癌に対するconversion surgeryの意義【International】腹膜播種を伴う進行胃癌症例に対する腹腔内投与を伴う全身化学療法後の外科手術の成績(Surgical outcomes for advanced gastric cancer with peritoneal metastases after intraperitoneal and systemic chemotherapy)
    深川 剛生; 石神 浩徳; 大森 健; 小寺 泰弘; 藪崎 裕; 福島 亮治; 今野 元博; 三澤 一成; 富田 寿彦; 秀村 晃生; 有上 貴明; 天貝 賢二; 辻 靖; 楠本 哲也; 岸 健太郎; 上田 修吾; 伏田 幸夫; 今村 和弘; 緒方 杏一; 北山 丈二
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 120回 SY - 6 2020/08
  • Mitsuki Tabata; Masanobu Tsubaki; Tomoya Takeda; Keisuke Tateishi; Katsumasa Tsurushima; Motohiro Imano; Takao Satou; Toshihiko Ishizaka; Shozo Nishida
    BMC complementary medicine and therapies 20 (1) 84 - 84 2020/03 
    BACKGROUND: Current chemotherapies for Burkitt lymphoma (BL) have dramatically improved its clinical outcome. However, chemoresistance can lead to chemotherapy failure and very poor prognosis; thus, novel strategies are urgently required for patients with drug-resistant BL. To investigate the mechanisms underlying drug resistance in BL, we established drug-resistant BL cell lines: HS-Sultan/ADM (adriamycin-resistant), HS-Sultan/VCR (vincristine-resistant), HS-Sultan/DEX (dexamethasone-resistant), and HS-Sultan/L-PAM (melphalan-resistant). METHODS: Drug transporter and survival factor expression were investigated the using western blotting and real time polymerase chain reaction. Cell survival was analyzed by trypan blue dye exclusion method. RESULTS: The established cell lines acquired cross-resistance to adriamycin, vincristine, dexamethasone, and melphalan and exhibited 50% inhibitory concentration values 106-, 40-, 81-, and 45-fold higher than the parental cell lines, respectively. We found that protein and mRNA expression of MDR1 and Survivin were higher in drug-resistant BL cells than in the parent cells. Treatment with verapamil, an MDR1 inhibitor, or Survivin siRNA alongside each anti-cancer drug suppressed the proliferation of all drug-resistant BL cells. Src kinase activity was higher in all resistant cell lines than the parental cells; suppressing Src with dasatinib restored drug sensitivity by reducing MDR1 and Survivin expression. CONCLUSIONS: MDR1 and Survivin upregulation are responsible for resistance to conventional drugs and dasatinib can restore drug sensitivity by reducing MDR1 and Survivin expression in drug-resistant BL cells. Src inhibitors could therefore be a novel treatment strategy for patients with drug resistant BL.
  • Osamu Shiraishi; Hiroaki Kato; Mituru Iwama; Yoko Hiraki; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Yutaka Kimura; Motohiro Imano; Takushi Yasuda
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 33 (2) 1120-8694 2020/03 [Refereed]
     
    Unexpected dysphagia is an important problem affecting life prognosis in patients who have undergone an esophagectomy for esophageal cancer. For nutritional support in patients suffering from dysphagia after a previous esophagectomy, a simplified percutaneous endoscopic transgastric conduit feeding jejunostomy approach was developed that can be performed regardless of the patient's condition. The feasibility of this procedure in 25 patients with esophageal cancer who underwent three-stage esophagectomy with retrosternal gastric conduit reconstruction from April 2009 to December 2016 was evaluated retrospectively. Under fluoroscopy, a percutaneous endoscopic transgastric conduit feeding jejunostomy catheter (9 French) was introduced into the jejunum in the epigastric region using the Seldinger's technique. The following patient data were analyzed retrospectively: operating time, complications, reasons for oral intake difficulty, and clinical data describing patients' nutritional status before and 1 month after percutaneous endoscopic transgastric conduit jejunostomy treatment, such as serum albumin and clinical course. Median patients' age was 68 years (range 50-76 years). Indications for the procedure were late swallowing dysfunction (n = 12), early swallowing dysfunction secondary to surgical complication (n = 8), anastomotic leakage (n = 3), and anorexia (n = 2). Causes of late swallowing dysfunction were radiation injury (n = 8), advanced age (n = 2), or cerebral infarction (n = 2). The median operating time was 29 minutes (range 14-82 minutes). Four patients developed mild erosions at the stoma secondary to bile reflux along the side of the catheter. No patient experienced severe complications such as ileus and peritonitis. Patients were treated for a median of 160 days (range 18-3106 days) with percutaneous endoscopic transgastric conduit jejunostomy. Patient's serum albumin significantly increased from 2.8 to 3.3 g/dl in 1 month. Of the eight patients with early swallowing dysfunction, six successfully regained sufficient oral nutrition after receiving enteral feeding nutritional management. Although all except one late swallowing dysfunction patient could not discontinue tube feeding, five patients were long-term survivors at the time this report was written. This jejunostomy procedure is simple, safe, and useful for patients with unexpected dysphagia and accompanying malnutrition after esophagectomy.
  • Conversion症例に対する治療戦略 腹膜播種陽性初発胃癌に対するIP療法後の手術加療の意義(Treatment strategy for down-staged cases from stage IV Gastrectomy after intraperitoneal/systemic chemotherapy in gastric cancer with peritoneal metastasis)
    廣野 靖夫; 石神 浩徳; 大森 健; 藪崎 裕; 松木 淳; 今野 元博; 新海 政幸; 富田 寿彦; 有上 貴明; 藤本 大裕; 山下 直行; 松村 卓樹; 北山 丈二
    日本胃癌学会総会記事 (一社)日本胃癌学会 92回 225 - 225 2020/03
  • 腹膜播種陽性進行胃癌に対するPaclitaxel+CDDP+S-1(PCS)療法の治療経験
    新海 政幸; 今野 元博; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 92回 453 - 453 2020/03
  • Conversion症例に対する治療戦略 腹膜播種陽性初発胃癌に対するIP療法後の手術加療の意義(Treatment strategy for down-staged cases from stage IV Gastrectomy after intraperitoneal/systemic chemotherapy in gastric cancer with peritoneal metastasis)
    廣野 靖夫; 石神 浩徳; 大森 健; 藪崎 裕; 松木 淳; 今野 元博; 新海 政幸; 富田 寿彦; 有上 貴明; 藤本 大裕; 山下 直行; 松村 卓樹; 北山 丈二
    日本胃癌学会総会記事 (一社)日本胃癌学会 92回 225 - 225 2020/03
  • Atsushi Yasuda; Takushi Yasuda; Haruhiko Imamoto; Yoko Hiraki; Kohta Momose; Hiroaki Kato; Mitsuru Iwama; Osamu Shiraishi; Masayuki Shinkai; Motohiro Imano; Yutaka Kimura
    Surgical case reports 6 (1) 44 - 44 2020/02 
    BACKGROUND: Granular cell tumors (GCT) in the gastrointestinal tract are rare. Herein, we describe a case of a gastric GCT diagnosed preoperatively by endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) and successfully resected by single-incision laparoscopic surgery (SILS). CASE PRESENTATION: A 46-year-old Japanese woman had a tumor located in the angle of the stomach that was approximately 1.5 cm in diameter. Abdominal computed tomography (CT) revealed a submucosal tumor (SMT), which was finally diagnosed as a gastric GCT using EUS-FNAB. The tumor was not identified by CT 1 year and 4 months before diagnosis; therefore, because there was a possibility that the tumor was malignant, we performed surgical wedge resection using SILS. The patient had an uneventful recovery postoperatively and was discharged without complications 3 days after surgery. The tumor was pathologically diagnosed as a benign GCT that remained within the muscular layer. No recurrence or complications have occurred in the first 16 months since the surgery. CONCLUSION: Because gastric GCTs are generally benign and are rarely associated with lymph node metastasis, SILS seems to be a safe and feasible surgical approach for treating GCTs.
  • Tetsuji Terazawa; Jin Matsuyama; Masahiro Goto; Ryohei Kawabata; Shunji Endo; Motohiro Imano; Shoichiro Fujita; Yusuke Akamaru; Hirokazu Taniguchi; Mitsutoshi Tatsumi; Sang-Woong Lee; Yoshitaka Kurisu; Hisato Kawakami; Yukinori Kurokawa; Toshio Shimokawa; Daisuke Sakai; Takeshi Kato; Kazumasa Fujitani; Taroh Satoh
    The oncologist 25 (2) 119-e208  2020/02 [Refereed]
     
    LESSONS LEARNED: Perioperative capecitabine and oxaliplatin (CapeOx) therapy showed favorable efficacy with sufficient pathological response. Small sample size limited the statistical power of this result. Perioperative CapeOx therapy showed good feasibility. Further studies with larger sample size are required to validate this novel approach. BACKGROUND: D2 gastrectomy followed by adjuvant S-1 is the standard therapy for patients (pts) with stage III gastric cancer (GC) in Japan; however, the outcome is not satisfactory. We examined the efficacy of perioperative capecitabine and oxaliplatin (CapeOx) in pts with GC. METHODS: The eligibility criteria included confirmed clinical T3(SS)/T4a(SE) N1-3 M0 GC according to the Japanese Classification (JCGC; 3rd English Edition). Three cycles of neoadjuvant CapeOx (NAC; capecitabine, 2,000 mg/m2 for 14 days; oxaliplatin, 130 mg/m2 on day 1, every 3 weeks) were administered, followed by five cycles of adjuvant CapeOx (AC) after D2 gastrectomy. The primary endpoint was the pathological response rate (pRR) according to the JCGC (≥grade 1b). RESULTS: Thirty-seven pts were enrolled on CapeOx. An R0 resection rate of 78.4% (n = 29) and a pRR of 54.1% (n = 20, p = .058; 90% confidence interval [CI], 39.4-68.2) were demonstrated. Among 27 pts who initiated AC, 21 (63.6%) completed the treatment. Grade 3-4 toxicities during NAC included neutropenia (8%), thrombocytopenia (8%), and anorexia (8%) and during AC included neutropenia (37%), diarrhea (4%), and anorexia (4%). CONCLUSION: Perioperative CapeOx showed good feasibility and favorable efficacy with sufficient pathological response, although statistical significance at .058 did not reach the commonly accepted cutoff of .05. The data obtained using this novel approach warrant further investigations.
  • 木村 豊; 白石 治; 岩間 密; 加藤 寛章; 川上 尚人; 奥野 達哉; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 中川 和彦; 安田 卓司
    癌と化学療法 (株)癌と化学療法社 46 (13) 2173 - 2175 0385-0684 2019/12 
    腎機能低下を伴う進行食道癌に対して術前化学療法(NAC)として5-FU+DTX+nedaplatin(NED)(UDON)療法を施行し、その有用性をretrospectiveに検討した。クレアチニン・クリアランス(Ccr)が50mL/min未満の進行食道癌5例を対象として、NACとしてUDON療法[5-FU640mg/m2(day1〜5)、NED72mg/m2(day1)、DTX28mg/m2(day1、15)、休薬2週間を1コース]を2コース施行した後に根治手術を施行した。化学療法の有害事象(AE)を評価し、臨床的な効果について検討した。患者背景は、男性4例、女性1例、年齢の中央値(範囲)79(58〜80)歳、performance status(PS)1:3、PS2:2例であった。腫瘍の主占居部位は、Ce 1、Ut 1、Mt 3例、進行度はcStage IIA1、IIIA2、IIIC2例であった。grade(Gr)3以上のAEは、好中球減少、低Na血症がそれぞれ2例、発熱性好中球減少、下痢がそれぞれ1例であった。抗腫瘍効果は部分奏効4例、安定1例、組織学的効果は、Gr 1a:Gr 1b=2:3であった。腎機能低下のため高用量CDDP投与が困難な進行食道癌患者に対するNACとして、UDON療法は有用である。(著者抄録)
  • Yutaka Kimura; Osamu Shiraishi; Mitsuru Iwama; Hiroaki Kato; Hisato Kawakami; Tatsuya Okuno; Yoko Hiraki; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Kazuhiko Nakagawa; Takushi Yasuda
    Gan to kagaku ryoho. Cancer & chemotherapy 46 (13) 2173 - 2175 0385-0684 2019/12 [Refereed]
     
    BACKGROUND: In Japan, pre-operative 5-FU and cisplatin(CDDP)(FP)combination therapy has been the standard neoadjuvant chemotherapy(NAC)for advanced resectable esophageal cancer(EC); furthermore, the efficacy of the docetaxel (DTX)-containing triplet regimen, FP plus DTX, has been reported. However, patients with impaired renal function should not receive high-dose CDDP. We have been developing a non-CDDP-containing triplet regimen, comprising 5-FU, DTX, and nedaplatin(NED)(UDON), on a phase Ⅰ/Ⅱtrial basis. This retrospective study aimed to investigate the safety and efficacy of NAC with UDON in advanced EC patients with impaired renal function. METHODS: Five patients with advanced resectable EC with impaired renal function were enrolled in this study. Patients received NAC(5-FU, 640mg/m / 2, days 1-5; DTX, 28 mg/m2, days 1 and 15; and NED, 72mg/m2, day 1, q28, 2 courses); following this, they underwent esophagectomy. The primary endpoint was response rate, and the secondary endpoint was adverse event(AE). RESULTS: The median age was 79 years (range: 58-80 years). The ECOG performance status was 1/2 : 3/2. The main tumor locations were Ce/Ut/Mt : 1/1/3 and the cStages were ⅡA/ⅢA/ⅢC : 1/2/2. The RR(CR/PR/SD/PD : 0/4/1/0)was 80%. The pathological response was grade 1a/1b : 2/3. Major grade 3 or 4 AEs included neutropenia(40%), febrile neutropenia(20%), diarrhea(20%), and hyponatremia( 40%). There was no treatment-related death or reoperation. CONCLUSIONS: NAC with UDON might be feasible and effective in patients with advanced resectable EC with impaired renal function, who are ineligible for high-dose CDDP administration. We are planning a phaseⅡclinical study based on the present results.
  • 木村 豊; 白石 治; 岩間 密; 加藤 寛章; 川上 尚人; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 中川 和彦; 安田 卓司
    日本消化器病学会雑誌 (一財)日本消化器病学会 116 (臨増大会) A832 - A832 0446-6586 2019/11
  • 高齢食道癌患者の術後誤嚥性肺炎の発症予測における血中substance P測定の意義と展望
    木村 豊; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 安田 卓司
    日本消化器外科学会雑誌 (一社)日本消化器外科学会 52 (Suppl.2) 274 - 274 0386-9768 2019/11
  • Tsubaki M; Takeda T; Noguchi M; Jinushi M; Seki S; Morii Y; Shimomura K; Imano M; Satou T; Nishida S
    Cancers 11 (12) 2019/11 [Refereed]
     
    RAS and BRAF-mutated colorectal cancers are associated with resistance to chemotherapy and poor prognosis, highlighting the need for new therapeutic strategies. Although these cancers sometimes respond to mitogen activated protein kinase kinase (MEK) inhibitor treatment, they often acquire resistance via mechanisms, which are poorly understood. Here, we investigated the mechanism of MEK inhibitor resistance in primary- and acquired-resistant cells. Cell viability was examined using the trypan blue dye exclusion assay. Protein expression was analyzed by western blotting. Somatic mutations in colorectal cancer cells were investigated using the polymerase chain reaction array. PD0325901 and trametinib induced cell death in LoVo and Colo-205 cells but not in DLD-1 and HT-29 cells, which have a PIK3CA mutation constitutively activating Akt and NF-κB. Treatment with PD0325901 and trametinib suppressed ERK1/2 activation in all four cell lines but only induced Akt and NF-κB activation in DLD-1 and HT-29 cells. Inhibition of Akt but not NF-κB, overcame MEK inhibitor resistance in DLD-1 and HT-29 cells. Acquired-resistant LoVo/PR, Colo-205/PR and LoVo/TR cells have constitutively active Akt due to a M1043V mutation in the kinase activation loop of PIK3CA and Akt inhibitor resensitized these cells to MEK inhibitor. These results demonstrate that the overactivation of Akt plays a critical role in MEK inhibitor primary and acquired resistance and implicate combined Akt/MEK inhibition as a potentially useful treatment for RAS/BRAF-mutated colorectal cancer.
  • ディベートセッション:最新のエビデンスに基づいた食道外科手術(開胸vs鏡視下) 食道外科手術における胸腔鏡の拡大視と開胸の術野展開イメージの融合
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 木村 豊; 今野 元博
    日本臨床外科学会雑誌 日本臨床外科学会 80 (増刊) 388 - 388 1345-2843 2019/10
  • 上部胃癌に対する内視鏡外科手術の郭清と再建手技の定型化 逆流防止を考慮した安全で簡便な食道残胃吻合再建(残胃食道裂孔挿入法)の治療成績
    木村 豊; 安田 篤; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 80 (増刊) 431 - 431 1345-2843 2019/10
  • 新規臨床試験最新情報 根治切除可能な4型・大型3型胃癌に対する術前化学放射線療法 第II相試験(OGSG1205)
    李 相雄; 今野 元博; 古河 洋; 横川 正樹; 西村 恭昌; 安田 卓司; 遠藤 俊治; 後藤 昌弘; 紀 貴之; 内山 和久; 川上 尚人; 下川 敏雄; 坂井 大介; 黒川 幸典; 佐藤 太郎; 大阪消化管がん化学療法研究会(OGSG)
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 57回 SSY14 - 5 2019/10
  • 75歳以上の根治切除可能な大型3型/4型胃癌に対する術前S-1併用化学放射線療法OGSG1303
    遠藤 俊治; 今野 元博; 古河 洋; 安田 卓司; 横川 正樹; 西村 恭昌; 中川 朋; 足立 真一; 木村 豊; 坂井 大介; 川上 尚人; 下川 敏雄; 黒川 幸典; 佐藤 太郎
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 57回 P71 - 1 2019/10
  • 胃癌Up to Date 腹膜播種陽性胃癌に対する腹腔内化学療法 腹腔内化学療法研究会の臨床試験
    石神 浩徳; 小寺 泰弘; 今野 元博; 福島 亮治; 藪崎 裕; 大森 健; 門脇 重憲; 富田 寿彦; 有上 貴明; 秀村 晃生; 廣野 靖夫; 辻 靖; 天貝 賢二; 山口 博紀; 北山 丈二
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 57回 SY10 - 4 2019/10
  • Tabata M; Tsubaki M; Takeda T; Tateishi K; Maekawa S; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
    Clinical and experimental medicine 20 (1) 63 - 71 1591-8890 2019/10 [Refereed]
     
    Multiple myeloma (MM) is the second most common hematologic malignancy. In spite of the development of new therapeutic agents, MM remains incurable due to multidrug resistance (MDR) and the 5-year survival rate is approximately 50%. Thus, further study is needed to investigate the mechanism of MDR and improve MM prognosis. Heat shock protein 90 (HSP90) is a molecular chaperone that is responsible for the stability of a number of client proteins, most of which are involved in tumor progression. Therefore, HSP90 inhibitors represent potential new therapeutic agents for cancer. Furthermore, inhibition of HSP90 leads to degradation of client proteins, overcoming acquired anti-cancer drug resistance. In this study, we assessed the role of HSP90 in MDR using established melphalan-resistant MM cells. We found that expression of HSP90 was higher in melphalan-resistant MM cells than in parent cells and that HSP90 inhibitors KW-2478 and NUV-AUY922 restored drug sensitivity to the level observed in parent cells. Activation of the unfolded protein response is a hallmark of MM, and expression of endoplasmic reticulum stress signaling molecules is reduced in melphalan-resistant cells; however, KW-2478 did not affect endoplasmic reticulum stress signaling. We demonstrated that treatment with KW-2478 decreased expression of Src, a client of HSP90, and suppressed the activity of ERK, Akt, and NF-κB. Our findings indicate that inhibition of HSP90 results in suppression of Src and its downstream effectors, including ERK, Akt, and NF-κB, and therefore that HSP90 inhibitors could be useful for treatment of MDR MM.
  • Tetsuji Terazawa; Jin Matsuyama; Masahiro Goto; Ryohei Kawabata; Shunji Endo; Motohiro Imano; Shoichiro Fujita; Yusuke Akamaru; Hirokazu Taniguchi; Mitsutoshi Tatsumi; Sang-Woong Lee; Yoshitaka Kurisu; Hisato Kawakami; Yukinori Kurokawa; Toshio Shimokawa; Daisuke Sakai; Takeshi Kato; Kazumasa Fujitani; Taroh Satoh
    The oncologist 2019/09 [Refereed]
     
    LESSONS LEARNED: Perioperative capecitabine and oxaliplatin (CapeOx) therapy showed favorable efficacy with sufficient pathological response. Small sample size limited the statistical power of this result.Perioperative CapeOx therapy showed good feasibility.Further studies with larger sample size are required to validate this novel approach. BACKGROUND: D2 gastrectomy followed by adjuvant S-1 is the standard therapy for patients (pts) with stage III gastric cancer (GC) in Japan; however, the outcome is not satisfactory. We examined the efficacy of perioperative capecitabine and oxaliplatin (CapeOx) in pts with GC. METHODS: The eligibility criteria included confirmed clinical T3(SS)/T4a(SE) N1-3 M0 GC according to the Japanese Classification (JCGC; 3rd English Edition). Three cycles of neoadjuvant CapeOx (NAC; capecitabine, 2,000 mg/m2 for 14 days; oxaliplatin, 130 mg/m2 on day 1, every 3 weeks) were administered, followed by five cycles of adjuvant CapeOx (AC) after D2 gastrectomy. The primary endpoint was the pathological response rate (pRR) according to the JCGC (≥grade 1b). RESULTS: Thirty-seven pts were enrolled on CapeOx. An R0 resection rate of 78.4% (n = 29) and a pRR of 54.1% (n = 20, p = .058; 90% confidence interval [CI], 39.4-68.2) were demonstrated. Among 27 pts who initiated AC, 21 (63.6%) completed the treatment. Grade 3-4 toxicities during NAC included neutropenia (8%), thrombocytopenia (8%), and anorexia (8%) and during AC included neutropenia (37%), diarrhea (4%), and anorexia (4%). CONCLUSION: Perioperative CapeOx showed good feasibility and favorable efficacy with sufficient pathological response, although statistical significance at .058 did not reach the commonly accepted cutoff of .05. The data obtained using this novel approach warrant further investigations.
  • Tsubaki M; Takeda T; Obata N; Kawashima K; Tabata M; Imano M; Satou T; Nishida S
    Journal of cellular physiology 234 (10) 17975 - 17989 0021-9541 2019/08 [Refereed]
     
    Malignant melanoma is a highly aggressive skin cancer, and the overall median survival in patients with metastatic melanoma is only 6-9 months. Although molecular targeted therapies have recently been developed and have improved the overall survival, melanoma patients may show no response and acquisition of resistance to these drugs. Thus, other molecular approaches are essential for the treatment of metastatic melanoma. In the present study, we investigated the effect of cotreatment with dacarbazine and statins on tumor growth, metastasis, and survival rate in mice with metastatic melanomas. We found that cotreatment with dacarbazine and statins significantly inhibited tumor growth and metastasis via suppression of the RhoA/RhoC/LIM domain kinase/serum response factor/c-Fos pathway and enhanced p53, p21, p27, cleaved caspase-3, and cleaved poly(ADP-ribose) polymerase 1 expression in vivo. Moreover, the cotreatment significantly improved the survival rate in metastasis-bearing mice. Importantly, treatment with dacarbazine plus 100 mg/kg simvastatin or fluvastatin prevented metastasis-associated death in 4/20 mice that received dacarbazine + simvastatin and in 8/20 mice that received dacarbazine + fluvastatin (survival rates, 20% and 40%, respectively). These results suggested that cotreatment with dacarbazine and statins may thus serve as a new therapeutic approach to control tumor growth and metastasis in melanoma patients.
  • 食道癌に対する術前化学療法後のリンパ節における微小転移の臨床的意義
    平木 洋子; 木村 豊; 今野 元博; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 土岐 祐一郎; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 74回 P2 - 3 2019/07
  • 【食道】頸部〜頸胸境界部食道癌の治療戦略 当院における進行頸胸境界部食道癌の治療戦略とその成績
    白石 治; 加藤 寛章; 岩間 密; 平木 洋子; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 74回 WS1 - 2 2019/07
  • 胃粘膜下腫瘍に対する腹腔鏡下胃内手術について
    安田 篤; 木村 豊; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 74回 P42 - 6 2019/07
  • 【胃】切除不能胃癌に対するConversion Surgeryの現状 胃癌腹膜播種に対する腹腔内+全身化学療法奏功例に対するconversion手術の治療成績
    新海 政幸; 今野 元博; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 74回 WS3 - 8 2019/07
  • Hiroshi Nakano; Hiroshi Furukawa; Makoto Nakamuro; Yoshiaki Kondo; Kazuo Ishikawa; Yuhei Okubo; Masahiro Hoshimoto; Yoshio Oota; Takao Sato; Yutaka Kimura; Motohiro Imano; Takushi Yasuda
    Gan to kagaku ryoho. Cancer & chemotherapy 46 (3) 505 - 507 0385-0684 2019/03 [Refereed]
     
    We experienced a case of early gastric cancer. A 69-year-old woman with a thick gastric wall, thickened folds, and undifferentiated cancer cells in biopsy was diagnosed with scirrhous gastric cancer. The patient underwent total gastrectomy for scirrhous gastric cancer and was found to have only an early gastric cancer lesion located on the upper gastric wall. The thick wall diagnosed before surgery was diagnosed as angiodysplasia occupying the submucosal layer.
  • 胃がんに対する多職種チーム医療の役割 高齢者胃切除における嚥下リハビリ介入の有用性(The role of multidisciplinary team medical treatment for gastric cancer Perioperative intervention of dysphagia rehabilitation for elderly gastric cancer patients)
    安田 篤; 木村 豊; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 91回 233 - 233 2019/02
  • Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
    Clinical and experimental medicine 19 (1) 133 - 141 1591-8890 2019/02 [Refereed]
     
    The survival and growth of multiple myeloma (MM) cells are facilitated by cell-cell interactions with bone marrow stromal cells and the bone marrow microenvironment. These interactions induce de novo drug resistance known as cell adhesion-mediated drug resistance. Our previous results recently revealed that the receptor activator of NF-κB (RANK) ligand (RANKL), which is expressed by bone marrow stromal cells, contributes to anti-cancer drug resistance through the activation of various signaling molecules and suppression of Bim expression in RANK-expressing MM cells. However, the detailed mechanisms underlying RANKL-induced drug resistance remain uncharacterized. In the present study, we investigated the mechanism of RANKL-induced drug resistance in RANK-expressing MM cell lines. We found treatment of MM cells with RANKL-induced c-Src phosphorylation and activation of the downstream signaling molecules Akt, mTOR, STAT3, JNK, and NF-κB. In addition, treatment with dasatinib, a c-Src inhibitor, overcame RANKL- and bone marrow stromal cell-induced drug resistance to adriamycin, vincristine, dexamethasone, and melphalan by suppressing c-Src, Akt, mTOR, STAT3, JNK, and NF-κB activation and enhancing expression of Bim. Overall, RANKL- and bone marrow stromal cell-induced drug resistance correlated with the activation of c-Src signaling pathways, which caused a decrease in Bim expression. Dasatinib treatment of RANK-expressing MM cells re-sensitized them to anti-cancer drugs. Therefore, inhibition of c-Src may be a new therapeutic approach for overcoming RANKL-induced drug resistance in patients with MM.
  • Kimura Y; Mikami J; Makari Y; Fujii C; Hiraki Y; Imano M; Fujita J; Yasuda T
    Gan to kagaku ryoho. Cancer & chemotherapy 46 (2) 245 - 249 0385-0684 2019/02 [Refereed]
     
    BACKGROUND: Ramucirumab, an antiangiogenic agent, often causes proteinuria as a characteristic adverse effect. We retro- spectively evaluated proteinuria and clarified the significance of the protein/creatinine ratio by using single urine samples from patients with advanced gastric cancer who were treated with ramucirumab. METHODS: Twenty-three patients who received ramucirumabb etween June 2015 and April 2016 were enrolled. A total of 199 urinalysis specimens were qualitatively analyzed to obtain urine protein levels and the protein/creatinine ratio, and the values were compared. RESULTS: Frequency of proteinu- ria was 43.5%(grade 1: 26.1%, grade 2: 8.7%, and grade 3: 8.7%). The protein/creatinine ratio was less than 2 in -, ±, and 1+ based on the urine protein qualitative examination; 12.5% of 2+ and 71.4% of 3+ or 4+ had a protein/creatinine ratio over 2. CONCLUSIONS: In patients with gastric cancer, treated with ramucirumab, the protein/creatinine ratio should be examined in cases of 2+, 3+ or 4+ via a qualitative examination.
  • Tsubaki M; Takeda T; Tomonari Y; Koumoto YI; Imano M; Satou T; Nishida S
    Laboratory investigation; a journal of technical methods and pathology 99 (1) 72 - 84 0023-6837 2019/01 [Refereed]
     
    Multiple myeloma (MM) commonly displays multidrug resistance and is associated with poor prognosis. Therefore, it is important to identify the mechanisms by which MM cells develop multidrug resistance. Our previous study showed that multidrug resistance is correlated with overexpression of multidrug resistance protein 1 (MDR1) and Survivin, and downregulation of Bim expression in melphalan-resistant RPMI8226/L-PAM cells; however, the underlying mechanism of multidrug resistance remains unclear. In the present study, we investigated the mechanism of multidrug resistance in melphalan-resistant cells. We found that RPMI8226/L-PAM and ARH-77/L-PAM cells showed increased phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) and Akt, and nuclear localization of nuclear factor κB (NF-κB). The combination of ERK1/2, Akt, and NF-κB inhibitors with melphalan reversed melphalan resistance via suppression of Survivin expression and enhanced Bim expression in melphalan-resistant cells. In addition, RPMI8226/L-PAM and ARH-77/L-PAM cells overexpressed hypoxia-inducible factor 1α (HIF-1α) via activation of ERK1/2, Akt, and NF-κB. Moreover, suppression of HIF-1α by echinomycin or HIF-1α siRNA resensitized RPMI8226/L-PAM cells to melphalan through downregulation of Survivin expression and upregulation of Bim expression. These results indicate that enhanced Survivin expression and decreased Bim expression by HIF-1α via activation of ERK1/2, Akt, and NF-κB play a critical role in melphalan resistance. Our findings suggest that HIF-1α, ERK1/2, Akt, and NF-κB inhibitors are potentially useful as anti-MDR agents for the treatment of melphalan-resistant MM.
  • Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    Journal of surgical oncology 119 (1) 56 - 63 0022-4790 2019/01 [Refereed]
     
    BACKGROUND: We carried out a phase II trial to evaluate the feasibility and efficacy of neoadjuvant chemotherapy comprising a single intraperitoneal administration of paclitaxel, followed by intravenous administrations of paclitaxel and cisplatin with S-1 for clinical stage III gastric cancer. METHODS: Patients with potentially resectable gastric cancer were eligible. A laparoscopic survey was performed to confirm CY0 and P0. Intraperitoneal paclitaxel (60 mg/m 2 ) was administered, followed by systemic chemotherapy. Surgery was performed after two cycles of chemotherapy. The primary endpoint was the response rate of chemotherapy. Secondary endpoints were adverse events, pathological response rate, and overall survival rate. RESULTS: Twenty patients were enrolled. Planned cycles were completed in all patients. Grade 3/4 leukopenia and grade 3/4 neutropenia were observed in four (20%) and seven (35%) patients, respectively. The overall response rate was 70% (partial response: 14, stable disease: 5, progressive disease: 1). All patients underwent R0 gastrectomy with D2 lymph-node dissection, with no surgery-related deaths. The pathological response rate was 65% (13 of 20). The 3- and 5-year overall survival rates were 90.0% and 77.1%, respectively. CONCLUSIONS: Neoadjuvant chemotherapy including intraperitoneal paclitaxel followed by sequential intravenous paclitaxel and cisplatin with S-1 for resectable advanced gastric cancer is feasible and effective.
  • Kimura Y; Shiraishi O; Kawakami H; Ueda H; Okuno T; Hiraki Y; Kato H; Iwama M; Yasuda A; Shinkai M; Chikugo T; Imano M; Imamoto H; Nakagawa K; Yasuda T
    Gan to kagaku ryoho. Cancer & chemotherapy 45 (13) 1812 - 1814 0385-0684 2018/12 [Refereed]
     
    A 71-year-old man with a history of hypertension, diabetes mellitus, and cerebral infarction was admitted to our hospital with dysphagia. Gastroduodenoscopy, thoracoabdominal CT, and PET-CT findings showed type 2 advanced esophageal cancer( squamous cell carcinoma)with upper mediastinal and cervical lymph node(LN)metastasis: cT3N2M1(LYM #104L), cStage Ⅳ. Two courses of neoadjuvant UDONchemotherapy containing 5-FU(640mg/m / 2, days 1-5), docetaxel(28mg/m2, days 1 and 15), and nedaplatin(72mg/m2, day 1)were administered every 4 weeks. UDONtherapy caused grade(Gr)3 febrile neutropenia, Gr 2 diarrhea, and Gr 1 thrombopenia; the tumor and LNs partially responded to the therapy. After 2 courses of UDONtherapy, esophagectomy with right thoracotomy, 3-field LNdissection, and reconstruction of the gastric tube were performed. The postoperative course was almost uneventful besides recurrent nerve palsy, aspiration, pneumonia, and delirium, and the patient was discharged 60 days after surgery. The pathological diagnosis was ypT0N0M0, ypStage 0, and the histological response of the primary tumor and LNs were evaluated as Gr 3. Neoadjuvant UDON therapy is feasible for elderly patients with advanced esophageal cancer and renal failure or comorbidities, for whom CDDP could not be administered. We are planning a clinical trial to assess the effectiveness of neoadjuvant UDONtherapy.
  • Hiraki Y; Kimura Y; Imano M; Yasuda A; Kato H; Iwama M; Shiraishi O; Shinkai M; Imamoto H; Furukawa H; Yasuda T
    Gan to kagaku ryoho. Cancer & chemotherapy 45 (13) 2381 - 2383 0385-0684 2018/12 [Refereed]
     
    The usefulness of intraperitoneal(IP)chemotherapy for gastric cancer with intraperitoneal metastasis has been examined in some clinical trials. We report a case of intestinal perforation caused by a catheter for IP ports. A 75-year-old man had undergone IP therapy for type 4 gastric cancer. After IP therapy, he underwent total gastrectomy. He had no recurrence for 3 years. He complained of high fever and abdominal pain more than 1 week ago. Based on contrast-enhanced CT, we diagnosed him with peritonitis by intestinal perforation due to the catheter, and on the same day, we removed the catheter and performed intraperitoneal drainage by emergent laparotomy. The tube penetrated the ileum 20 cm from the ileocecal portion. We resected the ileocecal area and damaged intestinal tract and removed the subcutaneous IP port. He was discharged on the 25th postoperative day. IP ports should be removed after the completion of IP chemotherapy because the incidence of perforation by IP ports was reported as 0 to 3.5%in a previous report.
  • 進行食道癌における気管前106pre LN郭清手技のコツと安全性
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 木村 豊; 今野 元博
    日本消化器外科学会雑誌 (一社)日本消化器外科学会 51 (Suppl.2) 142 - 142 0386-9768 2018/11
  • 高用量CDDPの使用が困難な進行食道癌患者に対する術前化学療法の検討
    木村 豊; 白石 治; 川上 尚人; 植田 勲人; 奥野 達哉; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 中川 和彦; 安田 卓司
    日本消化器外科学会雑誌 (一社)日本消化器外科学会 51 (Suppl.2) 268 - 268 0386-9768 2018/11
  • Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
    MASAYUKI SHINKAI; MOTOHIRO IMANO; YASUTAKA CHIBA; MITSURU IWAMA; OSAMU SHIRAISHI; ATSUSHI YASUDA; MASAHIRO TSUBAKI; SHOZO NISHIDA; YUTAKA KIMURA; TAKUSHI YASUDA
    J Surg Oncol. 119 (1) 56 - 63 2018/11 [Refereed]
  • Tsubaki M; Takeda T; Matsumoto M; Kato N; Yasuhara S; Koumoto Y; Imano M; Satou T; Nishida S
    Tumour Biol. 40 (10) 1010428318808670 - 1010428318808670 1010-4283 2018/10 [Refereed]
     
    Chemotherapy-induced neuropathy is a highly problematic, dose-limiting effect of potentially curative regimens of cancer chemotherapy. When neuropathic pain is severe, patients often either switch to less-effective chemotherapy agents or choose to discontinue chemotherapy entirely. Conventional chemotherapy drugs used to treat lung and breast cancer, multiple myeloma, and lymphoma include paclitaxel, vincristine, and bortezomib. Approximately 68% of patients receiving these anticancer drugs develop neuropathy within the first month of treatment, and while strategies to prevent chemotherapy-induced neuropathy have been investigated, none have yet been proven as effective. Recent reports suggest that chemotherapy-induced neuropathy is associated with signal transduction molecules, including protein kinase C and mitogen-activated protein kinases. It is currently unclear whether protein kinase C inhibition can prevent chemotherapy-induced neuropathy. In this study, we found that tamoxifen, a protein kinase C inhibitor, suppressed paclitaxel-, vincristine-, and bortezomib-induced cold and mechanical allodynia in mice. In addition, chemotherapy drugs induce neuropathy via the protein kinase C/extracellular signal-regulated kinase pathway in the spinal cord in lumbar segments 4-6 and dorsal root ganglions. In addition, tamoxifen was shown to act synergistically with paclitaxel to inhibit tumor-growth in mice injected with tumor cells. Our results indicated that paclitaxel-, vincristine-, and bortezomib-induced neuropathies were associated with the protein kinase C/extracellular signal-regulated kinase pathway in the lumbar spinal cord and dorsal root ganglions, which suggest that protein kinase C inhibitors may be therapeutically effective for the prevention of chemotherapy-induced neuropathy when administered with standard chemotherapy agents.
  • MASAYUKI SHINKAI; MOTOHIRO IMANO; YASUTAKA CHIBA; YOKO HIRAKI
    ANTICANCER RESEARCH 38 (10) 5975 - 5981 0250-7005 2018/10 [Refereed]
     
    AIM: To conduct a phase II study of single intraperitoneal (i.p.) administration of paclitaxel followed by paclitaxel, cisplatin, and S-1 (PCS) chemotherapy for patients with gastric cancer with peritoneal metastasis (PM). PATIENTS AND METHODS: Staging laparotomy was performed to confirm PM. Initially, patients received i.p. paclitaxel. Beginning 7 days later, PCS was given every 3 weeks followed by second-look laparoscopy. Primary and secondary endpoints were the overall survival (OS) rate, and response rate and patient safety, respectively. RESULTS: Seventeen patients were enrolled. The overall response rate was 70.5% (12/17). Grade 3/4 toxic effects included neutropenia and leukopenia. After chemotherapy, PM disappearance was confirmed in 11 patients. Gastrectomy was eventually performed in 11 patients. The 1-year OS rate was 82.4% and the median survival time was 23.9 months considering the overall cohort. CONCLUSION: Combination chemotherapy with i.p. paclitaxel and PCS is well tolerated and effective in patients with gastric cancer with PM.
  • MASAYUKI SHINKAI; MOTOHIRO IMANO; YASUTAKA CHIBA; YOKO HIRAKI
    ANTICANCER RESEARCH 38 (10) 5969 - 5974 0250-7005 2018/10 [Refereed]
     
    BACKGROUND/AIM: A preliminary study evaluating the feasibility of single intraperitoneal (IP) administration of paclitaxel followed by paclitaxel and cisplatin with S-1 (PCS) systemic chemotherapy for cytology-positive (CY1) gastric cancer. PATIENTS AND METHODS: Staging laparoscopy was performed to confirm CY1 and P0 status. Initially, patients received IP paclitaxel. Beginning 7 days later PCS was given every 3 weeks followed by second-look laparoscopy. RESULTS: Nine patients were enrolled. The toxic effects of IP and systemic chemotherapy were acceptable. After chemotherapy, 8 patients converted from CY1P0 to CY0P0 and 1 patient from CY1P0 to CY1P1. Gastrectomy was performed on 8 patients except for the CY1P1 patient. Four patients were alive without recurrence. The 2-year overall and progression-free survival rates were 76% and 65%, respectively. CONCLUSION: Combination chemotherapy with IP paclitaxel and sequential PCS is safe and may be effective for CY1 gastric cancer.
  • 開腹手技の継承により鏡視下手術への導入を容易にする改良型食道残胃吻合法
    安田 篤; 木村 豊; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 73回 469 - 469 2018/07
  • 胸部食道癌に対する縦隔側からの101-106recリンパ節徹底郭清
    白石 治; 加藤 寛章; 岩間 密; 平木 洋子; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 73回 657 - 657 2018/07
  • 胃癌腹膜播種症例に対するconversion surgeryの意義
    今野 元博; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 木村 豊; 今本 治彦; 古河 洋; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 73回 796 - 796 2018/07
  • 胃癌腹膜播種に対するPTX腹腔内投与+PCS全身化学療法による集学的治療の可能性
    新海 政幸; 今野 元博; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 73回 1005 - 1005 2018/07
  • 胃癌腹膜転移に対する腹腔内化学療法における腹腔内アクセスポート関連合併症の報告
    平木 洋子; 今野 元博; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 木村 豊; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 73回 1041 - 1041 2018/07
  • Tsubaki M; Takeda T; Matsumoto M; Kato N; Asano RT; Imano M; Satou T; Nishida S
    Am J Cancer Res. 8 (7) 1239 - 1248 2156-6976 2018/07 [Refereed]
     
    Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of some anti-cancer drugs and leads to discontinuation of chemotherapy and detrimental dose reductions, thereby affecting the quality of life of cancer patients. Currently, no treatment can effectively prevent or treat chemotherapy-induced neuropathy. Therefore, understanding its underlying molecular mechanisms may help to identify novel therapies for treating it. Some disease-induced neuropathy involve the activation of mitogen-activated protein kinases (MAPKs), such as extracellular-regulated protein kinase 1/2 (ERK1/2). In the present study, we investigated whether ERK1/2 inhibition can prevent chemotherapy-induced neuropathy. We found that trametinib, an MEK inhibitor, suppressed oxaliplatin-, paclitaxel-, vincristine-, and bortezomib-induced cold and mechanical allodynia in mice. In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation. In conclusion, we demonstrated that the disruption of this pathway by MEK inhibitors suppresses oxaliplatin-, paclitaxel-, vincristine-, and bortezomib-induced neuropathy. This suggests that inhibition of the MEK/ERK pathway could prevent chemotherapy-induced neuropathy and MEK inhibitors could be used in combination with anti-tumor drugs during pharmacotherapy.
  • Ishigami H; Fujiwara Y; Fukushima R; Nashimoto A; Yabusaki H; Imano M; Imamoto H; Kodera Y; Uenosono Y; Amagai K; Kadowaki S; Miwa H; Yamaguchi H; Yamaguchi T; Miyaji T; Kitayama J
    J-Clin Oncol 36 (19) 1922 - 1929 0732-183X 2018/07 [Refereed]
     
    Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (< 2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 plus S-1 80 mg/m2 per day on days 1 to 14 for a 3-week cycle) or S-1 plus cisplatin (SP; S-1 80 mg/m2 per day on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 for a 5-week cycle), stratified by center, previous chemotherapy, and extent of peritoneal metastasis. The primary end point was overall survival. Secondary end points were response rate, 3-year overall survival rate, and safety. Results We enrolled 183 patients and performed efficacy analyses in 164 eligible patients. Baseline characteristics were balanced between the arms, except that patients in the IP arm had significantly more ascites. The median survival times for the IP and SP arms were 17.7 and 15.2 months, respectively (hazard ratio, 0.72; 95% CI, 0.49 to 1.04; stratified log-rank P = .080). In the sensitivity analysis adjusted for baseline ascites, the hazard ratio was 0.59 (95% CI, 0.39 to 0.87; P = .008). The 3-year overall survival rate was 21.9% (95% CI, 14.9% to 29.9%) in the IP arm and 6.0% (95% CI, 1.6% to 14.9%) in the SP arm. Both regimens were well tolerated. Conclusion This trial failed to show statistical superiority of intraperitoneal paclitaxel plus systemic chemotherapy. However, the exploratory analyses suggested possible clinical benefits of intraperitoneal paclitaxel for gastric cancer.
  • Masanobu Tsubaki; Tomoya Takeda; Yoshika Tomonari; Kenji Mashimo; Yu-Ichi Koumoto; Sachi Hoshida; Tatsuki Itoh; Motohiro Imano; Takao Satou; Katsuhiko Sakaguchi; Shozo Nishida
    Journal of cellular physiology 233 (5) 4258 - 4271 0021-9541 2018/05 [Refereed]
     
    Several autocrine soluble factors, including macrophage inflammatory protein-1α (MIP-1α), tumor necrosis factor-α, and hepatocyte growth factor, promote cell survival and growth in multiple myeloma (MM) cells. We hypothesized that inhibition of the MIP-1α autocrine loop may enhance the cytotoxic effect of anticancer drugs in MM cell lines. In the present study, an MIP-1α neutralizing antibody suppressed cell proliferation and enhanced the cytotoxic effect of melphalan or bortezomib on MM cells. In addition, melphalan resistance cells (RPMI8226/L-PAM and HS-sultan/L-PAM cells) secreted MIP-1α and neutralizing antibody of MIP-1α partially overcame melphalan resistance. Moreover, combination treatment with MIP-1α neutralizing antibody and melphalan or bortezomib inhibited extracellular signal regulated kinase 1/2 (ERK1/2), Akt, and mammalian target of rapamycin (mTOR) activation, Bcl-2, Bcl-xL, and Survivin expression, and upregulated the expression of Bim and cleaved Poly (ADP-ribose) polymerase (PARP). Treatment of IM9 cells with MIP-1α siRNA suppressed the activation of ERK1/2, Akt, and mTOR, and enhanced the cytotoxic effect of melphalan and bortezomib. These results indicate that MIP-1α neutralizing antibodies or MIP-1α siRNA enhance the cytotoxic effect of melphalan and bortezomib by suppressing the chemokine receptor/ERK and chemokine receptor/Akt/mTOR pathways. The inhibition of MIP-1α may thus provide a new therapeutic approach to control tumor progression and bone destruction in patients with MM.
  • Tomoya Takeda; Masanobu Tsubaki; Yoshika Tomonari; Keishi Kawashima; Tatsuki Itoh; Motohiro Imano; Takao Satou; Shozo Nishida
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 100 486 - 494 0753-3322 2018/04 [Refereed]
     
    Bavachin is a phytoestrogen purified from natural herbal plants such as Psoralea corylifolia. In this study, we examined the effect of bavachin in multiple myeloma (MM) cell lines. We found that bavachin decreased the viability of MM cell lines, but was not cytotoxic towards normal cells. It inhibited the activation of nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3). Furthermore, bavachin increased the expression of p53 and NOXA, and decreased the expression of X-linked inhibitor of apoptosis protein (XIAP), survivin, B cell lymphoma-extra large (Bcl-xL), and Bcl-2. Additionally, bavachin induced apoptosis by the activation of caspase-3 and caspase-9, implicating the involvement of the mitochondrial pathway. Our results suggest that bavachin induces apoptosis through the inhibition of NF-κB and STAT3 activation in MM cell lines. Most importantly, few NF-κB and STAT3 inhibitors with high efficiency, specificity, and safety are currently available for clinical cancer therapy. Hence, bavachin, which targets NF-κB and STAT3, is a potential anticancer agent for the treatment of MM.
  • Masanobu Tsubaki; Tomoya Takeda; Yoshika Tomonari; Keishi Kawashima; Tatsuki Itoh; Motohiro Imano; Takao Satou; Shozo Nishida
    Journal of cellular physiology 233 (4) 3638 - 3647 0021-9541 2018/04 [Refereed]
     
    Pioglitazone is an anti-diabetic agent that belongs to the thiazolidinedione class, which target peroxisome proliferator-activated receptor γ (PPARγ), a transcription factor in the nuclear receptor family. Different cancer cells expressing high levels of PPARγ and PPARγ ligands induce cell cycle arrest, cell differentiation, and apoptosis. However, the mechanisms underlying these processes remain unknown. Here, we investigated the mechanism underlying pioglitazone-induced apoptosis in human cancer cells. We showed that at similar concentrations, pioglitazone induced death in cancer cells expressing high or low levels of PPARγ. Combined treatment of pioglitazone and GW9662, a PPARγ antagonist, did not rescue this cell death phenotype. Z-VAD-fmk, a pan-caspase inhibitor, did not reverse pioglitazone-induced apoptosis in cancer cells expressing PPARγ at high or low levels. Pioglitazone suppressed the activation of signal transducers and activator of transcription 3 (STAT3) and Survivin expression, and enhanced the apoptosis-inducing factor (AIF) levels in these cells. Furthermore, pioglitazone enhanced the cytotoxic effect of cisplatin and oxaliplatin by suppressing Survivin and increasing AIF expression. These results indicated that pioglitazone induced apoptosis via a PPARγ-independent pathway, thus describing pioglitazone as a potential therapeutic agent for controlling the progression of different cancers.
  • Naoto Takahashi; Mitsuro Kanda; Takaki Yoshikawa; Nobuhiro Takiguchi; Kazumasa Fujitani; Katsufumi Miyamoto; Yuichi Ito; Osamu Takayama; Motohiro Imano; Norio Mitsumori; Junichi Sakamoto; Satoshi Morita; Yasuhiro Kodera
    Gastric Cancer Springer Tokyo 21 (6) 1 - 10 1436-3305 2018/03 [Refereed]
     
    Background: Intraperitoneal administration of paclitaxel had been considered a promising option to treat peritoneal metastasis, the most frequent pattern of recurrence in gastric cancer after D2 gastrectomy, but its safety and efficacy after gastrectomy had not been fully explored. Methods: A phase II randomized comparison of postoperative intraperitoneal (IP) vs. intravenous (IV) paclitaxel was conducted. Patients with resectable gastric linitis plastica, cancer with minimal amount of peritoneal deposits (P1), or cancer positive for the peritoneal washing cytology (CY1) were eligible. After intraoperative confirmation of the above disease status and of resectability, patients were randomized to be treated either by the IP therapy (paclitaxel 60 mg/m2 delivered intraperitoneally on days 0, 14, 21, 28, 42, 49, and 56) or the IV therapy (80 mg/m2 administered intravenously using the identical schedule) before receiving further treatments with evidence-based systemic chemotherapy. The primary endpoint was 2-year survival rate. Results: Of the 86 patients who were randomized intraoperatively, 83 who actually started the protocol treatment were eligible for analysis (n = 39, IP group n = 44, IV group). The 2-year survival rate of the IP and IV groups was 64.1% (95% CI 47.9–76.9) and 72.3% (95% CI 56.3–83.2%), respectively (p = 0.5731). The IP treatment did not confer significant overall or progression-free survival benefits, and was associated with particularly poor performance in patients with residual disease, including the CY1 P0 population. Conclusions: We were unable to prove superiority of the IP paclitaxel over IV paclitaxel delivered after surgery to control advanced gastric cancer with high risk of peritoneal recurrence.
  • Naoto Takahashi; Mitsuro Kanda; Takaki Yoshikawa; Nobuhiro Takiguchi; Kazumasa Fujitani; Katsufumi Miyamoto; Yuichi Ito; Osamu Takayama; Motohiro Imano; Norio Mitsumori; Junichi Sakamoto; Satoshi Morita; Yasuhiro Kodera
    Gastric Cancer Springer Tokyo 21 (6) 1 - 10 1436-3305 2018/03 [Refereed]
     
    Background: Intraperitoneal administration of paclitaxel had been considered a promising option to treat peritoneal metastasis, the most frequent pattern of recurrence in gastric cancer after D2 gastrectomy, but its safety and efficacy after gastrectomy had not been fully explored. Methods: A phase II randomized comparison of postoperative intraperitoneal (IP) vs. intravenous (IV) paclitaxel was conducted. Patients with resectable gastric linitis plastica, cancer with minimal amount of peritoneal deposits (P1), or cancer positive for the peritoneal washing cytology (CY1) were eligible. After intraoperative confirmation of the above disease status and of resectability, patients were randomized to be treated either by the IP therapy (paclitaxel 60 mg/m2 delivered intraperitoneally on days 0, 14, 21, 28, 42, 49, and 56) or the IV therapy (80 mg/m2 administered intravenously using the identical schedule) before receiving further treatments with evidence-based systemic chemotherapy. The primary endpoint was 2-year survival rate. Results: Of the 86 patients who were randomized intraoperatively, 83 who actually started the protocol treatment were eligible for analysis (n = 39, IP group n = 44, IV group). The 2-year survival rate of the IP and IV groups was 64.1% (95% CI 47.9–76.9) and 72.3% (95% CI 56.3–83.2%), respectively (p = 0.5731). The IP treatment did not confer significant overall or progression-free survival benefits, and was associated with particularly poor performance in patients with residual disease, including the CY1 P0 population. Conclusions: We were unable to prove superiority of the IP paclitaxel over IV paclitaxel delivered after surgery to control advanced gastric cancer with high risk of peritoneal recurrence.
  • 腹腔鏡下胃全摘と比較した腹腔鏡下噴門側胃切除(食道残胃吻合)のメリット(残胃を残す意義)(Advantage of proximal gastrectomy compared with total gastrectomy in laparoscopic surgery)
    安田 篤; 木村 豊; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 90回 283 - 283 2018/03
  • Masanobu Tsubaki; Tomoya Takeda; Ryo-Ta Asano; Tomoyuki Matsuda; Shin-Ichiro Fujimoto; Tatsuki Itoh; Motohiro Imano; Takao Satou; Shozo Nishida
    Toxicology in vitro : an international journal published in association with BIBRA 46 284 - 293 0887-2333 2018/02 [Refereed]
     
    Oral mucositis is a common adverse effect of chemotherapy that limits the required dose of chemotherapeutic agents. Numerous attempts to mitigate chemotherapy-induced oral mucositis have failed to identify an appropriate treatment. Recently, it has been indicated that rebamipide prevents chemoradiotherapy-induced oral mucositis in patients. However, the details of the underlying mechanism involved in the cytoprotective effect of rebamipide remain obscure. In the present study, we investigated the mechanism behind rebamipide cytoprotective effect in the oral mucosa using primary normal human oral keratinocytes (NHOK cells). We found that rebamipide prevented 5-fluorouracil (5-FU)-induced cell death in NHOK cells. In addition, rebamipide increased the levels of phosphorylated Akt and mTOR, enhanced the Bcl-2 and Bcl-xL expressions, and suppressed the expression of Bax and Bim. This is in contrast to 5-FU-induced suppression of Akt and mTOR activation, Bcl-2 and Bcl-xL expressions, and the enhanced expression of Bax and Bim. These findings suggest that rebamipide can potentially be used for the protection of oral mucosa from chemotherapy-induced mucositis. This is the first study that elucidates the specific molecular pathway for the cytoprotective effect of rebamipide.
  • Kazuhiro Nishikawa; Toru Aoyama; Mari S. Oba; Takaki Yoshikawa; Chu Matsuda; Yoshinori Munemoto; Nobuhiro Takiguchi; Kazuaki Tanabe; Naoki Nagata; Motohiro Imano; Mitsuru Oshiro; Ryoji Fukushima; Masato Kataoka; Satoshi Morita; Akira Tsuburaya; Hideyuki Mishima; Toru Kono; Junichi Sakamoto
    Journal of Cancer Ivyspring International Publisher 9 (10) 1725 - 1730 1837-9664 2018 [Refereed]
     
    Background: The current pooled analysis evaluated the efficacy of Hangeshashinto (TJ-14) in the prevention and/or treatment of chemotherapy-induced oral mucositis (COM) in gastric cancer and colorectal cancer using two prospective, multi-institutional, randomized, double-blind, placebo-controlled phase II trials. Patients and Methods: HANGESHA-G and HANGESHA-C randomly assigned patients with gastric cancer or colorectal cancer who developed moderate to severe COM (grade ≥1) during any cycle of chemotherapy to receive either TJ-14 or a placebo as a double-blind trial. The patients received a placebo or TJ-14 for four to six weeks, according to the chemotherapy regimen, from the start of their next course of chemotherapy. The primary endpoint was the incidence of grade ≥2 COM in the protocol treatment course, and the secondary endpoints were the time to disappearance of COM and the incidence of adverse events. Results: The pooled population included 181 patients. The incidence of grade ≥2 COM in the TJ-14 group was 55.7% (49 patients), while that in the placebo group was 53.8% (50 patients) there was no significant difference between the two groups (p = 0.796). The median time to remission of grade ≥2 COM to grade < 1 was 8 days in the TJ-14 group and 15 days in the placebo group (p = 0.072). The hazard ratio was 1.54 [1.02 to 2.31] in favor of TJ-14. Treatment with TJ-14 was associated with marginally significant reduction in the duration of severe grade ≥2 COM in comparison to patients receiving placebo indicating the effect of TJ-14 in reducing the severity of COM. Conclusion: The present-pooled analysis showed that TJ-14 had a treatment effect in gastric cancer and colorectal cancer patients with COM in comparison to a placebo. Further phase III studies with a larger sample size are needed to clarify the protective effects of TJ-14 against COM.
  • 平木洋子; 木村豊; 今野元博; 安田篤; 加藤寛章; 岩間密; 白石治; 新海政幸; 今本治彦; 古河洋; 安田卓司
    癌と化学療法 (株)癌と化学療法社 45 (13) 2381 - 2383 0385-0684 2018 [Refereed]
     
    腹腔内転移を伴う胃癌に対する治療法として、腹腔内化学療法(IP療法)の有用性が臨床試験で検証されている。今回われわれは、IPポートのカテーテルによる腸管穿孔の症例を経験したので報告する。症例は75歳、男性。4型胃癌に対してIP療法施行後、胃全摘出術を施行し術後化学療法を行い、再発なく経過観察中であった。1週間前よりの発熱、腹痛を主訴に受診し造影CT検査を施行したところ、カテーテルの腸管への穿通を認めた。カテーテルによる腸管穿孔からの腹膜炎と診断し、同日カテーテル抜去、腹腔内ドレナージ術を施行した。チューブは回盲部から20cm口側の回腸に穿通していた。回盲部と損傷腸管を切除、皮下ポートを抜去した。術後25日目に退院となった。以前の報告ではIPポートのカテーテルによる腸管穿孔の頻度は0〜3.5%と報告されており、まれではあるが発生すると致命的な合併症となり得る。化学療法が終了した患者の腹腔内アクセスポートは、可能な限り早期に抜去することが望ましいと考えられる。(著者抄録)
  • スキルス胃がんが疑われた早期胃癌の切除例
    中野博史; 古河洋; 中室誠; 近藤禎晃; 大久保遊平; 星本真弘; 太田善夫; 佐藤隆夫; 木村豊; 今野元博; 安田卓司
    癌と化学療法 45 (12) 2018 [Refereed]
  • Yasuda A; Yasuda T; Kato H; Iwama M; Shiraishi O; Hiraki Y; Tanaka Y; Shinkai M; Imano M; Kimura Y; Imamoto H
    Surgical case reports 3 (1) 79 - 79 2017/12 [Refereed]
     
    BACKGROUND: An incisional hernia in a case of antethoracic pedicled jejunal flap esophageal reconstruction after esophagectomy is a very rare occurrence, and this hernia was distinctive in that the reconstructed jejunum had passed through the hernial orifice; a standard surgical treatment for such a presentation has not been established. Herein, we describe a case of repair using mesh prosthesis for an atypical and distinctive incisional hernia after antethoracic pedicled jejunal flap esophageal reconstruction. CASE PRESENTATION: A 77-year-old woman with a history of subtotal esophagectomy who had undergone antethoracic pedicled jejunal flap reconstruction complained of epigastric prominence and discomfort without pain. On examination, she had an abdominal protrusion between the xiphoid process and the umbilicus that contained the small bowel. Computed tomography showed that the fenestration of the abdominal wall that was intentionally created for jejunum pull-up was dehisced in a region measuring 9 × 15 cm and the small intestine protruded through it into the subcutaneous space without strangulation. Because the hernial orifice was too large and the reconstructed jejunum was passing through the hernial orifice in this case, we applied a parastomal hernia repair method that was modified from the inguinal hernia repair using the Lichtenstein technique. After 3 years and 5 months following surgery, the patient has recovered without hernia recurrence or other complications. CONCLUSION: We consider this to be the first case of repair using Composix mesh prosthesis for repair of an atypical and distinctive incisional hernia after an antethoracic pedicled jejunal flap reconstruction. This method seems to be useful and could potentially be widely adopted as the surgical treatment for this condition.
  • 古河 洋; 中室 誠; 中野 博史; 近藤 禎晃; 石川 和男; 大久保 遊平; 今野 元博; 安田 卓司; 木村 豊; 今本 治彦; 新海 政幸; 安田 篤; 白石 治; 岩間 密; 加藤 寛章
    癌と化学療法 (株)癌と化学療法社 44 (12) 1077 - 1079 0385-0684 2017/11 
    4型胃がん(スキルス胃がん)のなかに、「診断困難な症例」が少なからず存在する。内視鏡検査で粘膜面から異常が指摘できないもの、内視鏡では"太い襞"がありスキルス胃がんであるが、生検でがん組織が得られない場合である。患者は85歳、男性。太い雛壁がありスキルス胃がんと診断されたが、生検でがん組織が得られず当院に紹介された。狭窄があるため、開腹による精査と治療を説明し実施した。開腹により適切な診断ができ、本人の希望どおりに手術(胃全摘)を行った。術後化学療法なしに1年生存中である。スキルス胃がんは内視鏡生検の結果だけに頼らず試験開腹まで行って早期に診断を付け、治療を開始すべきである。(著者抄録)
  • 木村 豊; 間狩 洋一; 三上 城太; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 藤田 淳也; 古河 洋; 安田 卓司
    癌と化学療法 (株)癌と化学療法社 44 (12) 1080 - 1082 0385-0684 2017/11 
    はじめに:進行再発胃癌の二次治療として推奨されているramucirumab(RAM)+paclitaxel(PTX)療法の特徴的な有害事象(AE)として蛋白尿があげられる。今回、RAM+PTX療法によりgrade(gr)3の蛋白尿を来したためRAMを中止し、PTX単剤を続行し、奏効を得た高齢の再発胃癌の1例を経験した。症例:77歳、女性。76歳時に胃癌のため幽門側胃切除術、D2郭清を施行され、粘液癌、T4aN3H0P0CY0M0、fStage IIICであった。S-1による1年間の補助化学療法後、術後1年4ヵ月目に腹膜転移再発を来した。二次治療としてRAM(8mg/kg:第1、15日)+PTX(80mg/m2:第1、8、15日)を開始した。2コース目にgr3の尿蛋白(定性3+、尿中蛋白/Cr比8.30)を認めたためRAMを中止し、以後はPTX単剤の投与を施行した。RAM中止後に蛋白尿は速やかに改善し、2コース後のCT検査で腹水は減少、4コース後には腹水は消失した。考察:RAMの適正使用ガイドでは、投与前には尿蛋白定性検査を行い、2+以上では尿蛋白定量検査を行い、3g以上では投与の中止が推奨されている。本症例では、適正使用ガイドに則りPTX単剤を続行することによって奏効を得た。(著者抄録)
  • 新海 政幸; 今野 元博; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本 治彦; 古河 洋; 安田 卓司
    癌と化学療法 (株)癌と化学療法社 44 (12) 1355 - 1357 0385-0684 2017/11 
    背景と目的:CY1P0胃癌の予後を改善する目的にpaclitaxel(PTX)腹腔内投与とPTX、cisplatin(CDDP)、S-1(PCS)3剤による全身化学療法を施行したので報告する。対象と方法:審査腹腔鏡によりCY1P0と診断した症例に対し、PTX腹腔内投与、逐次化学療法としてPCS療法を施行。2コース施行時にRECIST評価法にてPDでなければ、再度審査腹腔鏡を施行した。結果:症例は4例、腹腔内投与および全身化学療法によるGrade3以上の有害事象として1例に白血球減少、好中球減少を認めた。奏効度はPR1例、SD3例。全例に再度審査腹腔鏡を施行した。4例ともCY0P0にdown stageしていたため、D2郭清を伴う胃切除術を施行した。術後合併症は食道空腸吻合部の縫合不全1例と膵液瘻1例を認めた。組織学的治療効果判定はGrade 1a 3例、Grade 1b 1例。長期成績:肝再発1例、#16リンパ節再発を1例に認め原病死するも腹膜再発はなく、残り2例は無再発生存中である。結語:P0CY1胃癌に対する本治療法の有害事象は認容範囲であり、長期生存例も認めた。(著者抄録)
  • 岩間 密; 木村 豊; 白石 治; 加藤 寛章; 平木 洋子; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    癌と化学療法 (株)癌と化学療法社 44 (12) 1720 - 1722 0385-0684 2017/11 
    気管に浸潤したT4食道癌に対し化学放射線療法(CRT)と化学療法による集学的治療により、R0切除し得た症例を経験したので報告する。症例は75歳、男性。嗄声を自覚し、上部消化管内視鏡検査で胸部上部(Ut)に3型腫瘍を認め、CT検査でNo.106recRリンパ節(LN)の胸膜・気管浸潤を認めたため、食道扁平上皮癌、Ut、cT4b(No.106recR-気管)N1M0、cStage IIIC(UICC 7th)と診断した。5-FU+CDDP(CF)療法を併用したCRT(60Gy)を施行したがT4解除には至らず、docetaxel+CF(DCF)療法を2コース追加した。内視鏡上はほぼCRで、No.106recR LNも著明に縮小してFDG-PETの集積も消失したためT4解除と判断し、サルベージ手術を行った。Utの腫瘍からNo.106recR LNにかけては高度の瘢痕化を呈するも気管や反回神経の剥離は可能で、合併切除せずともR0切除が可能であった。T4局所進行食道癌に対しては、CRTにDCF療法を加えた集学的治療でT4解除が得られた後に手術を行うことで、安全かつ臓器機能の温存や予後の改善が期待できると考えられた。(著者抄録)
  • 平木 洋子; 加藤 寛章; 白石 治; 田中 裕美子; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    癌と化学療法 (株)癌と化学療法社 44 (12) 1723 - 1725 0385-0684 2017/11 
    播種や他臓器浸潤が疑われる巨大胃gastrointestinal stromal tumor(GIST)に対して、イマチニブによる術前化学療法後に腫瘍切除を行った症例を経験したので報告する。症例は69歳、男性。急速に増大する腹部膨満感を主訴に受診した。CT検査にて壁外結節を伴い膵臓、脾臓と広範囲に接する巨大な胃原発を疑う嚢胞性腫瘤を認め、超音波内視鏡下穿刺吸引細胞診にてGISTと診断された。前治療なしでの手術では、術中の偽被膜破損や他臓器合併切除のリスクがあると判断し、術前化学療法としてイマチニブ400mg/日を6ヵ月間内服した。腫瘍活性が低下したが嚢胞部分の大きさが変化せず、腹部膨満の訴えが強いため手術を行った。イマチニブは術前1週間前に休薬し、合併切除や偽被膜破損なく腫瘍摘出術を行うことができ、術後2週目からイマチニブを再開した。術後経過は順調で、術後1年8ヵ月経過して無再発生存中である。(著者抄録)
  • 安田 篤; 安田 卓司; 木村 豊; 加藤 寛章; 平木 洋子; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 今本 治彦
    癌と化学療法 (株)癌と化学療法社 44 (12) 1943 - 1945 0385-0684 2017/11 
    cStage II/III食道癌に対する治療戦略は術前化学療法(neoadjuvant chemotherapy:NAC)+根治手術が標準であるが、深い潰瘍症例などでは腫瘍穿通が生じて治療戦略を変更せざるを得ない状況に陥ることも経験される。今回、進行食道癌症例に対してNACを施行し、腫瘍壊死のため大動脈穿通のリスクを来したため緊急手術を施行して危険を回避し得た1症例を報告する。症例は62歳、女性。胸部つまり感と吐血を認め、内視鏡検査にて胸部食道癌(扁平上皮癌、cT4N2M0)と診断された。docetaxel+CDDP+5-FU(DCF)によるNACを施行したが2コース終了後に腫瘍が大動脈へ穿通寸前であることが判明し、緊急手術にて右開胸食道亜全摘、胸骨後経路細径胃管再建を行った。本症例は腫瘍がBotallo靱帯へ浸潤して根治切除はできなかったが、胸腔内穿通による縦隔炎や大動脈穿通などの危機的状態を回避することができた。進行癌の集学的治療では、常にoncologic emergencyに対する緊急対応を想定し、発症時には迅速に対処することが肝要と考えられた。(著者抄録)
  • 白石 治; 加藤 寛章; 岩間 密; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    癌と化学療法 (株)癌と化学療法社 44 (12) 1844 - 1846 0385-0684 2017/11 
    食道入口部に及ぶ頸部食道癌を化学放射線療法(CRT)と術式の工夫によって、quality of life(QOL)と根治性を両立し得た喉頭温存手術の1例を報告する。症例は58歳、男性。腫瘍は食道入口部から胸骨切痕の高さまで及ぶT3頸部食道癌で、左右101リンパ節に転移を認めた。まずCRT(5-FU+CDDP+30Gy)で腫瘍を縮小させ、切離断端の腫瘍陰性を確保した。手術においては切離断端距離を最大限確保するため、両側輪状咽頭筋、下咽頭収縮筋下端を切離し、輪状軟骨上縁の高さでの食道を切離した。また、術後の誤嚥対策として、術後に瘢痕拘縮して喉頭挙上運動に拮抗作用を呈する舌骨下筋群を胸骨付着部で切離した。再建は遊離空腸で行った。病理結果は扁平上皮癌、ypT2、INFb、ly0、v0、PM0(10mm)、ypN0、ypStage IIAであった。術後4日目に抜管し、右反回神経麻痺を認めたが誤嚥はなく経過し、嚥下リハビリに時間を要したものの経口摂取は良好で、術後71日目に退院した。その後は社会復帰し、術後5年間再発なく経過した。(著者抄録)
  • Hiroshi Furukawa; Makoto Nakamuro; Hiroshi Nakano; Yoshiaki Kondo; Kazuo Ishikawa; Yuhei Okubo; Motohiro Imano; Takushi Yasuda; Yutaka Kimura; Haruhiko Imamoto; Masayuki Shinkai; Atsushi Yasuda; Osamu Shiraishi; Mitsuru Iwama; Hiroaki Kato
    Gan to kagaku ryoho. Cancer & chemotherapy 44 (12) 1077 - 1079 0385-0684 2017/11 
    Some of scirrhous gastric cancer are difficult to diagnose on the surface view or to take correct biopsy specimen.A 85-yearold man with dysphagia was diagnosed scirrhous gastric cancer endoscopically, but could not be taken a biopsy specimen showing cancer.We informed cases of scirrhous gastric cancer difficult to take correct biopsy specimen and recommended surgical operation to take correct specimen and to start a treatment.Patient underwent total gastrectomy after cancer diagnosis( P0CY0cT4aN0).He can eat more food and survive longer than 1 year without any chemotherapies.Scirrhous gastric cancer needs early diagnosis and treatment to improve patient prognosis.
  • Mitsuru Iwama; Yutaka Kimura; Osamu Shiraishi; Hiroaki Kato; Yoko Hiraki; Yumiko Tanaka; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Haruhiko Imamoto; Takushi Yasuda
    Gan to kagaku ryoho. Cancer & chemotherapy 44 (12) 1720 - 1722 0385-0684 2017/11 
    Prognosis of locally advanced esophageal cancer is poor. The greatest prognostic factor of locally advanced esophageal cancer is a local control. We experienced a case of T4 locally advanced thoracic esophageal cancer who was successfully resected without any combined resection after multimodality therapy. A male in 75-year-old. was diagnosed with type 3 locally advanced upper thoracic esophageal cancer whose metastatic right recurrent laryngeal lymph node invaded into the trachea. Definitive chemoradiation therapy(CRT)was performed, leading to a significant shrinkage of the main tumor, but T4 lesion remained. Next, adding DCF therapy(docetaxel, CDDP and 5-FU), a relief of T4 was finally obtained. Then, salvage surgery with subtotalesophagectomy and retrosternalesophagealreconstruction with gastric tube was performed, resulting in R0 resection without any combined resection. The postoperative course was uneventful, and the patient has been alive without recurrence for 1 year after surgery. In locally advanced cancer, focusing on T4 downstaging, it is significantly important in terms of safety, curativity and organ preservation to perform surgery after a sure sign of T4 relief by multimodality therapy.
  • 幕谷 悠介; 白石 治; 岩間 密; 平木 洋子; 加藤 寛章; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    癌と化学療法 (株)癌と化学療法社 44 (12) 1577 - 1579 0385-0684 2017/11 [Refereed]
     
    症例は76歳、男性。69歳時に胸部食道癌に対し右開胸食道亜全摘術、胸骨後経路胃管再建術を施行され、術中に心室細動から心停止を来した既往があった。今回、上部消化管内視鏡検査にて再建胃管幽門前庭部小彎の3型胃管癌(中分化型腺癌、cT2N0M0、cStage IIA)と診断された。高度のるい痩(BMI 15kg/m2)があり、間質性肺炎に対するステロイドの長期間の内服、前回手術時の心停止の既往があり、胸骨縦切開胃管全摘術を行うにはリスクが極めて高いと判断した。そのため胃管幽門側部分切除術とし、#4d、#6リンパ節は右胃大網動静脈をすだれ状に郭清し口側胃管への血流を温存、右胃動脈は切離し、#5リンパ節を郭清して病巣を摘出した。周術期に合併症はなく、術後40日目に退院となった。予備力の非常に乏しい患者には、根治性と安全性のバランスを考慮した本術式の選択が有用であったと考えられる。(著者抄録)
  • Yusuke Makutani; Osamu Shiraishi; Mitsuru Iwama; Yoko Hiraki; Hiroaki Kato; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Yutaka Kimura; Haruhiko Imamoto; Takushi Yasuda
    Gan to kagaku ryoho. Cancer & chemotherapy 44 (12) 1577 - 1579 0385-0684 2017/11 [Refereed]
     
    A 76-year-old man was admitted to our hospital for treatment of gastric tube cancer(cT2N0M0, cStage II A)detected by a screening upper gastrointestinal endoscopy. Seven years previously, he had undergone subtotal esophagectomy for esophageal cancer with gastric pull-up via the retrosternal route. At that time, he experienced cardiopulmonary arrest due to ventric- ular tachycardia. He was in a state of poor nutrition(BMI 15 kg/m2). Therefore, reducing operative stress as much as possible, minimizing complications after surgery, and aiming for a satisfactory postoperative course are all important goals. Based on his past history, we performed distal gastrectomy(resection of the distal part of the gastric tube)without excision of the right gastroepiploic artery. The postoperative course was uneventful. He was discharged 40 days after surgery. By considering the risks of surgery due to cardiac dysfunction and malnutrition, we were able to provide effective and safe therapy for the patient.
  • Hiraki Y; Kato H; Shiraishi O; Tanaka Y; Iwama M; Yasuda A; Shinkai M; Kimura Y; Imano M; Imamoto H; Yasuda T
    Gan to kagaku ryoho. Cancer & chemotherapy 44 (12) 1723 - 1725 0385-0684 2017/11 [Refereed]
     
    The usefulness and safety of imatinibfor neoadjuvant chemotherapy for resectable gastrointestinal stromal tumor(GIST) has not been established. We reported a case of a huge GIST of the stomach that was safely resected following preoperative imatinibtherapy. A 69-year-old man was hospitalized with abdominal fullness which increased rapidly from a month ago. A CT scan showed a huge tumor containing solid and cystic component which was accompanied by an extra-wall nodule. The tumor was strongly suspected to be originated from the stomach and EUS-FNA revealed GIST. We diagnosed GIST of the stomach and initiated preoperative adjuvant chemotherapy with imatinib because there was a risk for the break of tumor capsule and composite resection of the other organs without prior chemotherapy. After the administration of imatinib4 00 mg/day for 6months, the solid component was decreased in size and its' activity by PET-CT had declined, but the size of the cystic component was not changed and the patient's complaint of fullness was not reduced. Then, after a week cessation of imatinib, we performed surgical removal of the tumor with partial gastrectomy without surgical complication during and after the operation. Imatinibwas resumed 2 weeks later postoperatively and 1 year and 8 months has passed since the operation without recurrence. Neoadjuvant chemotherapy with imatinibhas the potential to become an important therapeutic option for the treatment of huge GISTs.
  • Shiraishi O; Kato H; Iwama M; Hiraki Y; Yasuda A; Shinkai M; Imano M; Kimura Y; Imamoto H; Yasuda T
    Gan to kagaku ryoho. Cancer & chemotherapy 44 (12) 1844 - 1846 0385-0684 2017/11 [Refereed]
     
    The patient was a 58-year-old man suffering from dysphagia. He was diagnosed with T3 cervicalesophagealcancer that invaded the posterior hypopharyngealwal lwith lymph node metastasis. The patient received neoadjuvant chemoradiotherapy (30 Gy with CDDP/5-FU), followed by larynx-preserving surgery(LPS)for cervicalesophagealcancer. Two techniques for successfulLPS consist of the dissections of cricopharyngealmuscl e and the inferior pharyngealsphincter, and the complete division of the bilateral infrahyoid muscles attached to the sternum(CDBIMS). The former technique of releasing the esophagus from the trachea at the cricoid cartilage level results in the extension of the oral surgical margin. The latter technique is expected to prevent postoperative aspiration pneumonia, as the lack of flexibility of scarred infrahyoid muscles is regarded as one of the major causes of dysfunction in swallowing. Free jejunum was transferred for cervical reconstruction. Pathological examination indicated degenerated squamous cell carcinoma(ypT2, INF b, ly0, v0, PM0, ypN0, ypStage II A). Although the patient had recurrent nerve palsy, he could eat meals without aspiration. He returned to normal life after discharge from the hospital. Five years after surgery, no recurrence had been observed.
  • Yasuda A; Yasuda T; Kimura Y; Kato H; Hiraki Y; Iwama M; Shiraishi O; Shinkai M; Imano M; Imamoto H
    Gan to kagaku ryoho. Cancer & chemotherapy 44 (12) 1943 - 1945 0385-0684 2017/11 [Refereed]
     
    According to the Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus in Japan, the standard treatment of esophageal cancer with cStage II / III is preoperative chemotherapy and radical resection. But when the tumor has deep ulcer, the perforation of it is sometimes occurred due of the anti-tumor effect and we are forced to change the standard treatment. In this time, we report a case of emergency resection of esophageal cancer which is on the brink of perforation after neoadjuvant chemotherapy. A 62-year-old woman had locally advanced esophageal cancer(cT4N2M0)and performed neoadjuvant chemotherapy(NAC). After 2 courses of NAC, the patient got into critical condition that the esophageal cancer was on the brink of perforation, thus we immediately performed emergency resection of the tumor. Unfortunately, the tumor was not completely resected because of invasion to the Botallo ligament, but we were able to avoid a critical state such as mediastinitis or penetration to the aorta. In multimodality therapy for locally advanced tumor, immediate response to oncologic emergency is significantly required, impacting on the prognosis and quality of life.
  • 食道癌補助療法後の至適郭清[3領域vs2領域] 胸部食道癌補助療法後の頸部郭清省略の選別の妥当性
    白石 治; 加藤 寛章; 岩間 密; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 78 (増刊) 373 - 373 1345-2843 2017/10
  • 胃切除後症候群の予防と治療 胃切除術後症候群に対する膵酵素補充剤の有用性に関する検討
    木村 豊; 三上 城太; 間狩 洋一; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 78 (増刊) 390 - 390 1345-2843 2017/10
  • 外科手術での補助器具開発 左側臥位食道切除術における安定した術野確保のための肺圧排固定器具の開発
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦
    日本臨床外科学会雑誌 日本臨床外科学会 78 (増刊) 404 - 404 1345-2843 2017/10
  • 木村 豊; 岩間 緑; 白石 治; 平木 洋子; 加藤 寛章; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本外科感染症学会雑誌 (一社)日本外科感染症学会 14 (5) 647 - 647 1349-5755 2017/10
  • 「それぞれの癌」最善の治療とは?食道癌 内科と外科の立場から cT4食道癌の外科治療の限界と成績
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 宮田 博志; 新海 政幸; 今野 元博; 木村 豊; 矢野 雅彦; 今本 治彦
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 55回 PD9 - 5 2017/10
  • 食道癌特異的ペプチドワクチンの術後補助療法としての有用性と腫瘍微小環境との関連
    安田 卓司; 錦 耕平; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 奥野 清隆; 中村 祐輔
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 55回 P128 - 2 2017/10
  • 既治療に耐性の進行再発胃癌に対するramucirumab療法における蛋白尿に関する検討
    木村 豊; 間狩 洋一; 三上 城太; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 藤田 淳也; 安田 卓司
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 55回 P170 - 4 2017/10
  • 良性潰瘍に対する胃切既往のある胸部食道癌における、腹部リンパ節転移状況の検討
    加藤 寛章; 白石 治; 岩間 密; 平木 洋子; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本消化器外科学会雑誌 (一社)日本消化器外科学会 50 (Suppl.2) 182 - 182 0386-9768 2017/10
  • 進行再発胃癌に対するramucirumab使用例における蛋白尿の検討
    木村 豊; 間狩 洋一; 三上 城太; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 藤田 淳也; 安田 卓司
    日本消化器外科学会雑誌 (一社)日本消化器外科学会 50 (Suppl.2) 260 - 260 0386-9768 2017/10
  • 食道癌術後気管切開における甲状腺上アプローチの有用性
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦
    日本消化器外科学会雑誌 (一社)日本消化器外科学会 50 (Suppl.2) 456 - 456 0386-9768 2017/10
  • 白石 治; 加藤 寛章; 岩間 密; 平木 洋子; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    消化器内視鏡 (株)東京医学社 29 (9) 1757 - 1764 0915-3217 2017/09 
    食道胃接合部癌はこれまでは食道癌、胃癌としておのおの扱われてきたため、その手術治療方針は確立されていない。術式決定の鍵となるのは開胸に関わる縦隔リンパ節、胃全摘に関わる胃大彎側のリンパ節、転移率の高い傍大動脈リンパ節(#16a2lat)の郭清の要否である。これまでの報告と自験例を合わせて検討すると、縦隔リンパ節転移は食道浸潤位置と関連があり、胃大彎リンパ節(#4d)は転移頻度が低く、進行癌では大動脈周囲リンパ節(#16a2lat)は転移をきたしやすい。現在、本邦では西分類食道胃接合部癌に対して、扁平上皮癌および食道浸潤長30mmを超える腺癌は"右開胸食道亜全摘+上中下縦隔リンパ節郭清"、30mmを超えない腺癌は"経裂孔的下部食道切除+下縦隔リンパ節郭清"、16a2latリンパ節の追加郭清、胃全摘は規定しない方針で前向き介入臨床試験が進んでおり、結果が待たれるところである。(著者抄録)
  • 岩間 密; 安田 卓司; 白石 治; 加藤 寛章; 平木 洋子; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦
    胸部外科 (株)南江堂 70 (8) 720 - 727 0021-5252 2017/07
  • 食道胃接合部腺癌の至適リンパ節郭清と術式選択 リンパ節転移状況に基づく進行EGJ腺癌に対するNAC+胸腹連続郭清
    白石 治; 平木 洋子; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 72回 O1 - 3 2017/07
  • CY(+)進行胃癌に対するPTX腹腔内投与+PCS全身化学療法の有用性の検討
    新海 政幸; 今野 元博; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 72回 PG6 - 4 2017/07
  • 胃切既往のある胸部食道癌の腹部リンパ節転移の検討 残胃全摘の省略は許容されるか
    加藤 寛章; 白石 治; 岩間 密; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 72回 PK7 - 3 2017/07
  • 食道癌に対する縦隔リンパ節郭清の手術手技 安定した術野確保のための右肺圧排固定器具の開発と胸腔鏡拡大画像に基づく左側臥位縦隔リンパ節郭清手技
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 平木 羊子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦
    日本消化器外科学会総会 (一社)日本消化器外科学会 72回 O2 - 2 2017/07
  • 胃上部癌に対する腹腔鏡下手術の郭清・再建手技の定型化 菱形残胃作成と食道裂孔挿入を付加した噴門側胃切除・食道残胃吻合法
    安田 篤; 新海 政幸; 加藤 寛章; 平木 洋子; 岩間 密; 白石 治; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 72回 O2 - 4 2017/07
  • cT4局所進行食道癌に対するSalvage手術を前提とした導入化学放射線療法による治療戦略
    岩間 密; 白石 治; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 72回 RS3 - 2 2017/07
  • 高齢・胃切後胸部食道癌に対する嚥下機能温存と血行付加を考慮した新規縦隔横断胸骨後経路高位胸腔内吻合
    平木 洋子; 白石 治; 岩間 密; 加藤 寛章; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 72回 PK17 - 7 2017/07
  • Mitsuru Iwama; Takushi Yasuda; Osamu Shiraishi; Hiroaki Kato; Yoko Hiraki; Yumiko Tanaka; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Yutaka Kimura; Haruhiko Imamoto
    Kyobu geka. The Japanese journal of thoracic surgery 70 (8) 720 - 727 0021-5252 2017/07 
    Patients with esophageal cancer are often treated with definitive chemoradiotherapy (dCRT). Regardless of arrival at dCRT, the risk of local/regional recurrence during follow-up is significant. Many patient are faced with limited options for therapy once dCRT has failed. Salvage surgery is the only way for complete cure of patients with local/regional recurrent esophageal cancer after dCRT. However, salvage surgery has a significant high risk of fatal complications. We examine our preventive measures to reduce the incidence of postoperative complications after salvage surgery for thoracic esophageal cancer. The points of our preventive measures are them; I. the ingenuity of surgery, II. the securement of blood supply for the respiratory tract, III. standard lymphadenectomy, IV. countermeasures of anastomotic failure, V. countermeasures of dead space, VI. countermeasures of respiratory complications, VII. perioperative managements. Salvage surgery is a reasonable option to treat patients with local/regional recurrence after failed dCRT. Our preventive mesures are effective, therefore, we have to make the further technological developments and the safety of salvage surgery.
  • 岩間 密; 安田 卓司; 白石 治; 加藤 寛章; 平木 洋子; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦
    胸部外科 (株)南江堂 70 (8) 720 - 727 0021-5252 2017/07
  • Masanobu Tsubaki; Tomoya Takeda; Toshiki Kino; Kazuko Sakai; Tatsuki Itoh; Motohiro Imano; Takashi Nakayama; Kazuto Nishio; Takao Satou; Shozo Nishida
    Oncotarget 8 (24) 38717 - 38730 2017/06 [Refereed]
     
    Resistance to the breakpoint cluster region-abelson 1 (BCR-ABL1) tyrosine kinase inhibitor (TKI) imatinib poses a major problem when treating chronic myeloid leukemia (CML). Imatinib resistance often results from a secondary mutation in BCR-ABL1. However, in the absence of a mutation in BCR-ABL1, the basis of BCR-ABL1-independent resistance must be elucidated. To gain insight into the mechanisms of BCR-ABL1-independent imatinib resistance, we performed an array-based comparative genomic hybridization. We identified various resistance-related genes, and focused on MET. Treatment with a MET inhibitor resensitized K562/IR cells to BCR-ABL1 TKIs. Combined treatment of K562/IR cells with imatinib and a MET inhibitor suppressed extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK) activation, but did not affect AKT activation. Our findings implicate the MET/ERK and MET/JNK pathways in conferring resistance to imatinib, providing new insights into the mechanisms of BCR-ABL1 TKI resistance in CML.
  • サルベージ手術の成績と問題点 当科におけるSalvage手術の安全性と有効性に関する検討
    岩間 密; 白石 治; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 71回 S4 - 7 2017/06
  • 高齢食道癌患者に対する手術における誤嚥、肺炎の発症の低減を目指した治療選択
    木村 豊; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 71回 P6 - 8 2017/06
  • 胃癌、頭頸部癌との重複食道癌に対する治療戦略
    加藤 寛章; 白石 治; 岩間 密; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 71回 P67 - 3 2017/06
  • 白石 治; 田中 由美子; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本気管食道科学会会報 (NPO)日本気管食道科学会 68 (2) 115 - 115 0029-0645 2017/04
  • 再発食道癌の治療戦略 外科的介入の有用性は 胸部食道癌根治術後再発とその治療戦略 再び根治を目指して
    加藤 寛章; 白石 治; 岩間 密; 平木 洋子; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 117回 WS - 4 2017/04
  • 胃癌手術における逆流防止の工夫と長期成績 噴門側胃切除・食道残胃吻合における食道胃逆流防止の工夫
    安田 篤; 平木 洋子; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 今本 治彦; 木村 豊; 古河 洋; 安田 卓司; 奥野 清隆
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 117回 WS - 4 2017/04
  • 胸部食道癌手術における頸部郭清の合理化は可能か Standard or Selective Selective
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 117回 DB - 2 2017/04
  • 切除可能進行胃癌に対する術前TS-1+Cisplatin+Paclitaxel併用療法(PCS療法)
    新海 政幸; 今野 元博; 平木 洋子; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本 治彦; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 117回 SF - 6 2017/04
  • 安全性を目指した胸部食道癌手術における再建術の工夫
    岩間 密; 加藤 寛章; 白石 治; 平木 洋子; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 117回 PS - 1 2017/04
  • 腹腔鏡下にD2郭清を伴う腹腔鏡下胃切除術を安全に行うための工夫
    木村 豊; 三上 城太; 間狩 洋一; 藤田 淳也; 平木 洋子; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 古河 洋; 今本 治彦; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 117回 PS - 5 2017/04
  • 高齢社会の癌治療 高齢者胸部食道癌手術におけるリスク因子と対策
    白石 治; 田中 由美子; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本気管食道科学会会報 (NPO)日本気管食道科学会 68 (2) 115 - 115 0029-0645 2017/04
  • 幽門側胃切除術後の高齢者における呼吸器合併症に対する周術期の嚥下リハビリ介入についての検討
    田中 裕美子; 安田 篤; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 89回 241 - 241 2017/03
  • 根治切除可能な大型3型/4型胃癌に対する術前化学放射線療法の実現可能性
    白石 治; 田中 裕美子; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 古河 洋; 塩崎 均; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 89回 243 - 243 2017/03
  • 当科での幽門保存胃切除術の検討
    安田 篤; 平木 洋子; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 古河 洋; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司; 奥野 清隆
    日本胃癌学会総会記事 (一社)日本胃癌学会 89回 316 - 316 2017/03
  • 切除可能進行胃癌に対する術前PCS療法(Neoadjuvant combination chemotherapy with S-1, CDDP and PTX for resectable advanced gastric cancer)
    新海 政幸; 今野 元博; 平木 洋子; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本 治彦; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 89回 329 - 329 2017/03
  • 胃全摘術後早期の体重減少に影響を及ぼす因子に関する検討(The examination of factors affecting body weight loss in patients after total gastrectomy)
    木村 豊; 三上 城太; 間狩 洋一; 藤田 淳也; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 有田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 89回 431 - 431 2017/03
  • 胸部食道癌術後胃管癌に関する検討(A study about gastric tube cancer after radical esophagectomy for thoracic esophageal cancer)
    岩間 密; 白石 治; 加藤 寛章; 平木 洋子; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 89回 447 - 447 2017/03
  • Masanobu Tsubaki; Daichiro Fujiwara; Tomoya Takeda; Toshiki Kino; Yoshika Tomonari; Tatsuki Itoh; Motohiro Imano; Takao Satou; Katsuhiko Sakaguchi; Shozo Nishida
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY WILEY 44 (2) 222 - 234 1440-1681 2017/02 [Refereed]
     
    Statins induce apoptosis of tumour cells by inhibiting the prenylation of small G-proteins. However, the details of the apoptosis-inducing mechanisms remain poorly understood. The present study showed that the induction of apoptosis by statins in four different human head and neck squamous cell carcinoma ( HNSCC) cell lines, HSC-3, HEp-2, Ca9-22, and SAS cells was mediated by increased caspase-3 activity. Statins induced apoptosis by the suppression of geranylgeranyl pyrophosphate biosynthesis. Furthermore, statins decreased the levels of phosphorylated ERK and mTOR by inhibiting the membrane localization of Ras and enhancing Bim expression in HSC-3 and HEp-2 cells. We also found that in all the cell types analyzed, the IC50 values for fluvastatin and simvastatin were highest in HEp-2 cells. In addition, HSC-3, Ca9-22, and SAS cells had higher Ras expression and membrane localization, higher activation of ERK1/2 and mTOR, and lower levels of Bim expression than HEp-2 cells. Our results indicate that statins induce apoptosis by increasing the activation of caspase-3 and by enhancing Bim expression through inhibition of the Ras/ERK and Ras/mTOR pathways. Furthermore, the sensitivity of HNSCC cells to statin treatment was closely related to Ras expression and prenylation levels, indicating that statins may act more effectively against tumours with high Ras expression and Ras-variability. Therefore, our findings support the use of statins as potential anticancer agents.
  • Masanobu Tsubaki; Daichiro Fujiwara; Tomoya Takeda; Toshiki Kino; Yoshika Tomonari; Tatsuki Itoh; Motohiro Imano; Takao Satou; Katsuhiko Sakaguchi; Shozo Nishida
    Clinical and experimental pharmacology & physiology 44 (2) 222 - 234 0305-1870 2017/02 [Refereed]
     
    Statins induce apoptosis of tumour cells by inhibiting the prenylation of small G-proteins. However, the details of the apoptosis-inducing mechanisms remain poorly understood. The present study showed that the induction of apoptosis by statins in four different human head and neck squamous cell carcinoma (HNSCC) cell lines, HSC-3, HEp-2, Ca9-22, and SAS cells was mediated by increased caspase-3 activity. Statins induced apoptosis by the suppression of geranylgeranyl pyrophosphate biosynthesis. Furthermore, statins decreased the levels of phosphorylated ERK and mTOR by inhibiting the membrane localization of Ras and enhancing Bim expression in HSC-3 and HEp-2 cells. We also found that in all the cell types analyzed, the IC50 values for fluvastatin and simvastatin were highest in HEp-2 cells. In addition, HSC-3, Ca9-22, and SAS cells had higher Ras expression and membrane localization, higher activation of ERK1/2 and mTOR, and lower levels of Bim expression than HEp-2 cells. Our results indicate that statins induce apoptosis by increasing the activation of caspase-3 and by enhancing Bim expression through inhibition of the Ras/ERK and Ras/mTOR pathways. Furthermore, the sensitivity of HNSCC cells to statin treatment was closely related to Ras expression and prenylation levels, indicating that statins may act more effectively against tumours with high Ras expression and Ras-variability. Therefore, our findings support the use of statins as potential anticancer agents.
  • Toru Aoyama; Kazuhiro Nishikawa; Mari Oba; Takaki Yoshikawa; Chu Matsuda; Yoshinori Munemoto; Nobuhiro Takiguchi; Kazuaki Tanabe; Naoki Nagata; Motohiro Imano; Mitsuru Oshiro; Ryoji Fukushima; Masato Kataoka; Satoshi Morita; Akira Tsuburaya; Hideyuki Mishima; Toru Kono; Junichi Sakamoto
    Annals of Cancer Research and Therapy PJD Publications Ltd 25 (2) 92 - 94 1344-6835 2017 [Refereed]
     
    This meta-analysis will be performed to evaluate the efficacy of Hangeshashinto (TJ-14) in patients with chemotherapyinduced oral mucositis (COM) for gastroenterological cancer. Individual patient-level data from two prospective, doubleblind, placebo-controlled randomized trials employing the same regimens using TJ-14 will be collected for this study. Cumulative data from 181 patients will help conclude whether TJ-14 is effective to COM for gastroenterological cancer or not. We will select the patients with severe (CTCAE grade ≥2) COM who did not reduce the dose of chemotherapy to evaluate the effect of TJ-14 precisely. The primary endpoint of this study is time to remission of severe (CTCAE grade ≥2) COM to grade ≤1 in the protocol treatment course, and the secondary end points are the incidence of grade ≥2 COM, and predictive factors of time to remission and of incidence of grade ≥2 COM.
  • 【胃癌・食道癌のリンパ節郭清のすべて】 食道癌に対する頸部リンパ節郭清
    白石 治; 岩間 密; 加藤 寛章; 平木 洋子; 田中 裕美子; 中野 敬次; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    消化器外科 (株)へるす出版 40 (1) 17 - 29 0387-2645 2017/01
  • Yasuhiro Kodera; Naoto Takahashi; Takaki Yoshikawa; Nobuhiro Takiguchi; Kazumasa Fujitani; Yuichi Ito; Katsufumi Miyamoto; Osamu Takayama; Motohiro Imano; Daisuke Kobayashi; Yumi Miyashita; Satoshi Morita; Junichi Sakamoto
    GASTRIC CANCER SPRINGER 20 (1) 190 - 199 1436-3291 2017/01 [Refereed]
     
    Background Peritoneal carcinomatosis is common after curative resection of gastric cancer. Intraperitoneal administration of paclitaxel (PTX) is known to control ovarian peritoneal metastases. Patients with either linitis plastica or T4 cancer with high risk of peritoneal metastasis or recurrence but whose cancer was considered resectable were preregistered. After their cancer had been confirmed intraoperatively as resectable, the patients were randomized into either group A (PTX at 60 mg/m(2) intraperitoneally on the day of surgery and on days 14, 21, 28, 42, 49, and 56) or group B (PTX at 80 mg/m(2) administered intravenously by the identical schedule) before being treated by evidence-based chemotherapy. The primary end point was the 2-year survival rate. Safety, the secondary end point, was also analyzed. The study has been registered as UMIN000002957. Of 177 preregistered patients, 83 underwent treatment (39 by intraperitoneal administration and 44 by intravenous administration). There was no difference in patient demographics between the two groups. The incidences of surgical complications were similar between the groups, except for transient bowel obstruction observed exclusively in group A. The relative dose intensity of PTX was 81.4 % for group A and 76.3 % for group B. There was one death due to pulmonary thrombosis and a case of anaphylaxis that led to termination of the protocol treatment (group B). Other adverse events were mild and manageable. Intraperitoneal administration of PTX from the day of gastrectomy did not result in a higher incidence of surgical complications and adverse reactions when compared with intravenous administration of PTX.
  • 早期胃癌に対する噴門側胃切除術のメリットとデメリット 噴門胃切除後の菱形残胃作成と偽穹窿部食道裂孔挿入による食道残胃吻合法
    安田 篤; 今本 治彦; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 新海 政幸; 木村 豊; 今野 元博; 古河 洋; 安田 卓司; 奥野 清隆
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 21 (7) RS41 - 4 1344-6703 2016/12
  • Y. Fujiwara; H. Ishigami; R. Fukushima; A. Nashimoto; H. Yabusaki; H. Imamoto; M. Imano; Y. Kodera; Y. Uenosono; K. Amagai; S. Kadowaki; H. Miwa; H. Yamaguchi; T. Yamaguchi; J. Kitayama
    ANNALS OF ONCOLOGY OXFORD UNIV PRESS 27 0923-7534 2016/10
  • そこが知りたいPros and Cons 胸部食道癌縮小手術 積極派vs.慎重派 症例毎のリスク軽減の工夫による根治的リンパ節郭清を伴う食道癌外科治療戦略
    安田 卓司; 白石 治; 岩間 密; 加藤 寛章; 田中 裕美子; 平木 洋子; 安田 篤; 新海 政幸; 今野 元博; 木村 豊; 今本 治彦
    日本臨床外科学会雑誌 日本臨床外科学会 77 (増刊) 337 - 337 1345-2843 2016/10
  • 胃切除後症例における食道癌再建手術の工夫 当院の胃切除後における食道切除後有茎空腸再建術の工夫
    白石 治; 田中 裕美子; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 77 (増刊) 376 - 376 1345-2843 2016/10
  • 胸部食道癌周術期管理の進歩 合併症ゼロへ向けて 胸部食道癌手術における術後合併症予防の工夫
    岩間 密; 田中 裕美子; 加藤 寛章; 白石 治; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 77 (増刊) 423 - 423 1345-2843 2016/10
  • 当院における腹腔鏡下胃切除術の工夫 臓器把持用クリップの活用
    木村 豊; 三上 城太; 間狩 洋一; 藤田 淳也; 平木 洋子; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 古河 洋; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 77 (増刊) 618 - 618 1345-2843 2016/10
  • 輪状咽頭筋切開による喉頭温存食道切除・高位吻合の有用性
    加藤 寛章; 田中 裕美子; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 77 (増刊) 659 - 659 1345-2843 2016/10
  • CY1胃癌に対するPTX腹腔内投与+PCS全身化学療法の治療成績
    新海 政幸; 今野 元博; 平木 洋子; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本 治彦; 古河 洋; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 77 (増刊) 705 - 705 1345-2843 2016/10
  • 胃癌術後5年目に発症した脾転移の1切除例
    田中 裕美子; 平木 洋子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 木村 豊; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 77 (増刊) 709 - 709 1345-2843 2016/10
  • Shigefumi Yoshino; Kazuhiro Nishikawa; Satoshi Morita; Tsuyoshi Takahashi; Koichiro Sakata; Jiro Nagao; Hiroshi Nemoto; Nozomu Murakami; Takeru Matsuda; Hiroyasu Hasegawa; Ryoichi Shimizu; Takaki Yoshikawa; Hiroyuki Osanai; Motohiro Imano; Hiroshi Naitoh; Akiyoshi Tanaka; Takashi Tajiri; Akira Gochi; Michinari Suzuki; Junichi Sakamoto; Shigetoyo Saji; Masaaki Oka
    EUROPEAN JOURNAL OF CANCER ELSEVIER SCI LTD 65 164 - 171 0959-8049 2016/09 [Refereed]
     
    Background: Lentinan (LNT) is a purified beta-1, 3-glucan that augments immune responses. The present study was conducted to assess the efficacy of LNT in combination with S-1 as a first-line treatment for unresectable or recurrent gastric cancer. Patients and methods: Eligible patients were randomly assigned to receive S-1 alone or S-1 plus LNT. The primary end-point was overall survival (OS). Secondary end-points were time-to-treatment failure (TTF), overall response rate (ORR), safety, quality of life (QOL), and biomarker. The percentages of LNT-binding monocytes in peripheral blood prior to treatment were analysed for the biomarker assessment. Results: One hundred and fifty-four and 155 patients were randomly assigned to receive S-1 alone or S-1 plus LNT, respectively. The median OS was 13.8 and 9.9 months (P = 0.208), the median TTF was 4.3 and 2.6 months (P < 0.001), the ORR was 22.3% and 18.7% for the S-1 and S-1 plus LNT groups, respectively. The incidences of haematologic and non-haematologic adverse events were similar, and no significant changes in QOL scores were observed during the treatment in both groups. In a subpopulation of patients with LNT-binding monocytes >= 2%, patients who received more than two cycles of chemotherapy showed a longer survival time in the S-1 plus LNT group. Conclusions: OS did not improve and TTF was significantly worse in the S-1 plus LNT group as compared with the S-1-only group. This study showed no efficacy of LNT when combined with S-1 treatment in patients with unresectable or recurrent gastric cancer. (C) 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
  • Tomoya Takeda; Masanobu Tsubaki; Kotaro Sakamoto; Eri Ichimura; Aya Enomoto; Yuri Suzuki; Tatsuki Itoh; Motohiro Imano; Genzoh Tanabe; Osamu Muraoka; Hideaki Matsuda; Takao Satou; Shozo Nishida
    Toxicology and applied pharmacology 306 105 - 12 0041-008X 2016/09 [Refereed]
     
    Advanced metastatic melanoma, one of the most aggressive malignancies, is currently without reliable therapy. Therefore, new therapies are urgently needed. Mangiferin is a naturally occurring glucosylxanthone and exerts many beneficial biological activities. However, the effect of mangiferin on metastasis and tumor growth of metastatic melanoma remains unclear. In this study, we evaluated the effect of mangiferin on metastasis and tumor growth in a mouse metastatic melanoma model. We found that mangiferin inhibited spontaneous metastasis and tumor growth. Furthermore, mangiferin suppressed the nuclear translocation of nuclear factor kappa B (NF-κB) and expression of phosphorylated NF-κB-inducing kinase (NIK), inhibitor of kappa B kinase (IKK), and inhibitor of kappa B (IκB) and increases the expression of IκB protein in vivo. In addition, we found that mangiferin inhibited the expression of matrix metalloproteinases (MMPs) and very late antigens (VLAs) in vivo. Mangiferin treatment also increased the expression of cleaved caspase-3, cleaved Poly ADP ribose polymerase-1 (PARP-1), p53 upregulated modulator of apoptosis (PUMA), p53, and phosphorylated p53 proteins, and decreased the expression of Survivin and Bcl-associated X (Bcl-xL) proteins in vivo. These results indicate that mangiferin selectivity suppresses the NF-κB pathway via inhibition of NIK activation, thereby inhibiting metastasis and tumor growth. Importantly, the number of reported NIK selective inhibitors is limited. Taken together, our data suggest that mangiferin may be a potential therapeutic agent with a new mechanism of targeting NIK for the treatment of metastatic melanoma.
  • 高度進行胃癌に対する放射線化学療法を用いた集学的治療
    新海 政幸; 今野 元博; 曽我部 俊介; 田中 裕美子; 加藤 寛章; 岩間 密; 安田 篤; 今本 治彦; 古河 洋; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 71回 P3 - 9 2016/07
  • 再発食道癌の治療、なおcureをめざすのは誤りか? 胸部食道癌根治術後における再発現状と再発例に対する治療戦略
    新海 政幸; 曽我部 俊介; 田中 裕美子; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 70回 54 - 54 2016/07
  • 明日の食道癌非手術治療 前治療後手術のpN(+)食道扁平上皮癌に対する術後補助ペプチドワクチン第2相試験
    安田 卓司; 錦 耕平; 白石 治; 岩間 密; 加藤 寛章; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 70回 57 - 57 2016/07
  • リンパ節転移状況に基づく至適郭清範囲 中下縦隔から腹腔動脈周囲までの連続的郭清
    白石 治; 田中 裕美子; 曽我部 俊介; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 70回 66 - 66 2016/07
  • 腹臥位での重力差とCT値による客観評価での新しい進行食道癌大動脈浸潤評価の有用性
    田中 裕美子; 白石 治; 曽我部 俊介; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 70回 70 - 70 2016/07
  • サルベージ手術を前提とした導入化学放射線療法によるcT4局所進行食道癌治療戦略
    岩間 密; 曽我部 俊介; 田中 裕美子; 加藤 寛章; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 70回 72 - 72 2016/07
  • Barrett食道癌と乳頭部癌に対し一期的切除をしえた同時性重複癌の1例
    田中 裕美子; 曽我部 俊介; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 71回 P1 - 9 2016/07
  • 当院におけるGISTに対する腹腔鏡手術の検討
    安田 篤; 今本 治彦; 加藤 寛章; 岩間 満; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 安田 卓司; 奥野 清隆
    日本消化器外科学会総会 (一社)日本消化器外科学会 71回 P1 - 6 2016/07
  • 食道癌手術における合併症軽減のための工夫 胸部食道癌手術における術後合併症の予防策に関する検討
    岩間 密; 曽我部 俊介; 田中 裕美子; 加藤 寛章; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 71回 WS12 - 5 2016/07
  • 食道切除後胃管再建術 縫合不全ゼロの追求
    加藤 寛章; 曽我部 俊介; 田中 裕美子; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 71回 P2 - 6 2016/07
  • 食道切除後の胃再建不能例における血管吻合を付加する挙上空腸再建
    白石 治; 曽我部 俊介; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 71回 P2 - 4 2016/07
  • Masanobu Tsubaki; Tomoya Takeda; Misako Yoshizumi; Emi Ueda; Tatsuki Itoh; Motohiro Imano; Takao Satou; Shozo Nishida
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 37 (7) 9099 - 110 1010-4283 2016/07 [Refereed]
     
    Interaction between multiple myeloma (MM) cells and the bone marrow microenvironment plays a critical role in MM pathogenesis and the development of drug resistance. Recently, it has been reported that MM cells express the receptor activator of nuclear factor-κB (NF-κB) (RANK). However, the role of the RANK/RANK ligand (RANKL) system in drug resistance remains unclear. In this study, we demonstrated a novel function of the RANK/RANKL system in promoting drug resistance in MM. We found that RANKL treatment induced drug resistance in RANK-expressing but not RANK-negative cell lines. RANKL stimulation of RANK-expressing cells increased multidrug resistance protein 1 (MDR1), breast cancer resistance protein (BCRP), and lung resistance protein 1 (LRP1) expression and decreased Bim expression through various signaling molecules. RNA silencing of Bim expression induced drug resistance, but the RANKL-mediated drug resistance could not be overcome through the RNA silencing of MDR1, BCRP, and LRP1 expression. These results indicate that the RANK/RANKL system induces chemoresistance through the activation of multiple signal transduction pathways and by decreasing Bim expression in RANK-positive MM cells. These findings may prove to be useful in the development of cell adhesion-mediated drug resistance inhibitors in RANK-positive MM cells.
  • 田中 裕美子; 白石 治; 熊野 正士; 曽我部 俊介; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 村上 卓道; 奥野 清隆; 安田 卓司
    近畿大学医学雑誌 近畿大学医学会 41 (1-2) 27 - 38 0385-8367 2016/06 
    切除困難な局所進行食道癌cT4(大動脈)も化学療法(ChT)/化学放射線療法(CRT)の進歩に伴い治癒切除率が向上し、より精度の高い深達度診断が求められている。我々は通常の仰臥位CTでのcT4診断(Picus角(PA)≧90度)に加え、重力差を利用した腹臥位CTとの比較による動的評価法を考案し、その有用性を検討した。対象は初診時仰臥位造影CTでcT3以深の食道癌22例(cT3/T4=17/5)35測定、全例ChT/CRTを先行し18例で手術を施行。腫瘍-大動脈壁間距離(T-A D)とPAを仰/腹CTで測定し、最終深達度(fT4=R1、2、fT3.5=R0 and著明な瘢痕化(+)、fT3=R0 and瘢痕化(-)、非手術例はEUS所見)と比較した。全35測定の平均後縦隔前後径(下縦隔)は仰/腹の順に12.3/26.0mmで、PA<60度(21測定)の平均T-A DとPAは3.0/4.4mm、23.2/16度と腹臥位で距離は延長し角度は縮小した(p<0.05)。治療前PA≧60度の10例はfT3/T3.5/T4=5/2/3。fT3は腹臥位で全例PAは減少しT-A Dも3/5例で延長、fT3.5はいずれかが不変、fT4は両方不変であった。以上より、仰/腹CTにおけるT-A D/PAの比較はT3(両方変化)、T3.5(いずれか不変)、T4(両方不変)を鑑別できる可能性が示唆された。(著者抄録)
  • Tomoya Takeda; Masanobu Tsubaki; Toshiki Kino; Ayako Kawamura; Shota Isoyama; Tatsuki Itoh; Motohiro Imano; Genzoh Tanabe; Osamu Muraoka; Hideaki Matsuda; Takao Satou; Shozo Nishida
    International journal of oncology 48 (6) 2704 - 12 1019-6439 2016/06 [Refereed]
     
    Multiple myeloma (MM) is still an incurable hematological malignancy with a 5-year survival rate of ~35%, despite the use of various treatment options. The nuclear factor κB (NF-κB) pathway plays a crucial role in the pathogenesis of MM. Thus, inhibition of the NF-κB pathway is a potential target for the treatment of MM. In a previous study, we showed that mangiferin suppressed the nuclear translocation of NF-κB. However, the treatment of MM involves a combination of two or three drugs. In this study, we examined the effect of the combination of mangiferin and conventional anticancer drugs in an MM cell line. We showed that the combination of mangiferin and an anticancer drug decreased the viability of MM cell lines in comparison with each drug used separately. The decrease in the combination of mangiferin and an anticancer drug induced cell viability was attributed to increase the expression of p53 and Noxa and decreases the expression of XIAP, survivin, and Bcl-xL proteins via inhibition of NF-κB pathway. In addition, the combination treatment caused the induction of apoptosis, activation of caspase-3 and the accumulation of the cells in the sub-G1 phase of the cell cycle. Our findings suggest that the combination of mangiferin and an anticancer drug could be used as a new regime for the treatment of MM.
  • Tomoya Takeda; Masanobu Tsubaki; Toshiki Kino; Misa Yamagishi; Megumi Iida; Tatsuki Itoh; Motohiro Imano; Genzoh Tanabe; Osamu Muraoka; Takao Satou; Shozo Nishida
    Chemico-biological interactions 251 26 - 33 0009-2797 2016/05 [Refereed]
     
    Mangiferin is a naturally occurring glucosyl xanthone, which induces apoptosis in various cancer cells. However, the molecular mechanism underlying mangiferin-induced apoptosis has not been clarified thus far. Therefore, we examined the molecular mechanism underlying mangiferin-induced apoptosis in multiple myeloma (MM) cell lines. We found that mangiferin decreased the viability of MM cell lines in a concentration-dependent manner. We also observed an increased number of apoptotic cells, caspase-3 activation, and a decrease in the mitochondrial membrane potential. In addition, mangiferin inhibited the nuclear translocation of nuclear factor kappa B (NF-κB) and expression of phosphorylated inhibitor kappa B (IκB) and increased the expression of IκB protein, whereas no changes were observed in the phosphorylation levels of extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal protein kinase 1/2 (JNK1/2), and mammalian target of rapamycin (mTOR). The molecular mechanism responsible for mangiferin-induced inhibition of nuclear translocation of NF-κB was a decrease in the expression of phosphorylated NF-κB-inducing kinase (NIK). Moreover, mangiferin decreased the expression of X-linked inhibitor of apoptosis protein (XIAP), survivin, and Bcl-xL proteins. Knockdown of NIK expression showed results similar to those observed with mangiferin treatment. Our results suggest that mangiferin induces apoptosis through the inhibition of nuclear translocation of NF-κB by suppressing NIK activation in MM cell lines. Our results provide a new insight into the molecular mechanism of mangiferin-induced apoptosis. Importantly, since the number of reported NIK inhibitors is limited, mangiferin, which targets NIK, may be a potential anticancer agent for the treatment of MM.
  • 鼠径リンパ節穿刺リピオドールリンパ管造影が有効であった食道癌術後乳糜腹水の2例
    加藤 寛章; 田中 裕美子; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本外科系連合学会誌 日本外科系連合学会 41 (3) 523 - 523 0385-7883 2016/05
  • 食道胃接合部癌のリンパ節転移・再発状況に基づく治療戦略及び中下縦隔から腹腔動脈周囲までの連続的郭清
    白石 治; 田中 裕美子; 曽我部 俊介; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 塩崎 均; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 116回 OP - 7 2016/04
  • 胃噴門部GISTに対する腹腔鏡下胃内手術
    安田 篤; 今本 治彦; 曽我部 俊介; 田中 裕美子; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 安田 卓司; 奥野 清隆
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 116回 PS - 2 2016/04
  • 食道癌における高難度手術 コツと技 Salvage縦隔気管瘻手術における気管血流温存と根治CRT後の気管食道瘻手術における術式の工夫
    安田 卓司; 白石 治; 岩間 密; 曽我部 俊介; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 古河 洋; 今本 治彦; 奥野 清隆
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 116回 SY - 6 2016/04
  • 胸部食道癌における鎖骨上リンパ節転移の意義 遠隔転移 or 領域内転移?
    岩間 密; 曽我部 俊介; 田中 裕美子; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 116回 OP - 3 2016/04
  • 75歳以上根治切除可能4型/大型3型胃癌に対する術前化学放射線療法の試み
    曽我部 俊介; 岩間 密; 田中 裕美子; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 116回 PS - 6 2016/04
  • 仰臥位と腹臥位CTにおける重力差とCT値による客観評価を用いた新しい進行食道癌大動脈浸潤の評価の有用性
    田中 裕美子; 白石 治; 熊野 正士; 曽我部 俊介; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 村上 卓道; 安田 卓司
    日本外科学会定期学術集会抄録集 (一社)日本外科学会 116回 OP - 2 2016/04
  • 消化器外科手術アトラス 右開胸食道亜全摘術 縦隔からの反回神経周囲リンパ節徹底郭清
    白石 治; 田中 裕美子; 曽我部 俊介; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    消化器外科 (株)へるす出版 39 (4) 373 - 384 0387-2645 2016/04
  • 胃癌と栄養 胃全摘後の栄養評価 CT画像による脂肪量と筋量の経時変化について
    安田 篤; 曽我部 俊介; 田中 裕美子; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 今本 治彦; 安田 卓司; 奥野 清隆
    日本胃癌学会総会記事 (一社)日本胃癌学会 88回 181 - 181 2016/03
  • P1進行胃癌に対するPTX腹腔内投与+PCS全身化学療法の治療成績
    新海 政幸; 今野 元博; 田中 裕美子; 曽我部 俊介; 岩間 密; 白石 治; 安田 篤; 今本 治彦; 古河 洋; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 88回 293 - 293 2016/03
  • 噴門側胃切除後の食道残胃吻合法(円錐状胃管作成+食道裂孔挿入法)
    安田 篤; 今本 治彦; 曽我部 俊介; 田中 裕美子; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 安田 卓司; 奥野 清隆
    日本胃癌学会総会記事 (一社)日本胃癌学会 88回 477 - 477 2016/03
  • Masanobu Tsubaki; Kenji Mashimo; Tomoya Takeda; Toshiki Kino; Arisa Fujita; Tatsuki Itoh; Motohiro Imano; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 78 23 - 29 0753-3322 2016/03 [Refereed]
     
    Macrophage inflammatory protein-1alpha (MIP-1α) is detected at high concentrations in patients with multiple myeloma. It is thought to play an important role in the etiology of multiple myeloma and osteolysis. Thus, inhibiting MIP-1α expression may be useful in developing therapeutic treatments for multiple myeloma-induced osteolysis. In this study, we investigated the potential of statins to inhibit mRNA expression and secretion of MIP-1α in mouse myeloma cells (MOPC-31C). We found that statins inhibited the lipopolysaccharide (LPS)-induced MIP-1α mRNA expression and protein secretion in MOPC-31C cells. This inhibition was reversed when farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), intermediates of the mevalonate pathway, were combined with statins. Furthermore, statins reduced the GTP form of Ras, a phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2), and phosphorylated Akt. Our results indicate that statins inhibit biosynthesis of FPP and GGPP and thereby down regulate signal transduction of Ras/ERK and Ras/Akt pathways. The net effect suppresses LPS-induced MIP-1α mRNA expression and protein secretion in MOPC-31C cells. Thus, statins hold great promise for developing effective therapies against myeloma-induced osteolysis.
  • 白石 治; 田中 裕美子; 曽我部 俊介; 加藤 寛章; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均; 安田 卓司
    消化器内視鏡 (株)東京医学社 28 (1) 115 - 121 0915-3217 2016/01 
    本稿では、喉頭温存手術の適応限界とその術式を紹介した。頸部食道癌は喉頭、気管と密接な解剖学的問題があり、切離マージンの根治性と術後嚥下障害リスクの安全性の問題から喉頭温存手術の適応は限られている。そこで、筆者らは喉頭温存手術の適応を限界まで広げるために術式の工夫を考案した。まずは、輪状咽頭筋、下咽頭収縮筋下縁を切離することで、喉頭気管と頸部食道の剥離は輪状軟骨上縁付近まで延長でき、最大限に切離マージンを確保できる。次に、舌骨上筋群には剥離操作を入れず舌骨下筋群を全切離し、術後の喉頭挙上の妨げになる瘢痕、癒着を回避することで誤嚥を減少させ安全性を確保できる。これらをもってすると、喉頭温存手術の適応限界は下咽頭から食道入口部に内視鏡を進め、内腔が広がり始める狭窄帯下端から尾側の病巣まで、CTでは輪状軟骨下縁まで及んでいない病巣である。本論にその詳細を記述した。(著者抄録)
  • Yumiko Tanaka; Motohiro Imano; Shunsuke Sogabe; Mitsuru Iwama; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Haruhiko Imamoto; Hiroshi Furukawa; Takushi Yasuda
    Japanese Journal of Gastroenterological Surgery Japanese Society of Gastroenterological Surgery 49 (9) 857 - 866 1348-9372 2016 
    A 71-year-old man underwent staging laparoscopy for HER2-positive advanced gastric cancer staging laparoscopy revealed peritoneal dissemination. He received neoadjuvant chemotherapy including trastuzumab (T-mab). After the chemotherapy, he underwent staging laparoscopy again. Peritoneal dissemination was not found, and he underwent total gastrectomy (D2) and splenectomy. Pathological diagnosis was poorly differentiated adenocarcinoma invading the submucosa. Harvested lymph nodes were all free of metastasis. Peritoneal dissemination and peritoneal cytology was negative. After curative resection, combination therapy of S-1 and T-mab was administered. At 8 months after the gastric cancer surgery, nausea appeared. Serum CEA concentration was elevated. Recurrent signs were not found on chest and abdominal enhanced CT. He was urgently hospitalized for decreased level of consciousness. Enhanced MRI revealed abnormal enhancement effects of the pia mater of the cerebellum, midbrain and right temporal lobe. Because there were not infection signs, infectious meningitis was denied. Meningeal carcinomatosis was diagnosed from progress, and he died 12 days after being diagnosed. Meningeal carcinomatosis is a rare complication of gastric cancer, and its prognosis is poor. There are a wide variety of symptoms in meningeal carcinomatosis. In some cases, a definitive diagnosis is very difficult. We considered it important to report our experience to emphasize the need to include meningeal carcinomatosis in the differential diagnoses for patients presenting with cerebral and cranial signs.
  • 腹腔鏡下噴門側胃切除後の再建 革新を目指して 腹腔鏡補助下噴門側胃切除・食道残胃吻合(胃管様作成+食道裂孔挿入)の有用性
    安田 篤; 今本 治彦; 田中 裕美子; 曽我部 俊介; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 安田 卓司; 奥野 清隆
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 20 (7) PD10 - 3 1344-6703 2015/12
  • 腹腔鏡下造設空腸瘻のイレウス対策"カーテン法"
    白石 治; 田中 裕美子; 曽我部 俊介; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 20 (7) OS63 - 2 1344-6703 2015/12
  • 食道疾患に対する手術手技 食道癌手術におけるoncologyに基づいた徹底郭清と低侵襲手技の融合
    安田 卓司; 白石 治; 岩間 密; 曽我部 俊介; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 古河 洋; 今本 治彦
    日本臨床外科学会雑誌 日本臨床外科学会 76 (増刊) 381 - 381 1345-2843 2015/10
  • 合併症ゼロを目指した再建、吻合手術手技(食道・胃) 縫合不全1%の食道癌術後胃管再建
    白石 治; 田中 裕美子; 曽我部 俊介; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 76 (増刊) 390 - 390 1345-2843 2015/10
  • 再発癌の治療方針(食道、胃) 食道癌術後再発に対する治療戦略
    曽我部 俊介; 白石 治; 岩間 密; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 76 (増刊) 411 - 411 1345-2843 2015/10
  • 縫合・吻合不全の予防と治療(食道、胃、十二指腸) 縫合不全0を目指した食道癌切除後再建法
    岩間 密; 田中 裕美子; 曽我部 俊介; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 76 (増刊) 439 - 439 1345-2843 2015/10
  • 胃癌・大腸癌の腹膜播種に対する治療戦略 胃癌腹膜播種症例に対する外科的介入の意義
    今野 元博; 岩間 密; 田中 裕美子; 曽我部 俊介; 白石 治; 安田 篤; 新海 政幸; 今本 治彦; 古河 洋; 安田 卓司; 光冨 徹哉; 竹山 宣典; 奥野 清隆
    日本臨床外科学会雑誌 日本臨床外科学会 76 (増刊) 442 - 442 1345-2843 2015/10
  • 胃癌腹膜播種症例におけるPTX単回腹腔内投与とTS-1+PTX+CDDPによる逐次全身化学療法の安全性と効果における検討
    田中 裕美子; 今野 元博; 曽我部 俊介; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今本 治彦; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 76 (増刊) 540 - 540 1345-2843 2015/10
  • 高齢者幽門側胃切除術後の呼吸器合併症に対する嚥下リハビリ介入の効果について
    安田 篤; 今本 治彦; 田中 裕美子; 曽我部 俊介; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 安田 卓司; 奥野 清隆
    日本臨床外科学会雑誌 日本臨床外科学会 76 (増刊) 609 - 609 1345-2843 2015/10
  • 大型3型、4型胃癌に対する放射線化学療法後の開腹手術の留意点
    新海 政幸; 古河 洋; 田中 裕美子; 曽我部 俊介; 岩間 密; 白石 治; 安田 篤; 今野 元博; 今本 治彦; 奥野 清隆; 安田 卓司
    日本臨床外科学会雑誌 日本臨床外科学会 76 (増刊) 778 - 778 1345-2843 2015/10
  • Atsushi Yasuda; Takushi Yasuda; Haruhiko Imamoto; Hiroaki Kato; Kohei Nishiki; Mitsuru Iwama; Tomoki Makino; Osamu Shiraishi; Masayuki Shinkai; Motohiro Imano; Hiroshi Furukawa; Kiyokata Okuno; Hitoshi Shiozaki
    GASTRIC CANCER SPRINGER 18 (4) 850 - 858 1436-3291 2015/10 [Refereed]
     
    An optimal reconstruction method for proximal gastrectomy (PG) remains elusive. Esophagogastrostomy (EG) is technically simple but suffers from the disadvantage of gastroesophageal reflux. Jejunal interposition (JI) has a low rate of gastroesophageal reflux, but the procedure is more complicated, and delayed gastric emptying is a problem. We created a modified EG and have used the modified technique for PG since 2006. The procedure involves shaping the remnant stomach into a gastric conduit. The EG is performed high on the anterior wall, and the conduit is kept straight by applying a circular stapler inserted from the anterior wall of the antrum. The tip of the gastric conduit is then inserted into the lower mediastinum, creating a sharp angle of His. In this retrospective cohort study, the clinical and physiological outcomes were compared between 25 patients who underwent this procedure and 21 patients who underwent JI from 2001 to 2005. Laparoscopic procedures were performed more frequently, and residual food and bile reflux were less common in the EG group than in the JI group. No significant differences in remnant gastritis or reflux esophagitis were observed between the two groups. However, the late complication of intestinal obstruction occurred only in the JI group. The modified EG technique has advantages over the JI technique because of its simplicity and low incidence of residual food and bile reflux. The next step would be to explore this technique further by a prospective multi-institutional study to confirm the reproducibility of its benefits. Miniabstract: The modified EG technique has advantages over the JI technique because of its simplicity, high rate of laparoscopy use, and low incidence of gastroesophageal reflux.
  • 白石 治; 田中 裕美子; 曽我部 俊介; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均; 安田 卓司
    臨床外科 (株)医学書院 70 (9) 1083 - 1089 0386-9857 2015/09 
    <ポイント>pT3,pN2,鎖骨上リンパ節陽性例,ly+,v+であったものが,再発高リスク群であり,また再発の70%が術後1年内に確認され,88%が2年内に確認された.リンパ節再発が最も多く,次に血行性再発が多い.また血行性転移の内訳は肺が33%,肝が30%,次いで骨が17%を占めた.寛解,長期生存できる可能性があるのは,頸部および縦隔のリンパ節や肺の1〜2個の転移再発であり,可能ならば積極的に切除を検討する.(著者抄録)
  • 岩間 密; 今野 元博; 安田 卓司
    臨床腫瘍プラクティス (株)ヴァンメディカル 11 (3) 204 - 209 1880-3083 2015/08 
    <View Points!>4型胃癌における最も大きな予後規定因子は腹膜播種である。我々は4型胃癌をはじめ進行胃がんにおける腹膜播種制御を目的に、以下の2つの治療戦略を計画した。■局所効果により将来の腹膜播種再発予防を期待した術前化学放射線療法(OGSG1205、OGSG1301)■漿膜浸潤胃癌症例に対し腹腔内微小転移を対象とした周術期腹腔内化学療法(GAPS study)(著者抄録)
  • 頸部食道癌の治療戦略 CRTと外科的治療の住み分けと合併治療 頸部食道癌の導入CRTによる治療戦略
    白石 治; 田中 裕美子; 曽我部 俊介; 錦 耕平; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 69回 30 - 30 2015/07
  • 食道再建法・吻合法 最良の方法は 縫合不全を回避する胃管再建の要点
    白石 治; 田中 裕美子; 曽我部 俊介; 錦 耕平; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 69回 33 - 33 2015/07
  • 胸部食道癌におけるFDG-PETによるpN予測、術前化学療法の適応とその効果予測
    岩間 密; 曽我部 俊介; 田中 裕美子; 錦 耕平; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 69回 75 - 75 2015/07
  • 腹臥位CTにおける腫瘍-大動脈間のCT値測定による進行食道癌大動脈浸潤の評価の有用性
    田中 裕美子; 白石 治; 曽我部 俊介; 錦 耕平; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 69回 76 - 76 2015/07
  • 根治CRT後の食道-気管/気管支瘻に対し有茎心膜を用い気管膜様部再建術で救命し得た1例
    錦 耕平; 白石 治; 田中 裕美子; 曽我部 俊介; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 69回 103 - 103 2015/07
  • 頸部食道癌CRT後再々発に対し咽喉食摘、縦隔気管瘻造設術(Grillo)を施行した1例
    新海 政幸; 曽我部 俊介; 田中 裕美子; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 69回 119 - 119 2015/07
  • 腐食性食道炎による頸部食道狭窄に対し、狭窄部切開・遊離空腸パッチ術を施行した1例
    曽我部 俊介; 白石 治; 岩間 密; 錦 耕平; 田中 裕美子; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 69回 196 - 196 2015/07
  • 食道癌術後合併症を減らす術式の工夫 縫合不全を回避する胃管再建の工夫と反回神経リンパ節郭清
    白石 治; 田中 裕美子; 曽我部 俊介; 錦 耕平; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 70回 PD - 1 2015/07
  • Stage II/III食道癌に対する治療戦略 当院におけるStage II/III食道癌に対するFDG-PETを用いた個別化治療戦略
    錦 耕平; 白石 治; 岩間 密; 田中 裕美子; 曽我部 俊介; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 70回 WS - 2 2015/07
  • 根治切除不能胃癌に対する治療戦略 胃癌腹膜播種症例に対するPTX単回腹腔内投与およびTS-1+PTX+CDDPによる逐次全身化学療法の試み
    岩間 密; 今野 元博; 曽我部 俊介; 錦 耕平; 白石 治; 安田 篤; 新海 政幸; 今本 治彦; 古河 洋; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 70回 RS - 3 2015/07
  • 胃体上部早期癌に対する腹腔鏡補助下噴門側胃切除と胃全摘の比較検討
    安田 篤; 今本 治彦; 里井 俊平; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 竹山 宜典; 安田 卓司; 奥野 清隆
    日本消化器外科学会総会 (一社)日本消化器外科学会 70回 O - 2 2015/07
  • 胃癌腹膜播種の病態と診断・治療 胃癌腹膜播種症例に対する外科的介入を併用した治療戦略の検討
    今野 元博; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今本 治彦; 古河 洋; 安田 卓司; 竹山 宜典; 奥野 清隆
    日本消化器外科学会総会 (一社)日本消化器外科学会 70回 WS - 9 2015/07
  • 細径胃管を用いた食道切除後胸骨後胃管再建術の工夫と治療成績
    田中 裕美子; 白石 治; 曽我部 俊介; 錦 耕平; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 安田 卓司
    日本消化器外科学会総会 (一社)日本消化器外科学会 70回 P - 2 2015/07
  • Masanobu Tsubaki; Tomoya Takeda; Tadahumi Tani; Hirotaka Shimaoka; Naohiro Suzuyama; Kotaro Sakamoto; Arisa Fujita; Naoki Ogawa; Tatsuki Itoh; Motohiro Imano; Yoshinori Funakami; Seiji Ichida; Takao Satou; Shozo Nishida
    INTERNATIONAL JOURNAL OF CANCER WILEY-BLACKWELL 137 (1) 243 - 250 0020-7136 2015/07 [Refereed]
     
    Oxaliplatin is a key drug commonly used in colorectal cancer treatment. Despite high clinical efficacy, its therapeutic application is limited by common, dose-limiting occurrence of neuropathy. As usual symptomatic neuropathy treatments fail to improve the patients' condition, there is an urgent need to advance our understanding of the pathogenesis of neuropathy to propose effective therapy and ensure adequate pain management. Oxaliplatin-induced neuropathy was recently reported to be associated with protein kinase C (PKC) activation. It is unclear, however, whether PKC inhibition can prevent neuropathy. In our current studies, we found that a PKC inhibitor, tamoxifen, inhibited oxaliplatin-induced neuropathy via the PKC/extracellular signal-regulated kinase (ERK)/c-Fos pathway in lumbar spinal cords (lumbar segments 4-6). Additionally, tamoxifen was shown to act in synergy with oxaliplatin to inhibit growth in tumor cells-implanted mice. Moreover, mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, PD0325901, suppressed oxaliplatin-induced neuropathy and enhanced oxaliplatin efficacy. Our results indicate that oxaliplatin-induced neuropathy is associated with PKC/ERK/c-Fos pathway in lumbar spinal cord. Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin-induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin-induced neuropathy and could aid in combination antitumor pharmacotherapy.
  • Kohei Nishiki; Yumiko Tanaka; Shunsuke Sogabe; Mitsuru Iwama; Tomoki Makino; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Haruhiko Imamoto; Hiroshi Furukawa; Takushi Yasuda
    Japanese Journal of Cancer and Chemotherapy Japanese Journal of Cancer and Chemotherapy Publishers Inc. 42 (6) 739 - 742 0385-0684 2015/06 [Refereed]
     
    A 58-year-old woman was diagnosed with scirrhous gastric cancer suspected because of lymphangitis carcinomatosa. She was treated with 10 courses of S-1+CDDP chemotherapy. After 3 years and 6 months, CR was obtained and she underwent curative total gastrectomy with D2 lymph node dissection plus resection of the spleen and transverse colon. The pathological results of the resected specimen were tub2 > por, pT1a, N1 (No. 7), MO, CYO, P0, and HER2 (3+). After surgical treatment, supraclavicular lymph node metastasis occurred, and the patient underwent trastuzumab+capecitabine therapy, which resulted in CR for 1 year and 6 months. Thus, for unresectable scirrhous gastric cancer, multidisciplinary therapy such as longterm chemotherapy including trastuzumab and surgery is useful.
  • 癌性リンパ管症併発を疑うスキルス胃癌に対し化学療法にてCR後根治切除し長期生存中の1例
    錦 耕平; 田中 由美子; 曽我部 俊介; 岩間 密; 牧野 知紀; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 安田 卓司
    癌と化学療法 (株)癌と化学療法社 42 (6) 739 - 742 0385-0684 2015/06 
    症例は58歳、女性。癌性リンパ管症を伴うスキルス胃癌に対し、S-1+CDDP化学療法10コース施行しCRを得た。3年6ヵ月後に根治切除施行。切除標本の病理結果はtub2>por、pT1a、N1(No.7)、M0、CY0、P0、HER2(3+)であった。その後、鎖骨上窩リンパ節再発を来し、trastuzumab+capecitabine併用化学療法施行。1年6ヵ月、画像上病巣は認めていない。切除不能スキルス胃癌に対しても長期にわたる化学療法、手術治療など集学的治療が有用であると考えられた。(著者抄録)
  • Ying-Feng Peng; Motohiro Imano; Tatsuki Itoh; Takao Satoh; Yasutaka Chiba; Haruhiko Imamoto; Masahiro Tsubaki; Shozo Nishida; Takushi Yasuda; Hiroshi Furukawa
    JOURNAL OF SURGICAL ONCOLOGY WILEY-BLACKWELL 111 (8) 1041 - 1046 0022-4790 2015/06 [Refereed]
     
    Background and ObjectivesWe carried out a phase II trial to evaluate the feasibility, efficacy, and tolerability of perioperative chemotherapy including single intraperitoneal(IP) administration of paclitaxel(PTX) followed by intravenous(IV) administrations of PTX with S-1 in a neoadjuvant setting for serosa-positive gastric cancer. MethodsPatients with cT4a gastric cancer were enrolled. A laparoscopic survey was performed before study inclusion for the confirmation of serosal invasion, negative lavage cytology, and negative peritoneal metastasis. IP PTX (80mg/m(2)) was administered, followed by systemic chemotherapy. Surgery was performed after the completion of chemotherapy. The primary endpoint was the treatment completion rate. Results37 patients were recruited. The treatment completion rate was 67.6% (25/37; 90% CI, 52.8-80.1%), which was significantly higher than 50%; we set this as a threshold value (P=2.4% [one-sided]). 14 patients had target lesions; of these, 10 showed a partial response (71.4%), three had stable disease (21.4%), and one had progressive disease(7.2%). The response rate was 71.4% (10/14). All patients underwent gastrectomy with D2 lymph node dissection. The 3- and 5-year OS rates were 78.0 and 74.9%, respectively. ConclusionsPerioperative chemotherapy including neoadjuvant IP PTX followed by sequential IV PTX with S-1 for serosa-positive gastric cancer is feasible, safe, and efficient. J. Surg. Oncol. 2015 111:1041-1046. (c) 2015 Wiley Periodicals, Inc.
  • Masanobu Tsubaki; Tomoya Takeda; Naoki Ogawa; Kotaro Sakamoto; Hirotaka Shimaoka; Arisa Fujita; Tatsuki Itoh; Motohiro Imano; Toshihiko Ishizaka; Takao Satou; Shozo Nishida
    LEUKEMIA RESEARCH PERGAMON-ELSEVIER SCIENCE LTD 39 (4) 445 - 452 0145-2126 2015/04 [Refereed]
     
    The acquisition of anti-cancer drug resistance is a major limitation of chemotherapy for multiple myeloma(MM) and it is thus important to identify the mechanisms by which MM cells develop such drug resistance. In a previous study, we showed that multidrug resistance (MDR) involves the overexpression of MDR1 and survivin in vincristine-resistant RPMI8226/VCR cells. However, the underlying mechanism of MDR remains unclear. In this study, we investigated the mechanism of MDR in RPMI8226/VCR cells, and found that RPMI8226/VCR cells exhibit increased levels of activated ERK1/2, Akt, and NF-kappa B, while the levels of activated mTOR, p38MAPK, and JNK do not differ between RPMI8226/VCR cells and their vincristine-susceptible counterparts. In addition, the inhibition of ERK1/2, Akt, or NF-kappa B by inhibitors reversed thedrug resistance of RPMI8226/VCR cells via the suppression of survivin expression, but did not affect MDR1 expression; RNA silencing of survivin expression completely reversed vincristine resistance, while MDR1 silencing only weakly suppressed vincristine resistance in RPMI8226/VCR cells. These results indicate that enhanced survivin expression via the activation of ERK1/2, Akt, and NF-kappa B plays a critical role in vincristine resistance in RPMI8226/VCR cells. Our findings suggest that ERK1/2, Akt, and NF-kappa B inhibitors are potentially useful as anti-MDR agents for the treatment of vincristine-resistant MM. (C) 2015 Elsevier Ltd. All rights reserved.
  • 腹腔鏡下噴門側胃切除術の再建手技 当科における腹腔鏡補助下噴門側胃切除・食道残胃吻合法について
    安田 篤; 今本 治彦; 曽我部 俊介; 錦 耕平; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 安田 卓司; 奥野 清隆
    日本胃癌学会総会記事 (一社)日本胃癌学会 87回 204 - 204 2015/03
  • 食道胃接合部癌に対する下縦隔郭清のコツとピットフォール 開腹手術の立場から 進行食道胃接合部癌に対する中下縦隔から腹腔動脈周囲までの連続的郭清
    白石 治; 田中 由美子; 曽我部 俊介; 錦 耕平; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 塩崎 均; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 87回 207 - 207 2015/03
  • 食道胃接合部癌のリンパ節転移状況から導かれる治療方針
    白石 治; 田中 由美子; 曽我部 俊介; 錦 耕平; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 塩崎 均; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 87回 256 - 256 2015/03
  • 術前化学放射線療法にてpCRを得た大型3型胃癌の1切除例
    錦 耕平; 田中 裕美子; 曽我部 俊介; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 古河 洋; 今本 治彦; 安田 卓司
    日本胃癌学会総会記事 (一社)日本胃癌学会 87回 346 - 346 2015/03
  • Masanobu Tsubaki; Tomoya Takeda; Toshiki Kino; Tatsuki Itoh; Motohiro Imano; Genzo Tanabe; Osamu Muraoka; Takao Satou; Shozo Nishida
    American journal of translational research 7 (8) 1371 - 81 1943-8141 2015 [Refereed]
     
    Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic inflammation of synovial joints, ultimately leading to a progressive and irreversible joint destruction. Activation of nuclear factor-kappa B (NF-κB) promotes production of proinflammatory cytokines in various inflammatory diseases including rheumatoid arthritis. Mangiferin, 1,3,6,7-tetrahydroxyxanthone-C2-β-D-glucoside (C-glucosyl xanthone), is a naturally occurring polyphenol. Our previous results showed that mangiferin suppressed NF-κB activation. However, it is unclear, whether mangiferin can prevent rheumatoid arthritis through suppression of NF-κB activation and expression of various cytokines, such as tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6), which play a critical role in the pathogenesis of rheumatoid arthritis. In the present study, we found that mangiferin suppressed the progression and incidence of CIA in DBA1/J mice. In CIA mice, mangiferin inhibited the mRNA expression of cytokine genes in thymus and spleen of CIA mie and led to decreased serum levels of IL-1β, IL-6, TNF-α, and receptor activator NF-κB ligand (RANKL) via inhibition of NF-κB and activation of extracellular signal-regulated kinase 1/2 (ERK1/2). In addition, mangiferin markedly inhibited not only developing but also clinically evident CIA. These findings suggest that mangiferin has potential clinical applications for the treatment of rheumatoid arthritis.
  • Masanobu Tsubaki; Tomoya Takeda; Toshiki Kino; Naoya Obata; Tatsuki Itoh; Motohiro Imano; Kenji Mashimo; Daichiro Fujiwara; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
    American journal of cancer research 5 (10) 3186 - 97 2156-6976 2015 [Refereed]
     
    Metastatic melanoma is a life-threatening disease for which no effective treatment is currently available. In melanoma cells, Rho overexpression promotes invasion and metastasis. However, the effect of statins on spontaneous metastasis and tumor growth remains unclear. In the present study, we investigated the mechanism of statin-mediated tumor growth and metastasis inhibition in an in vivo model. We found that statins significantly inhibited spontaneous metastasis and tumor growth. Statins inhibited the mRNA expression and enzymatic activities of matrix metalloproteinases (MMPs) in vivo and also suppressed the mRNA and protein expression of very late antigens (VLAs). Moreover, statins inhibited the prenylation of Rho as well as the phosphorylation of LIM kinase, serum response factor (SRF), and c-Fos downstream of the Rho signaling pathway. In addition, statins enhanced p53, p21, and p27 expression and reduced phosphorylation of cyclin-dependent kinase and expression of cyclin D1 and E2. These results indicate that statins suppress Rho signaling pathways, thereby inhibiting tumor metastasis and growth. Furthermore, statins markedly improved the survival rate in a metastasis model, suggesting that statins have potential clinical applications for the treatment of metastatic cancers.
  • Masanobu Tsubaki; Tomoya Takeda; Kotaro Sakamoto; Hirotaka Shimaoka; Arisa Fujita; Tatsuki Itoh; Motohiro Imano; Kenji Mashimo; Daiichiro Fujiwara; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
    AMERICAN JOURNAL OF CANCER RESEARCH E-CENTURY PUBLISHING CORP 5 (1) 168 - 179 2156-6976 2015 [Refereed]
     
    Osteolytic bone disease in multiple myeloma (MM) is associated with upregulated osteoclast activity. Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is crucially involved in the development of osteolytic bone lesions in MM. We previously reported that minodronate inhibited lipopolysaccharide-induced MIP-1 alpha secretion in mouse myeloma cells. However, it remains unknown whether bisphosphonates and statins inhibit MIP-1 alpha secretion by human MM cells. In present study, we investigated whether bisphosphonates and statins had any inhibitory effect on MIP-1 alpha secretion by human myeloma cells and the mechanism underlying this effect. In this study, we found that bisphosphonates and statins inhibited MIP-1 alpha mRNA and MIP-1 alpha secretion and suppressed extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt phosphorylation by inhibiting Ras prenylation. Moreover, bisphosphonates and statins suppressed the expression of acute myeloid leukemia-1 alpha (AML-1A) mRNA, a MIP-1 alpha transcription factor. These results indicate that bisphosphonates and statins suppress the Ras/mitogen-activated protein kinase kinase/ERK/AML-1A and Ras/phosphatidylinositol-3 kinase/Akt/AML-1A pathways, thereby inhibiting MIP-1 alpha secretion by MM cells. Therefore, use of MIP-1 alpha expression inhibitors such as bisphosphonates and statins may provide a new therapeutic approach to inhibiting tumour progression and bone destruction in MM patients.
  • 術前のTS-1内服投与、パクリタキセル静脈内及び腹腔内投与並びに術後のパクリタキセル静脈内投与及び腹腔内投与の併用療法B47根治切除が可能な漿膜浸潤を伴う胃がん(洗浄細胞診により、が細胞の存在が認められないものに限る) がん先進医療NAVIGATOR―がん治療研究の最前線―
    今野元博
    日本医学出版社 12 36 - 38 2015 [Refereed]
  • Atsushi Yasuda; Haruhiko Imamoto; Hiroshi Furukawa; Motohiro Imano; Takushi Yasuda; Kiyokata Okuno
    Japanese Journal of Cancer and Chemotherapy Japanese Journal of Cancer and Chemotherapy Publishers Inc. 41 (12) 2322 - 2325 0385-0684 2014/11 [Refereed]
     
    We report 2 rare cases of afferent loop syndrome caused by obstruction at the jejuno-jejunostomy site in the Roux-en-Y loop after total gastrectomy, which was successfully treated by endoscopic balloon dilatation of the anastomotic stenosis. Case 1: A 62-year-old woman presented with malaise and lower abdominal distension 6 months after laparoscopy-assisted total gastrectomy with Roux-en-Y reconstruction. She was diagnosed with afferent loop syndrome CT imaging indicated marked dilatation of the afferent loop, with membranous obstruction at the jejuno-jejunostomy site in the Roux-en-Y loop. Although almost complete occlusion was noted at the jejuno-jejunostomy site, the obstruction was successfully relieved by endoscopic balloon dilation using Tandem™ XL Triple Lumen ERCP Cannula (Boston Scientific)®. Case 2: A 70-year-old man presented with malaise and lower abdominal distension 3 years after laparoscopy-assisted total gastrectomy with Roux-en-Y reconstruction. He was diagnosed with afferent loop syndrome CT imaging indicated complete obstruction at the jejunojejunostomy site in the Roux-en-Y loop. As in case 1, the obstruction was successfully treated by endoscopic balloon dilatation of the occluded anastomosis.
  • 胃全摘後Roux-en-Y脚吻合部の完全狭窄による輸入脚症候群に対し内視鏡的拡張術にて治療完遂し得た2例の報告
    安田 篤; 今本 治彦; 古河 洋; 今野 元博; 安田 卓司; 奥野 清隆
    癌と化学療法 (株)癌と化学療法社 41 (12) 2322 - 2325 0385-0684 2014/11 
    はじめに:われわれは極めてまれなY脚吻合部のほぼ完全閉塞よる輸入脚症候群に対し、侵襲の少ない内視鏡的バルーン拡張術にて狭窄を解除し得た2症例を経験したので報告する。症例1:62歳、女性。腹腔鏡補助下胃全摘、Roux-en-Y再建施行後6ヵ月目で全身倦怠と下腹部の膨満感出現、CTで輸入脚の著明な拡張変化を認め、輸入脚症候群と診断した。Y脚吻合部はほぼ完全狭窄の状態であったが、透明キャップとタンデムXL ERCPカニューレ(Boston Scientific)を用いて内視鏡的バルーン拡張術を完遂し得た。症例2:70歳、男性。腹腔鏡補助下胃全摘施行後3年目で軽度全身倦怠と易疲労、下腹部の膨満が出現、採血結果は特に異常を認めなかったが、CTで輸入脚の著明な拡張を認め、輸入脚症候群と診断した。Y脚吻合部完全狭窄であったが同様に透明キャップとタンデムカニューレを用いて内視鏡的バルーン拡張術を完遂し得た。まとめ:本疾患は迅速な対応が求められる場合が多いが、治療方法はできる限り低侵襲なものを選択すべきである。内視鏡的処置はその一つとして試みるべき手技と考える。(著者抄録)
  • Masanobu Tsubaki; Naoki Ogawa; Tomoya Takeda; Kotaro Sakamoto; Hirotaka Shimaoka; Arisa Fujita; Tatsuki Itoh; Motohiro Imano; Takao Satou; Shozo Nishida
    Biomedicine and Pharmacotherapy Elsevier Masson SAS 68 (8) 999 - 1005 1950-6007 2014/10 [Refereed]
     
    Dimethyl fumarate (DMF) is a fumaric acid ester that is used to treat psoriasis and multiple sclerosis. Recently, DMF was found to exhibit anti-tumor effects. However, the molecular mechanisms underlying these effects have not been elucidated. In this study, we investigated the mechanism of DMF-induced apoptosis in different human hematopoietic tumor cell lines. We found that DMF induced apoptosis in different human hematopoietic tumor cell lines but it did not affect the normal human B lymphocyte cell line RPMI 1788. We also observed a concurrent increase in caspase-3 activity and in the number of Annexin-V-positive cells. Furthermore, an examination of the survival signals, which are activated by apoptotic stimuli, revealed that DMF significantly inhibited nuclear factor-κB (NF-κB) p65 nuclear translocation. In addition, DMF suppressed B-cell lymphoma extra-large (Bcl-xL) and X-linked inhibitor of apoptosis (XIAP) expression whereas Bcl-2, survivin, Bcl-2-associated X protein (Bax), and Bim levels did not change. These results indicated that DMF induced apoptosis by suppressing NF-κB activation, and Bcl-xL and XIAP expression. These findings suggested that DMF might have potential as an anticancer agent that could be used in combination therapy with other anticancer drugs for the treatment of human hematopoietic tumors.
  • 術前治療後pN(+)食道扁平上皮癌に対するペプチドワクチンを用いた術後補助免疫療法
    錦 耕平; 岩間 密; 牧野 知之; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 古河 洋; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 68回 61 - 61 2014/07
  • 食道癌術後における再建胃管癌8例の検討
    錦 耕平; 岩間 密; 牧野 知之; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 古河 洋; 今本 治彦; 安田 卓司
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 68回 138 - 138 2014/07
  • CY1進行胃癌に対する治療戦略とその成績
    新海 政幸; 今野 元博; 村瀬 貴昭; 曽我部 俊介; 錦 耕平; 牧野 智紀; 岩間 密; 白石 治; 安田 篤; 今本 治彦; 奥野 清隆; 古河 洋; 安田 卓司
    日本癌治療学会誌 (一社)日本癌治療学会 49 (3) 1003 - 1003 0021-4671 2014/06
  • 胃癌術前・術後の化学放射線療法をどう考えるか
    佐野 武; 高橋 常浩; 伊藤 芳紀; 今野 元博
    胃がんperspective (株)メディカルレビュー社 7 (2) 87 - 95 1883-3330 2014/06
  • Toru Aoyama; Kazuhiro Nishikawa; Nobuhiro Takiguchi; Kazuaki Tanabe; Motohiro Imano; Ryoji Fukushima; Junichi Sakamoto; Mari S. Oba; Satoshi Morita; Toru Kono; Akira Tsuburaya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY SPRINGER 73 (5) 1047 - 1054 0344-5704 2014/05 [Refereed]
     
    Hangeshashinto (TJ-14, a Kampo medicine), which reduces the level of prostaglandin E2 and affects the cyclooxygenase activity, alleviates chemotherapy-induced oral mucositis (COM). We conducted a randomized comparative trial to investigate whether TJ-14 prevents and controls COM in patients with gastric cancer. We randomly assigned patients with gastric cancer who developed moderate-to-severe oral mucositis (CTCAE v4.0 grade a parts per thousand 1) during any cycle of chemotherapy to receive either TJ-14 or a placebo as a double-blind trial. The patients received a placebo or TJ-14 for 2-6 weeks according to the chemotherapy regimen from the beginning of the next course of chemotherapy. The primary end point was the incidence of grade a parts per thousand 2 oral mucositis in the protocol treatment course, and the secondary end points were the time to disappearance of oral mucositis and the incidence of adverse events. Following the key opening of the blinding protocol, we analyzed 91 eligible patients (TJ-14: 45, placebo: 46) using a "per protocol set" analysis. The incidence of a parts per thousand grade 2 COM was 40.0 % in the TJ-14 group and 41.3 % in the placebo group (p = 0.588). The median duration of a parts per thousand grade 2 COM was 14 days in the TJ-14 group and 16 days in the placebo group (p = 0.894). Meanwhile, the median duration of any grade of COM was 9 days in the TJ-14 group and 17 days in the placebo group among the patients who developed grade 1 symptoms during the screening cycle [hazard ratio 0.60; 95 % CI (0.23-1.59), p = 0.290]. Although TJ-14 treatment did not reduce the incidence of a parts per thousand yen2 COM in the patients who developed mucositis during chemotherapy for gastric cancer, a trend was observed in which TJ-14 reduced the risk of COM in the patients who developed grade 1 COM during the screening cycle. Further, phase III studies with a larger sample size are needed to clarify the protective effects of TJ-14 for COM.
  • Takushi Yasuda; Yasuhiro Nakamori; Osamu Shiraishi; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinakai; Motohiro Imano; Haruhiko Imamoto; Hitoshi Shiozaki
    ESOPHAGUS SPRINGER JAPAN KK 11 (2) 99 - 107 1612-9059 2014/04 [Refereed]
     
    Background Postoperative pneumonia is the most common complication after esophagectomy and is closely associated with swallowing dysfunction and silent aspiration. Silent aspiration in the elderly is associated with decreased secretion of substance P (SP), which controls the swallowing and cough reflexes. The majority of patients with esophageal cancer are elderly. We hypothesized that surgical stress would decrease SP secretion, thereby increasing the risk of postoperative aspiration after esophagectomy, and prospectively investigated. Methods Thirty patients with esophageal cancer scheduled to undergo esophagectomy were enrolled in the study. Plasma and salivary SP concentrations and cough reflex sensitivity were measured before surgery and on postoperative days 2 and 7 to examine the association with postoperative aspiration. Results Postoperative silent aspiration was observed in 6 patients, 4 of whom developed pneumonia. Plasma SP concentration did not change significantly during the perioperative period. Salivary SP concentration and cough reflex sensitivity could not be measured in nearly one-third of patients because of postoperative dry mouth and unwillingness of patients to undergo measurement, respectively; thus, these perioperative changes could not be assessed. Preoperative plasma and salivary SP concentrations had a significant association with postoperative aspiration on univariate analysis and multivariate logistic regression analysis using variables selected by stepwise forward selection identified preoperative plasma SP concentration as the only significant risk factor for postoperative aspiration (p = 0.023). Conclusion Definitive results supporting our hypothesis could not be obtained. However, multivariate analysis suggested that decreased preoperative plasma SP concentration is likely associated with postoperative silent aspiration after esophagectomy.
  • Motohiro Imano; Kiyotaka Okuno
    SURGERY TODAY SPRINGER 44 (3) 399 - 404 0941-1291 2014/03 [Refereed]
     
    Although the treatment of gastric cancer improves the clinical outcomes, the survival of gastric cancer patients with peritoneal metastasis is still very poor. Effective drugs against peritoneal metastasis, coupled with new therapeutic modalities, are needed to improve the prognoses of these patients. Paclitaxel and TS-1 are candidate drugs for peritoneal metastasis, and intraperitoneal chemotherapy and targeted therapy are potential new therapeutic modalities. Two phase II studies using TS-1 and intraperitoneal and systemic paclitaxel for gastric cancer patients with peritoneal metastasis showed respectable survival results. In addition, peritoneal metastatic lesions showed high levels of epithelial cellular adhesion molecule (ECAM) and very low levels of human epidermal growth factor receptor 2 (HER2), thus indicating that an anti-ECAM monoclonal antibody, catumaxomab, would be effective against gastric cancer-derived peritoneal metastasis. Although catumaxomab and intraperitoneally administered paclitaxel are not generally used in Japan at present, these treatment strategies might therefore be effectively used in Japan in the near future.
  • Masanobu Tsubaki; Makiko Komai; Tatsuki Itoh; Motohiro Imano; Kotaro Sakamoto; Hirotaka Shimaoka; Tomoya Takeda; Naoki Ogawa; Kenji Mashimo; Daiichiro Fujiwara; Junji Mukai; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
    Journal of Biomedical Science BioMed Central Ltd. 21 (1) 10  1423-0127 2014/02 [Refereed]
     
    Background: Bisphosphonates are an important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Recent studies have shown that nitrogen-containing bisphosphonates induced apoptosis in rabbit osteoclasts and prevented prenylated small GTPase. However, whether bisphosphonates inhibit osteoclast formation has not been determined. In the present study, we investigated the inhibitory effect of minodronate and alendronate on the osteoclast formation and clarified the mechanism involved in a mouse macrophage-like cell lines C7 and RAW264.7. Results: It was found that minodronate and alendronate inhibited the osteoclast formation of C7 cells induced by receptor activator of NF-κB ligand and macrophage colony stimulating factor, which are inhibited by the suppression of geranylgeranyl pyrophosphate (GGPP) biosynthesis. It was also found that minodronate and alendronate inhibited the osteoclast formation of RAW264.7 cells induced by receptor activator of NF-κB ligand. Furthermore, minodronate and alendornate decreased phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt similarly, U0126, a mitogen protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, inhibited osteoclast formation. Conclusions: This indicates that minodronate and alendronate inhibit GGPP biosynthesis in the mevalonate pathway and then signal transduction in the MEK/ERK and PI3K/Akt pathways, thereby inhibiting osteoclast formation. These results suggest a novel effect of bisphosphonates that could be effective in the treatment of bone metabolic diseases, such as osteoporosis. © 2014 Tsubaki et al. licensee BioMed Central Ltd.
  • Hiroshi Imamura; Tomono Kishimoto; Hiroya Takiuchi; Yutaka Kimura; Takashi Morimoto; Motohiro Imano; Shohei Iijima; Keishi Yamashita; Kentaro Maruyama; Toshio Otsuji; Yukinori Kurokawa; Hiroshi Furukawa
    Journal of chemotherapy (Florence, Italy) 26 (1) 57 - 61 1120-009X 2014/02 [Refereed]
     
    BACKGROUND: S-1+cisplatin (CDDP) is the standard treatment for advanced gastric cancer (AGC) in Japan and Korea. However, the usefulness of S-1 based chemotherapy for elderly patients is unclear. Therefore, we conducted a multicenter phase II study of S-1 monotherapy for AGC in elderly patients. MATERIALS AND METHODS: Chemotherapy-naïve patients aged over 75 years with AGC were enrolled. The starting dose of S-1 was determined on the basis of body surface area and modified according to the creatinine clearance value. S-1 was administered twice a day during a 4-week period followed by a 2-week rest period. RESULTS: Thirty-five patients were enrolled. The response rate (RR) was 14.3% and the median overall survival was 14.6 months. Grade 3 or more severe adverse events consisted of anaemia (3%), neutropaenia (3%), anorexia (3%), and fatigue (6%). There were no treatment-related deaths. CONCLUSION: Our study indicates that S-1 monotherapy is safe and well tolerated in chemotherapy-naïve elderly patients with AGC, but exerts limited activity when given using a tailor-made dosing strategy based on renal function.
  • Naotoshi Sugimoto; Kazumasa Fujitani; Hiroshi Imamura; Noriya Uedo; Shohei Iijima; Motohiro Imano; Toshio Shimokawa; Yukinori Kurokawa; Hiroshi Furukawa; Masahiro Goto
    Anticancer research 34 (2) 851 - 7 0250-7005 2014/02 [Refereed]
     
    BACKGROUND: S-1-based regimens are commonly used for advanced gastric cancer (AGC) in Japan. We performed this trial to evaluate the efficacy and safety of S-1 plus irinotecan (SIri) and S-1 plus paclitaxel (SPac) as first-line treatments for AGC in order to select the optimal regimen for a subsequent phase III trial. PATIENTS AND METHODS: Patients with previously untreated, locally advanced or metastatic measurable gastric adenocarcinoma were randomly assigned to receive SIri (irinotecan 80 mg/m(2) was administered intravenously (i.v.) on day 1 and 15, while 40 mg/m(2) S-1 was orally administered twice daily for three weeks from days 1-21 followed by a two-week pause) or SPac (paclitaxel 50 mg/m(2) was administered i.v. on day 1 and 8, while 40 mg/m(2) S-1 was orally administered twice daily for two weeks from day 1-14 followed by a one-week pause) regimen. The primary end-point was the overall response rate (ORR), and the secondary end-points were progression-free survival (PFS), overall survival (OS), and toxicity. RESULTS: A total of 102 patients were enrolled. The ORR was 33.3% for SIri and 31.4% for SPac, which did not achieved the predicted ORR in either group. PFS and OS were 5.7 and 12.4 months for SIri, 4.6 and 11.9 months for SPac respectively. No treatment-related deaths occurred during the study. Although grade 3/4 neutropenia and anemia were more frequent in the Siri group, both regimens were well-tolerated. CONCLUSION: Both regimens were well-tolerated in patients with AGC, but we conclude that neither regimen was optimal for a phase III trial.
  • 白石 治; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩崎 均; 安田卓司
    日本気管食道科学会会報 (NPO)日本気管食道科学会 65 (2) 144 - 147 0029-0645 2014 [Refereed]
     
    頸部食道癌に対し、喉頭温存を重視した治療戦略として、導入化学放射線療法の中間判定による治療選択と、次のような術式工夫を行い、良好な成績が得られているので報告した。1)喉頭温存手術の適応を拡大するため、輪状咽頭筋と下咽頭収縮筋下端を輪状軟骨付着部で切離することにより、輪状軟骨上縁までの食道剥離を可能とする。2)術後嚥下障害を回避するため、手術のさい舌骨上筋群には皮弁剥離操作をしないことで瘢痕を予防し、舌骨下筋群を胸骨付着部で全切離することで喉頭下方牽引力を取り除き、温存した舌骨上筋群で喉頭を挙上させることにより安全性を確保する。3)移植空腸を長めに採取し、犠牲腸管余剰腸間膜で気管全体を被覆し、死腔を埋めて気管を保護し感染を防ぐことにより気管壊死を予防する。4)再建腸管は緊張をもって直線的に再建することで通過性を良くし、誤嚥を予防する。
  • Hajime Ishikawa; Motohiro Imano; Osamu Shiraishi; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Takushi Yasuda; Haruhiko Imamoto; Hitoshi Shiozaki
    GASTRIC CANCER SPRINGER 17 (1) 173 - 180 1436-3291 2014/01 [Refereed]
     
    Lymphocyte antigen 6 complex locus K (LY6K) has been identified as a tumor-associated antigen in lung cancers and esophageal squamous cell carcinomas. The immunogenicity of LY6K-177 peptide vaccine therapy has been demonstrated in patients with advanced esophageal cancer. This study extends this treatment to gastric cancer. LY6K expression in clinical samples obtained from gastric cancer patients was examined by immunochemistry. As a phase I clinical trial, the safety and immunogenicity of LY6K-177 peptide vaccine emulsified with Montanide ISA 51 was evaluated in six patients with unresectable advanced gastric cancer. LY6K-177 peptide (1 mg in 1 ml sterile saline) was emulsified with incomplete Freund's adjuvant (1 ml) and intracutaneously administered to the inguinal region or axilla. One treatment course comprised four vaccinations, performed weekly for the first and second treatment courses and biweekly for the third treatment course. LY6K expression was confirmed in 85 % of gastric cancer tissues. Induration and redness at the vaccination site (grade I), possibly a delayed-type hypersensitivity reaction, was observed in all patients; however, no systemic toxicology was identified in any patient throughout the observation period. Three of the six patients had stable disease, and a tumor contraction effect was observed in one patient. LY6K was expressed in 85 % of observed gastric cancers. Vaccination with LY6K-177 peptide/Montanide ISA 51 appeared to be tolerated by advanced gastric cancer patients, and moreover anticancer efficacy was suggested. This trial was registered with ClinicalTrial.gov (no. NCT00845611).
  • Masanobu Tsubaki; Makiko Komai; Tatsuki Itoh; Motohiro Imano; Kotaro Sakamoto; Hirotaka Shimaoka; Tomoya Takeda; Naoki Ogawa; Kenji Mashimo; Daiichiro Fujiwara; Junji Mukai; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
    LEUKEMIA RESEARCH PERGAMON-ELSEVIER SCIENCE LTD 38 (1) 121 - 130 0145-2126 2014/01 [Refereed]
     
    The calcium channel blocker verapamil inhibits the transport function of multidrug resistance protein 1 (MDR1). Although verapamil acts to reverse MDR in cancer cells, the underlying mechanism remains unclear. In the present study, we investigated the mechanism of reversing MDR by verapamil in anticancer drug-resistant multiple myeloma (MM) cell lines. We found that verapamil suppresses MDR1 and survivin expressions and increases Bim expression via suppression of Src activation. Furthermore, dasatinib reversed the drug-resistance of the drug-resistant cell lines. These findings suggest that Src inhibitors are potentially useful as an anti-MDR agent for the treatment of malignant tumor cells. (C) 2013 Elsevier Ltd. All rights reserved.
  • 安田 篤; 今野 元博; 今本 治彦; 安田 卓司; 古河 洋; 塩崎 均
    近畿大学医学雑誌 近畿大学医学会 38 (3-4) 149 - 152 0385-8367 2013/12 
    はじめに 近年の新規抗癌剤出現により、進行癌に対するいくつかの集学的治療が行われているが、その一つとして術前化学療法+手術の有用性が報告されている。今回我々は2型噴門部進行胃癌に対してTS-1/CDDPによる術前化学療法を施行した結果、病理組織学的にCRを得た症例を経験したので報告する。症例 67歳男性、健診にて胃病変を指摘され、近医にてGIF施行したところ噴門部後壁に2型胃癌認めたため当科紹介となった。経過 当初、画像診断で肝転移を伴う高度進行胃癌(T4aN1H1Stage IV)と診断してTS-1/CDDPの化学療法を3クール施行した。効果判定では主病変と所属リンパ節は著明に縮小したが、肝病変は治療効果を認めず、血管腫の可能性も出てきたため肝部分切除+胃全摘術を行った。摘出病理標本では原発巣、リンパ節ともに癌細胞は認めず、肝病変は硬化性血管腫であったため、pathological CRと判断した。術後経過は良好で、退院後adjuvant chemotherapyとしてTS-1内服を1年半施行、26ヵ月経過した現在、無再発にて経過観察中である。(著者抄録)
  • Motohiro Imano; Tatsuki Itoh; Takao Satou; Atsushi Yasuda; Kohei Nishiki; Hiroaki Kato; Osamu Shiraishi; Ying-Feng Peng; Masayuki Shinkai; Masahiro Tsubaki; Takushi Yasuda; Haruhiko Imamoto; Shozo Nishida; Yoshifumi Takeyama; Hiroshi Furkawa; Kiyokata Okuno; Hitoshi Shiozaki
    Targeted Oncology 8 (4) 231 - 235 1776-2596 2013/12 [Refereed]
     
    Intraperitoneally administrated epithelial cellular adhesion molecule (EpCAM) monoclonal antibody is a therapeutic agent in patients with malignant effusion in several types of carcinoma. However, the role of EpCAM in peritoneal metastasis (PM) lesions and primary lesions of gastric cancer (GC) is still unclear. Therefore, in this study, we investigated EpCAM expression in GC patients with PM. We investigated the expression of EpCAM in 35PM lesions and 104 biopsy samples as primary lesions. Immunohistochemical staining was performed using the Ventana Benchmark XT (Roche Diagnostics) system. EpCAM expression was evaluated by calculating the total immunostaining score, which is the product of the proportion score and the intensity score. Overexpression was defined as a total score greater than 4. All PM specimens showed overexpression of EpCAM, and GC cells in both the surface layer and the deep layer of the PM showed a high expression of EpCAM. Meanwhile, in the biopsy sample, the expression of EpCAM ranged from none to strong. The EpCAM score results for PM specimens and biopsy samples were 11.0 ± 2.0 and 6.9 ± 3.9, respectively. The difference between the scores was statistically significant (P < 0.05). The intraperitoneally administrated EpCAM antibody might have a anti-cancer effect in PM lesions of GC. Additionally, it can be assumed that only GC cells which express a high level of EpCAM might metastasize to the peritoneum. © 2012 Springer-Verlag France.
  • 安田 篤; 今本 治彦; 安田 卓司; 新海 政幸; 今野 元博; 古河 洋; 奥野 清隆; 塩崎 均
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 18 (6) 657 - 664 1344-6703 2013/11 
    [目的]高齢者胃切除症例に対する腹腔鏡下手術の安全性と有用性を検討した.[対象]当科で施行した80歳以上の胃切除症例を腹腔鏡群(Lap群)58例と開腹群(Open群)59例に分け,術中の呼吸変動と血圧変動,術後合併症などを検討した.[結果]術中血圧変動は両群間に有意差を認めず,術中のETCO2はLap群で若干の高値であったが,術後高炭酸ガス血症が遷延することはなかった.術後合併症はOpen群25.4%,Lap群13.8%で,最も割合の多かった呼吸器合併症はLap群5.2%,Open群8.5%であった.[結論]高齢者胃癌症例に対する腹腔鏡下手術は術後合併症,特に呼吸器合併症に対して有利と思われ,有用な治療法として筆者らは現在積極的に導入している.(著者抄録)
  • Masanobu Tsubaki; Makiko Komai; Tatsuki Itoh; Motohiro Imano; Kotaro Sakamoto; Hirotaka Shimaoka; Naoki Ogawa; Kenji Mashimo; Daichiro Fujiwara; Tomoya Takeda; Junji Mukai; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
    EUROPEAN JOURNAL OF CANCER ELSEVIER SCI LTD 49 (17) 3708 - 3717 0959-8049 2013/11 [Refereed]
     
    Several autocrine soluble factors, including macrophage inflammatory protein-1 alpha and tumour necrosis factor-alpha (TNF-alpha), promote the survival and growth of multiple myeloma (MM) cells. We hypothesised that inhibition of the TNF-alpha autocrine loop may enhance the cytotoxic effect of anticancer drugs in MM cell lines. In the present study, a TNF-alpha-neutralizing antibody suppressed cell proliferation and enhanced the cytotoxic effect of anticancer drugs onMMcells. In addition, combination treatment with the TNF-alpha-neutralizing antibody and the chemotherapy agent melphalan inhibited nuclear factor kappa B (NF-kappa B) p65 nuclear translocation and mammalian target of rapamycin (mTOR) activation and upregulated the expression of Bax and Bim. Treatment of ARH-77 cells with the NF-kappa B inhibitor dimethyl fumarate or the mTOR inhibitor rapamycin suppressed NF-kappa B p65 nuclear translocation and enhanced the cytotoxic effect of melphalan. Furthermore, infliximab, a monoclonal antibody against TNF-alpha, also enhanced the cytotoxic effect of anticancer drugs in ARH-77 cells. These results indicated that TNF-alpha-neutralizing antibodies or infliximab enhanced the cytotoxic effect of anticancer drugs by suppressing the TNF receptor/mTOR/NF-kappa B pathways. The inhibition of TNF-alpha may thus provide a new therapeutic approach to control tumour progression and bone destruction in MM patients. (C) 2013 Elsevier Ltd. All rights reserved.
  • Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
    Journal of experimental & clinical cancer research : CR 32 62  0392-9078 2013/09 [Refereed]
  • 胸部食道癌手術における術後合併症(縫合不全・誤嚥性肺炎)の予防策とその治療効果に関する検討
    岩間 密; 安田 卓司; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 68回 O - 5 2013/07
  • 当科における噴門側胃切除後の食道残胃吻合再建の工夫
    安田 篤; 今本 治彦; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 安田 卓司; 古河 洋; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 68回 P - 4 2013/07
  • 当科における胃管再建術の工夫 縫合不全ゼロを目指して
    加藤 寛章; 安田 卓司; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 68回 RV - 5 2013/07
  • 術後pN(+)食道癌に対する腫瘍特異的ペプチドワクチンを用いた術後補助療法
    錦 耕平; 安田 卓司; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 68回 RS - 6 2013/07
  • Tatsuki Itoh; Masaki Tabuchi; Nobuyuki Mizuguchi; Motohiro Imano; Masahiro Tsubaki; Shozo Nishida; Shigeo Hashimoto; Kazuhiko Matsuo; Takashi Nakayama; Akihiko Ito; Hiroshi Munakata; Takao Satou
    JOURNAL OF NEURAL TRANSMISSION SPRINGER WIEN 120 (5) 767 - 783 0300-9564 2013/05 [Refereed]
     
    Our previous study indicated that consuming (-)-epigallocatechin gallate (EGCG) before or after traumatic brain injury (TBI) eliminated free radical generation in rats, resulting in inhibition of neuronal degeneration and apoptotic death, and improvement of cognitive impairment. Here we investigated the effects of administering EGCG at various times pre- and post-TBI on cerebral function and morphology. Wistar rats were divided into five groups and were allowed access to (1) normal drinking water, (2) EGCG pre-TBI, (3) EGCG pre- and post-TBI, (4) EGCG post-TBI, and (5) sham-operated group with access to normal drinking water. TBI was induced with a pneumatic controlled injury device at 10 weeks of age. Immunohistochemistry and lipid peroxidation studies revealed that at 1, 3, and 7 days post-TBI, the number of 8-Hydroxy-2'-deoxyguanosine-, 4-Hydroxy-2-nonenal- and single-stranded DNA (ssDNA)-positive cells, and levels of malondialdehyde around the damaged area were significantly decreased in all EGCG treatment groups compared with the water group (P < 0.05). Although there was a significant increase in the number of surviving neurons after TBI in each EGCG treatment group compared with the water group (P < 0.05), significant improvement of cognitive impairment after TBI was only observed in the groups with continuous and post-TBI access to EGCG (P < 0.05). These results indicate that EGCG inhibits free radical-induced neuronal degeneration and apoptotic death around the area damaged by TBI. Importantly, continuous and post-TBI access to EGCG improved cerebral function following TBI. In summary, consumption of green tea may be an effective therapy for TBI patients.
  • Hiroaki Kato; Tokuzo Arao; Kazuko Matsumoto; Yoshihiko Fujita; Hideharu Kimura; Hidetoshi Hayashi; Kouhei Nishiki; Mitsuru Iwama; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Haruhiko Imamoto; Takushi Yasuda; Kiyotaka Okuno; Hitoshi Shiozaki; Kazuto Nishio
    INTERNATIONAL JOURNAL OF ONCOLOGY SPANDIDOS PUBL LTD 42 (4) 1151 - 1158 1019-6439 2013/04 [Refereed]
     
    Molecular targeted therapy is expected to be a promising therapeutic approach for the treatment of esophageal squamous cell carcinoma (ESCC); however, the gene amplification status of molecular targeted genes in ESCC remains largely unclear. The gene amplification of EGFR, HER2, FGFR2 and MET was examined using a real-time PCR-based copy number assay of 245 ESCC surgical specimens of formalin-fixed, paraffin-embedded samples. Fluorescence in situ hybridization (FISH) and comparative genomic hybridization analyses verified the results of the copy number assay. EGFR mutation was detected using the Scorpions-ARMS method. The EGFR status and drug sensitivity to an EGFR tyrosine kinase inhibitor was then evaluated in vitro. Gene amplification of EGFR and HER2 was observed in 7% (16/244) and 11% (27/245) of the ESCC specimens. A multivariate analysis revealed that HER2 amplification was a significant predictor of a poor prognosis in patients with stage III post-operative ESCC. The L861Q type of EGFR mutation with hypersensitivity to EGFR tyrosine kinase inhibitor was found in one of the eight ESCC cell lines and one de1745 type of EGFR mutation was identified in 107 clinical samples. In addition, we demonstrated for the first time that FGFR2 amplification was observed in 4% (8/196) of the ESCC specimens. MET amplification was observed in 1% (2/196). In conclusion, the frequent gene amplification of EGFR, HER2 and FGFR2 and the presence of active EGFR mutations were observed in ESCC specimens. Our results strongly encourage the development of molecular targeted therapy for ESCC.
  • Motohiro Imano; Tatsuki Itoh; Takao Satou; Akira Kido; Masahiro Tsubaki; Atsushi Yasuda; Hiroaki Kato; Haruhiko Imamoto; Shozo Nishida; Hiroshi Furukawa; Yoshifumi Takeyama; Kiyokata Okuno; Hitoshi Shiozaki
    ANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 33 (4) 1439 - 1446 0250-7005 2013/04 [Refereed]
     
    Aim: Patients with scirrhous carcinoma of the gastrointestinal tract frequently develop peritoneal carcinomatosis particularly of the peritoneal extension type (PET), which has a bad prognosis. We developed a novel animal model, suitable for testing treatments for PET. Material and Methods: In order to develop the model, we scraped the entire peritoneum of Fischer 344 rats with sterile cotton swabs and injected 1x10(6) cells of the RCN-9 cell type into the peritoneal cavity. Results: In the novel experimental model, RCN-9 cells adhered only to the exposed basement membrane. The submesothelial layer and fibroblasts in the submesothelial layer grew and increased to a maximum at day 7, then decreased during late-phase peritoneal carcinomatosis. At day 14, RCN-9 cells coated the peritoneum in a manner similar to PET. Conclusion: We successfully established a novel animal model of peritoneal carcinomatosis that mimics clinicopathological features of PET. Fibroblasts in the submesothelial layer potentially play an important role in peritoneal carcinomatosis.
  • Motohiro Imano; Hiroshi Furukawa; Masaki Yokokawa; Yasumasa Nishimura; Yukinori Kurokawa; Taroh Satoh; Daisuke Sakai; Takushi Yasuda; Haruhiko Imamoto; Toshimasa Tujinaka; Toshio Shimokawa; Hitoshi Shiozaki
    Japanese journal of clinical oncology 43 (4) 431 - 5 0368-2811 2013/04 [Refereed]
     
    A Phase I/II trial of radiotherapy administered concurrently with TS-1 plus cisplatin has been initiated in Japanese patients with clinical resectable type 4 or large type 3 gastric cancer. The aim of this trial is to determine the recommended dose of TS-1 and cisplatin combined with radiotherapy at a fixed dose in the Phase I study, and to evaluate the efficacy and safety in the Phase II study. The primary endpoint for Phase II is the pathological complete response rate, assessed using surgically resected specimens. Secondary endpoints are the response rate, progression-free survival, overall survival, operation transitional rate, R0 resection rate, rate of treatment completion, rate of down-staging and rates of postoperative complications and adverse events. In Phase II, a total of 30 patients will be enrolled in the Osaka Gastrointestinal Cancer Chemotherapy Study Group trial over a period of 6 years.
  • Tatsuki Itoh; Motohiro Imano; Shozo Nishida; Masahiro Tsubaki; Takashi Nakayama; Nobuyuki Mizuguchi; Shigeaki Yamanaka; Masaki Tabuchi; Hiroshi Munakata; Shigeo Hashimoto; Akihiko Ito; Takao Satou
    JOURNAL OF NEURAL TRANSMISSION SPRINGER WIEN 120 (3) 361 - 374 0300-9564 2013/03 [Refereed]
     
    We have previously reported free radical production after traumatic brain injury (TBI), which induces neural stem cell (NSC) degeneration and death. However, the effects of aging on NSC proliferation around the damaged area following TBI have not been investigated. Therefore, in this study, we used 10-week (young group) and 24-month-old (aged group) rat TBI models to investigate the effects of aging on NSC proliferation around damaged tissue using immunohistochemical and ex vivo techniques. Young and aged rats received TBI. At 1, 3 and 7 days after TBI, immunohistochemical and lipid peroxidation studies were performed. Immunohistochemistry revealed that the number of nestin-positive cells around the damaged area after TBI in the aged group decreased significantly when compared with those in the young group (P < 0.01). However, the number of 8-hydroxy-2'-deoxyguanosine-, 4-hydroxy-2-nonenal- and single-stranded DNA (ssDNA)-positive cells and the level of peroxidation around the damaged area after TBI significantly increased in the aged group, compared with those in the young group (P < 0.01). Furthermore, almost all ssDNA-positive cells in young and aged groups co-localized with NeuN and nestin staining. Ex vivo studies revealed that neurospheres, which differentiated into neurons and glia in culture, could only be isolated from injured brain tissue in young and aged groups at 3 days after TBI. These results indicate that, although there were fewer NSCs that have the potential to differentiate into neurons and glia, these NSCs escaped free radical-induced degeneration around the damaged area after TBI in the aged rat brain.
  • Yutaka Kimura; Hiroshi Yano; Hiroshi Imamura; Kazumasa Fujitani; Motohiro Imano; Yukihiko Tokunaga; Masaki Matsuoka; Yukinori Kurokawa; Toshio Shimokawa; Hiroya Takiuchi; Toshimasa Tsujinaka; Hiroshi Furukawa
    Japanese journal of clinical oncology 43 (2) 125 - 31 0368-2811 2013/02 [Refereed]
     
    OBJECTIVE: S-1 and cisplatin combination therapy is a standard regimen for patients with advanced gastric cancer in Japan. The primary objective of this study was to determine the maximum tolerated dose and dose-limiting toxicities of a triplet regimen adding paclitaxel to S-1 and cisplatin combination therapy. METHODS: Patients with previously untreated metastatic or recurrent gastric cancer were enrolled. Patients received S-1 (40 mg/m(2) p.o., twice daily, on days 1-21 every 35 days), cisplatin (30 mg/m(2) divided, on days 1 and 15) and paclitaxel (divided on days 1 and 15). The starting dose of paclitaxel was 50 mg/m(2) (level 1); the dose was escalated to 60 (level 2), 70 (level 3) and 80 mg/m(2) (level 4) in a stepwise fashion. Dose-limiting toxicity was determined during the first treatment cycle. RESULTS: Eighteen patients enrolled. During the first cycle, no dose-limiting toxicity was observed at dose levels 1 and 2. At dose level 3, one of the six patients had dose-limiting toxicity (one patient had grade 4 neutropenia) and at dose level 4, one of the six patients had dose-limiting toxicity (one patient had febrile neutropenia, hypoalbuminemia and fatigue of grade 3). The maximum tolerated dose was not reached at level 4; however, grade 3 hyponatremia and hypokalemia in two of the six patients occurred during the second treatment course at level 4. From the point of view of safety in the outpatient setting, the recommended dose of paclitaxel was determined at 70 mg/m(2). The overall response rate was 50%. CONCLUSIONS: The recommended dose of paclitaxel added to S-1 (80 mg/m(2) days 1-21) plus cisplatin (30 mg/m(2) days 1 and 15) was 70 mg/m(2) on days 1 and 15 of a 5-week cycle.
  • Masanobu Tsubaki; Makiko Komai; Shin-Ichiro Fujimoto; Tatsuki Itoh; Motohiro Imano; Kotaro Sakamoto; Hirotaka Shimaoka; Tomoya Takeda; Naoki Ogawa; Kenji Mashimo; Daiichiro Fujiwara; Junji Mukai; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
    Journal of Experimental and Clinical Cancer Research 1 32 (1) 62  1756-9966 2013 [Refereed]
     
    Background: Increased motility and invasiveness of cancer cells are reminiscent of the epithelial-mesenchymal transition (EMT), which occurs during cancer progression and metastasis. Recent studies have indicated the expression of receptor activator of nuclear factor-κB (RANK) in various solid tumors, including breast cancer. Although activation of the RANK ligand (RANKL)/RANK system promotes cell migration, metastasis, and anchorage-independent growth of tumor-initiating cells, it remains to be investigated if RANKL induces EMT in breast cancer cells. In this study, we investigated whether RANKL induces EMT in normal breast mammary epithelial cells and breast cancer cells, and the mechanism underlying such induction. Methods. Expression levels of vimentin, N-cadherin, E-cadherin, Snail, Slug, and Twist were examined by real-time polymerase chain reaction. Cell migration and invasion were assessed using Boyden chamber and invasion assays, respectively. The effects of RANKL on signal transduction molecules were determined by western blot analyses. Results: We found that stimulation by RANKL altered the cell morphology to the mesenchymal phenotype in normal breast epithelial and breast cancer cells. In addition, RANKL increased the expression levels of vimentin, N-cadherin, Snail, and Twist and decreased the expression of E-cadherin. We also found that RANKL activated nuclear factor-κB (NF-κB), but not extracellular signal-regulated kinase 1/2, Akt, mammalian target of rapamycin, c-Jun N-terminal kinase, and signal transducer and activator of transcription 3. Moreover, dimethyl fumarate, a NF-κB inhibitor, inhibited RANKL-induced EMT, cell migration, and invasion, and upregulated the expressions of Snail, Twist, vimentin, and N-cadherin. Conclusions: The results indicate that RANKL induces EMT by activating the NF-κB pathway and enhancing Snail and Twist expression. These findings suggest that the RANKL/RANK system promotes tumor cell migration, invasion, and metastasis via the induction of EMT. © 2013 Tsubaki et al. licensee BioMed Central Ltd.
  • Tatsuki Itoh; Motohiro Imano; Shozo Nishida; Masahiro Tsubaki; Nobuyuki Mizuguchi; Shigeo Hashimoto; Akihiko Ito; Takao Satou
    Brain Structure and Function 218 (1) 209 - 220 1863-2653 2013/01 [Refereed]
     
    Progressive age-associated increases in cerebral dysfunction have been shown to occur following traumatic brain injury (TBI). Moreover, levels of neuronal mitochondrial antioxidant enzymes in the aged brain are reduced, resulting in free radical-induced cell death. It was hypothesized that cognitive impairment after TBI in the aged progresses to a greater degree than in younger individuals, and that damage involves neuronal degeneration and death by free radicals. In this study, we investigated the effects of free radicals on neuronal degeneration, cell death, and cognitive impairment in 10-week-old (young group) and 24-month-old rats (aged group) subjected to TBI. Young and aged rats received TBI with a pneumatic controlled injury device. At 1, 3 and 7 days after TBI, immunohistochemistry, lipid peroxidation and behavioral studies were performed. At 1, 3 and 7 days post-TBI, the number of 8-hydroxy-2′- deoxyguanosine-, 4-hydroxy-2-nonenal- and single-stranded DNA (ssDNA)-positive cells, and the levels of malondialdehyde around the damaged area after TBI significantly increased in the aged group when compared with the young group (P < 0.05). In addition, the majority of ssDNA-positive cells in both groups co-localized with neuronal cells around the damaged area. There was a significant decrease in the number of surviving neurons and an increase in cognitive impairment after TBI in the aged group when compared with the young group (P < 0.05). These results indicate that following TBI, high levels of free radicals are produced in the aged rat brain, which induces neuronal degeneration and apoptotic cell death around the damaged area, resulting in cognitive impairment. © 2012 Springer-Verlag.
  • Masanobu Tsubaki; Tatsuki Itoh; Takao Satou; Motohiro Imano; Makiko Komai; Naoki Ogawa; Junji Mukai; Shozo Nishida
    BIOCHEMICAL PHARMACOLOGY PERGAMON-ELSEVIER SCIENCE LTD 85 (2) 163 - 172 0006-2952 2013/01 [Refereed]
     
    Nitrogen-containing bisphosphonates (N-Bps) induce apoptosis in tumor cells by inhibiting the prenylation of small G-proteins. However, the details of the apoptosis-inducing mechanism remain obscure. The present study showed that the induction of apoptosis by N-Bps in hematopoietic tumor cells is mediated by mitochondrial apoptotic signaling pathways, which are activated by the suppression of geranylgeranyl pyrophosphate (GGPP) biosynthesis. Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression. The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways. The accumulation of N-BPs in bones suggests that they may act more effectively on tumors that have spread to bones or on Ras-variable tumors. This is the first study to show that the specific molecular pathways of N-BP-induced apoptosis. (C) 2012 Elsevier Inc. All rights reserved.
  • 当科における進行胃癌に対する腹腔鏡補助下幽門側胃切除の妥当性の検討
    安田 篤; 今本 治彦; 錦 耕平; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 安田 卓司; 奥野 清隆; 古河 洋; 塩崎 均
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 17 (7) 397 - 397 1344-6703 2012/12
  • 安田 篤; 今本 治彦; 加藤 寛章; 今野 元博; 安田 卓司; 塩崎 均
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 17 (6) 789 - 795 1344-6703 2012/12 
    心不全・肥満を伴った成人Bochdalek孔ヘルニアを経験したので報告する.患者は47歳,女性.2010年2月から急性心不全にて当院循環器内科で加療中であった.咳嗽と心窩部痛にてCT検査を施行し,Bochdalek孔ヘルニアと診断され当科を紹介された.腹腔鏡下に手術を開始したがヘルニア内容の癒着や内臓脂肪による視野不良のために施行困難となり,hand-assisted laparoscopic surgery(HALS)に変更した.その後脱出した横行結腸,大網を還納し,ヘルニア門を縫合閉鎖,さらにpolypropylene meshで補完して手術を完遂した.24ヵ月経った現在,再発は認めていない.自験例のような肥満・癒着症例,心合併症症例で完全腹腔鏡下での修復術が困難な場合に,HALSは良好な視野で安全かつ低侵襲に施行でき,有用な手技と考える.(著者抄録)
  • Motohiro Imano; Takao Satou; Tatsuki Itoh; Atsushi Yasuda; Hiroaki Kato; Masayuki Shinkai; Ying-Feng Peng; Masahiro Tsubaki; Takushi Yasuda; Haruhiko Imamoto; Shozo Nishida; Yoshifumi Takeyama; Kiyokata Okuno; Hitoshi Shiozaki
    TARGETED ONCOLOGY SPRINGER 7 (4) 213 - 216 1776-2596 2012/12 [Refereed]
     
    The prognosis of gastric cancer patients with peritoneal metastasis is very poor. Recent findings suggest that use of trastuzumab, a monoclonal antibody-based agent that targets human epidermal growth factor receptor 2 (HER2), may improve the prognosis of gastric cancer patients with HER2 overexpression and/or gene amplification. However, whether these mechanisms of HER2 upregulation are present in gastric cancer patients with peritoneal metastasis is unclear. The status of HER2 expression in a cohort of samples obtained from 35 gastric cancer patients with peritoneal metastasis was investigated using immunohistochemistry and fluorescence in situ hybridization. In 18 cases, we also investigated the influence of induction chemotherapy on HER2 overexpression. The frequency of HER2 overexpression and gene amplification was 2.9 % (1/35) in peritoneal metastatic lesions. There was concurrence in HER2 status in the samples examined prior to and following induction of chemotherapy. Most samples from the gastric cancer patients with peritoneal metastasis did not show HER2 amplification and/or overexpression. Although our study size was small, these results suggest that trastuzumab, which is critically dependent on HER2 expression, might not be an effective agent for these patients. Consequently, other therapeutic approaches for these patients must be developed.
  • Motohiro Imano; Atsushi Yasuda; Tatsuki Itoh; Takao Satou; Ying-Feng Peng; Hiroaki Kato; Masayuki Shinkai; Masahiro Tsubaki; Yasutaka Chiba; Takushi Yasuda; Haruhiko Imamoto; Shozo Nishida; Yoshifumi Takeyama; Kiyokata Okuno; Hiroshi Furukawa; Hitoshi Shiozaki
    JOURNAL OF GASTROINTESTINAL SURGERY SPRINGER 16 (12) 2190 - 2196 1091-255X 2012/12 [Refereed]
     
    We conducted a phase II study involving a single administration of intraperitoneal chemotherapy with paclitaxel followed by sequential systemic chemotherapy with S-1+ paclitaxel for advanced gastric cancer patients with peritoneal metastasis. Gastric cancer patients with peritoneal metastasis were enrolled. Paclitaxel (80 mg/m(2)) was administered intraperitoneally at staging laparoscopy. Within 7 days, patients received systemic chemotherapy with S-1 (80 mg/m(2)/day on days 1-14) plus paclitaxel (50 mg/m(2) on days 1 and 8), followed by 7-days rest. The responders to this chemotherapy underwent second-look laparoscopy, and gastrectomy with D2 lymph node dissection was performed in patients when the disappearance of peritoneal metastasis had been confirmed. The primary endpoint of the study was overall survival rate. Thirty-five patients were enrolled. All patients were confirmed as having localized peritoneal metastasis by staging laparoscopy. Eventually, gastrectomy was performed in 22 patients. The median survival time of the total patient population and those patients in which gastrectomy was performed was 21.3 and 29.8 months, respectively. The overall response rate was 65.7 % for all patients. The frequent grade 3/4 toxic effects included neutropenia and leukopenia. Sequential intraperitoneal and intravenous paclitaxel plus S-1 was well tolerated in gastric cancer patients with peritoneal metastasis.
  • 食道癌根治化学放射線療法後のsalvage surgery 食道癌根治化学放射線療法後のSalvage手術の克服と安全性の確立
    新海 政幸; 安田 卓司; 田中 裕美子; 加藤 寛章; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 今野 元博; 今本 治彦; 奥野 清隆; 古河 洋; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 73 (増刊) 394 - 394 1345-2843 2012/10
  • 食道癌に対する至適郭清範囲 2領域か3領域か 胸腔内からの徹底郭清と反回神経リンパ節術中病理診による胸部食道癌選択的2領域郭清
    白石 治; 安田 卓司; 加藤 寛章; 錦 耕平; 岩間 密; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 古河 洋; 奥野 清隆; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 73 (増刊) 413 - 413 1345-2843 2012/10
  • Masanobu Tsubaki; Takao Satou; Tatsuki Itoh; Motohiro Imano; Makiko Komai; Minori Nishinobo; Megumi Yamashita; Masashi Yanae; Yuzuru Yamazoe; Shozo Nishida
    LEUKEMIA RESEARCH PERGAMON-ELSEVIER SCIENCE LTD 36 (10) 1315 - 1322 0145-2126 2012/10 [Refereed]
     
    Multidrug resistance represents a major obstacle for the chemotherapy of a wide variety of human tumors. To investigate the underlying mechanisms associated with resistance to anti-cancer drugs, we established anti-cancer drug-resistant multiple myeloma (MM) cell lines RPMI8226/ADM, RPMI8226/VCR, RPMI8226/DEX, and RPMI8226/L-PAM, the 50% inhibitory concentration values of which were 77-, 58-, 79-, and 30-fold higher than their parental cell lines, respectively. The resistant cell lines overexpressed MDR1 and survivin, or showed decreased Bim expression. These results indicated that regulating these factors with inhibitors might be a viable approach to increasing the susceptibility of quiescent MM cells to chemotherapy. (C) 2012 Elsevier Ltd. All rights reserved.
  • Akira Kido; Kazuhiro Yoshitani; Takamasa Shimizu; Manabu Akahane; Hiromasa Fujii; Shinji Tsukamoto; Yumiko Kondo; Kanya Honoki; Motohiro Imano; Yasuhito Tanaka
    ONCOLOGY LETTERS SPANDIDOS PUBL LTD 4 (4) 745 - 750 1792-1074 2012/10 [Refereed]
     
    The beta 2-adrenergic receptor (beta 2AR) mediates the effects of chronic stress in several neoplasms, however, beta 2AR signaling is impaired by hypoxia in various tissues. While hypoxia is a common feature significant in the progression of solid tumors, little is known about the effect of hypoxia on beta 2AR signaling in the tumor microenvironment. Previously, it has been reported that the systemic administration of mesenchymal stem cells (MSCs) increased the engraftment and metastatic colonization of rat osteosarcoma (OS) cells. In the current study, the effect of MSCs on the hypoxia-induced desensitization of the beta 2AR in OS cells was investigated. Epinephrine, norepinephrine and isoproterenol increased the cellular proliferation of the rat OS cell line COSINR and rat MSCs in a dose-dependent and beta 2AR antagonist-sensitive manner. While isoproterenol had significant proliferative effects on MSCs under normoxic and hypoxic conditions, COSINR cells did not respond under hypoxic conditions. A sensitivity assay for the beta 2AR revealed that hypoxia impaired the sensitivity of COSINR cells, whereas hypoxia did not affect MSCs. An immunoassay revealed no significant change in the expression of hypoxia-inducible factor-la (HIF1 alpha) in COSINR cells, whilst an immunoassay demonstrated a 15% increase in MSCs following isoproterenol stimulation. In COSINR cells co-cultured with MSCs under hypoxic conditions, isoproterenol caused a significant increase in proliferation and this effect was inhibited by an anti-interleukin (IL)-6 antibody. A tumor formation assay in syngeneic rats revealed that the systemic administration of MSCs enhances the growth of OS and the effect of MSCs was inhibited by IL-6 neutralization. In conclusion, MSCs are resistant to the hypoxia-induced desensitization to beta 2AR. Hypoxia caused a siginificant desensitization of the beta 2AR in COSINR cells alone, whereas MSCs may support tumor progression through cellular interactions.
  • Masanobu Tsubaki; Takao Satou; Tatsuki Itoh; Motohiro Imano; Masashi Yanae; Chisato Kato; Risa Takagoshi; Makiko Komai; Shozo Nishida
    MOLECULAR AND CELLULAR ENDOCRINOLOGY ELSEVIER IRELAND LTD 361 (1-2) 219 - 231 0303-7207 2012/09 [Refereed]
     
    Osteoclast differentiation is influenced by receptor activator of the NF-kappa B ligand (RANKL), macrophage colony-stimulating factor (M-CSF), and CD9, which are expressed on bone marrow stromal cells and osteoblasts. In addition, osteoprotegerin (OPG) is known as an osteoclastogenesis inhibitory factor. In this study, we investigated whether bisphosphonates and statins increase OPG expression and inhibit the expression of CD9, M-CSF, and RANKL in the bone marrow-derived stromal cell line ST2. We found that bisphosphonates and statins enhanced OPG mRNA expression and inhibited the expression of CD9, M-CSF, and RANKL mRNA. Futhermore, bisphosphonates and statins decreased the membrane localization of Ras and phosphorylated ERK1/2, and activated the p38MAPK. This indicates that bisphosphonates and statins enhanced OPG expression, and inhibited the expression of CD9. M-CSF, and RANKL through blocking the Ras/ERK pathway and activating p38MAPK. Accordingly, we believe that its clinical applications will be investigated in the future for the development of osteoporosis therapy. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
  • Motohiro Imano; Ying-Feng Peng; Tatsuki Itoh; Masayasu Nishikawa; Takao Satou; Atsushi Yasuda; Keisuke Inoue; Hiroaki Kato; Masayuki Shinkai; Masahiro Tsubaki; Takushi Yasuda; Haruhiko Imamoto; Shozo Nishida; Hiroshi Furukawa; Yoshifumi Takeyama; Kiyokata Okuno; Hitoshi Shiozaki
    ANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 32 (9) 4071 - 4075 0250-7005 2012/09 [Refereed]
     
    Aim: A preliminary study with the aim of evaluating the safety and efficacy of a single intraperitoneal administration of paclitaxel, combined with intravenous administration of paclitaxel plus S-1, was carried out in gastric cancer patients with peritoneal metastasis. Patients and Methods: Paclitaxel was administered intraperitoneally at 80 mg/m(2). After one to two weeks, S-1 was administered at 80 mg/m(2)/day for 14 consecutive days, followed by seven days' rest. Paclitaxel was administered intravenously at 50 mg/m(2) on days 1 and 8. The safety, pharmacokinetic analysis and efficacy of this therapy were investigated. Results: Fifteen patients were enrolled in this study. The toxic effects of the intraperitoneal chemotherapy were mild. The toxic effects with the systemic chemotherapy were acceptable. The ratio of (AUC peri)/(AUC pla) was 1065:1 in the pharmacokinetic analysis. The one-year overall survival rate was 10/15 (66.7%). Conclusion: A single intraperitoneal administration of paclitaxel combined with intravenous administration of paclitaxel plus S-1 is a well-tolerated and feasible treatment for patients with gastric cancer with peritoneal metastasis.
  • Tatsuki Itoh; Motohiro Imano; Shozo Nishida; Masahiro Tsubaki; Nobuyuki Mizuguchi; Shigeo Hashimoto; Akihiko Ito; Takao Satou
    JOURNAL OF NEURAL TRANSMISSION SPRINGER WIEN 119 (8) 877 - 890 0300-9564 2012/08 [Refereed]
     
    A major component of green tea is (-)-epigallocatechin gallate (EGCG), which has strong antioxidant properties. Here, we investigated the effect of EGCG on neural stem cell (NSC) proliferation around the damaged area following traumatic brain injury (TBI). In this study, male Wistar rats that had access to normal drinking water, or water containing 0.1% (w/v) EGCG, ad libitum received TBI at 10 weeks of age. Immunohistochemistry revealed that the number of nestin-positive cells around the damaged area after TBI in the EGCG treatment group increased significantly compared with the normal water group (P < 0.05). However, the number of 8-hydroxy-2'-deoxyguanosine-, 4-hydroxy-2-nonenal-, single-stranded DNA (ssDNA)-positive cells and the level of peroxidation around the damaged area after TBI significantly decreased in the EGCG treatment group when compared with the water group (P < 0.05). Furthermore, in contrast to the EGCG group, almost all ssDNA-positive cells in the water group co-localized with NeuN and nestin-staining. Ex vivo studies revealed that spheres could only be isolated from injured brain tissue in the water group at 3 days following TBI. However, in the EGCG group, spheres could be isolated at both 3 and 7 days following TBI. A greater number of spheres could be isolated from the EGCG group, which differentiated into neurons and glia in culture without basic fibroblast growth factor. These results indicate that consumption of water containing EGCG pre- and post-TBI inhibits free radical-induced degradation of NSCs, which have the potential to differentiate into neurons and glia around the area of damage following TBI.
  • 胃癌における術前、術後補助化学療法の位置づけ T4a胃癌に対するNAC(PTX腹腔内化療法+逐次PTX+S-1による全身化学療法)の有用性
    安田 篤; 今野 元博; 今本 治彦; 加藤 寛章; 錦 耕平; 白石 治; 彭 英峰; 新海 政幸; 安田 卓司; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 67回 1 - 1 2012/07
  • リンパ節転移を伴う切除可能漿膜浸潤胃癌に対する術前補助化学療法としてのS-1+PTX+CDDP療法
    今野 元博; 安田 篤; 今本 治彦; 新海 政幸; 加藤 寛章; 白石 治; 安田 卓司; 竹山 宜典; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 67回 1 - 1 2012/07
  • 食道癌サルベージ手術 Salvage手術の克服とSalvage手術を前提としたcT4に対する新たな治療戦略
    新海 政幸; 安田 卓司; 錦 耕平; 白石 治; 安田 篤; 彭 英峰; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 67回 2 - 2 2012/07
  • 食道疾患;最良の手術とは 術前治療後の瘢痕化食道癌手術における手術精度と機能性の追求
    安田 卓司; 新海 政幸; 安田 篤; 白石 治; 錦 耕平; 加藤 寛章; 彭 英峰; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 66回 143 - 143 2012/06
  • 食道疾患におけるチーム医療のあり方 食道癌周術期管理における当院でのチーム医療の取り組み
    新海 政幸; 安田 卓司; 加藤 寛章; 錦 耕平; 白石 治; 安田 篤; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 66回 151 - 151 2012/06
  • cT3.5食道癌に対する局所制御を重視した治療戦略"non split 50GyCRT+切除"
    白石 治; 安田 卓司; 加藤 寛章; 錦 耕平; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 66回 257 - 257 2012/06
  • リンパ節陽性食道癌に対する腫瘍特異的ペプチドワクチンを用いた術後アジュバント療法
    錦 耕平; 安田 卓司; 新海 政幸; 安田 篤; 白石 治; 加藤 寛章; 彭 英峰; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 66回 296 - 296 2012/06
  • 切除可能進行食道癌におけるFDG-PETに基づいた個別化治療戦略
    錦 耕平; 安田 卓司; 新海 政幸; 安田 篤; 白石 治; 加藤 寛章; 彭 英峰; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 66回 317 - 317 2012/06
  • Hajime Ishikawa; Motohiro Imano; Osamu Shiraishi; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Takushi Yasuda; Haruhiko Imamoto; Kazuyoshi Takeda; Hitoshi Shiozaki
    ESOPHAGUS SPRINGER TOKYO 9 (2) 105 - 112 1612-9059 2012/06 [Refereed]
     
    Up-regulated gene in lung cancer 10 (URLC10), confirmed to be lymphocyte antigen 6 complex locus K and defined as an oncoantigen, has been identified as a tumor-associated antigen by systematic analysis of expression levels of thousands of genes in lung cancer tissues and esophageal squamous cell carcinoma tissues, which were compared with those of normal human tissues by use of cDNA microarray analysis. Human leukocyte antigen (HLA)-A*2402-positive dendritic cells pulsed with URLC10-derived epitope peptide induced CD8(+) cytotoxic T lymphocytes to exert specific cytotoxicity against the HLA-A*2402-positive URLC10-expressing esophageal carcinoma cell lines. In a phase I clinical trial we evaluated the safety and immunogenicity of a URLC10-177 peptide vaccine emulsified with Montanide ISA51 for patients with unresectable advanced esophageal cancer. One milligram of URLC10-177 peptide in 1 mL sterile saline was emulsified with 1 mL incomplete Freund's adjuvant and administered subcutaneously to the inguinal region or axilla of the patients. One course of treatment comprised four vaccinations, which were performed every week in the first and second treatment courses and subsequently every 2 weeks after the first vaccination in the third treatment course. Redness and induration of the skin were the only adverse events at the injection site and were believed to be a delayed-type hypersensitivity (DTH) reaction against the peptide vaccine. A URLC10-177-specific immune reaction in the enzyme-linked immunospot assay was detected in three of four DTH-positive patients (75 %) and in one of three DTH-negative patients (33 %). Furthermore, patients who had a DTH reaction seemed to survive longer than those who had no DTH reaction. URLC10-177 peptide/Montanide vaccine therapy was well tolerated and induced a URLC10-177 peptide-specific immune response. Therapeutic URLC10-177 peptide vaccination is expected to have clinical benefit in prolonging the survival of patients with unresectable advanced esophageal cancer.
  • Shigeyuki Tamura; Motohiro Imano; Hiroya Takiuchi; Kenji Kobayashi; Haruhiko Imamoto; Hirofumi Miki; Yoshihiro Goto; Taro Aoki; Ying-Feng Peng; Toshimasa Tsujinaka; Hiroshi Furukawa
    ANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 32 (4) 1403 - 1408 0250-7005 2012/04 [Refereed]
     
    Background: The aims of this multiple-institution phase II study were to evaluate the efficacy and tolerability of docetaxel, cisplatin and 5-fluorouracil (DCF) for the therapy of patients with metastatic squamous cell carcinoma of the esophagus (SCCE). Patients and Methods: Eligible patients included those with previously untreated SCCE, score of ECOG 0-2 and adequate organ function. Patients received 60 mg/m(2) docetaxel and 70 mg/m(2) cisplatin on day 1, and 600 mg/m(2) 5-fluorouracil on days 1-5 every four weeks. Results: Twenty-nine (22 male, 7 female) patients with metastatic SCCE (M1a: 20, M1b: 9) were enrolled. Three cases achieved complete response and seven a partial response. In addition to these patients, three patients achieved good response and underwent surgical resection, giving an overall response rate of 34.5% (95% Confidene Interval=17.9-54.3) in confirmed cases and 44.8% (95% CI=26.4-64.3) in unconfirmed cases. Grade 3 or 4 hematological toxicities were as follows: leukopenia in 15 patients (52%), neutropenia in 22 patients (76%) and febrile neutropenia in 6 patients (21%), while grade 3 or 4 non-hematological toxicities were relatively rare. Conclusion: This DCF regimen was well tolerated; the results of this study provide information on the potential of DCF for treatment of patients with metastatic SCCE.
  • 安田 卓司; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 錦 耕平; 加藤 寛章; 井上 啓介; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本外科学会雑誌 (一社)日本外科学会 113 (臨増2) 176 - 176 0301-4894 2012/03
  • Masanobu Tsubaki; Takao Satou; Tatsuki Itoh; Motohiro Imano; Mitsuhiko Ogaki; Masashi Yanae; Shozo Nishida
    TOXICOLOGY AND APPLIED PHARMACOLOGY ACADEMIC PRESS INC ELSEVIER SCIENCE 259 (3) 402 - 410 0041-008X 2012/03 [Refereed]
     
    Osteosarcoma is one of the most common primary malignant bone tumors in children and adolescents. Some patients continue to have a poor prognosis, because of the metastatic disease. YM529/ONO-5920 is a nitrogen-containing bisphosphonate that has been used for the treatment of osteoporosis. YM529/ONO-5920 has recently been reported to induce apoptosis in various tumors including osteosarcoma. However, the mode of metastasis suppression in osteosarcoma by YM529/ONO-5920 is unclear. In the present study, we investigated whether YM529/ONO-5920 inhibited tumor cell migration, invasion, adhesion, or metastasis in the LM8 mouse osteosarcoma cell line. We found that YM529/ONO-5920 significantly inhibited metastasis, cell migration, invasion, and adhesion at concentrations that did not have antiproliferative effects on LM8 cells. YM529/ONO-5920 also inhibited the mRNA expression and protein activities of matrix metalloproteinases (MMPs). In addition, YM529/ONO-5920 suppressed phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) and the serine/threonine protein kinase B (Akt) by the inhibition of Ras prenylation. Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP. The results indicated that YM529/ONO-5920 suppressed the Ras/MEK/ERK and Ras/PI3K/Akt pathways, thereby inhibiting LM8 cell migration, invasion, adhesion, and metastasis. These findings suggest that YM529/ONO-5920 has potential clinical applications for the treatment of tumor cell metastasis in osteosarcoma. (C) 2012 Elsevier Inc. All rights reserved.
  • 進行再発胃癌におけるTS-1+CDDP+PTX併用化学療法の多施設共同第2相臨床試験(OGSG0703)
    間狩 洋一; 飯島 正平; 木村 豊; 今村 博司; 藤谷 和正; 後藤 昌弘; 今野 元博; 尾下 正秀; 上田 修吾; 下川 敏雄; 黒川 幸典; 瀧内 比呂也; 辻仲 利政; 古河 洋
    日本胃癌学会総会記事 (一社)日本胃癌学会 84回 240 - 240 2012/02
  • 開腹術および腹腔鏡下手術における消化管再建方法(幽門側胃切除、噴門側胃切除、胃全摘) 中長期的な評価も含めて 噴門側胃切除における食道残胃吻合法と空腸間置法の比較検討
    安田 篤; 今本 治彦; 今野 元博; 白石 治; 彭 英峰; 新海 政幸; 安田 卓司; 奥野 清隆; 塩崎 均
    日本胃癌学会総会記事 (一社)日本胃癌学会 84回 149 - 149 2012/02
  • Tatsuki Itoh; Motohiro Imano; Shozo Nishida; Masahiro Tsubaki; Shigeo Hashimoto; Akihiko Ito; Takao Satou
    Stem Cells and Cancer Stem Cells, Volume 5: Therapeutic Applications in Disease and Injury Springer Netherlands 59 - 72 2012/01 [Refereed]
     
    Exercise enhances neuronal stem cell (NSC) proliferation and neurogenesis. However, the effect of exercise on NSC proliferationsurrounding the area of damage after traumatic brain injury (TBI) isunknown. Here, we investigate the effect of running on NSCproliferation following TBI in the rat. Wistar rats received TBI andwere randomly divided into two groups: (1) non-exercise group and(2) exercise group. The exercise group ran on a treadmill for 30min/day at 22 m/min for 7 consecutive days. Immunohistochemistry wasused to monitor NSC proliferation around the damaged area and ex vivo techniques were used to isolate NSCs from the damaged region in both groups. The number of nestin-and Ki-67-positive cells observed at 3 and 7 days after TBI was significantly greater in the exercise group than in the non-exercise group (P < 0.01). Furthermore, most nestin-positive cells in the exercise group co-localized with Ki-67-positive cells. In ex vivo studies, spheres could be isolated from injured brain tissue from the exercise group at 3 and 7 days following TBI, but at only 3 days in the non-exercise group. The number of spheres isolated from injured brain tissue was greater in the exercise group than in the non-exercise group. Spheres were immunopositive for nestin and comprised of NSCs that could differentiate into neurons and glia. Exercise increases the proliferation of NSCs around the damaged area following TBI. Therefore, exercise therapy (rehabilitation) in the early phase following TBI is important for recuperation from cerebral dysfunction induced by TBI.
  • Tatsuki Itoh; Kumiko Takemori; Motohiro Imano; Shozo Nishida; Masahiro Tsubaki; Shigeo Hashimoto; Hiroyuki Ito; Akihiko Ito; Takao Satou
    Stem Cells and Cancer Stem Cells, Volume 2: Stem Cells and Cancer Stem Cells, Therapeutic Applications in Disease and Injury: Volume 2 Springer Netherlands 199 - 209 2012/01 [Refereed]
     
    Stroke-prone spontaneously hypertensive rats (SHRSP) are the only animal model that suffers from spontaneous cerebral stroke. In this study, we investigated the appearance of neural stem cells (NSCs) and new neurons in the penumbra and the subventricular zone (SVZ) after cerebral stroke in SHRSP. SHRSP before cerebral stroke were intraperitoneally injected with 5-bromo-2′-deoxyuridine (BrdU). SHRSP were divided into acute and chronic phase groups after cerebral stroke. Brain sections from both groups were studied with cellspecific markers such as BrdU, a cell division and proliferation marker, SOX2, a marker of NSCs, nestin, an NSC and immature astrocyte marker, doublecortin (DCX), an immature new neuron marker, and NeuN, a marker of mature neurons. NSCs and new neurons appeared in the penumbra in the early stages after cerebral stroke, and these cells differentiated into mature neurons in the chronic phase. Furthermore, soon after being affected by a cerebral stroke, there were many new neurons and immature cells, which appear to be NSCs, in the ipsilateral SVZ. The findings of the study indicate that immature cells and new neurons from the ipsilateral SVZ might migrate into the penumbra after cerebral stroke.
  • Motohiro Imano; Haruhiko Imamoto; Tatsuki Itoh; Takao Satou; Ying-Feng Peng; Atsushi Yasuda; Hiroaki Kato; Osamu Shiraishi; Masayuki Shinkai; Takushi Yasuda; Yoshifumi Takeyama; Kiyokata Okuno; Hitoshi Shiozaki
    JOURNAL OF SURGICAL ONCOLOGY WILEY-BLACKWELL 105 (1) 43 - 47 0022-4790 2012/01 [Refereed]
     
    Background The aim of this study was to examine the safety, pharmacokinetics, and cytological efficacy against free intraperitoneal cancer cells of intraperitoneal chemotherapy (IPC) with paclitaxel after gastrectomy with en-bloc D2 lymph node dissection (GD2) in cases of gastric cancer with peritoneal carcinomatosis (PC) and/or positive cytological findings in peritoneal washings (CFPW). Methods: Twenty-one patients with gastric cancer with PC and/or positive CFPW who underwent GD2 were treated with early, post-operative, intraperitoneal paclitaxel. Intra-chemotherapeutic toxicity and operative complication were measured using the common toxicity criteria of the National Cancer Institute, version 3.0. Intraperitoneal and plasma paclitaxel concentrations were measured using a high-performance liquid chromatography assay. Results: Grade 3 anemia occurred in two patients (9.5%) and neutropenia was observed in three patients (14.3%). No grade 4 toxicity was observed. A grade 2 operative complication was a superficial surgical site infection (4.8%) that was treated with antibiotics. Cytologically, no viable cancer cells were observed in the intra-abdominal fluid 24 hr after intraperitoneal administration of paclitaxel. The intraperitoneal/plasma area under the drug concentration-time curve (AUC) ratio was 596.9:1. Conclusion: IPC with paclitaxel after GD2 is a safe and cytologically effective treatment modality for free intraperitoneal cancer cells. However, additional data are required to determine the effect on survival. J. Surg. Oncol. 2012;105:43-47. (C) 2011 Wiley Periodicals, Inc.
  • 腹腔鏡補助下胃癌手術の適応拡大(治療成績) 当科における腹腔鏡補助下胃切除の適応拡大とその成績
    安田 篤; 今本 治彦; 井上 啓介; 加藤 寛章; 錦 耕平; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 奥野 清隆; 塩崎 均
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 16 (7) 312 - 312 1344-6703 2011/12
  • 心機能低下・肥満を合併した成人Bochdalek孔ヘルニアに対し経腹的HALSで修復した1例
    加藤 寛章; 今本 治彦; 錦 耕平; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 奥野 清隆; 塩崎 均
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 16 (7) 440 - 440 1344-6703 2011/12
  • Tatsuki Itoh; Motohiro Imano; Shozo Nishida; Masahiro Tsubaki; Shigeo Hashimoto; Akihiko Ito; Takao Satou
    NeuroMolecular Medicine Springer 13 (4) 300 - 309 1535-1084 2011/12 
    A major component of green tea, a widely consumed beverage, is (-)-epigallocatechin gallate (EGCG), which has strong antioxidant properties. Our previous study has indicated that free radical production following rat traumatic brain injury (TBI) induces neural degeneration. In this study, we investigated the effects of EGCG on cerebral function and morphology following TBI. Six-week-old male Wistar rats that had access to normal drinking water, or water containing 0.1% (w/v) EGCG ad libitum, received TBI with a pneumatic controlled injury device at 10 weeks of age. Immunohistochemistry and lipid peroxidation studies revealed that at 1, 3 and 7 days post-TBI, the number of 8-hydroxy-2′-deoxyguanosine-, 4-hydroxy-2-nonenal- and single-stranded DNA (ssDNA)-positive cells, and the levels of malondialdehyde (MDA) around the damaged area after TBI, significantly decreased in the EGCG treatment group compared with the water group (P < 0.05). Most ssDNA-positive cells in the water group co-localized with neuronal cells. However, in the EGCG treatment group, few ssDNA-positive cells co-localized with neurons. In addition, there was a significant increase in the number of surviving neuronal cells and an improvement in cerebral dysfunction after TBI in the EGCG treatment group compared with the water group (P < 0.05). These results indicate that consumption of water containing EGCG pre- and post-TBI inhibits free radical-induced neuronal degeneration and apoptotic cell death around the damaged area, resulting in the improvement of cerebral function following TBI. In summary, consumption of green tea may be an effective therapy for TBI patients. © Springer Science+Business Media, LLC 2011.
  • Motohiro Imano; Kiyotaka Okuno; Tatsuki Itoh; Takao Satou; Eizaburo Ishimaru; Takushi Yasuda; Jin-Ichi Hida; Haruhiko Imamoto; Yoshifumi Takeyama; Hitoshi Shiozaki
    AMERICAN SURGEON SOUTHEASTERN SURGICAL CONGRESS 77 (11) 1515 - 1520 0003-1348 2011/11 [Refereed]
     
    Even after radical surgery for stage II and stage III colorectal cancer, metachronous liver metastasis is frequently observed. The aim of this study was to identify the risk of metachronous liver metastasis with retrospective clinicopathological study. Immunohistochemistry was performed to evaluate the expression of Osteopontin (OPN), CD-68, and CD105 in 41 cases of stage II and stage III colorectal cancer tissue. Stage II and stage III colorectal cancer patients who had undergone R0 resection were classified into two groups: with metachronous liver metastasis (m-LM; n = 17) and without liver metastases (control; n = 24). Additionally, double-immunofluorescence staining was performed using antibodies to OPN and CD68. OPN-positive cells were frequently colocalized with CD68 immunoreactivity. OPN and microvascular density expression in the central area were significantly higher in the m-LM (OPN; control 4.3 +/- 0.56, m-LV 10.8 +/- 1.48, P < 0.05; microvascular density control 18.5 +/- 2.86, m-LV 31.4 +/- 4.39, P < 0.05), while CD68 expression in the invasive margin was significantly higher in the control group (control 98.9 +/- 7.31, m-LV 28.2 +/- 3.18, P < 0.05). These results suggest that the risk of metachronous liver metastasis could be well predicted by immunohistochemical staining of OPN in the central areas, and CD68 in the invasive margins of tumors.
  • 胃癌に対する化学療法の新展開 T4a胃癌に対するPTX腹腔内化学療法+逐次PTX+S-1による全身化学療法
    彭 英峰; 今野 元博; 井上 啓介; 加藤 寛章; 錦 耕平; 白石 治; 安田 篤; 新海 政幸; 安田 卓司; 今本 治彦; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 72 (増刊) 383 - 383 1345-2843 2011/10
  • 外来化学療法の効率化と安全への取り組み 近畿大学医学部附属病院における外来化学療法の効率化と安全への取り組み
    今野 元博; 竹山 宜典; 錦 耕平; 井上 啓介; 加藤 寛章; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 安田 卓司; 今本 治彦; 奥野 清隆; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 72 (増刊) 384 - 384 1345-2843 2011/10
  • 食道・胃管吻合術の工夫 縫合不全ゼロを目指した当科における胃管再建
    白石 治; 安田 卓司; 加藤 寛章; 井上 啓介; 錦 耕平; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 72 (増刊) 413 - 413 1345-2843 2011/10
  • 他臓器浸潤を疑う局所進行食道癌に対するno split 50Gy induction CRT+surgeryの治療成績
    新海 政幸; 安田 卓司; 井上 啓介; 加藤 寛章; 錦 耕平; 白石 治; 安田 篤; 彭 英峰; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 72 (増刊) 532 - 532 1345-2843 2011/10
  • 当科における幽門保存胃切除術の適応と有用性について
    安田 篤; 今本 治彦; 加藤 寛章; 錦 耕平; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 奥野 清隆; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 72 (増刊) 534 - 534 1345-2843 2011/10
  • 胸部食道癌根治切除後7年目の異時性直腸癌に対する術後補助化学療法中に認めた、再建胃管穿孔の1例
    錦 耕平; 安田 卓司; 井上 啓介; 加藤 寛明; 中森 康浩; 白石 治; 安田 篤; 彭 英峰; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 72 (増刊) 627 - 627 1345-2843 2011/10
  • 合併症軽減を目指した食道癌胃管再建術における工夫
    白石 治; 安田 卓司; 今本 治彦; 今野 元博; 新海 政幸; 彭 英峰; 安田 篤; 錦 耕平; 加藤 寛章; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 65回 166 - 166 2011/09
  • 胸部食道癌に対する術前補助療法の個別化
    白石 治; 安田 卓司; 今本 治彦; 今野 元博; 新海 政幸; 彭 英峰; 安田 篤; 錦 耕平; 加藤 寛章; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 65回 331 - 331 2011/09
  • cT4を疑う局所進行食道癌に対するno split 50 Gy導入化学放射線療法+surgeryの治療成績
    新海 政幸; 安田 卓司; 錦 耕平; 中森 康浩; 白石 治; 安田 篤; 彭 英峰; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 65回 331 - 331 2011/09
  • 食道癌治癒切除術後再発症例の検討
    彭 英峰; 安田 卓司; 加藤 寛章; 錦 耕平; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 65回 336 - 336 2011/09
  • 胃管後縦隔経路再建後に縫合不全と膿胸を生じ、外科的治療にて治癒し得た1症例
    安田 篤; 安田 卓司; 加藤 寛章; 中森 康弘; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 65回 347 - 347 2011/09
  • Tatsuki Itoh; Motohiro Imano; Shozo Nishida; Masahiro Tsubaki; Shigeo Hashimoto; Akihiko Ito; Takao Satou
    Journal of Neural Transmission 118 (9) 1263 - 1272 0300-9564 2011/09 [Refereed]
     
    Exercise is reported to inhibit neuronal apoptotic cell death in the hippocampus and improve learning and memory. However, the effect of exercise on inhibition of neuronal apoptosis surrounding the area of damage after traumatic brain injury (TBI) and the improvement of cerebral dysfunction following TBI are unknown. Here, we investigate the effect of exercise on morphology and cerebral function following TBI in rats. Wistar rats received TBI by a pneumatic controlled injury device were randomly divided into two groups: (1) non-exercise group and (2) exercise group. The exercise group ran on a treadmill for 30 min/day at 22 m/min for seven consecutive days. Immunohistochemical and behavioral studies were performed following TBI. The number of single-stranded DNA (ssDNA)-positive cells around the damaged area early after TBI was significantly reduced in the exercise group compared with the non-exercise group (P < 0.05). Furthermore, most ssDNA-positive cells in the non-exercise group co-localized with neuronal cells. However, in the exercise group, a few ssDNA-positive cells co-localized with neurons. In addition, there was a significant increase in neuronal cell number and improvement in cerebral dysfunction after TBI in the exercise group compared with the non-exercise group (P < 0.05). These results indicate that exercise following TBI inhibits neuronal degeneration and apoptotic cell death around the damaged area, which results in improvement of cerebral dysfunction. In summary, treadmill running improved cerebral dysfunction following TBI, indicating its potential as an effective clinical therapy. Therefore, exercise therapy (rehabilitation) in the early phase following TBI is important for recuperation from cerebral dysfunction. © 2011 Springer-Verlag.
  • 胸部食道癌に対する外科治療と補助療法の接点 胸部食道癌に対する補助療法の個別化 PET-N診断に基づく術前化学療法の適応選別
    白石 治; 安田 卓司; 中森 康浩; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 66回 192 - 192 2011/07
  • 高齢者消化器外科手術の諸問題(上部消化管) 高齢者胃癌症例に対する開腹手術と鏡視下手術の比較
    安田 篤; 今本 治彦; 加藤 寛章; 中森 博康; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 66回 229 - 229 2011/07
  • 食道再建術・吻合法の工夫 当科における胸部食道癌手術 胸骨後経路細径胃管再建術の工夫と治療成績
    新海 政幸; 安田 卓司; 中森 康浩; 白石 治; 安田 篤; 彭 英峰; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 66回 244 - 244 2011/07
  • ハイリスク症例に対する胸部食道癌手術症例の検討
    彭 英峰; 安田 卓司; 中森 康浩; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 66回 333 - 333 2011/07
  • リンパ節転移陽性腹膜転移胃癌症例に対するPTX腹腔内化学療法+逐次S-1+CDDP+PTXによる全身化学療法
    中森 康浩; 今野 元博; 今本 治彦; 白石 治; 安田 篤; 彭 秀峰; 新海 政幸; 安田 卓司; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 66回 347 - 347 2011/07
  • 局所進行食道癌に対する50Gy no split導入化学放射線療法による治療戦略
    錦 耕平; 安田 卓司; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 66回 696 - 696 2011/07
  • 高度リンパ節転移の食道胃接合部癌に対しCisplatin/Capecitabine/Cetuximab投与後に根治切除を施行した1例
    加藤 寛章; 安田 卓司; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 66回 773 - 773 2011/07
  • CY(+)胃癌に対する治療戦略 CY(+)胃癌に対するPTX腹腔内化学療法+逐次PTX+S-1全身化学療法
    彭 英峰; 今野 元博; 今本 治彦; 加藤 寛章; 錦 耕平; 中森 康浩; 白石 治; 安田 篤; 新海 政幸; 安田 卓司; 塩崎 均
    日本胃癌学会総会記事 (一社)日本胃癌学会 83回 144 - 144 2011/03
  • 経口摂取不能に対する化学療法 経口摂取不能P1胃癌症例に対するバイパス手術付加の意義について
    安田 篤; 今野 元博; 中森 康浩; 白石 治; 彭 英峰; 新海 政幸; 安田 卓司; 今本 治彦; 奥野 清隆; 塩崎 均
    日本胃癌学会総会記事 (一社)日本胃癌学会 83回 155 - 155 2011/03
  • Tatsuki Itoh; Motohiro Imano; Shozo Nishida; Masahiro Tsubaki; Shigeo Hashimoto; Akihiko Ito; Takao Satou
    Journal of Neural Transmission Springer 118 (2) 193 - 202 0300-9564 2011/02 
    Exercise enhances neuronal stem cell (NSC) proliferation and neurogenesis. However, the effect of exercise on NSC proliferation surrounding the area of damage after traumatic brain injury (TBI) is unknown. Here, we investigate the effect of running on NSC proliferation following TBI in the rat. Wistar rats received TBI and were randomly divided into two groups: (1) non-exercise group and (2) exercise group. The exercise group ran on a treadmill for 30 min/day at 22 m/min for 7 consecutive days. Immunohistochemistry was used to monitor NSC proliferation around the damaged area, and ex vivo techniques were used to isolate NSCs from the damaged region in both groups. The number of nestin- and Ki67-positive cells observed at 3 and 7 days after TBI was significantly greater in the exercise group than in the non-exercise group (P< 0.01). Furthermore, most nestin-positive cells in the exercise group co-localized with Ki67-positive cells. In ex vivo studies, spheres could be isolated from injured brain tissue from the exercise group at 3 and 7 days following TBI, but at only 3 days in the non-exercise group. The number of spheres isolated from injured brain tissue was greater in the exercise group than in the non-exercise group. Spheres were immunopositive for nestin and comprised NSCs that could differentiate into neurons and glia. Exercise increases the proliferation of NSCs around the damaged area following TBI. Therefore, exercise therapy (rehabilitation) in the early phase following TBI is important for recuperation from cerebral dysfunction induced by TBI. © Springer-Verlag 2010.
  • Yasuhiro Kodera; Motohiro Imano; Takaki Yoshikawa; Naoto Takahashi; Akira Tsuburaya; Yumi Miyashita; Satoshi Morita; Akimasa Nakao; Junichi Sakamoto; Mitsuru Sasako
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY OXFORD UNIV PRESS 41 (2) 283 - 286 0368-2811 2011/02 [Refereed]
     
    Owing to its peculiar pharmacological characteristics, paclitaxel attains substantial intra-peritoneal concentration for a prolonged period when delivered intra-peritoneally, and is active against peritoneal metastasis of ovarian cancer. It is also considered promising against disseminated gastric cancer. However, the fact that the intra-peritoneal paclitaxel has not been approved in Japan has rendered its evaluation by a formal clinical trial impossible. The authors designed a randomized phase II trial using the Kodo Iryo Hyoka system, a new system to legally test an yet unapproved mode of treatment. It is hoped that this trial will result in a breakthrough in the treatment of peritoneal carcinomatosis from gastric cancer.
  • Masashi Yanae; Masanobu Tsubaki; Takao Satou; Tatsuki Itoh; Motohiro Imano; Yuzuru Yamazoe; Shozo Nishida
    Journal of Experimental and Clinical Cancer Research 30 (1) 74  1756-9966 2011 [Refereed]
     
    Background: Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis. The inhibition of this key enzyme in the mevalonate pathway leads to suppression of cell proliferation and induction of apoptosis. However, the molecular mechanism of apoptosis induction by statins is not well understood in glioblastoma. In the present study, we attempted to elucidate the mechanism by which statins induce apoptosis in C6 glioma cells. Methods. The cytotoxicity of statins toward the C6 glioma cells were evaluated using a cell viability assay. The enzyme activity of caspase-3 was determined using activity assay kits. The effects of statins on signal transduction molecules were determined by western blot analyses. Results: We found that statins inhibited cell proliferation and induced apoptosis in these cells. We also observed an increase in caspase-3 activity. The apoptosis induced by statins was not inhibited by the addition of farnesyl pyrophosphate, squalene, ubiquinone, and isopentenyladenine, but by geranylgeranyl-pyrophosphate (GGPP). Furthermore, statins decreased the levels of phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt. Conclusions: These results suggest that statins induce apoptosis when GGPP biosynthesis is inhibited and consequently decreases the level of phosphorylated ERK1/2 and Akt. The results of this study also indicate that statins could be used as anticancer agents in glioblastoma. © 2011 Yanae et al licensee BioMed Central Ltd.
  • Expression and Cerebral function of amyloid precursor protein after rat traumatic brain injury.
    Itoh T; Imano M; Nishida S; Tsubaki M; Hashimoto S; Ito A; Satou T
    Alzheimer's Disease pathogenesisi-core concepts, shifting paradigmas and therapeutic targets 31 - 52 2011 [Refereed]
  • M. Imano; H. Imamoto; T. Itoh; T. Satou; Y. F. Peng; A. Yasuda; H. Kato; K. Nishiki; O. Shiraishi; M. Shinkai; M. Tsubaki; T. Yasuda; S. Nishida; Y. Takeyama; K. Okuno; H. Shiozaki
    EUROPEAN SURGICAL RESEARCH KARGER 47 (4) 254 - 259 0014-312X 2011 [Refereed]
     
    Background: There is no standard treatment available for gastric cancer patients whose sole 'non-curative factor' is positive cytological findings in peritoneal washings (CFPW). The aim of this study was to examine the safety, pharmacokinetics and efficacy for free intraperitoneal cancer cells of intraperitoneal chemotherapy with paclitaxel after gastrectomy with en bloc D2 lymph node dissection in cases of gastric cancer with positive CFPW. Methods: Ten patients with gastric cancer who underwent gastrectomy and systemic lymphadenectomy with D2 dissection, without any other non-curative factors besides positive CFPW, were treated with early postoperative intraperitoneal paclitaxel. Intra-chemotherapeutic toxicity and operative complications were measured using NCI-CTC version 3.0. Intraperitoneal and plasma paclitaxel concentrations were measured using a high-performance liquid chromatographic assay. Results: Grade 3/4 toxic effects included anemia (20%) and neutropenia (10%) that required no treatment. Operative complications were, for example, superficial surgical site infections (10%) that were treated with antibiotics. No viable cancer cells were observed in the intra-abdominal fluid 24 h after intraperitoneal administration of paclitaxel. The intraperitoneal/plasma area under the drug concentration-time curve ratio was 2,003.3: 1. Conclusion: Intraperitoneal chemotherapy with paclitaxel is a safe and effective treatment modality for free intraperitoneal cancer cells. Copyright (C) 2011 S. Karger AG, Basel
  • 胃癌腹腔鏡手術の長期成績・予後 当科における胃癌腹腔鏡手術の成績
    安田 篤; 今本 治彦; 中森 康浩; 錦 耕平; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 塩崎 均
    日本臨床外科学会雑誌 日本臨床外科学会 71 (増刊) 355 - 355 1345-2843 2010/10
  • 噴門部胃粘膜下腫瘍に対する腹腔鏡下胃内手術9例の経験とその成績
    安田 篤; 今本 治彦; 加藤 寛章; 錦 耕平; 中森 康浩; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 塩崎 均
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 15 (7) 469 - 469 1344-6703 2010/10
  • M. Imano; T. Itoh; T. Satou; Y. Sogo; H. Hirai; H. Kato; A. Yasuda; Y. F. Peng; M. Shinkai; T. Yasuda; H. Imamoto; K. Okuno; H. Shiozaki; H. Ohyanagi
    EJSO ELSEVIER SCI LTD 36 (10) 963 - 968 0748-7983 2010/10 [Refereed]
     
    Background: We performed short-term neoadjuvant chemotherapy (s-NAC) to examine whether anticancer drugs can change the proliferative ability of cancer cells in gastric cancer patients. Methods: Chemotherapy was performed for 72 h before gastrectomy in 63 gastric cancer patients. Patients were classed into four groups: Group F, 16 cases who received a single administration of 5-fluorouracil (5-FU); Group C, 15 cases who received a single administration of cis-diamminedichloroplatinum (CDDP; cisplatin); Group FC, 16 cases who received both 5-FU+CDDP; and a Control group, 16 cases who did not receive chemotherapy. We reviewed neoadjuvant biopsy tissue and gastric cancer tissue delivered by operation in these cases. The TUNEL method and immunohistochemistry with an anti-MIB-1 antibody were used to evaluate cellular apoptosis and proliferative ability, respectively. The apoptotic index (Al) and an MIB-1 index (MI) were also calculated. Results: There were no differences in Al or MI in biopsy tissue between the groups. The Al of gastric cancer tissue in Group FC was significantly higher than in the other groups (P < 0.01). The MI of Group FC was significantly lower than in the other groups (P < 0.05). In addition, after s-NAC operation there was a significant inhibition of proliferative potency and an induction of apoptosis in Group FC. Conclusion: Combination of CDDP and 5-FU reduced proliferative potency and increased cellular apoptosis in gastric cancer cells. (C) 2010 Elsevier Ltd. All rights reserved.
  • 進行・再発胃癌に対するS-1+CPT11療法とS-1+TXL療法のランダム化比較第二相試験
    飯島 正平; 藤谷 和正; 瀧内 比呂也; 上堂 文也; 今村 博司; 木村 豊; 今野 元博; 黒川 幸典; 後藤 昌弘; 杉本 直俊; 井上 健太郎; 下川 敏雄; 辻仲 利政; 古河 洋
    日本癌治療学会誌 (一社)日本癌治療学会 45 (2) 531 - 531 0021-4671 2010/09
  • 進行胃がんに対する集学的治療の展望 漿膜浸潤を伴う胃癌に対するPTX腹腔内化学療法+逐次PTX+S-1による全身化学療法
    彭 英峰; 安田 卓司; 今本 治彦; 今野 元博; 新海 政幸; 安田 篤; 白石 治; 中森 康浩; 錦 耕平; 加藤 寛章
    日本癌治療学会誌 (一社)日本癌治療学会 45 (2) 327 - 327 0021-4671 2010/09
  • 腹膜転移陽性胃癌に対する単回腹腔内化学療法+全身化学療法の組織学的治療効果の検討
    今野 元博; 今本 治彦; 安田 卓司; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 中森 康浩; 錦 耕平; 加藤 寛章; 奥野 清隆; 塩崎 均
    日本癌治療学会誌 (一社)日本癌治療学会 45 (2) 534 - 534 0021-4671 2010/09
  • P0、CY1胃癌症例に対する当科での治療方針別の成績
    安田 篤; 今野 元博; 加藤 寛章; 中森 康浩; 白石 治; 彭 英峰; 新海 政幸; 安田 卓司; 今本 治彦; 奥野 清隆; 塩崎 均
    日本癌治療学会誌 (一社)日本癌治療学会 45 (2) 801 - 801 0021-4671 2010/09
  • 頸部食道癌の治療 手術と化学放射線療法の接点 導入化学放射線療法の効果別による頸部食道癌喉頭温存治療戦略
    白石 治; 安田 卓司; 今本 治彦; 今野 元博; 新海 政幸; 彭 英峰; 安田 篤; 岩間 密; 中森 康浩; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 64回 116 - 116 2010/08
  • 術前治療群選別を考慮した胸部食道癌リンパ節転移診断におけるPETの意義と有用性
    白石 治; 安田 卓司; 今本 治彦; 今野 元博; 新海 政幸; 彭 英峰; 安田 篤; 中森 康浩; 錦 耕平; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 64回 173 - 173 2010/08
  • 有茎空腸皮下再建後の腹壁瘢痕ヘルニアに対するクーゲルパッチを用いた修復術の1症例
    安田 篤; 安田 卓司; 中森 康弘; 錦 耕平; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 64回 195 - 195 2010/08
  • Motohiro Imano; Kiyokata Okuno; Tatsuki Itoh; Eizaburo Ishimaru; Takao Satou; Hitoshi Shiozaki
    WORLD JOURNAL OF SURGERY SPRINGER 34 (8) 1930 - 1936 0364-2313 2010/08 [Refereed]
     
    The macrophages that infiltrate the tumor stroma are termed tumor-associated macrophages (TAMs). TAMs contribute to hematogenous spread of cancer cells especially liver metastasis. Osteopontin (OPN) is also related to tumor metastasis and proliferation of tumors. OPN is mainly expressed in macrophages of stroma other than that of tumor cells. The aim of the present study was to investigate differences in OPN-positive TAMs between cases of colorectal cancer with synchronous liver metastasis and those without liver metastasis. A total of 54 subjects who had undergone resection of a primary tumor of advanced colorectal cancer were classified into two groups: synchronous colorectal liver metastasis group (s-CLM group; n = 30) and no liver metastasis group (controls; n = 24). The number of OPN- and CD68-positive cells and the microvascular density (MVD) were determined using the CD105 antibody in the stroma of the invasive margin of the tumor and in the stroma of the central area. There was no difference in the patient profiles between the two groups. OPN and MVD expression in the central area were significantly higher in the s-CLM group (OPN: control 4.3 +/- A 1.42, s-CML 12.1 +/- A 1.42, P < 0.05; MVD: control 18.5 +/- A 2.86, s-CML 27.5 +/- A 2.94, P < 0.05), whereas CD68 expression in the invasive margin was significantly higher in the control group (control 98.9 +/- A 7.31, s-CML 29.0 +/- A 4.44, P < 0.05). These data suggest that OPN in the central area may have induced high microvascular density, which led to liver metastasis. Thus, OPN might be a potential target for novel antiangiogenesis therapy for treating colorectal cancer.
  • 胸部食道癌における術前・術後補助療法の有用性 胸部食道癌に対する成績向上を目指した積極的補助療法
    安田 卓司; 今本 治彦; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 今野 元博; 重岡 宏典; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 46 - 46 2010/07
  • 食道粘膜下腫瘍に対する鏡視下手術の工夫
    重岡 宏典; 今本 治彦; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 今野 元博; 安田 卓司; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 73 - 73 2010/07
  • P0、CY1胃癌に対するネオアジュバントとしての腹腔内化学療法+逐次全身化学療法
    彭 英峰; 安田 卓司; 今本 治彦; 中森 康浩; 岩間 密; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 21 - 21 2010/07
  • 術前合併症を有する食道癌手術の治療成績
    新海 政幸; 安田 卓司; 岩間 密; 白石 治; 安田 篤; 彭 英峰; 今野 元博; 重岡 宏典; 今本 治彦; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 98 - 98 2010/07
  • 食道癌手術再建の工夫と実績
    白石 治; 安田 卓司; 今本 治彦; 重岡 宏典; 今野 元博; 新海 政幸; 彭 英峰; 安田 篤; 岩間 密; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 152 - 152 2010/07
  • 腹膜播種陽性症例胃癌に対するAdditional therapyとしての外科的治療
    今野 元博; 安田 卓司; 今本 治彦; 中森 康浩; 岩間 密; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 129 - 129 2010/07
  • 臓器予備能が低下したハイリスク症例に対する内視鏡外科手術の有用性
    安田 篤; 今本 治彦; 中森 康浩; 岩間 密; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 42 - 42 2010/07
  • エチレフリン・オクトレオチド併用療法にて保存的に治癒した乳糜腹水の3症例
    中森 康浩; 今本 治彦; 安田 卓司; 今野 元博; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 373 - 373 2010/07
  • 食道癌根治切除後pN(+)症例に対するJCOG9204術後補助化学療法の有用性の検証
    岩間 密; 安田 卓司; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 重岡 宏典; 今野 元博; 今本 治彦; 塩崎 均
    日本消化器外科学会総会 (一社)日本消化器外科学会 65回 374 - 374 2010/07
  • Michiko Furugaito; Motohiro Imano; Tomoyo Kinboshi; Keisuke Yonemoto; Yumiko Takaie; Terumi Shimokawa; Mayumi Imoto; Yoshiyuki Morishima; Syouchi Naitou; Toshinori Kamisako; Megumi Nikake; Megumi Shichijyou; Kiyoko Matsubayashi; Masami Kado; Satoshi Hara; Kazuhiko Nakagawa; Yasumasa Nishimura; Kiyotaka Okuno; Hitoshi Shiozaki
    Japanese Journal of Cancer and Chemotherapy Japanese Journal of Cancer and Chemotherapy Publishers Inc. 37 (3) 555 - 558 0385-0684 2010/03 [Refereed]
     
    As interprofessional work in cancer treatment becomes increasingly important, medical technologists are required to play active roles as part of the team. The cancer center of our hospital organized a lecture meeting, "The 6th Lecture Meeting: Living Together," for cancer patients and their families, and a medical technologist presented a lecture entitled: "Cancer treatment and clinical examinations." According to the results of a questionnaire survey conducted following the meeting, most participants were able to understand the lecture and were satisfied with it. Based on the opinions expressed by meeting participants and the questionnaire results, medical technologists initiate the following services and activities: Circled digit one They explain the results of white blood cell and neutrophil counts of patients on chemotherapy and/or radiation therapy and Circled digit two provide medical examinations and consultation at outpatient chemotherapy centers. We believe that these efforts will help improve cancer treatment and further contribute to interprofessional health care.
  • 中森 康治; 安田 卓司; 今本 治彦; 今野 元博; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 加藤 寛章; 荒木 麻利子; 塩崎 均
    日本外科学会雑誌 一般社団法人日本外科学会 111 (2) 431 - 431 0301-4894 2010/03
  • 高齢者(75歳以上)の進行・再発胃癌に対するTS-1単独療法の第II相臨床試験(OGSG0404)
    木村 豊; 今村 博司; 後藤 昌弘; 森本 卓; 今野 元博; 飯島 正平; 山下 啓史; 松岡 正樹; 丸山 憲太郎; 黒川 幸典; 下川 敏雄; 瀧内 比呂也; 古河 洋
    日本胃癌学会総会記事 (一社)日本胃癌学会 82回 371 - 371 2010/03
  • 術前補助化療(NAC)の新展開 漿膜浸潤を伴う胃癌に対するPTX腹腔内化学療法+逐次PTX+S-1による全身化学療法の安全性
    彭 英峰; 今野 元博; 今本 治彦; 安田 卓司; 新海 政幸; 安田 篤; 白石 治; 岩間 密; 中森 康浩; 加藤 寛章; 村瀬 貴昭; 塩崎 均
    日本胃癌学会総会記事 (一社)日本胃癌学会 82回 139 - 139 2010/03
  • 腹膜播種に対する集学的治療 腹膜播種陽性胃癌症例における集学的治療
    今野 元博; 安田 卓司; 今本 治彦; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 中森 康浩; 加藤 寛章; 村瀬 貴昭; 奥野 清隆; 塩崎 均
    日本胃癌学会総会記事 (一社)日本胃癌学会 82回 146 - 146 2010/03
  • 当科における高齢者胃癌症例の検討
    安田 篤; 今本 治彦; 加藤 寛章; 中森 康浩; 岩間 密; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 塩崎 均
    日本胃癌学会総会記事 (一社)日本胃癌学会 82回 248 - 248 2010/03
  • P0、CY1胃癌に対する術前化学療法としての腹腔内化学療法+全身化学療法
    加藤 寛章; 今野 元博; 中森 康浩; 岩間 密; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 安田 卓司; 今本 治彦; 塩埼 均
    日本胃癌学会総会記事 (一社)日本胃癌学会 82回 306 - 306 2010/03
  • TS-1/CDDPによる術前化学療法が著効し、組織学的CRを得た進行胃癌の1例
    村瀬 貴昭; 安田 篤; 今野 元博; 安田 卓司; 今本 治彦; 新海 政幸; 彭 英峰; 白石 治; 岩間 密; 中森 康浩; 加藤 寛章; 奥野 清隆; 塩崎 均
    日本胃癌学会総会記事 (一社)日本胃癌学会 82回 309 - 309 2010/03
  • 中森 康浩; 安田 卓司; 今本 治彦; 加藤 寛章; 岩間 密; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 塩崎 均
    近畿大学医学雑誌 近畿大学医学会 35 (1) 31 - 40 0385-8367 2010/03 
    高齢者が多く侵襲度の高い食道癌術後の誤嚥性肺炎は最も危険な合併症のひとつである。高齢者の誤嚥はサブスタンスP(SP)の分泌低下による咳嗽反射低下がその要因とされている。食道癌周術期における血中SP濃度と咳反射の推移および誤嚥/肺炎の発症との関連を明らかにする。胸部食道癌手術予定で文書により同意が得られた26例を対象とした。術前、術後2日目(POD2)、術後7日目(POD7)に血中SP濃度測定、クエン酸誘発咳嗽反射閾値検査を行い、誤嚥/肺炎の発症との関連を前向き臨床研究で検討する。血中SPの平均値は術前、POD2、POD7の順に108.2pg/ml、66.8pg/ml、62.2pg/mlと推移しPOD2に大きく低下した。クエン酸誘発咳嗽反射閾値は測定可能の23例中19例(82.6%)でPOD2に閾値の上昇(15例)または最大のレベル10(4例)を示した。65歳以上のE群と65歳未満のY群に分けて検討したところ肺炎は3例(E群:2例、Y群:1例)、不顕性誤嚥を2例(E群)に認め、全例POD2に咳嗽反射閾値の上昇をみた。E群の誤嚥/肺炎の4例はいずれも術前血中SP濃度は40pg/ml以下でPOD2においても上昇をみなかった。食道癌術後の誤嚥/肺炎とのリスク因子を検討した結果、E群において術前の血中SP濃度≦40pg/mlが最も有意なリスク因子と判明した(p=0.008)。食道癌術後は血中SP濃度の低下と咳嗽反射閾値の上昇により誤嚥性肺炎を容易に発症する状態にある。65歳以上で術前の血中SP濃度≦40pg/mlは術後の誤嚥/肺炎に対するハイリスク群と考えられた。(著者抄録)
  • Tatsuki Itoh; Takao Satou; Shozo Nishida; Masahiro Tsubaki; Motohiro Imano; Shigeo Hashimoto; Hiroyuki Ito
    NEUROCHEMICAL RESEARCH SPRINGER/PLENUM PUBLISHERS 35 (2) 348 - 355 0364-3190 2010/02 
    Edaravone is a novel free radical scavenger used clinically in patients with acute cerebral infarction; however, it has not been assessed in traumatic brain injury (TBI). We investigated the effects of edaravone on cerebral function and morphology following TBI. Rats received TBI with a pneumatic controlled injury device. Edaravone (3 mg/kg) or physiological saline was administered intravenously following TBI. Numbers of 8-OHdG-, 4-HNE-, and ssDNA-positive cells around the damaged area after TBI were significantly decreased in the edaravone group compared with the saline group (P < 0.01). There was a significant increase in neuronal cell number and improvement in cerebral dysfunction after TBI in the edaravone group compared with the saline group (P < 0.01). Edaravone administration following TBI inhibited free radical-induced neuronal degeneration and apoptotic cell death around the damaged area. In summary, edaravone treatment improved cerebral dysfunction following TBI, suggesting its potential as an effective clinical therapy.
  • Shigefumi Yoshino; Seiji Watanabe; Motohiro Imano; Tetsuya Suga; Saburo Nakazawa; Shoichi Hazama; Masaaki Oka
    HEPATO-GASTROENTEROLOGY H G E UPDATE MEDICAL PUBLISHING S A 57 (97) 172 - 177 0172-6390 2010/01 [Refereed]
     
    Background/Aims: Intravenous lentinan administration has life prolongation effect for gastric cancer patients when combined with chemotherapy. Recently, superfine dispersed lentinan - an oral formulation - has become clinically available. In order to evaluate the efficacy of superfine dispersed lentinan, was conducted multi-center clinical study. Methodology: Twenty-seven patients with unresectable or recurrent gastric cancer were enrolled and answered the quality of life questionnaire before and 4, 8, and 12 weeks after the initiation of superfine dispersed lentinan administration. Survival times were evaluated according to results of 3-year follow-up survey. Results: There was no adverse event with causal relation to superfine dispersed lentinan. Median survival time was 17.1 months (95% confidence interval: 6.9-25.9 months) in 26 eligible patients. Six (23%) out of 26 patients were alive longer than 3 years. There was a significant correlation between the quality of life scores at 12 weeks of superfine dispersed lentinan treatment and survival times. Conclusions: Superfine dispersed lentinan is deemed free of anything harmful. Quality of life status at 12 weeks of superfine dispersed lentinan treatment appears to be a promising prognostic predictor.
  • Motohiro Imano; Takao Satou; Tatsuki Itoh; Yoshifumi Takeyama; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Seiji Haji; Chikao Yasuda; Takuya Nakai; Takushi Yasuda; Haruhiko Imamoto; Kiyotaka Okuno; Hitoshi Shiozaki; Harumasa Ohyanagi
    AMERICAN SURGEON SOUTHEASTERN SURGICAL CONGRESS 76 (1) 91 - 95 0003-1348 2010/01 [Refereed]
     
    Mucin glycoproteins from the gallbladder epithelium are thought to contribute to the matrix or nucleus of gallstones and other biomineralization systems. The involved acidic glycoproteins have been reported in bile and gallstones. In addition, osteopontin (Opn) is a noncollagenous acidic bone matrix glycoprotein that possesses calcium-binding properties. To investigate the role of Opn in pigment gallstone formation, the involvement of Opn in pigment gallstone formation was studied immunohistochemically in the gallbladder wall and in the stones. Staining for Opn was strongly positive in the epithelium of stone-laden gallbladders and in their stones. The stone-laden gallbladders were infiltrated by macrophages, which intensely stained for Opn. Sections of the pigment stones, under low magnification, showed a lamellar pattern of Opn immunolabeling and showed a reticular pattern under high magnification. Our results indicate that Opn, an acidic glycoprotein from the gallbladder epithelium, seems to be involved in lithiasis. Opn from macrophages and/or the epithelium seems to help form the matrix protein.
  • 食道癌手術における当科でのHALS胃管作成について
    安田 篤; 今本 治彦; 加藤 寛章; 岩間 密; 武本 智樹; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 塩崎 均
    日本内視鏡外科学会雑誌 (一社)日本内視鏡外科学会 14 (7) 319 - 319 1344-6703 2009/12
  • 切除不能進行・再発胃癌に対するS-1+CPT-11併用化学療法の治療効果 多施設第2相試験
    上堂 文也; 楢原 啓之; 石原 立; 瀧内 比呂也; 後藤 昌弘; 藤谷 和正; 平尾 元素; 辻仲 利政; 今野 元博; 古河 洋; 津熊 秀明; 田口 鐵雄
    成人病 (公財)大阪成人病予防協会 49 (3) 7 - 8 0387-2297 2009/10 
    現在、進行・再発胃癌に対する化学療法について標準的な化学療法メニューは確立されていない。われわれは、以前S-1+CPT-11併用療法の多施設第I相試験を行い同治療法の推奨投与量を決定した。本研究ではS-1+CPT-11併用療法の、切除不能進行・再発胃癌に対する効果と安全性を評価する。23例の切除不能進行・再発胃癌に対してCPT-11:80mg/m2を第1・15病日と、S-1:40(体表面積<1.25m2)、50(体表面積≧1.25to<1.5m2)または60mg(体表面積≧1.5m2)を第1-21病日に投与した。奏効率は47.8%(23例中11例、95%信頼区間:27.4-68.2%)で、非進行期間中央値は210日(95%信頼区間:145-322日)、生存期間中央値は394日(95%信頼区間:241-484日)であった。グレード3以上の血液毒性と非血液毒性の頻度は、それぞれ17.4%と8.7%であった。本レジメンの奏効率は従来の併用療法と遜色なく、有害反応が少なく外来治療が可能であるため、切除不能進行・再発胃癌に対する有用な治療法のひとつとなりうる。(著者抄録)
  • Motohiro Imano; Takao Satou; Tatsuki Itoh; Kenichi Sakai; Eizaburo Ishimaru; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Fumiharu Akai; Takushi Yasuda; Haruhiko Imamoto; Kiyokata Okuno; Hiroyuki Ito; Hitoshi Shiozaki; Harumasa Ohyanagi
    JOURNAL OF GASTROINTESTINAL SURGERY SPRINGER 13 (9) 1577 - 1582 1091-255X 2009/09 [Refereed]
     
    Osteopontin (OPN) is significantly overexpressed in a variety of malignancies. However, little is known concerning the significance of OPN expression in human cancers. Thus, the aim of this study was to determine the relationship between the degree of OPN expression, the proliferative activity of cancer cells, and the clinicopathological findings for surgically resected gastric cancer. We evaluated the immunohistochemical expression of OPN in 85 specimens of cancer. Additionally, we investigated a cancer cell proliferative index using an anti-MIB-1 antibody and terminal deoxynucleotidyl transferase-mediated dUTP biotin nick end labeling staining. Levels of OPN expression in gastric cancers were classified into three groups. To compare the relationship between OPN expression and clinicopathological findings, the features of cancer lesions were classified using the TNM Classification of Malignant Tumors, 6th Edition. Immunohistochemical examination of OPN expression in gastric cancer revealed diffuse granular staining in the cytoplasm. High OPN expression was observed in 37 of 85 carcinomas. Strong OPN expression was significantly associated with a low apoptotic index, a high proliferative index, depth of invasion, lymphatic invasion, and venous invasion. Pathologically, intestinal type carcinoma showed strong expression of OPN. These data suggested that OPN may play an important role in the invasiveness and the progressive nature of gastric cancer.
  • Non-T4 StageII/III食道癌に対する治療戦略 成績向上を目指したNon-T4 StageII/III胸部食道扁平上皮癌に対する至適治療
    安田 卓司; 今本 治彦; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 武本 智樹; 岩間 密; 今野 元博; 塩崎 均
    日本消化器外科学会雑誌 (一社)日本消化器外科学会 42 (7) 935 - 935 0386-9768 2009/07
  • 根治的化学放射線療法後のSalvage治療の諸問題 術後成績よりみた食道癌根治的化学放射線療法後のSalvage手術の適応と合併症対策
    安田 卓司; 今本 治彦; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 武本 智樹; 岩間 密; 今野 元博; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 63回 97 - 97 2009/06
  • 食道癌術後の呼吸機能、サイトカイン変動に対するシベレスタットナトリウムの効果検討
    彭 英峰; 安田 卓司; 岩間 密; 武本 智樹; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 63回 190 - 190 2009/06
  • 進行食道癌化学療法良好例はCRTで予後を改善し得るか? 当科での2症例をもとに
    安田 篤; 安田 卓司; 岩間 密; 武本 智樹; 白石 治; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 63回 201 - 201 2009/06
  • 胸部食道癌のリンパ節転移に対するFDG-PET診断と予後
    白石 治; 岩間 密; 武本 智樹; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 今本 治彦; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 63回 206 - 206 2009/06
  • 化学療法+根治的CRT後の再発に対しsalvage手術を行った高度進行食道扁平上皮癌の1例
    武本 智樹; 新海 政幸; 今本 治彦; 安田 卓司; 今野 元博; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 塩崎 均
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 63回 235 - 235 2009/06
  • 郭清 当科における膜播種陽性胃癌化学療法著効例に対するNo.4s a,bならびに脾門部周囲リンパ節郭清の工夫
    今野 元博; 安田 卓司; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 武本 智樹; 西山 厚子; 岩間 満; 中森 康浩; 今本 治彦; 奥野 清隆; 塩崎 均; 大柳 治正
    日本胃癌学会総会記事 (一社)日本胃癌学会 81回 187 - 187 2009/03
  • Hideaki Ichikawa; Motohiro Imano; Yoshifumi Takeyama; Hitoshi Shiozaki; Harumasa Ohyanagi
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY SPRINGER TOKYO 16 (2) 197 - 203 0944-1166 2009/03 
    Matrix proteins are considered to be essential for biomineralization and to be important factors in the formation and growth of gallstones. Osteopontin (Opn) is a noncollagenous, acidic bone-matrix glycoprotein, which is sialated and phosphorylated and which has a cell-binding peptide sequence of glycine-arginine-glycine-aspartate-serine (GRGDS). To investigate the role of Opn in cholesterol gallstone formation, we have studied the involvement of Opn in cholesterol gallstone formation in the human gallbladder wall, in the stones, and in the mouse gallbladder using a gallstone experimental model. Immunohistochemical staining was used in the human gallbladder wall and human gallstones and the determination of mRNA expression by reverse transcriptase-PCR was used in the mouse gallbladder of a gallstone experimental model. The epithelium of stone-laden gallbladders demonstrated high Opn reactivity, as did the core of the stones. Microscopically detected early stones without macroscopic evidence of lithiasis showed the same immunoreactivity as larger stones. Stone-laden gallbladders were infiltrated by macrophages showing intense Opn expression. In gallstone-forming mice, the expression of Opn mRNA and its protein were significantly increased in the gallbladder wall in the early phase of a lithogenic diet intake, before the initiation of inflammation. These results suggest that Opn is possibly involved as a core protein in the formation of cholesterol gallstones.
  • Akihiro Nakai; Motohiro Imano; Yoshifumi Takeyama; Hitoshi Shiozaki; Harumasa Ohyanagi
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY SPRINGER TOKYO 15 (6) 615 - 621 0944-1166 2008/11 
    Mucin glycoprotein from the intrahepatic bile ducts, and from the intramural and extramural glandular epithelia, is thought to contribute to the formation of the matrix, or nucleus, in hepatolithiasis and to contribute to biomineralization systems. Osteopontin (OPN), a noncollagenous acidic bone matrix glycoprotein that possesses calcium-binding properties. To investigate the role of OPN in the genesis of hepatolithiasis, OPN was immunohistochemically studied in the intrahepatic bile ducts, intramural and extramural glands, and in stones. An immunohistochemical study was performed in 21 human liver specimens with hepatolithiasis, by the EnVision (Dako Japan, Kyoto, Japan) method. Staining for OPN was strongly positive in the epithelium of stone-laden intrahepatic bile ducts, intramural and extramural glands, and in stones. The stone-laden intrahepatic bile ducts were infiltrated by macrophages showing intense staining for OPN. Sections of the hepatolithiasis, viewed under low magnification, showed a lamellar pattern of OPN immunolabeling, and they showed a reticular pattern under high magnification. In the center of the stones, large nestlike membranous structures were frequently present. Our result indicates that OPN, an acidic glycoprotein from intrahepatic bile ducts and from intramural and extramural glandular epithelia, seems to be involved in lithiasis, both as a core protein in the early phase, and in the late phase.
  • 進行・再発胃癌に対するセカンドライン以降の化学療法は何を選ぶか 進行・再発胃癌に対する二次治療としてのCPT-11+CDDP併用化学療法の第II相臨床試験(OGSG0504)
    今村 博司; 飯島 正平; 平尾 素宏; 中江 史郎; 石田 秀之; 森本 卓; 今野 元博; 後藤 昌弘; 上堂 文也; 藤田 淳也; 岸本 朋乃; 宮崎 安弘; 下川 敏雄; 黒川 幸典; 瀧内 比呂也; 辻仲 利政; 古河 洋
    日本癌治療学会誌 (一社)日本癌治療学会 43 (2) 297 - 297 0021-4671 2008/10
  • 大学病院における外来化学療法センターの運営
    今野 元博; 奥野 清隆; 上嶋 一臣; 岡本 勇; 辰己 陽一; 愼 玉姫; 藤原 季美子; 野村 守; 山添 譲; 渡部 洋; 中川 和彦; 塩崎 均
    日本癌治療学会誌 (一社)日本癌治療学会 43 (2) 513 - 513 0021-4671 2008/10
  • Hiroya Takiuchi; Masahiro Goto; Hiroshi Imamura; Hiroshi Furukawa; Motohiro Imano; Haruhiko Imamoto; Yutaka Kimura; Hideyuki Ishida; Kazumasa Fujitani; Hiroyuki Narahara; Toshio Shimokawa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY OXFORD UNIV PRESS 38 (3) 176 - 181 0368-2811 2008/03 [Refereed]
     
    Background: A pre-clinical study demonstrated that paclitaxel induced thymidine phosphorylase in the tumor tissues. The combination of paclitaxel and doxifluridine is expected to exert extra anti-tumor effects. We evaluated the efficacy of this combination in patients with unresectable or recurrent gastric cancer who had been previously treated with S-1. Methods: Registration was started to enroll 35 patients with advanced/recurrent gastric cancer, who were selected among those with measurable lesions fitting to response evaluation criteria in solid tumors, and with resistant to S-1 treatment. This regimen is consisted of paclitaxel, 80 mg/m(2), iv on days 1 and 8; and doxifluridine, 600 mg/m(2), po on days 1-14. The treatment was repeated every three weeks. Primary endpoint was response rate (RR); and secondary endpoints were overall survival (OS), progression free survival (PFS) and onset rate of adverse events. Results: From September 2003 to March 2005, 35 patients were registered: including 28 men; 7 women; median age of 66 years (range, 49-75 years); and performance status (PS) levels were, zero with 21 and one with 14 patients. In 33 eligible patients, except two, clinical usefulness was evaluated resulting in RR of 18.2% (partial response, 6; stable disease, 15; progressive disease, 10; and not evaluable, 2 patients). Median survival time was 321 days and median PFS was 119 days. Severe adverse events were found in three patients to discontinue the present treatment. Conclusions: The combination of paclitaxel and doxifluridine might be a treatment of choice as a second line chemotherapy for patient undergone S-1 treatment.
  • 胃癌-基礎と臨床のアップデート 腹膜播種 化学療法-抗癌剤腹腔内投与・全身化学療法併用療法-
    今野 元博; 安田 卓司; 今本 治彦; 塩﨑 均; 大柳 治正
    日本臨床 596 - 602 2008
  • がん化学療法の実際 -進行食道癌の化学療法-
    今野 元博; 安田 卓司; 平井 紀彦; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 武本 智樹; 岩間 密; 清川 厚子; 中森 康浩; 今本 治彦; 奥野 清隆; 塩﨑 均
    永井書店 103 - 108 2008
  • 今野 元博; 安田 卓司; 平井 紀彦; 新海 政幸; 彭 英峰; 安田 篤; 白石 治; 武本 智樹; 西川 厚子; 岩間 密; 中森 康浩; 今本 治彦; 伊藤 龍生; 佐藤 隆夫; 奥野 清隆; 塩﨑 均; 大柳 治正
    癌の臨床 (株)篠原出版新社 54 (5) 329 - 336 0021-4949 2008
  • Duodenogastric Reflux after Choledochoduodenostomy:evaluation by Technetium-99mScintigraphy
    橋本 直樹; 保田 知生; 新海 政幸; 川西 賢秀; 平井 紀彦; 今野 元博; 重岡 宏典; 今本 治彦; 塩﨑 均
    Hepato-Gastroenterology 54 796 - 798 2007/11 
    胆管十二指腸吻合後、しばしば胃への胆汁逆流がみられ、胆嚢摘出後症候群と報告されている。今回、胆道シンチにて胃への逆流を定量的に評価した。
  • Hiroshi Imamura; Hiroshi Furukawa; Tomono Kishimoto; Siro Nakae; Kentaro Inoue; Yasuo Tsukahara; Motohiro Imano; Keiji Yamazaki; Shinji Okano; Takashi Morimoto; Seiichi Sugihara; Toshio Shimokawa
    HEPATO-GASTROENTEROLOGY H G E UPDATE MEDICAL PUBLISHING S A 54 (79) 2167 - 2171 0172-6390 2007/10 [Refereed]
     
    Background/Aims: TS-1 monotherapy with 4-week administration followed by 2-week rest is used as the community standard treatment for metastatic gastric-cancer in Japan. However, according to a postmarketing survey, the percentage of patients who received three or more courses was only 44.6%; for the reasons of discontinuation due to exacerbation of symptoms or adverse reactions during the first or second course. Therefore, we conducted the phase II study of 2-weeks administration with TS-1 followed by a 1-week rest against metastatic gastric cancer, aiming for mitigation of adverse reactions without reduction of antitumor effect. Methodology: Thirty-five patients were enrolled between 2001 and 2003 at nine institutes in Japan. One cycle of TS-1 treatment whose dosage was 80mg/m(2)/day consisted of administration for 2 weeks followed by a 1-week rest. The primary endpoint was overall response rate and the secondary endpoints were safety and feasibility. Results: There were 6 PRs, 13 NCs, 11 PDs, and 5 patients were not evaluab le (NE), yielding a response rate of 17%. The median survival time of all patients was 290 days. Severe adverse Grade 3 or 4 reactions were observed in 8 (23%) patients. The rate of patients who received six or more courses was 43%. The cumulative rate of the relative total administration days was 93%. Conclusions: We concluded that the schedule of TS-1 administration for 2 weeks followed by a 1-week rest might not be superior to the conventional schedule (4 weeks on and 2 weeks off) with regard to the antitumor effect, adverse reactions and prolonged medication, although it was acceptable from the point of view of survival.
  • 肝転移を伴う胃癌症例におけるHER2遺伝子の増幅とタンパク過剰発現について
    今野 元博; 安田 卓司; 平井 紀彦; 新海 政幸; 彭 英峰; 上杉 忠雄; 伊藤 龍生; 佐藤 隆夫; 奥野 清隆; 塩崎 均; 大柳 治正
    日本癌治療学会誌 (一社)日本癌治療学会 42 (2) 565 - 565 0021-4671 2007/09
  • 結紮・縫合による止血法
    塩﨑 均; 安田 卓司; 今本 治彦; 今野 元博; 平井 紀彦; 新海 政幸
    手術 金原出版 61 (10) 1441 - 1443 2007/09
  • 【腫瘍外科治療の最前線】 食道の腫瘍性疾患 稀な組織型の食道腫瘍 食道悪性黒色腫、悪性リンパ腫と神経鞘腫
    重岡 宏典; 彭 英峰; 平井 紀彦; 新海 政幸; 川西 賢秀; 今野 元博; 今本 治彦; 安田 卓司; 塩崎 均
    外科治療 (株)永井書店 96 (増刊) 417 - 421 0433-2644 2007/04 
    本邦では食道に発生する悪性腫瘍の大部分は扁平上皮癌であり、少数であるが腺癌もみられる。その他ごくまれな悪性腫瘍として、悪性黒色腫や悪性リンパ腫、GIST、癌肉腫などがあり本稿ではわれわれが経験した食道悪性黒色腫と悪性リンパ腫について述べる。食道の良性腫瘍には筋腫、ポリープ、線維腫、嚢胞、血管腫、乳頭腫、脂肪腫などがあり、平滑筋腫が最も頻度が高く、良性腫瘍の約70%を占める。非常にまれな良性腫瘍として食道神経鞘腫についても紹介する。(著者抄録)
  • Noriya Uedo; Hiroyuki Narahara; Ryu Ishihara; Hiroya Takiuchi; Masahiro Goto; Kazumasa Fujitani; Motohiro Hirao; Toshimasa Tsujinaka; Motohiro Imano; Hiroshi Furukawa; Hideaki Tsukuma; Tetsuo Taguchi
    ONCOLOGY KARGER 73 (1-2) 65 - 71 0030-2414 2007 [Refereed]
     
    Background/Aims: To investigate the efficacy and safety of the combination therapy of irinotecan (CPT-11) plus S-1 in patients with advanced gastric cancer at the dose recommended by a previous phase I study. Methods: A total of 23 patients received 80 mg/m(2) of CPT-11 on days 1 and 15, and S-1 at a dose level set on the basis of the body surface area (BSA): 40 (BSA < 1.25 m(2)), 50 (BSA >= 1.25 to <1.5 m(2)) or 60 mg (BSA >= 1.5 m(2)) b.i.d. was given from days 1-21. Results: The overall response rate was 47.8% (11 of 23, 95% confidence interval, CI: 27.4-68.2%). The median time to progression (TTP) was 210 days (95% CI: 145-322 days) and the median survival time was 394 days (95% CI: 241-484 days). The incidence of grade 3 or 4 hematological and non-hematological toxicity was 17.4 and 8.7%. The most common hematological toxicity was anemia and the most common non-hematological toxicity was diarrhea. Conclusion: The combination therapy of CPT-11 and S-1 provided prolonged TTP with low toxicity, and the results warrant a further phase III study to define the efficacy in improvement of survival in patients with advanced gastric cancer. Copyright (C) 2008 S. Karger AG, Basel.
  • 根治的CRT後の食道癌salvage手術の適応と限界
    新海 政幸; 安田 卓司; 清川 厚子; 武本 智樹; 安田 篤; 彭 英峰; 平井 紀彦; 今野 元博; 今本 治彦; 塩﨑 均
    癌の臨床 (53) 605 - 610 2007
  • 腹膜播種を伴う胃癌症例に対するPTX腹腔内投与と逐次S-1+Weekly PTX併用療法
    今野 元博; 今本 治彦; 安田 卓司; 平井 紀彦; 新海 政幸; 彭 英峰; 安田 篤; 武本 智樹; 清川 厚子; 杉浦 史哲; 奥野 清隆; 塩﨑 均; 大柳 治正
    Chemotherapy for Gastric cancer Chemotherapy for Gastric cancer Medical Front Int. Ltd. (2007) 10 - 11 2007
  • スキルス胃癌腹膜播種陽性症例に対するPaclitaxel腹腔内投与と逐次S-1+weekly paclitaxel併用療法
    今野 元博; 安田 卓司; 平井 紀彦; 新海 政幸; 彭 英峰; 安田 篤; 武本 智樹; 清川 厚子; 岩間 密; 中森 康浩; 今本 治彦; 伊藤 龍生; 佐藤 隆夫; 奥野 清隆; 塩﨑 均; 大柳 治正
    消化器科 科学評論社 42 (2) 169 - 175 0289-8756 2007
  • 開創器
    今野 元博; 今本 治彦; 塩﨑 均
    オペナーシング 20 (11) 64 - 67 2006/08 
    上部消化管手術で使用する開創器につき述べた
  • 手術症例報告 食道癌術後に胸壁穿通で発症した胸骨後経路再建胃管潰瘍の1手術例
    平井 紀彦; 杉浦 史哲; 今本 治彦; 重岡 宏典; 今野 元博; 塩崎 均
    手術 金原出版(株) 60 (7) 1083 - 1087 0037-4423 2006/06 
    63歳男.6年前に他院にて食道亜全摘(2領域郭清)+胸骨後経路胃管利用頸部吻合術を施行され,術後経過は良好であったが,10ヵ月前から右前胸部の傍胸骨に発赤と疼痛を認め,切開排膿が行われた.その後,食物通過障害も出現し入院となり精査の結果,胃管潰瘍が胸壁を穿通して皮膚瘻を形成していることが明らかとなり,保存的に9ヵ月治療したが軽快せず,紹介転院となった.入院時上部消化管造影では胃管上部に狭窄を認め,瘻孔部からの造影で胃管が造影され,内視鏡では門歯列から約36cmの前壁に潰瘍を認め,同部に瘢痕による狭窄を認め,胸部CTでは胃管の壁肥厚とそれに続いて胸骨を穿通するように胸壁に瘻孔を認めた.手術では胸骨下部及び胃管切除術+血行再建付加有茎空腸再建術を施行した.切除標本の病理組織所見では胃管中央部にUL-IVの潰瘍形成があり,胸骨を穿通するように皮膚瘻を形成していた.術後経過は順調で術後第10病日の上部消化管造影では縫合不全なく通過良好で経口摂取を開始,第27病日に退院となった
  • クリニカルパスに基づいた術後管理のすべて-胸腔鏡補助下食道切除術-
    今本 治彦; 川西 賢秀; 新海 政幸; 平井 紀彦; 彭 英峰; 今野 元博; 重岡 宏典; 塩﨑 均
    消化器外科 へるす出版 29 (5) 567 - 576 2006/04
  • N. Hashimoto; M. Inayama; M. Fujishima; H. Ho; M. Shinkai; N. Hirai; K. Kawanishi; M. Imano; H. Shigeoka; H. Imamoto; H. Shiozaki
    DISEASES OF THE ESOPHAGUS BLACKWELL PUBLISHING 19 (5) 346 - 349 1120-8694 2006 
    The effect of gastrectomy on the subsequent development of esophageal cancer was investigated. Duodenogastroesophageal reflux is thought to be common in patients after distal gastrectomy, but whether this contributes to the development of esophageal cancer in such patients is controversial. We retrospectively evaluated 153 patients who underwent subtotal esophagectomy for thoracic esophageal cancer between January 2002 and July 2005. They were divided into two groups, according to whether or not they had previously undergone a gastrectomy: group 1, comprising 14 patients who had undergone gastrectomy and group 2, comprising 139 patients who had not. Clinical profiles of the patients were obtained from the medical records and the whole resected esophagus was histopathologically examined. The interval between gastrectomy and esophagectomy in group 1 was significantly shorter in the patients who had undergone gastrectomy for gastric cancer (10.5 +/- 4.2 years) than in those who had undergone gastrectomy for a peptic ulcer (28.9 +/- 3.0 years). The interval was also somehow shorter in the patients for whom anastomosis had been performed by Billroth I (21.3 +/- 5.6 years) compared with Billroth II (29.7 +/- 3.2 years), although the difference did not reach its statistical significance (P = 0.11). Moreover, the proportion of lower third tumors in patients after gastrectomy was significantly higher compared with that of the patients with intact stomach. These findings suggest that a history of gastrectomy is associated with more lower-third squamous cell esophageal carcinoma.
  • 胃食道シンチよりみた胃食道逆流の評価
    橋本 直樹; 新海 政幸; 川西 賢秀; 平井 紀彦; 今野 元博; 重岡 宏典; 今本 治彦; 塩﨑 均
    THerapeutic research THerapeutic research 26 858 - 859 2005/10 
    胃食道シンチより、胃食道逆流の定量的評価をした。
  • Tanaka Akira; Shigeoka Hironori; Hashimoto Naoki; Imamoto Haruhiko; Imano Motohiro; Hirai Norihiko; Kawanishi Kensyu; Shinkai Masayuki
    Acta Med Kinki Univ Kinki University 30 (1) 31 - 37 0386-6092 2005/06 
    Background: Early gastric cancer arising in the upper third area (U-area) has increased in incidence, but the operative outcome and prognosis have improved. However, a standard reconstruction procedure has not been established. The aim of this study was to investigate the usefulness of jejunal interposition for reconstruction after proximal gastrectomy following with a modification for prevention gastro-esophageal reflux. Methods: The subjects were 9 patients with mucosal or submucosal gastric cancer in U-area, in whom jejunal interposition was performed for reconstruction after proximal gastrectomy. The control group was 8 patients with mucosal or submucosal gastric cancer and leiomyoma in whom esophagogastrostomy was performed. Results: After jejunal interposition, there were no symptoms of esophageal reflux such as heartburn and regurgitation, and no esophagitis was seen on endoscopic examination. Furthermore, reflux of gastric contents into the esophagus was not seen on either upper gastrointestinal series or scintigraphy. After esophagogastrostomy, however, esophageal reflux symptoms and endoscopic evidence of esophagitis due to reflux were noted in 7 out of 8 patients (87.5%), and medications were needed for symptomatic relief. Conclusions: Jejunal interposition following with a modification for prevention of gastro-esophageal reflux may be an excellent procedure for improving the postoperative quality of life after proximal gastrectomy.
  • 【外科手術教育の方法と実践 積極的に学ぶ系統的手術教育】 助手の役割と場の作り方
    塩崎 均; 今本 治彦; 重岡 宏典; 今野 元博; 新海 政幸; 平井 紀彦
    手術 金原出版(株) 59 (5) 607 - 612 0037-4423 2005/05
  • 【外科専門医に必要な消化管・腹部内臓手術手技】 下咽頭・頸部食道癌手術(切除)
    塩崎 均; 今本 治彦; 重岡 宏典; 今野 元博; 川西 賢秀; 彭 英峰
    手術 金原出版(株) 59 (6) 711 - 718 0037-4423 2005/05
  • 川西 賢秀; 彭 英峰; 新海 政幸; 平井 紀彦; 今野 元博; 重岡 宏典; 今本 治彦; 塩﨑 均
    臨床外科 医学書院 60 (2) 187 - 192 2005/02
  • 塩﨑 均; 今本 治彦; 重岡 宏典; 今野 元博; 平井 紀彦; 新海 政幸; 川西 賢秀; 彭 英峰
    臨床外科 医学書院 60 (13) 1541 - 1547 2005
  • 損傷修復のための基本手技
    塩﨑 均; 今本 治彦; 新海 政幸; 重岡 宏典; 今野 元博; 平井 紀彦
    手術 金原出版 59 (3) 303 - 308 2005
  • 新規抗癌剤の臨床応用(胃) TS-1/Paclitaxel併用療法における推奨用量と有効性および有害事象(胃癌を対象とした多施設共同第I/II相臨床試験OGSG0105)
    井上 健太郎; 中根 恭司; 藤谷 和正; 辻仲 利政; 後藤 昌弘; 瀧内 比呂也; 楢原 啓之; 上堂 文也; 木村 豊; 今野 元博; 今村 博司; 古河 洋
    日本癌治療学会誌 (一社)日本癌治療学会 39 (2) 366 - 366 0021-4671 2004/09
  • 【手術で役立つ臨床局所解剖の知識】 喉頭摘出を伴う頸部食道癌手術
    塩崎 均; 今本 治彦; 重岡 宏典; 今野 元博; 新海 政幸; 平井 紀彦; 川西 賢秀; 西川 正康
    手術 金原出版(株) 58 (10) 1533 - 1539 0037-4423 2004/09
  • 【救急マニュアル2004】 主要疾患の救急対応 消化器系 食道穿孔・食道狭窄
    塩崎 均; 重岡 宏典; 今本 治彦; 今野 元博; 平井 紀彦; 川西 賢秀; 新海 政幸; 西川 正康
    綜合臨床 (株)永井書店 53 (増刊) 1107 - 1112 0371-1900 2004/04
  • 【Oncogenic emergencyとその対応】 食道癌
    塩崎 均; 重岡 宏典; 今本 治彦; 今野 元博
    日本外科学会雑誌 (一社)日本外科学会 105 (4) 275 - 280 0301-4894 2004/04 
    食道悪性腫瘍による食道穿孔や食道狭窄は経験することが比較的多いが,食道異物による食道穿孔や特発性食道破裂は稀な疾患である.悪性腫瘍による穿孔の治療法は現状においては穿孔部位によって異なると考えている.異物による食道穿孔の治療は,異物の除去,起炎菌の同定と適切な抗生剤使用ならびにドレナージである.いずれの疾患にせよ,刻々と変化する患者の状況を正しく把握し,次の手を考えながら治療することが大切である
  • K Okada; S Ueshima; M Imano; K Kataoka; O Matsuo
    JOURNAL OF HEPATOLOGY ELSEVIER SCIENCE BV 40 (1) 110 - 116 0168-8278 2004/01 [Refereed]
     
    Background/Aims: The regeneration after liver injury is regulated by the release and activation of several growth factors. The role of the plasmin/alpha(2)-antiplasmin (alpha(2)-AP) system in liver regeneration was investigated. Methods: CCl4 was injected intraperitoneally into the mice deficient (-/-) in fibrinolytic factors: alpha(2)-AP plasminogen (Plg) -/-, and Plg -/-.alpha(2)-AP -/-, and wild-type (WT) mice. The liver tissue was examined for its microscopic appearance, fibrinolytic activity, and fibronectin levels. Results: In the gene deficient and WT mice, the livers exhibited the same extent of necrosis 2 days after the CCl4 injection. The livers of the WT mice normalized after 7 days, and the alpha(2)-AP -/- mice normalized after 5 days. In contrast, the livers of the Plg -/- and Plg -/-.alpha(2)-AP -/- mice remained in the damaged state until 14 days after the liver injury. The injection of anti-alpha(2)-AP antibody in the WT mice improved the regeneration after the liver injury, and the injection of tranexamic acid in the alpha(2)-AP -/- mice reduced. Conclusions: These results suggest that the plasmin/alpha(2)-AP system played an important role in hepatic repair via clearance from the injury area. (C) 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • 食道穿孔・食道狭窄
    塩﨑 均; 重岡 宏典; 今本 治彦; 今野 元博; 平井 紀彦; 新海 政幸; 川西 賢秀; 西川正康
    総合臨床 53 487 - 492 2004
  • 胃および十二指腸
    塩﨑 均; 今本 治彦; 重岡 宏典; 今野 元博; 平井 紀彦; 川西 賢秀; 新海 政幸
    ナースのための消化器外科 メディカ出版 57 - 85 2004
  • 頚部食道癌(早期・進行)
    塩﨑 均; 今本 治彦; 重岡 宏典; 今野 元博; 平井 紀彦; 川西 賢秀; 新海 政幸
    消化器外科 27 (11) 1639 - 1646 2004
  • 咽頭摘出を伴う頚部食道癌手術
    塩﨑 均; 今本 治彦; 重岡 宏典; 今野 元博; 新海 政幸; 平井 紀彦; 川西 賢秀
    手術 58 (4) 1533 - 1540 2004
  • 頚部食道癌手術
    塩﨑 均; 今本 治彦; 重岡 宏典; 今野 元博; 新海 政幸; 平井 紀彦; 川西 賢秀
    手術 58 (6) 777 - 784 2004
  • 【手術助手の全て 経験を無駄にしないコツ,役割,配慮】 助手の心構えと「べからず集」
    塩崎 均; 今本 治彦; 重岡 宏典; 今野 元博
    消化器外科 (株)へるす出版 26 (10) 1451 - 1455 0387-2645 2003/09 
    手術は術者,麻酔医,看護師,助手の共同作業であり,チームワークが求められる作業である.助手は術者,麻酔医,看護師のチームワークをまとめる役割を担うと共に,手術をリードするくらいの心構えが必要である.そこで,手術手技研究会でまとめた約28年前と10年前の「べからず」集を参照しながら,助手としての役割と配慮を通してのよい手術とはというテーマについて述べた.この「べからず」集を見直すことによって,よりよい助手になることが優れた術者になる近道であることが改めて認識された
  • Takao Satou; Tadao Uesugi; Yuka Nakai; Yoshiyuki Hayashi; Motohiro Imano; Shigeo Hashimoto
    Diagnostic Cytopathology 29 (2) 87 - 90 8755-1039 2003/08 
    Cytological diagnosis of adrenal cysts is becoming more important, with the increase in cases identified due to the widespread use of imaging modalities. Adrenal cysts have been classified into four main groups: endothelial, epithelial, parasitic, and pseudocyst, with endothelial cysts further classified as lymphangiomatous or angiomatous. We report on a case of adrenal lymphangioma with atypical lymphocytes found in the intraoperative aspirate, suggesting an inconclusive diagnosis, although immunohistochemical study led us to suppose their B-cell origin This case provided important cytological findings that may assist in the prevention of cytological overdiagnosis. © 2003 Wiley-Liss, Inc.
  • 【食道癌治療の進歩】 食道癌の手術治療の最前線 手術侵襲の軽減化(小切開手術)
    塩崎 均; 今本 治彦; 重岡 宏典; 今野 元博; 矢野 雅彦
    癌と化学療法 (株)癌と化学療法社 30 (7) 923 - 928 0385-0684 2003/07 
    著者等は,胸腔鏡を併用することにより良好な光量(視野)を得ることができることから,10cmの小開胸創で食道癌手術を行っている.又,腹部操作も腹腔鏡補助下の小切開創で行う術式(HALS)を基本術式としている.胸部食道癌の手術の第一のポイントは,両側反回神経沿いリンパ節(No.106-rec)の郭清である.第二のポイントは,癌の浸潤がない場合は両側迷走神経の肺枝や両側気管支動脈の温存,また奇静脈弓や胸管を温存し,侵襲を最小限度にとどめていることである.開胸,開腹創の大きさは創部痛を介して術後早期の呼吸機能とも重大な関連性をもっており,手術創を小さくすることが術後の合併症の軽減に関与すると予測される
  • 音声を考慮した切除・再建術
    塩﨑 均; 重岡 宏典; 今本 治彦; 今野 元博; 平井 紀彦; 川西 賢秀
    手術 金原出版株式会社 57 (8) 795 - 802 2003/07
  • 胃切除後の食道癌
    塩崎 均; 重岡 宏典; 今野 元博; 今本 治彦
    臨牀と研究 大道学館出版部 80 (5) 917 - 920 0021-4965 2003/05
  • 胃切除後の食道癌
    塩﨑 均; 重岡 宏典; 今野 元博; 今本 治彦
    臨床と研究 大道學館出版部 80 (5) 99 - 102 2003/05
  • M. Tanaka; K. Okada; S. Ueshima; M. Imano; H. Ohyanagi; P. Carmeliet; O. Matsuo
    Fibrinolysis and Proteolysis Churchill Livingstone 15 (1) 2 - 8 1369-0191 2001 [Refereed]
     
    Liver regeneration is regulated by variety of growth factors. Release and activation of these growth factors are deeply related to degradation of extracellular matrix (ECM), which is regulated by plasminogen-activating system. Since plasminogen is assumed to be essential in these functions in liver regeneration, partial 70% hepatectomy (PH) was performed on plasminogen deficient (Plg-/-) mice and wild-type (Plg+/+) mice. The sequential recovery of the liver weight after 70% PH gradually increased over 1 to 14 days in Plg+/+ mice. However, in Plg-/- mice, it increased over 1 to 7 days and thereafter increased no more. Thus, the recovery in Plg-/- mice was significantly impaired at 10 and 14 days compared with Plg+/+ mice. Plg+/+ mice exhibited an increase in DNA synthesis over 5 days, and then a decrease thereafter however, in Plg-/- mice, it increased over 3 days, and decreased thereafter, with the significant decrease at 14 days. The apoptotic nuclei labelling index slightly increased over 3 days, and decreased thereafter in Plg+/+ mice. In Plg-/- mice, it was few detected over 3 days, and gradually increased over 7 to 14 days. The apoptotic index in Plg-/- mice was higher than Plg+/+ mice at 14 days. In the histological examination of liver, focal area of cellular loss with fibrin deposition were detected in Plg-/- mice after PH, which were rarely detected in Plg+/+ mice. In Plg-/- mice, expressions of t-PA, u-PA and pro-MMP-9 were increased in the liver at 14 days after PH compared with Plg+/+ mice. These findings suggest that plasminogen plays an important role in liver regeneration after PH. © 2001 Harcourt Publishers Ltd.
  • がん患者への臨床検査技師の取り組みを考える がん患者と家族を対象とした「がん治療と臨床検査」の講演後のアンケート報告から
    古垣内美智子; 今野元博; 金星智世; 米本圭佑; 鷹家優美子; 下川てるみ; 井本真由美; 森嶋祥之; 内藤昭智; 上硲俊法; 荷掛恵; 七條恵; 松林輝代子; 加戸聖美; 原聡; 中川和彦; 西村恭昌; 奥野清隆; 塩崎均
    癌と化学療法 37 (3) 555 - 558 2000/03 [Refereed]
  • A. Kubota; T. Yonekura; D. Kuroda; T. Yasuda; M. Kato; H. Oyanagi; M. Imano; T. Sato; K. Fukushima; M. Okada
    Pediatric Surgery International Springer Verlag 11 (1) 45 - 46 0179-0358 1996 [Refereed]
     
    Infected intra-abdominal cystic lymphangiomas are very rare. We report a case of a purulent mesenteric cyst, histologically a cystic lymphangioma, which developed in a 1-year-old girl marked abdominal who presented with distension and high fever. Magnetic resonance imaging revealed that the huge cystic lesion occupied the entire peritoneal cavity. It originated from the mesocolon. It was removed completely, and contained sticky pus at the base where the right fallopian tube penetrated it, which indicated the focus of infection. This may be the first report of a purulent mesenteric cyst in which the route of infection was suspected.
  • 5-FU+docetaxel+nedaplatin併用術前化学療法が奏効した進行食道癌患者の1例
    木村豊; 白石治; 川上尚人; 植田勲人; 奥野達哉; 平木洋子; 加藤寛章; 岩間密; 安田篤; 新海政幸; 筑後孝章; 今野元博; 今本治彦; 中川和彦; 安田卓司
    癌と化学療法 45 (13) 1812 - 1814 [Refereed]

Conference Activities & Talks

  • 高齢食道癌患者における術後肺炎と予後に関する検討.  [Not invited]
    木村 豊; 岩間 密; 白石 治; 平木洋子; 加藤寛章; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第30回日本外科感染症学会総会  2017/11  東京
  • 胸部食道癌補助療法後の頸部郭清省略の選別の妥当性.  [Not invited]
    白石 治; 加藤寛章; 岩間 密; 平木洋子; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第79回日本臨床外科学会総会  2017/11  東京
  • 胃切除術後症候群に対する膵酵素補充剤の有用性に関する検討.  [Not invited]
    木村 豊; 三上城太; 間狩洋一; 平木洋子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第79回日本臨床外科学会総会  2017/11  東京
  • 左側臥位食道切除術における安定した術野確保のための肺圧排固定器具の開発.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 加藤寛章; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦
    第79回日本臨床外科学会総会  2017/11  東京
  • The effect of pancrelipase against diarrhea in patients after gastrectomy.  [Not invited]
    Kimura Y; Mikami J; Makari Y; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Fujita J; Yasuda T
    21st Asian Congress of Surgery  2017/11  東京
  • A newly modified esophagogastrostomy after proximal gastrectomy in our institution.  [Not invited]
    Yasuda A; Kimura Y; Hiraki Y; Kato H; Iwama M; Shiraishi O; Shinkai M; Imano M; Imamoto H; Yasuda T
    21st Asian Congress of Surgery  2017/11  東京
  • A Phase I/? Trial of Chemo-Radiotherapy for Resectable Type 4 or Large Type 3 Gastric Cancer.  [Not invited]
    Imano M; Furukawa H; Satoh T; Yasuda T
    日本放射線腫瘍学会 第30回学術大会 30th JASTRO  2017/11  大阪
  • Multidisciplinary treatment for gastric cancer; from a radiation oncologist’s point of view.  [Not invited]
    Masaki Yokokawa; Motohiro Imano; Hitoshi Tatebe; Kiyoshi Nakamatsu; Masahiro Inada; Kouhei Fukuda; Kazuki Ishikawa; Hajime Monzen; Shuichi Kanamon; Hiroshi Furukawa; Yasumasa Nishimura
    日本放射線腫瘍学会 第30回学術大会 30th JASTRO  2017/11  大阪
  • 既治療に耐性の進行再発胃癌に対するramu-cirumab療法における蛋白尿に関する検討.  [Not invited]
    木村 豊; 間狩洋一; 三上城太; 平木洋子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 藤田淳也; 安田卓司
    第55回日本癌治療学会学術集会  2017/10  横浜
  • 腹膜播種陽性胃癌に対するCape/CDDP+docetaxel腹腔内投与併用療法の第?相試験.  [Not invited]
    戸澤勝之; 石神浩徳; 福島亮治; 今野元博; 小林大介; 辻 靖; 秀村晃生; 楠本哲也; 大森 健; 藪崎 裕; 大橋紀文; 太田光彦; 山口博紀; 北山丈二
    第55回日本癌治療学会学術集会  2017/10  横浜
  • cT4食道癌の外科治療の限界と成績.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 加藤寛章; 平木洋子; 安田 篤; 宮田博志; 新海政幸; 今野元博; 木村 豊; 矢野雅彦; 今本治彦
    第55回日本癌治療学会学術集会  2017/10  横浜
  • 食道癌特異的ペプチドワクチンの術後補助療法としての有用性と腫瘍微小環境との関連.  [Not invited]
    安田卓司; 錦 耕平; 白石 治; 岩間 密; 加藤寛章; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 奥野清隆; 中村祐輔
    第55回日本癌治療学会学術集会  2017/10  横浜
  • 良性潰瘍に対する胃切既往のある胸部食道癌における、腹部リンパ節転移状況の検討.  [Not invited]
    加藤寛章; 白石 治; 岩間 密; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第25回日本消化器関連学会週間(JDDW)  2017/10  福岡
  • 外来化学療法室での安全な投与管理に向けた取り組み〜ハンドオフシートを導入して〜  [Not invited]
    山?里花; 田中美帆; 林真紀子; 原武めぐみ; 石田洋子; 藤原季美子; 今野元博
    第55回日本癌治療学会学術集会  2017/10  横浜
  • 食道癌術後気管切開における甲状腺上アプローチの有用性.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 加藤寛章; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦
    第25回日本消化器関連学会週間(JDDW)  2017/10  福岡
  • 進行再発胃癌に対するramucirumab使用例における蛋白尿の検討.  [Not invited]
    木村 豊; 間狩洋一; 三上城太; 平木洋子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 藤田淳也; 安田卓司
    第25回日本消化器関連学会週間(JDDW)  2017/10  福岡
  • 鏡視下手術の導入を考慮した当科における腹腔鏡補助下噴門側胃切除後食道残胃吻合法.  [Not invited]
    安田 篤; 木村 豊; 今本治彦; 平木洋子; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 今野元博; 安田卓司
    近畿内視鏡外科研究会 第30回記念大会  2017/09  大阪
  • Safety and efficacy of S-1 treatment in elderly patients with advanced or recurrent gastric cancer: a subgroup analysis from the phase III JFMC36-0701 trial.  [Not invited]
    K. Nishikawa; S. Yoshino; S. Morita; T. Takahashi; K. Sakata; J. Nagao; H. Nemoto; N. Murakami; H. Hasegawa; R. Shimizu; T. Yoshikawa; H. Osanai; M. Imano; H. Naitoh; A. Tanaka; J. Sakamoto; S. Saji; M. Oka
    ESMO2017  2017/09  スペイン(マドリード)
  • 進行食道癌に対する術前化学療法ランダム化比較試験FAP vs DCF(OGSG1003)におけるリンパ節微小転移制御効果.  [Not invited]
    平木洋子; 今野元博; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 木村 豊; 今本治彦; 安田卓司
    第26回日本がん転移学会学術集会・総会  2017/07  大阪
  • 高齢・胃切後胸部食道癌に対する嚥下機能温存と血行付加を考慮した新規縦隔横断胸骨後経路高位胸腔内吻合.  [Not invited]
    平木洋子; 白石 治; 岩間 密; 加藤寛章; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第72回日本消化器外科学会  2017/07  石川
  • cT4 局所進行食道癌に対するSalvage 手術を前提とした導入化学放射線療法による治療戦略.  [Not invited]
    岩間 密; 白石 治; 加藤寛章; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第72回日本消化器外科学会  2017/07  石川
  • 胃切除術後早期の体重減少抑制を目指した取り組み.  [Not invited]
    木村 豊; 三上城太; 間狩洋一; 藤田淳也; 平木洋子; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第72回日本消化器外科学会  2017/07  石川
  • 胃切既往のある胸部食道癌の腹部リンパ節転移の検討〜残胃全摘の省略は許容されるか〜.  [Not invited]
    加藤寛章; 白石 治; 岩間 密; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第72回日本消化器外科学会  2017/07  石川
  • 菱形残胃作成と食道裂孔挿入を付加した噴門側胃切除・食道残胃吻合法.  [Not invited]
    安田 篤; 新海政幸; 加藤寛章; 平木洋子; 岩間 密; 白石 治; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第72回日本消化器外科学会  2017/07  石川
  • 安定した術野確保のための右肺圧排固定器具の開発と胸腔鏡拡大画像に基づく左側臥位縦隔リンパ節郭清手技.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 加藤寛章; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦
    第72回日本消化器外科学会  2017/07  石川
  • リンパ節転移状況に基づく進行EGJ 腺癌に対するNAC+胸腹連続郭清.  [Not invited]
    白石 治; 平木洋子; 加藤寛章; 岩間 密; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第72回日本消化器外科学会  2017/07  石川
  • CY(+) 進行胃癌に対するPTX 腹腔内投与+PCS 全身化学療法の有用性の検討.  [Not invited]
    新海政幸; 今野元博; 平木洋子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本治彦; 安田卓司
    第72回日本消化器外科学会  2017/07  石川
  • 胸部食道癌における術後肺炎と縫合不全のリスク因子とその対策  [Not invited]
    白石 治; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第69回日本消化器外科学会総会  2017/07  郡山
  • 食道癌術後の進行胃管癌に対して胃管分節切除術で切除できた1例.  [Not invited]
    幕谷悠介; 白石 治; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • 巨大胃GISTに対して術前イマチニブ投与を行い、根治切除可能であった1例.  [Not invited]
    平木洋子; 加藤寛章; 安田 篤; 田中裕美子; 岩間 密; 白石 治; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • 集学的加療により咽頭温存とともにR0切除を得た胸部上部食道癌1切除例.  [Not invited]
    岩間 密; 白石 治; 加藤寛章; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • 食道入口部に及ぶ大型頸部食道癌に対し、喉頭温存手術を成し得た1例.  [Not invited]
    白石 治; 加藤寛章; 岩間 密; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • 胸部食道癌の術前化学療法にて腫瘍穿破寸前の状態に陥り、緊急手術を行った1例.  [Not invited]
    安田 篤; 木村 豊; 加藤寛章; 平木洋子; 田中裕美子; 岩間 密; 白石 治; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • 噴門部GISTに対する機能温存を配慮した腹腔鏡下胃内手術の有用性.  [Not invited]
    安田 篤; 木村 豊; 新海政幸; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 今野元博; 今本治彦; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • P0CY1胃癌に対するPTX腹腔内投与+PCS3剤全身化学療法の治療成績.  [Not invited]
    新海政幸; 今野元博; 平木洋子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 今本治彦; 木村 豊; 古河 洋; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • paclitaxel+ramcirumab療法によりgrade3の蛋白尿をきたした再発胃癌の1例.  [Not invited]
    木村 豊; 間狩洋一; 三上城太; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 藤田淳也; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • 内視鏡生検でがん細胞が検出できなかったスキルス胃癌の切除例.  [Not invited]
    古河 洋; 中室 誠; 中野博史; 近藤禎晃; 石川和男; 大久保遊平; 今野元博; 木村 豊; 安田卓司
    第39回日本癌局所療法研究会  2017/06  京都
  • 胃癌手術既往のある異時性重複食道癌における、腹腔内リンパ節転移の検討〜残胃温存は許容されるか?〜.  [Not invited]
    加藤寛章; 白石 治; 岩間 密; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第60回関西胸部外科学会学術集会  2017/06  大阪
  • 高齢者食道癌手術の対策と現状.  [Not invited]
    白石 治; 加藤寛章; 岩間 密; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第60回関西胸部外科学会学術集会  2017/06  大阪
  • 胃切除後の食道癌患者に対する新しい術式〜縦隔横断胸骨後経路高位胸腔内吻合〜.  [Not invited]
    木村 豊; 白石 治; 平木洋子; 岩間 密; 加藤寛章; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第60回関西胸部外科学会学術集会  2017/06  大阪
  • 胃癌,頭頸部癌との重複食道癌に対する治療戦略.  [Not invited]
    加藤寛章; 白石 治; 岩間 密; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第71回日本食道学会学術集会  2017/06  軽井沢
  • 当科におけるSalvage手術の安全性と有効性に関する検討.  [Not invited]
    岩間 密; 白石 治; 加藤寛章; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第71回日本食道学会学術集会  2017/06  軽井沢
  • 高齢食道癌患者に対する手術における誤嚥,肺炎の発症の低減を目指した治療選択.  [Not invited]
    木村 豊; 白石 治; 岩間 密; 加藤寛章; 平木洋子; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第71回日本食道学会学術集会  2017/06  軽井沢
  • 食道癌RO切除困難症例への挑戦.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 加藤寛章; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦
    第71回手術手技研究会  2017/05  名古屋
  • 頸部食道癌術後2年目発症の気管食道瘻に対し、遊離前腕皮弁による瘻孔閉鎖・気管孔再形成が有用であった1例.  [Not invited]
    加藤寛章; 白石 治; 岩間 密; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第71回手術手技研究会  2017/05  名古屋
  • 食道癌手術において捻転イレウスを回避できる腹腔鏡下空腸瘻増設術.  [Not invited]
    白石 治; 加藤寛章; 岩間 密; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第71回手術手技研究会  2017/05  名古屋
  • 胃切除術の既往のある高齢胸部食道癌患者に対する縦隔横断胸骨後経路高位胸腔内吻合.  [Not invited]
    木村 豊; 白石 治; 平木洋子; 岩間 密; 加藤寛章; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第71回手術手技研究会  2017/05  名古屋
  • 胸部食道癌根治術後再発とその治療戦略―再び根治を目指して―.  [Not invited]
    加藤寛章; 白石 治; 岩間 密; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第117回日本外科学会定期学術集会  2017/04  横浜
  • 噴門側胃切除・食道残胃吻合における食道胃逆流防止の工夫.  [Not invited]
    安田 篤; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 今野元博; 今本治彦; 木村 豊; 古河 洋; 安田卓司; 奥野清隆
    第117回日本外科学会定期学術集会  2017/04  横浜
  • 腹腔鏡下にD2郭清を伴う腹腔鏡下胃切除術を安全に行うための工夫.  [Not invited]
    木村 豊; 三上城太; 間狩洋一; 藤田淳也; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 古河 洋; 今本治彦; 安田卓司
    第117回日本外科学会定期学術集会  2017/04  横浜
  • 胸部食道癌手術における頸部郭清の合理化は可能か―Standard or Selective―.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 加藤寛章; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦
    第117回日本外科学会定期学術集会  2017/04  横浜
  • 安全性を目指した胸部食道癌手術における再建術の工夫.  [Not invited]
    岩間 密; 加藤寛章; 白石 治; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第117回日本外科学会定期学術集会  2017/04  横浜
  • 切除可能進行胃癌に対する術前TS-1+Cisplatin+Paclitaxel併用療法(PCS療法).  [Not invited]
    新海政幸; 今野元博; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本治彦; 安田卓司
    第117回日本外科学会定期学術集会  2017/04  横浜
  • A study about gastric tube cancer after radical esophagectomy for thoracic esophageal cancer. 胸部食道癌術後胃管癌に関する検討.  [Not invited]
    岩間 密; 白石 治; 加藤寛章; 平木洋子; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦; 安田卓司
    第89回日本胃癌学会総会  2017/03  広島
  • Feasibility of neoadjuvant chemoradiation therapy for resectable advanced gastric cancer. 根治切除可能な大型3型/4型胃癌に対する術前化学放射線療法の実現可能性.  [Not invited]
    白石 治; 田中裕美子; 加藤寛章; 岩間 密; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 古河 洋; 塩? 均; 安田卓司
    第89回日本胃癌学会総会  2017/03  広島
  • Examination of Pylorus Preserving Gastrectomy in our institution. 当科での幽門保存胃切除術の検討.  [Not invited]
    安田 篤; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 古河 洋; 今野元博; 木村 豊; 今本治彦; 安田卓司; 奥野清隆
    第89回日本胃癌学会総会  2017/03  広島
  • The examination of factors affecting body weight loss in patients after total gastrectomy. 胃全摘術後早期の体重減少に影響を及ぼす因子に関する検討.  [Not invited]
    木村 豊; 三上城太; 間狩洋一; 藤田淳也; 平木洋子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第89回日本胃癌学会総会  2017/03  広島
  • Neoadjuvant combination chemotherapy with S-1, CDDP and PTX for resectable advanced gastric cancer. 切除可能進行胃癌に対する術前PCS療法.  [Not invited]
    新海政幸; 今野元博; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 木村 豊; 今本治彦; 安田卓司
    第89回日本胃癌学会総会  2017/03  広島
  • Phase ? study of ip paclitaxel plus S-1/iv paclitaxel in GC pts.with positive peritoneal cytology. 腹腔内洗浄細胞診陽性症例に対するパクリタキセル腹腔内投与+S-1/パクリタキセル静脈投与法の第?相臨床試験.  [Not invited]
    今野元博; 石神浩徳; 梨本 篤; 藪崎 裕; 今本治彦; 山下裕玄; 岸健太郎; 小寺泰弘; 上之園芳一; 藤原義之; 秀村晃生; 田村茂行; 福島亮治; 山口博紀; 北山丈二
    第89回日本胃癌学会総会  2017/03  広島
  • 症例頃のリスク軽減の工夫による根治的リンパ節郭清を共な食道癌外科治療戦略.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 加藤寛章; 田中裕美子; 平木洋子; 安田 篤; 新海政幸; 今野元博; 木村 豊; 今本治彦
    第78回日本臨床外科学会総会  2016/11  東京
  • 75歳以上の根治切除可能な4型・大型3型胃癌に対する術前化学放射線療法の試み.  [Not invited]
    曽我部俊介; 田中裕美子; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第116回日本外科学会  2016  大阪
  • 胃癌術後5年目に発症した脾転移の1切除例.  [Not invited]
    田中裕美子; 平木洋子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第78回日本臨床外科学会総会  2016  東京
  • 高齢者幽門側胃切除後の呼吸器合併症に対する嚥下リハビリ介入の効果に対する検討.  [Not invited]
    田中裕美子; 安田 篤; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第46回胃外科・術後障害研究会  2016  鳥取
  • Barrett 食道癌と乳頭部癌に対し一期的切除をしえた同時性重複癌の1 例.  [Not invited]
    田中裕美子; 曽我部俊介; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第71 回日本消化器外科学会総会  2016  徳島
  • 腹臥位での重力差とCT値による客観評価での新しい進行食道癌大動脈浸潤評価の有用性.  [Not invited]
    田中裕美子; 白石 治; 熊野正士; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 村上卓道; 安田卓司
    第70回日本食道学会学術集会  2016  東京
  • 仰臥位と腹臥位CTにおける重力差とCT値による客観評価を用いた新しい進行食道癌大動脈浸潤の評価の有用性.  [Not invited]
    田中裕美子; 白石 治; 熊野正士; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 村上卓道; 安田卓司
    第116回日本外科学会  2016  大阪
  • 輪状咽頭筋切開による咽頭温存食道切除・高位吻合の有用性.  [Not invited]
    加藤寛章; 田中裕美子; 岩間 密; 白石 治; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第78回日本臨床外科学会総会  2016  東京
  • 当科における噴門側胃切除後食道残胃吻合(菱形残胃作成と食道裂孔挿入の意義).  [Not invited]
    加藤寛章; 安田 篤; 田中裕美子; 岩間 密; 白石 治; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第46回胃外科・術後障害研究会  2016  鳥取
  • 食道切除後胃管再建術-縫合不全ゼロの追求-.  [Not invited]
    加藤寛章; 曽我部俊介; 田中裕美子; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第71 回日本消化器外科学会総会  2016  徳島
  • 胸部食道癌手術における術後合併症予防の工夫.  [Not invited]
    岩間 密; 田中裕美子; 加藤寛章; 白石 治; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第78回日本臨床外科学会総会  2016  東京
  • 胸部食道癌手術における術後合併症の予防策に関する検討.  [Not invited]
    岩間 密; 曽我部俊介; 田中裕美子; 加藤寛章; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第71回日本消化器外科学会総会  2016  徳島
  • サルベージ手術を前提とした導入化学放射線療法によるcT4局所進行食道癌治療戦略.  [Not invited]
    岩間 密; 曽我部俊介; 田中裕美子; 加藤寛章; 白石治; 安田篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第70回日本食道学会学術集会  2016  東京
  • 胸部食道癌における鎖骨上リンパ節転移の意義〜遠隔転移 or 領域内転移?  [Not invited]
    岩間 密; 曽我部俊介; 田中裕美子; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第116回日本外科学会  2016  大阪
  • 当院の胃切除後における食道切除後有茎空腸再建術の工夫.  [Not invited]
    白石 治; 田中裕美子; 加藤寛章; 岩間 密; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第78回日本臨床外科学会総会  2016  東京
  • 高齢者胸部食道癌手術におけるリスク因子と対策.  [Not invited]
    白石 治; 田中裕美子; 加藤寛章; 岩間 密; 安田 篤; 新海政幸; 木村 豊; 今野元博; 今本治彦; 安田卓司
    第68回日本気管食道科学会  2016  東京
  • 食道切除後の胃再建不能例における血管吻合を付加する挙上空腸再.  [Not invited]
    白石 治; 曽我部俊介; 加藤寛章; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 奥野清隆; 安田卓司
    第71回日本消化器外科学会総会  2016  徳島
  • リンパ節転移状況に基づく至適郭清範囲“中下縦隔から腹腔動脈周囲までの連続的郭清”.  [Not invited]
    白石 治; 曽我部俊介; 田中裕美子; 加藤寛章; 岩間密; 安田篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第70回日本食道学会学術集会  2016  東京
  • 食道胃接合部癌のリンパ節転移・再発状況に基づく治療戦略及び中下縦隔から腹腔動脈周囲までの連続的郭清.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均; 安田卓司
    第116回日本外科学会  2016  大阪
  • 噴門胃切除後の菱形残胃作成と偽穹窿部食道裂孔挿入による食道残胃吻合法.  [Not invited]
    安田 篤; 今本治彦; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 木村 豊; 今野元博; 古河 洋; 安田卓司; 奥野清隆
    第29回日本内視鏡外科学会総会  2016  横浜
  • 高齢者に対する腹腔鏡補助下幽門側胃切除後の検討.  [Not invited]
    安田 篤; 今本治彦; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 木村 豊; 今野元博; 安田卓司
    第46回胃外科・術後障害研究会  2016  鳥取
  • 当院におけるGIST に対する腹腔鏡手術の検討.  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 安田卓司; 奥野清隆
    第71 回日本消化器外科学会総会  2016  徳島
  • 胃噴門側GISTに対する腹腔鏡下胃内手術.  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 田中裕美子; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 安田卓司; 奥野清隆
    第116回日本外科学会  2016  大阪
  • 噴門側胃切除後の食道残胃吻合法(円錐状胃管作成+食道裂孔挿入法).  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 田中裕美子; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 安田卓司; 奥野清隆
    第88回日本胃癌学会総会  2016  大分
  • 胃全摘後の栄養評価;CT画像による脂肪量と筋量の経時変化について.  [Not invited]
    安田 篤; 曽我部俊介; 田中裕美子; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 今本治彦; 安田卓司; 奥野清隆
    第88回日本胃癌学会総会  2016  大分
  • CY1胃癌に対するPTX腹腔内投与+PCS全身化学療法の治療成績.  [Not invited]
    新海政幸; 今野元博; 平木洋子; 加藤寛章; 岩間密; 白石治; 安田篤; 木村豊; 今本治彦; 古河洋; 安田卓司
    第78回日本臨床外科学総会  2016  東京
  • 高度進行胃癌に対する放射線化学療法を用いた集学的治療.  [Not invited]
    新海政幸; 今野元博; 曽我部俊介; 田中裕美子; 加藤寛章; 岩間密; 安田篤; 今本治彦; 古河洋; 安田卓司
    第71回日本消化器外科学会総会  2016  徳島
  • 胸部食道癌根治術後における再発の現状と再発例に対する治療戦略.  [Not invited]
    新海政幸; 曽我部俊介; 田中裕美子; 加藤寛章; 岩間密; 白石治; 安田篤; 今野元博; 今本治彦; 安田卓司
    第70回日本食道学会学術集会  2016  東京
  • P1進行胃癌に対するPTX腹腔内投与+PCS全身化学療法の治療成績.  [Not invited]
    新海政幸; 今野元博; 田中裕美子; 曽我部俊介; 岩間密; 白石治; 安田篤; 今本治彦; 古河洋; 安田卓司
    第88回日本胃癌学会総会  2016  大分
  • 腹腔鏡下胃切除術において出血を減少させるための工夫.  [Not invited]
    木村 豊; 三上城太; 間狩洋一; 藤田淳也; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第29回日本内視鏡外科学会総会  2016  横浜
  • 当院における腹腔鏡下胃切除術の工夫―臓器把持用クリップの活用―.  [Not invited]
    木村 豊; 三上城太; 間狩洋一; 藤田淳也; 平木洋子; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 古河 洋; 今本治彦; 安田卓司
    第78回日本臨床外科学会総会  2016  東京
  • 前治療後手術のpN(+)食道扁平上皮癌に対する術後補助ペプチドワクチン第2相試験.  [Not invited]
    安田卓司; 錦 耕平; 白石 治; 岩間 密; 加藤寛章; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 今本治彦
    第70回日本食道学会学術集会  2016  東京
  • Salvage縦隔気管瘻手術における気管血流温存と根治CRT後の気管食道瘻手術における術式の工夫.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 曽我部俊介; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 今本治彦
    第116回日本外科学会  2016  大阪
  • 腹腔鏡下造設空腸瘻のイレウス対策“カーテン法”.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第28回日本内視鏡外科学会  2015/12  大阪
  • 腹腔鏡補助下手術での噴門側胃切除・食道残胃吻合再建(胃管様作成+食道裂孔挿入).  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 安田卓司; 奥野清隆
    第28回日本内視鏡外科学会総会  2015/12  大阪
  • 食道癌術後再発に対する治療戦略.  [Not invited]
    曽我部俊介; 白石 治; 田中裕美子; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第77回日本臨床外科学会総会  2015/11  福岡
  • 胃癌腹膜播種症例におけるPTX単回腹腔内投与とTS-1+PTX+CDDPによる逐次全身化学療法の安全性と効果における検討.  [Not invited]
    田中裕美子; 今野元博; 曽我部俊介; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今本治彦; 安田卓司
    第77回日本臨床外科学会総会  2015/11  福岡
  • 縫合不全0を目指した食道癌切除後再建法.  [Not invited]
    岩間 密; 曽我部俊介; 田中裕美子; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第77回日本臨床外科学会  2015/11  福岡
  • 縫合不全1%の食道癌術切除後胃管再建.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第77回日本臨床外科学会  2015/11  博多
  • 嚥下リハビリ介入の効果について臨床外科学会総会高齢者幽門側胃切除術後の呼吸器合併症に対する嚥下リハビリ介入の効果について.  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 田中裕美子; 加藤寛章; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 安田卓司; 奥野清隆
    第77回日本臨床外科学会総会  2015/11  福岡
  • 大型3型、4型胃癌に対する放射線化学療法後の開腹手術の留意点.  [Not invited]
    新海政幸; 古河洋; 田中裕美子; 曽我部俊介; 岩間 密; 白石 治; 安田 篤; 今野元博; 今本治彦; 奥野清隆; 安田卓司
    第77回日本臨床外科学会総会  2015/11  福岡
  • 胃癌腹膜播種症例に対する外科的介入の意義.  [Not invited]
    今野元博; 岩間 密; 田中裕美子; 曽我部俊介; 白石 治; 安田 篤; 新海政幸; 今本治彦; 古河 洋; 安田卓司; 光冨徹哉; 竹山宜典; 奥野清隆
    第77回日本臨床外科学会総会  2015/11  福岡
  • 食道癌手術におけるoncologyに基づいた徹底覚醒と低侵襲手術の融合.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 錦 耕平; 曽我部俊介; 田中由美子; 安田 篤; 新海政幸; 今野元博; 古河 洋; 今本治彦
    第77回日本臨床外科学会総会  2015/11  福岡
  • 進行胸部食道癌に対するPET診断に基づくNAC個別化選別と予後予測.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第68回日本胸部外科学会  2015/10  神戸
  • T4食道癌に対する根治的化学放射線療法後の積極的Salvage手術治療戦略  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第23回JDDW  2015/10  東京
  • 頸部食道癌根治放射線治療後に喉頭温存をなし得た1切除例.  [Not invited]
    眞鍋弘暢; 岩間 密; 曽我部俊介; 田中裕美子; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    南大阪消化器外科懇談会  2015/09  大阪
  • 小開腹先行腹腔鏡補助下胃切除再建の有用性.  [Not invited]
    安田 篤; 今本治彦; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 安田卓司
    第28回日本小切開・鏡視外科学会  2015/09  福岡
  • 当科での胃体上部癌における腹腔鏡補助下噴門側胃切除と腹腔鏡補助下胃全摘術の比較検討.  [Not invited]
    今本治彦; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 安田卓司; 奥野清隆
    第28回近畿内視鏡外科研究会  2015/09  和歌山
  • 腐食性食道炎による頸部食道狭窄に対し、狭窄部切開・遊離空腸パッチ術を施行した1例.  [Not invited]
    曽我部俊介; 白石 治; 岩間 密; 錦 耕平; 田中裕美子; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第69回日本食道学会学術集会  2015/07  横浜
  • Techniques and outcomes of the retrosternal gastric tube reconstruction after esophagectomy using the narrow gastric tube.  [Not invited]
    田中裕美子; 白石 治; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第70回日本消化器外科学会総会  2015/07  浜松
  • 胃癌腹膜播種に対し術前化学療法施行後根治手術をしえたが、術後8ヶ月目に脳転移・髄膜癌腫症をきたした1例.  [Not invited]
    田中裕美子; 曽我部俊介; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第37回癌局所療法研究  2015/07  千葉
  • 腹臥位CTにおける腫瘍-大動脈間のCT値測定による進行食道癌大動脈浸潤の評価の有用性.  [Not invited]
    田中裕美子; 白石 治; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第69回日本食道学会学術集会  2015/07  横浜
  • 胃癌腹膜播種症例に対するPTX単回腹腔内投与およびTS-1+PTX+CDDPによる逐次全身化学療法の試み.  [Not invited]
    岩間 密; 今野元博; 白石 治; 安田 篤; 新海政幸; 今本治彦; 古河 洋; 安田卓司
    第70回日本消化器外科学会総会  2015/07  浜松
  • 胸部食道癌におけるFDG-PETによるpN予測、術前化学療法の適応とその効果予測.  [Not invited]
    岩間 密; 曽我部俊介; 田中裕美子; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第69回日本食道学会学術集会  2015/07  横浜
  • 縫合不全を回避する胃管再建の工夫と反回神経リンパ節郭清.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第70回日本消化器外科学会総会  2015/07  浜松
  • 縫合不全を回避する胃管再建の要点.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第69回日本食道学会学術集会  2015/07  横浜
  • 頸部食道癌の導入CRTによる治療戦略.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第69回日本食道学会学術集会  2015/07  横浜
  • 胃体上部早期癌に対する腹腔鏡補助下噴門側胃切除と胃全摘の比較検討.  [Not invited]
    安田 篤; 今本治彦; 里井俊平; 田中裕美子; 曽我部俊介; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 竹山宜典; 安田 卓司
    第70回日本消化器外科学会総会  2015/07  浜松
  • 高度進行胃癌に対する術前放射線化学療法.  [Not invited]
    新海政幸; 今野元博; 古河 洋; 安田 篤; 横川正樹; 西村恭昌; 黒川幸典; 辻中利政; 今本治彦; 安田卓司
    第70回日本消化器外科学会総会  2015/07  浜松
  • 頸部食道癌CRT後再々発に対し咽喉食摘、縦隔気管瘻造設(Grillo)を施行した1例.  [Not invited]
    新海政幸; 田中裕美子; 曽我部俊介; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 今野元博; 今本治彦; 安田卓司
    第69回日本食道学会学術集会  2015/07  横浜
  • 胃癌腹膜播種症例に対する外科的介入を併用した治療戦略の検討.  [Not invited]
    今野元博; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今本治彦; 古河 洋; 安田卓司; 竹山宜典; 奥野清隆
    第70回日本消化器外科学会総会  2015/07  浜松
  • Oncology、外科的画像読影、確かな治療戦略に裏付けられた食道手術手技の伝承と教育.  [Not invited]
    安田卓司; 白石 治; 岩間 密; 錦 耕平; 曽我部俊介; 田中由美子; 安田 篤; 新海政幸; 今野元博; 今本治彦
    第58回関西胸部外科学会学術集会  2015/06  岡山
  • NearT4食道癌に対する50Gy以上の根治的化学放射線療法後の積極的Salvage手術治療戦略.  [Not invited]
    白石 治; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均; 奥野清隆; 安田卓司
    第115回日本外科学会定期学術集会  2015/04  名古屋
  • 放射線化学療法後の開腹胃切除における手術手技の工夫.  [Not invited]
    新海政幸; 古河 洋; 田中裕美子; 曽我部俊介; 錦 耕平; 牧野知紀; 岩間 密; 白石 治; 安田 篤; 今野元博; 今本治彦; 奥野清隆; 安田卓司
    第115回日本外科学会定期学術集会  2015/04  名古屋
  • 根治切除可能な漿膜浸潤を伴う胃癌に対する周術期化学療法(TS-1、パクリタキセル経静脈・腹腔内投与併用療法) 第?相試験.  [Not invited]
    今野元博; 石神浩徳; 藪崎 裕; 小林大介; 伊藤誠二; 上之園芳一; 上田修吾; 木村 豊; 山口博紀; 今本治彦; 梨本 篤; 古河 洋; 安田卓司; 竹吉 泉; 福島亮治; 小寺泰弘; 北山丈二
    第115回日本外科学会定期学術集会  2015/04  名古屋
  • 術前化学放射線療法にてpCRを得た大型3型胃癌の1切除例.  [Not invited]
    錦 耕平; 田中裕美子; 岩間 密; 曽我部俊介; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第87回日本胃癌学会総会  2015/03  広島
  • 食道胃接合部癌のリンパ節転移状況から導かれる治療方針.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩崎 均; 安田卓司
    第87回日本胃癌学会総会  2015/03  広島
  • 進行食道胃接合部癌に対する中下縦隔から腹腔動脈周囲までの連続的郭清.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩崎 均; 安田卓司
    第87回日本胃癌学会総会  2015/03  広島
  • 噴門側胃切除術の術後機能評価 当科における噴門側胃切除後食道残胃吻合の有用性について.  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 錦 耕平; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 塩? 均; 安田卓司
    第87回日本胃癌学会総会  2015/03  広島
  • 腹腔鏡下噴門側胃切除術の再建手技 当科における腹腔鏡補助下噴門側胃切除・食道残胃吻合法について.  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 錦 耕平; 岩間 密; 白石 治; 新海政幸; 今野元博; 古河 洋; 塩? 均; 安田卓司
    第87回日本胃癌学会総会  2015/03  広島
  • P1進行胃癌に対する集学的治療とその成績.  [Not invited]
    新海政幸; 今野元博; 田中裕美子; 曽我部俊介; 錦 耕平; 牧野知紀; 岩間 密; 白石 治; 安田 篤; 今本治彦; 古河 洋; 安田卓司
    第87回日本胃癌学会総会  2015/03  広島
  • 食道癌 診断・治療ガイドライン.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩崎 均; 安田卓司
    第16回関西がんチーム医療研究会  2015/02  大阪
  • 進行食道癌に対する個別化集学的治療.  [Not invited]
    白石 治; 田中裕美子; 曽我部俊介; 岩間 密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩崎 均; 安田卓司
    第102回日本消化器病学会近畿支部  2015/02  京都
  • 胃癌腹膜播種に対し術前化学療法施行後根治手術をしえたが、術後8ヶ月目に脳転移・髄膜癌腫症をきたした1例.  [Not invited]
    田中裕美子; 曽我部俊介; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 古河 洋; 安田卓司
    第196回近畿外科学会  2014/11  京都
  • cT3.5食道癌に対するnon split 50Gy導入化学放射線療法の安全性および有用性の検討.  [Not invited]
    牧野知紀; 曽我部俊介; 田中裕美子; 錦 耕平; 岩間 密; 白石 治; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第67回日本胸部外科学会定期学術集会  2014/10  福岡
  • 当科における幽門保存胃切除術の適応について.  [Not invited]
    安田 篤; 今本 治彦; 曽我部 俊介; 錦 耕平; 岩間 密; 白石 治; 新海 政幸; 今野 元博; 古河 洋; 安田 卓司; 奥野 清隆
    第27回日本内視鏡外科学会総会  2014/10  岩手
  • 肺葉外肺分画症を合併した横隔膜上食道憩室症の1例.  [Not invited]
    家根由典; 牧野知紀; 今本治彦; 曽我部俊介; 田中裕美子; 錦 耕平; 岩間 密; 白石 治; 新海政幸; 今野元博; 安田卓司
    第27回近畿内視鏡外科研究会  2014/09  神戸
  • 食道疣贅扁平上皮癌の2切除例  [Not invited]
    曽我部俊介; 田中裕美子; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第68回日本食道学会学術集会  2014/07  東京
  • 当科における食道癌サルベージ手術の治療戦略の工夫と治療成績.  [Not invited]
    錦 耕平; 曽我部俊介; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第69回日本消化器外科学会総会  2014/07  郡山
  • 食道癌術後における再建胃管癌8例の検討.  [Not invited]
    錦 耕平; 曽我部俊介; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 古河 洋; 今本治彦; 安田卓司
    第68回日本食道学会学術集会  2014/07  東京
  • リンパ節郭清効果からみた食道胃接合部癌における至適リンパ節郭清範囲および治療戦略の検討.  [Not invited]
    牧野知紀; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第69回日本消化器外科学会総会  2014/07  郡山
  • 局所進行cT3.5食道癌に対するnon split 50GyCRT+切除の有用性.  [Not invited]
    牧野知紀; 曽我部俊介; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 安田卓司
    第68回日本食道学会学術集会  2014/07  東京
  • 残胃癌に対する臨床病理学的検討.  [Not invited]
    岩間 密; 錦 耕平; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第69回日本消化器外科学会総会  2014/07  郡山
  • 表層拡大型食道癌におけるリンパ節転移と予後―通常0-II型食道癌と相違―.  [Not invited]
    白石 治; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第68回日本食道学会学術集会  2014/07  東京
  • 放射線化学療法後・高度化学療法後の開腹胃切除におけるD2リンパ節郭清の実際  [Not invited]
    新海政幸; 古河 洋; 錦 耕平; 牧野知紀; 岩間 密; 白石 治; 安田 篤; 今野元博; 今本治彦; 安田卓司
    第69回日本消化器外科総会  2014/07  郡山
  • 食道切除後の再建における安全な吻合法.  [Not invited]
    安田卓司; 白石 治; 牧野知紀; 岩間 密; 錦 耕平; 曽我部俊介; 安田 篤; 新海政幸; 今野元博; 今本治彦
    第69回日本消化器外科学会総会  2014/07  郡山
  • 化学療法にてCR後、局所再発に対し根治切除した胃癌の1例.  [Not invited]
    錦 耕平; 曽我部俊介; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 古河 洋; 今本治彦; 安田卓司
    第36回癌局所療法研究会  2014/06  大阪
  • 術食道癌術後乳糜腹水6例の検討.  [Not invited]
    錦 耕平; 曽我部俊介; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 新海 政幸; 今野元博; 古河 洋; 今本治彦; 安田卓司
    第57回関西胸部外科学会学術集会  2014/06  大阪
  • cT4食道癌に対する導入化学放射線療法後の大動脈穿通に対して予防的大動脈ステント留置し一期的切除し得た1例.  [Not invited]
    牧野知紀; 白石 治; 錦 耕平; 岩間 密; 曽我部俊介; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第57回関西胸部外科学会学術集会  2014/06  大阪
  • 予防的頸部放射線照射後25年目に発生した胸部食道癌根治切除術後頸部食道癌の1切除例.  [Not invited]
    岩間 密; 白石 治; 牧野知紀; 曽我部俊介; 錦 耕平; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第57回関西胸部外科学会  2014/06  大阪
  • 胸腔内吻合及び血管吻合を同時に成し得る胸骨後→後縦隔横断経路による回結腸挙上再建.  [Not invited]
    白石 治; 村瀬貴昭; 曽我部俊介; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩崎 均; 安田卓司
    第57回関西胸部外科学会  2014/06  大阪
  • 胃全摘後 Roux-Y 脚吻合部完全狭窄による輸入脚症候群の 2 症例.  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 古河 洋; 奥野清隆; 安田卓司
    第36回日本癌局所療法研究会  2014/06  大阪
  • PET-N(-)切除可能進行胸部食道癌における術前化学療法.  [Not invited]
    錦 耕平; 白石 治; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均; 奥野清隆; 安田卓司
    第114回日本外科学会学術集会  2014/04  京都
  • Optimum surgical approach for esophago-gastric junction tumors based upon the metastatic status of mediastinal lymph node.  [Not invited]
    Tomoki Makino; Hiroaki Kato; Kohei Nishiki; Mitsuru Iwama; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Motohiro Imano; Haruhiko Imamoto; Hiroshi furukawa; Takushi Yasuda
    第114回日本外科学会定期学術集会  2014/04  京都
  • 進行食道癌に対するPET診断に基づくNAC至適個別化治療戦略.  [Not invited]
    白石 治; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均; 奥野清隆; 安田卓司
    第114回日本外科学会定期学術集会  2014/04  京都
  • 当科での噴門側胃切除後の食道残胃吻合法について.  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 古河 洋; 奥野清隆; 安田卓司
    第114回日本外科学会総会  2014/04  京都
  • 術前化学療法が奏効した食道胃接合部癌の1切除例.  [Not invited]
    藤島一樹; 牧野知紀; 村瀬貴昭; 曽我部俊介; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第54回南大阪消化器外科臨床懇話会  2014/03  大阪
  • 食道癌術後再建胃管癌6例の検討.  [Not invited]
    錦 耕平; 加藤寛章; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 古河 洋; 今本治彦; 安田卓司
    第86回日本胃癌学会学術集会  2014/03  横浜
  • 食道胃接合部癌における縦隔リンパ節状況からみた至適手術アプローチ法の検討.  [Not invited]
    牧野知紀; 加藤寛章; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第86回日本胃癌学会総会  2014/03  横浜
  • 75歳以上根治切除可能4型・大型3型胃癌に対する術前TS-1併用化学放射線療法(SRT)の可能性.  [Not invited]
    岩間 密; 今野元博; 加藤寛章; 錦 耕平; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今本治彦; 古河 洋; 安田卓司
    第86回日本胃癌学会総会  2014/03  横浜
  • 進行食道胃接合部癌のリンパ節転移状況から導かれる至適術式.  [Not invited]
    白石 治; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩崎 均; 安田卓司
    第86回日本胃癌学会総会  2014/03  横浜
  • ハイリスクである高齢者に対する幽門側胃切除術と腹腔鏡導入の意義.  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 古河 洋; 奥野清隆; 安田卓司
    第86回日本胃癌学会総会  2014/03  横浜
  • 腹腔鏡補助下幽門側胃切除(LADG)の成績からみた適応拡大の可能性について.  [Not invited]
    安田 篤; 今本治彦; 曽我部俊介; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 古河 洋; 奥野清隆; 安田卓司
    第86回日本胃癌学会総会  2014/03  横浜
  • CY1進行胃癌に対する治療戦略とその成績.  [Not invited]
    新海政幸; 今野元博; 村瀬貴昭; 曽我部俊介; 錦 耕平; 牧野知紀; 岩間 密; 白石 治; 安田 篤; 今本治彦; 奥野清隆; 古河 洋; 安田卓司
    第52回日本癌治療学会学術集会  2014/03  横浜
  • 放射線化学療法後・高度化学療法後の開腹手術  [Not invited]
    新海政幸; 古河 洋; 曽我部俊介; 加藤寛章; 錦 耕平; 牧野知紀; 岩間 密; 白石 治; 安田 篤; 今野元博; 今本治彦; 安田卓司
    第86回日本胃癌学会総会  2014/03  横浜
  • 根治切除可能な大型3型/4型胃癌に対する術前TS-1+CDDP併用化学放射線療法 第?/?相臨床試験(OGSG1205)  [Not invited]
    今野元博; 古河 洋; 横川正樹; 西村恭昌; 黒川幸典; 佐藤太郎; 坂井大介; 今本治彦; 安田卓司; 辻中利政; 下川敏雄; 塩? 均
    第86回日本胃癌学会総会  2014/03  横浜
  • 食道逆流に対する工夫を加えた噴門側胃切除後腹腔鏡補助下食道残胃吻合法  [Not invited]
    安田 篤; 今本 治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野 知紀; 白石 治; 新海政幸; 今野元博; 安田卓司; 古河 洋; 奥野清隆; 塩? 均
    第26回日本内視鏡外科学会  2013/11  福岡
  • 進行食道胃接合部癌の至適リンパ節郭清範囲と胸腹連続的切除  [Not invited]
    白石 治; 曽我部俊介; 錦 耕平; 岩間密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均; 奥野清隆; 安田卓司
    第75回日本臨床外科学会総会  2013/11  愛知
  • 食道癌周術期管理におけるチームアプローチの実際とその成績  [Not invited]
    新海政幸; 牛嶋北斗; 曽我部俊介; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石治; 安田 篤; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 安田卓司
    第75回日本臨床外科学会総会  2013/11  愛知
  • T4進行食道癌に対する化学放射線療法後の大動脈壁への穿通に対し緊急大動脈ステント留置後に一期的切除術を施行し得た1例  [Not invited]
    牧野知紀; 加藤寛章; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第75回日本臨床外科学会総会  2013/11  愛知
  • 頚胸境界部食道癌術後の気管孔狭窄に対し、遊離前腕皮弁にて気管孔再形成術を異時性胸部食道癌手術と同時に施行した1例  [Not invited]
    錦 耕平; 曽我部俊介; 加藤寛章; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 安田卓司
    第75回日本臨床外科学会総会  2013/11  愛知
  • 胃癌胃全摘術後繰り返す縫合不全に難渋するもT-portion遊離皮弁により再建し得た1例  [Not invited]
    岩間 密; 曽我部俊介; 加藤寛章; 錦 耕平; 牧野知紀; 白石 治; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 安田卓司
    第75回日本臨床外科学会総会  2013/11  愛知
  • 根治性と安全性を確保する胸部食道癌サルベージ手術対策  [Not invited]
    白石 治; 曽我部俊介; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均; 奥野清隆; 安田卓司
    第75回日本臨床外科学会総会  2013/11  愛知
  • 治療に難渋した特発性食道破裂の1例  [Not invited]
    曽我部俊介; 錦 耕平; 牧野知紀; 岩間 密; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 安田卓司
    第596回大阪外科集談会  2013/11  大阪
  • 食道疣贅扁平上皮癌の1切除例  [Not invited]
    松本正孝; 白石 治; 東 千尋; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    第596回大阪外科集談会  2013/11  大阪
  • 食道原発悪性黒色腫に対して右開胸食道亜全摘胃管再建術を行った一例  [Not invited]
    西野将矢; 白石 治; 錦 耕平; 岩間密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均; 奥野清隆; 安田卓司
    第194回近畿外科学会  2013/11  大阪
  • 当科での噴門側胃切除後の食道残胃吻合法の検討  [Not invited]
    松本正孝; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 古河 洋; 奥野清隆; 安田卓司
    第43回胃外科・術後障害研究会  2013/11  新潟
  • 80歳以上の超高齢者に対する幽門側胃切除の検討  [Not invited]
    安田 篤; 松本正孝; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 古河 洋; 奥野清隆; 安田卓司
    第43回胃外科・術後障害研究会  2013/11  新潟
  • 食道胃接合部癌における縦隔リンパ節転移状況および術式選択の検討  [Not invited]
    牧野知紀; 安田卓司; 安田 篤; 白石 治; 岩間 密; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均
    第68回日本消化器外科学会総会  2013/07  宮崎
  • リンパ節転移陽性食道癌に対する腫瘍特異的ペプチドワクチンを用いた術後補助免疫療法  [Not invited]
    錦 耕平; 安田卓司; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第68回日本消化器外科学会総会  2013/07  宮崎
  • 胸部食道癌手術における術後合併症(縫合不全・誤嚥性肺炎)の予防策とその治療効果に関する検討  [Not invited]
    岩間 密; 安田卓司; 曽我部俊介; 加藤寛章; 錦 耕平; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第68回日本消化器外科学会総会  2013/07  宮崎
  • 当科における噴門側胃切除後の食道残遺吻合再建の工夫  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 安田卓司; 古河 洋; 奥野清隆; 塩? 均
    第68回日本消化器外科学会総会  2013/07  宮崎
  • 治療成績からみた局所進行胸部食道癌に対する至適治療戦略  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第68回日本消化器外科学会総会  2013/07  宮崎
  • 腹腔鏡補助下・腹腔鏡下(SILS)に切除した胃glomus腫瘍の2例  [Not invited]
    古川健太郎; 岩間 密; 西野将矢; 曽我部俊介; 加藤寛章; 錦 耕平; 牧野知紀; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 安田卓司
    南大阪消化器外科臨床懇話会  2013/07  大阪
  • 高齢者食道癌に対する外科治療成績と問題点  [Not invited]
    新海政幸; 安田卓司; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第50回日本外科代謝栄養学会  2013/07  東京
  • リンパ節転移陽性食道癌に対する腫瘍特異的ペプチドワクチンを用いた術後補助免疫療法  [Not invited]
    錦 耕平; 安田卓司; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第67回日本食道学会学術集会  2013/06  大阪
  • FDG- PET-N(-)切除可能食道癌における予後予測に基づいた術前治療の個別化治療戦略  [Not invited]
    錦 耕平; 安田卓司; 新海政幸; 安田 篤; 白石 治; 牧野知紀; 岩間 密; 加藤寛章; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第67回日本食道学会学術集会  2013/06  大阪
  • 食道胃接合部癌における縦隔リンパ節転移状況および予後解析に基づいた外科治療戦略  [Not invited]
    牧野知紀; 安田卓司; 安田 篤; 白石 治; 岩間 密; 新海政幸; 今野元博; 今本治彦; 古河 洋; 塩? 均
    第67回日本食道学会学術集会  2013/06  大阪
  • FDG-PETによるpNおよびpT予測に基づいた食道癌に対する術前化学療法の適応と効果予測  [Not invited]
    白石 治; 安田卓司; 牧野知紀; 岩間 密; 錦 耕平; 加藤寛章; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第67回日本食道学会学術集会  2013/06  大阪
  • 局所制御および遠隔再発の予測に基づいた食道癌術前補助療法の個別化  [Not invited]
    白石 治; 安田卓司; 牧野知紀; 岩間 密; 錦 耕平; 加藤寛章; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第67回日本食道学会学術集会  2013/06  大阪
  • 大型3型胃癌に対し術前放射線化学療法を施行し、良好な病理組織結果を得た1例の検討  [Not invited]
    安田 篤; 今野元博; 古河 洋; 加藤寛章; 錦 耕平; 牧野知紀; 岩間 密; 白石 治; 新海政幸; 安田卓司; 今本治彦; 奥野清隆; 塩? 均
    日本外科系連合学会  2013/06  東京
  • 進行食道癌に対する化学療法多回数施行後の外科切除症例における臨床効果とそのfeasibility  [Not invited]
    牧野知紀; 安田卓司; 白石 治; 田中裕美子; 加藤寛章; 錦 耕平; 岩間 密; 安田 篤; 新海正幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩?均
    第113回日本外科学会定期学術集会  2013/04  福岡
  • 超高齢者に対する幽門側胃切除の安全性と根治性の検討  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 古河 洋; 奥野清隆; 安田卓司
    第113回日本外科学会定期学術集会  2013/04  福岡
  • 80歳以上の超高齢者に対する食道癌手術の検討  [Not invited]
    新海政幸; 安田卓司; 田中裕美子; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 安田 篤; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第113回日本外科学会定期学術集会  2013/04  福岡
  • FDG-PETによる客観評価に基づく進行食道癌に対する集学的治療の個別化戦略  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第113回日本外科学会定期学術集会  2013/04  福岡
  • <経胸>食道胃接合部癌に対する外科治療〜経胸の立場から  [Not invited]
    安田卓司; 安田 篤; 白石 治; 牧野知紀; 錦 耕平; 加籐寛章; 岩間 密; 新海政幸; 今野元博; 今本治彦; 古河 洋; 奥野清隆; 塩? 均
    第113回日本外科学会定期学術集会  2013/04  福岡
  • 80歳以上の高齢者胃癌に対する幽門側胃切除術の検討  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 今野元博; 安田卓司; 古河 洋; 奥野清隆; 塩? 均
    第85回日本胃癌学会  2013/02  大阪
  • 当科における進行胃癌に対する腹腔鏡補助下幽門側胃切除の妥当性の検討  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 安田卓司; 今野元博; 古河 洋; 奥野清隆; 塩? 均
    第25回日本内視鏡外科学会総会  2012/12  横浜
  • 胸腔内からの徹底郭清と反回神経リンパ節術中病理診による胸部食道癌 選択的 2 領域郭清  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 岩間密; 安田 篤; 新海政幸; 今野元博; 今本治彦; 古河洋; 奥野清隆; 塩? 均
    第74回日本臨床外科学会総会  2012/11  東京
  • 噴門側胃切除における食道残胃吻合法と空腸間置法の比較  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 安田卓司; 今野元博; 古河 洋; 奥野清隆; 塩? 均
    第42回胃外科・術後障害研究会  2012/11  東京
  • 食道癌根治化学放射線療法後のSalvage手術の克服と安全性の確立  [Not invited]
    新海政幸; 安田卓司; 田中裕美子; 加藤寛章; 錦耕平; 岩間密; 白石治; 安田篤; 今野元博; 今本治彦; 奥野清隆; 古河洋; 塩?均
    第74回日本臨床外科学会総会  2012/11  東京
  • 腹膜播種を伴う胃癌に対するパクリタキセル腹腔内投与併用化学療法の有用性を検証する第III相試験(PHOENIX-GC試験)  [Not invited]
    今野元博; 石神浩徳; 小寺泰弘
    第10回日本消化器外科学会大会 (JDDW 2012)  2012/10  神戸
  • がんチーム医療におけるスピリチュアルケアの役割  [Not invited]
    古河 洋; 伊藤高章; 西村恭昌; 竹山宜典; 今本治彦; 安田卓司; 今野元博; 新海政幸; 原 聡; 奥野清隆; 千葉鐘子; 塩? 均
    第50回日本癌治療学会学術集会  2012/10  横浜
  • 噴門部胃粘膜下腫瘍(SMT)に対する腹腔鏡下胃内手術  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 牧野知紀; 白石 治; 新海政幸; 安田卓司; 今野元博; 古河 洋; 奥野清隆; 塩? 均
    第6回TANKO式研究会  2012/08  札幌
  • 外科手術成績向上をめざした胸部食道癌に対する積極的補助療法の個別化戦略  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 安田 篤; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第67回日本消化器外科学会総会  2012/07  富山
  • T4a胃癌に対するNAC(PTX腹腔内化学療法+逐次PTX+S-1による全身化学療法)の有用性  [Not invited]
    安田 篤; 今野元博; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 白石 治; 新海政幸; 安田卓司; 古河 洋; 奥野清隆; 塩? 均
    第67回日本消化器外科学会総会  2012/07  富山
  • Salvage手術の克服とSalvage手術を前提としたcT4に対する新たな治療戦略  [Not invited]
    新海政幸; 安田卓司; 加藤寛章; 錦耕平; 白石治; 安田篤; 彭英峰; 今野元博; 今本治彦; 奥野清隆; 塩?均
    第67回日本消化器外科学会総会  2012/07  富山
  • リンパ節転移を伴う切除可能漿膜浸潤胃癌に対する術前補助化学療法としてのS-1+PTX+CDDP療法  [Not invited]
    今野 元博; 安田; 篤; 今本; 治彦; 新海; 政幸; 加藤; 寛章; 白石; 治; 安田; 卓司; 竹山; 宜典; 奥野; 清隆; 塩? 均
    第67回日本消化器外科学会総会  2012/07  富山
  • リンパ節陽性食道癌に対する腫瘍特異的ペプチドワクチンを用いた術後アジュバント療法  [Not invited]
    錦 耕平; 安田 卓司; 新海 政幸; 安田 篤; 白石 治; 加藤 寛章; 彭 英峰; 今野 元博; 今本 治彦; 塩? 均
    第66回日本食学会学術集会  2012/06  軽井沢
  • 切除可能食道癌におけるFDG-PETに基づいた個別化治療戦略  [Not invited]
    錦 耕平; 安田 卓司; 新海 政幸; 安田 篤; 白石 治; 加藤 寛章; 彭 英峰; 今野 元博; 今本 治彦; 塩? 均
    第66回日本食学会学術集会  2012/06  軽井沢
  • 傍大動脈リンパ節陽性食道癌に対し、免疫療法(ペプチドワクチン療法)を含めた集学的治療で長期生存が得られてる1例  [Not invited]
    錦 耕平; 安田 卓司; 加藤 寛章; 白石 治; 安田 篤; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩? 均
    第55回関西胸部外科学会学術集会  2012/06  大阪
  • cT3.5食道癌に対する局所制御を重視した治療戦略“non split 50GyCRT+切除”  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 安田 篤; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第66回日本食道学会学術集会  2012/06  軽井沢
  • 喉頭温存と経口摂取を両立した腐食性食道炎の 2 手術例  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 安田 篤; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第55回関西胸部外科学会学術集会  2012/06  大阪
  • 食道癌周術期管理における当院でのチーム医療の取り組み  [Not invited]
    新海政幸; 安田卓司; 加藤寛章; 錦耕平; 白石治; 安田篤; 今野元博; 今本治彦; 塩?均
    第66回日本食道学会学術集会  2012/06  軽井沢
  • 術前治療後の瘢痕化食道癌手術における手術精度と機能性の追求  [Not invited]
    安田卓司; 新海政幸; 安田 篤; 白石 治; 錦 耕平; 加藤寛章; 今野元博; 今本治彦; 奥野 清隆; 塩? 均
    第66回日本食道学会学術集会  2012/06  軽井沢
  • 腹膜転移陽性胃癌症例に対する分子標的薬使用の可能性  [Not invited]
    彭 英峰; 今野元博; 加藤寛章; 錦 耕平; 岩間 密; 白石 治; 安田 篤; 新海政幸; 安田卓司; 今本治彦; 古河 洋; 塩? 均
    第112回日本外科学会学術集会  2012/04  千葉
  • 胸部食道癌PET診断に基づく術前化学療法の適応選別の合理性  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 岩間 密; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第112回日本外科学会学術集会  2012/04  千葉
  • ラット後腹膜浸潤型腹膜播種モデルにおける中皮細胞と中皮下層の変化について  [Not invited]
    安田 篤; 今野元博; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 白石 治; 新海政幸; 安田卓司; 古河 洋; 奥野清隆; 塩? 均
    第112回日本外科学会学術集会  2012/04  千葉
  • NonT4c-StageII,IIIにおける高齢者食道癌の治療戦略  [Not invited]
    新海政幸; 安田卓司; 井上啓介; 加藤寛章; 錦耕平; 白石治; 安田篤; 彭英峰; 今野元博; 今本治彦; 奥野清隆; 塩?均
    第112回日本外科学会定期学術集会  2012/04  千葉
  • 術前治療後の瘢痕化における食道癌手術のqualityの確保  [Not invited]
    安田卓司; 新海政幸; 彭 英峰; 安田 篤; 白石 治; 錦 耕平; 加藤寛章; 井上啓介; 今野元博; 今本治彦; 奥野 清隆; 塩? 均
    第112回日本外科学会定期学術集会  2012/04  千葉
  • 術前診断に難渋した胃粘膜下腫瘍の1切除例  [Not invited]
    鍵岡賛典; 岩間密; 田中裕美子; 加藤寛章; 錦耕平; 牧野知紀; 白石治; 安田篤; 新海政幸; 今野元博; 安田卓司; 今本治彦; 古河洋; 奥野清隆; 塩?均
    第192回近畿外科学会  2012/02  大阪
  • 噴門側胃切除における食道残胃吻合法と空腸間置法の比較検討  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 岩間 密; 白石 治; 新海政幸; 今野元博; 安田卓司; 奥野清隆; 塩? 均
    第84回日本胃癌学会総会  2012/02  大阪
  • 胸部食道癌に対する術前補助療法の個別化  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第65回日本食道学会学術集会  2011  仙台
  • cT4胸部食道癌に対する局所制御に重点をおいた治療戦略  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 中森康浩; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第111回日本外科学会定期学術総会  2011  東京
  • 胃管後縦隔経路再建後に縫合不全と膿胸を生じ、外科的治療にて治癒し得た1症例  [Not invited]
    安田 篤; 安田卓司; 加藤 寛章; 錦 耕平; 白石 治; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第65回日本食道学会学術集会  2011  仙台
  • cT4を疑う局所進行食道癌に対するno split 50Gy 導入化学放射線療法+surgeryの治療成績  [Not invited]
    新海政幸; 安田卓司; 加藤寛章; 錦 耕平; 中森康浩; 白石 治; 安田 篤; 彭 英峰; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第65回日本食道学会学術集会  2011  仙台
  • 胸部食道癌に対する食道癌切除後早期再発死亡例の検討  [Not invited]
    新海政幸; 安田卓司; 錦耕平; 加藤寛章; 中森康浩; 白石治; 安田篤; 彭英峰; 今野元博; 今本治彦; 奥野清隆; 塩崎均
    第111回日本外科学会定期学術総会  2011  東京
  • 高度リンパ節転移を伴う進行食道胃接合部粘液癌に対しCisplatin/Capecitabine/Cetuximab投与後に根治切除術を施行した1例  [Not invited]
    加藤 寛章; 安田 卓司; 錦 耕平; 中森 康浩; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩? 均
    第66回日本消化器外科学会総会  2011  名古屋
  • 局所進行食道癌に対する50Gy no split 導入化学放射線療法による治療戦略  [Not invited]
    錦 耕平; 安田 卓司; 加藤 寛章; 中森 康浩; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩? 均
    第66回日本消化器外科学会総会  2011  名古屋
  • 心機能低下・肥満を合併した成人Bochdalek孔ヘルニアに対し経腹的にHALSで修復した1例  [Not invited]
    加藤 寛章; 今本 治彦; 錦 耕平; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 安田 卓司; 奥野 清隆; 塩? 均
    第24回日本内視鏡外科学会総会  2011  大阪
  • 胸部食道癌根治切除後7年目の異時性直腸癌に対する術後補助化学療法中に認めた、再建胃管穿孔の1例  [Not invited]
    錦 耕平; 安田 卓司; 井上 啓介; 加藤 寛章; 中森 康浩; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 奥野 清隆; 塩? 均
    第73回日本臨床外科学会総会  2011  東京
  • ハイリスク症例に対する胸部食道癌手術症例の検討  [Not invited]
    彭 英峰; 安田卓司; 中森康浩; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第66回日本消化器外科学会総会  2011  名古屋
  • 当科における幽門保存胃切除術の適応と有用性について  [Not invited]
    安田 篤; 今本治彦; 加藤 寛章; 錦 耕平; 白石 治; 彭 英峰; 新海政幸; 今野元博; 安田卓司; 塩? 均
    第73回日本臨床外科学会総会  2011  東京
  • 他臓器浸潤を疑う局所進行食道癌に対するno split 50Gy induction CRT+ surgeryの治療成績  [Not invited]
    新海政幸; 安田卓司; 井上啓介; 加藤寛章; 錦 耕平; 白石 治; 安田 篤; 彭 英峰; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第73回日本臨床外科学会総会  2011  東京
  • 合併症軽減を目指した食道癌胃管再建術における工夫  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第65回日本食道学会学術集会  2011  仙台
  • 縫合不全ゼロを目指した当科における胃管再建  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 井上啓介; 錦 耕平; 安田 篤 彭 英峰; 新海政幸; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第73回日本臨床外科学会総会  2011  東京
  • 当科における胸部食道癌手術:胸骨後経路細径胃管再建術の工夫と治療成績  [Not invited]
    新海政幸; 安田卓司; 加藤寛章; 錦 耕平; 中森康浩; 白石 治; 安田 篤; 彭 英峰; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第66回日本消化器外科学会総会  2011  名古屋
  • 経口摂取不能P1胃癌症例に対するバイパス手術付加の意義について  [Not invited]
    安田 篤; 今野元博; 加藤 寛章; 中森康浩; 錦 耕平; 白石 治; 彭 英峰; 新海政幸; 安田卓司; 今本治彦; 塩? 均
    第83回日本胃癌学会総会  2011  三沢市
  • T4a胃癌に対するPTX腹腔内化学療法+逐次PTX+S-1による全身化学療法  [Not invited]
    彭 英峰; 安田卓司; 中森康浩; 白石 治; 安田 篤; 新海政幸; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第73回日本臨床外科学会  2011  東京
  • CY(+)胃癌に対するPTX腹腔内化学療法+逐次PTX+S-1全身化学療法  [Not invited]
    彭 英峰; 今野元博; 今本治彦; 加藤寛章; 錦 耕平; 中森康浩; 白石 治; 安田 篤; 新海政幸; 安田卓司; 塩? 均
    第83回日本胃癌学会総会  2011  三沢市
  • 近畿大学医学部附属病院における外来化学療法の効率化と安全への取り組み  [Not invited]
    今野元博; 竹山宜典; 錦耕平; 井上啓介; 加藤寛章; 白石治; 安田篤; 彭英峰; 新海政幸; 安田卓司; 今本治彦; 奥野清隆; 塩?均
    第73回日本臨床外科学会総会  2011  東京
  • 当科における腹腔鏡補助下胃切除の適応拡大とその成績  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 白石 治; 彭 英峰; 新海政幸; 今野元博; 安田卓司; 塩? 均
    第24回日本内視鏡外科学会総会  2011  大阪
  • 高齢者胃癌症例に対する開腹手術と鏡視下手術の比較  [Not invited]
    安田 篤; 今本治彦; 加藤 寛章; 錦 耕平; 白石 治; 彭 英峰; 新海政幸; 今野元博; 安田卓司; 塩? 均
    第66回日本消化器外科学会総会  2011  名古屋
  • Paclitaxel腹腔内投与+逐次全身化学療法のResponderである腹膜転移陽性症例に対する胃切除付加の意義  [Not invited]
    今野元博; 今本治彦; 新海政幸; 彭英峰; 安田篤; 白石治; 中森康浩; 錦耕平; 加藤寛章; 安田卓司; 竹山宜典; 奥野清隆; 塩?均
    第111回日本外科学会定期学術総会  2011  東京
  • 胸部食道癌に対する補助療法の個別化〜PET-N診断に基づく術前化学療法の適応選別〜  [Not invited]
    白石 治; 安田卓司; 中森康浩; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第66回日本消化器外科学会総会  2011  名古屋
  • 集学的治療にて根治切除しえた、転移リンパ節転移による気管 浸潤陽性をきたした胸部食道癌の一例  [Not invited]
    錦 耕平; 安田 卓司; 中森 康浩; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 塩? 均
    第188回近畿外科学会  2010/11  大阪
  • 若手外科医でも根治性と機能温存を可能にするリンパ節領域廓 清のコツ  [Not invited]
    白石 治; 安田卓司; 加藤寛章; 錦 耕平; 中森康浩; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 奥野清隆; 塩? 均
    第188回近畿外科学会  2010/11  大阪
  • 当科における胃癌腹腔鏡手術の成績  [Not invited]
    安田 篤; 今本治彦; 加藤寛章; 錦 耕平; 白石 治; 彭 英峰; 新海政幸; 今野元博; 安田卓司; 塩? 均
    第72回日本臨床外科学会総会  2010/11  横浜
  • 胃管後縦隔経路再建後に縫合不全と膿胸を生じて対称的な転帰をたどった2症例の経験  [Not invited]
    彭 英峰; 安田 篤; 安田卓司; 加藤寛章; 錦 耕平; 中森康浩; 白石 治; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第16回過大侵襲研究会  2010/11  大阪
  • 局所進行食道癌に対するno split 50Gy導入化学放射線療法+adjuvant surgeryによる治療戦略  [Not invited]
    錦 耕平; 安田 卓司; 中森 康浩; 白石 治; 安田 篤; 彭 英峰; 新海 政幸; 今野 元博; 今本 治彦; 塩? 均
    第63回日本胸部外科学会定期学術集会  2010/10  大阪
  • 噴門部胃粘膜下腫瘍に対する腹腔鏡下胃内手術9例の経験とその成績  [Not invited]
    安田 篤; 今本治彦; 中森康浩; 白石 治; 彭 英峰; 新海政幸; 今野元博; 安田卓司; 塩? 均
    第23回日本内視鏡外科学会総会  2010/10  横浜
  • 当科でのP0Cy1胃癌症例に対する各治療方針の成績について  [Not invited]
    安田 篤; 今野元博; 加藤寛章; 中森康浩; 錦 耕平; 白石 治; 彭 英峰; 新海政幸; 安田 卓司; 今本治彦; 塩? 均
    第48回癌治療学会総会  2010/10  京都
  • 漿膜浸潤を伴う胃癌に対するPTX腹腔内化学療法+逐次PTX+S-1による全身化学療法  [Not invited]
    彭 英峰; 今野元博; 加藤寛章; 錦 耕平; 中森康浩; 白石 治; 安田 篤; 新海政幸; 安田卓司; 今本治彦; 塩? 均
    第48回日本癌治療学会  2010/10  京都
  • 院内中央部門としての通院治療センターの運営  [Not invited]
    今野元博; 川崎麻由; 田中美穂; 角森明日香; 西村統子; 國見美香; 愼 玉姫; 藤本さおり; 金星智世; 米本圭佑; 木寺康浩; 島本健次; 古川 論; 藤原希美子; 奥野清隆
    第48回日本癌治療学会学術集会  2010/10  京都
  • 腹膜転移陽性胃癌に対する単回腹腔内化学療法+全身化学療法の組織学的効果の検討  [Not invited]
    今野元博; 今本治彦; 安田卓司; 新海政幸; 彭 英峰; 安田 篤; 白石 治; 中森康浩; 錦 耕平; 加藤寛章; 奥野清隆; 塩? 均
    第48回日本癌治療学会学術集会  2010/10  京都
  • 有茎空腸皮下再建後の腹壁瘢痕ヘルニアに対するクーゲルパッチを用いた修復術の1症例  [Not invited]
    安田 篤; 安田卓司; 加藤寛章; 錦 耕平; 白石 治; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第64回日本食道学会学術集会  2010/09  久留米
  • 食道癌の診断と治療に於けるPETの応用  [Not invited]
    白石 治; 安田卓司; 今本治彦; 今野元博; 新海政幸; 彭 英峰; 安田 篤; 岩間 密; 中森康浩; 塩? 均
    第64回日本食道学会  2010/08  久留米
  • 導入化学放射線療法の効果別による頸部食道癌喉頭温存治療戦略  [Not invited]
    白石 治; 安田卓司; 今本治彦; 今野元博; 新海政幸; 彭 英峰; 安田 篤; 岩間 密; 中森康浩; 塩? 均
    第64回日本食道学会  2010/08  久留米
  • エチレフリン・オクトレオチド併用療法にて保存的に治癒した乳糜腹水の3症例  [Not invited]
    中森康浩; 今本治彦; 安田卓司; 今野元博; 新海政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 塩? 均
    第65回日本消化器外科学会総会  2010/07  下関
  • 食道癌手術再建の工夫と実績  [Not invited]
    白石 治; 安田卓司; 今本治彦; 今野元博; 新海政幸; 彭 英峰; 安田 篤; 岩間 密; 中森康浩; 塩? 均
    第65回日本消化器外科学会総会  2010/07  下関
  • 臓器予備能が低下したハイリスク症例に対する内視鏡外科手術の有用性  [Not invited]
    安田 篤; 今本治彦; 村瀬貴昭; 加藤寛章; 岩間 密; 白石 治; 彭 英峰; 新海政幸; 今野元博; 安田卓司; 塩? 均
    第65回日本消化器外科学会総会  2010/07  下関
  • P0,CY1胃癌に対するネオアジュバントとしての腹腔内化学療法+逐次全身化学療法  [Not invited]
    彭 英峰; 今野元博; 今本治彦; 加藤寛章; 錦 耕平; 中森康浩; 白石 治; 安田 篤; 新海政幸; 安田卓司; 塩? 均
    第65回日本消化器外科学会総会  2010/07  下関
  • 術前合併症を有する食道癌手術の治療成績  [Not invited]
    新海政幸; 安田卓司; 中森康浩; 岩間 密; 白石 治; 安田 篤; 彭 英峰; 今野元博; 重岡宏典; 今本治彦; 塩? 均
    第65回日本消化器外科学会総会  2010/07  下関
  • 腹膜播種陽性胃癌症例に対するAdditional therapyとしての外科治療  [Not invited]
    今野元博; 安田卓司; 今本治彦; 中森康浩; 岩間 密; 白石 治; 彭 英峰; 新海政幸; 塩? 均
    第65回日本消化器外科学会総会  2010/07  下関
  • 胸部食道癌に対する成績向上を目指した積極的補助療法  [Not invited]
    安田卓司; 今本治彦; 新海政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 今野元博; 重岡宏典; 塩? 均
    第65回日本消化器外科学会総会  2010/07  下関
  • 頸部食道癌術後の胸部下部食道癌に対する血行再建付加を考慮した縦隔横断経路(胸骨後→後縦隔)による回結腸再建の1例  [Not invited]
    白石 治; 安田卓司; 錦 耕平; 中森康浩; 安田 篤; 彭 英峰; 新海政幸; 今野元博; 今本治彦; 塩? 均
    第53回関西胸部外科学会  2010/06  名古屋
  • クエン酸誘発咳嗽反射閾値検査による食道癌術後誤嚥性肺炎のリスク評価  [Not invited]
    中森康浩; 安田卓司; 今本治彦; 今野元博; 新海政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 加藤寛章; 荒木麻利子; 塩? 均
    第110回日本外科学会  2010/04  名古屋
  • 腹膜播種に対する腹腔内投与の直接的効果と効果限界の検討(ラット腹膜播種モデルを用いて)  [Not invited]
    安田 篤; 今野元博; 加藤寛章; 中森康浩; 岩間 密; 白石 治; 彭 英峰; 新海政幸; 安田 卓司; 今本治彦; 塩? 均
    第110回日本外科学会定期学術集会  2010/04  名古屋
  • 腹膜播種陽性胃癌症例における外科切除の適応  [Not invited]
    今野元博; 安田卓司; 今本治彦; 新海政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 中森康浩; 加藤寛章; 荒木麻利子; 村瀬貴昭; 吉岡宏真; 塩? 均
    第110回日本外科学会定期学術集会  2010/04  名古屋
  • TS-1/CDDPによる術前化学療法が著効し、組織学的CRを得た進行胃癌の1例  [Not invited]
    村瀬貴昭; 安田 篤; 今野元博; 安田卓司; 今本治彦; 新海政幸; 彭 秀峰; 白石 治; 岩間 密; 中森康浩; 加藤寛章; 奥野清隆; 塩? 均
    第82回日本胃癌学会総会  2010/03  新潟
  • P0CY1胃癌に対する術前化学療法としての腹腔内化学療法+全身化学療法  [Not invited]
    加藤寛章; 今野元博; 岩間 密; 中森康浩; 白石 治; 安田 篤; 彭 英峰; 新海政幸; 安田卓司; 今本治彦; 塩? 均
    第82回日本胃癌学会総会  2010/03  新潟
  • Phase I study of TS-1, cisplatin and paclitaxel in patients with advanced gastric cancer (OGSG 0703)  [Not invited]
    Yasuda A; Imano M; Imamoto H; Kimura Y; Imamura H; Fujitani K; Tokunaga Y; Matuoka M; Simokawa T; Kurokawa Y; Takiuchi H; Tuzinaka T; Furukawa H
    第8回日本臨床腫瘍学会学術集会  2010/03  東京
  • 当科における高齢者胃癌症例に対する腹腔鏡手術の有用性について  [Not invited]
    安田 篤; 今本治彦; 岩間 密; 白石 治; 彭 英峰; 新海政幸; 今野元博; 安田卓司; 塩? 均
    第82回日本胃癌学会総会  2010/03  新潟
  • 漿膜浸潤を伴う胃癌に対するPTX腹腔内化学療法+逐次TX+S-1による全身化学療法の安全性  [Not invited]
    彭 英峰; 今野元博; 村瀬貴昭; 加藤寛章; 中森康浩; 岩間 密; 白石 治; 安田 篤; 新海政幸; 安田卓司; 今本治彦; 塩? 均
    第82回日本胃癌学会  2010/03  新潟
  • 腹膜播種陽性胃癌症例における集学的治療  [Not invited]
    今野元博; 安田卓司; 今本治彦; 新海政幸; 彭 英峰; 安田 篤; 白石 治; 岩間 密; 中森康浩; 加藤寛章; 村瀬貴昭; 奥野清隆; 塩? 均
    第82回日本胃癌学会総会  2010/03  新潟

MISC

Research Grants & Projects

  • 日本学術振興会:科学研究費助成事業
    Date (from‐to) : 2022/04 -2027/03 
    Author : 安田 卓司; 今野 元博; 新海 政幸; 安田 篤; 白石 治; 加藤 寛章; 百瀬 洸太; 平木 洋子
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2017/04 -2022/03 
    Author : Kato Hiroaki
     
    Malignant cells in the fluid that accumulated in the bag covering the esophagus between the end of the chest operation and the removal of the specimen during esophageal cancer surgery were studied. In three of 63 cases (4.8%), free cancer cells from the esophageal specimen were positive (two cases: positive cytology, one case only positive cell block). For the first time, it was found that free cancer cells leak from the esophagus between the end of chest manipulation and specimen removal during esophageal cancer surgery.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2015/04 -2020/03 
    Author : YASUDA Takushi
     
    Esophagectomy has a high risk of postoperative aspiration, which likely leads to severe pneumonia. Aspiration due to impaired swallowing movement has been improved by the refinement of surgical procedure and an intervention of swallowing rehabilitation, while aspiration due to decreased swallowing reflex remains a challenge. Swallowing reflex is regulated by substance P (SP) that is secreted by a stimulus of the brain. So, we investigated whether preoperative plasma SP value associated with subclinical cerebral infarction and pre- and post-operative swallowing function or not. Subclinical cerebral infarction reported to be observed in a half of the elderly aged over 60 years old was observed in only 5% of the study patients. However, the patients with low plasma SP level had postoperative swallowing dysfunction and showed a significantly high aspiration rate. Therefore, plasma SP value was suggested to be useful for predicting postoperative swallowing function.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2012/04 -2016/03 
    Author : Kido Akira; IMANO Motohiro; AKAHANE Manabu; TANAKA Yasuhito; HONOKI Kanya; GOJO Satoshi; SHIMIZU Takamasa; UEHA Tomoyuki
     
    Mesenchymal stem (stromal) cells play important role in cancer progression. In this study, we focused the (normal) bone microenvironment in patients with cancer. We designed in vitro and in vivo study to assess the interaction between bone marrow-derived stromal cells (BMSC) and malignant cells. We established the isolation method of BMSC from blood samples of patients, investigated bone microenvironment using the near infrared fluorescence endoscopy method, and performed coculture assays with BMDC and malignant cells.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2012/04 -2016/03 
    Author : YASUDA Takushi; IMAMOTO Haruhiko; IMANO Motohiro; SHINKAI Masayuki; YASUDA Atsushi; SHIRAISHI Osamu; IWAMA Mitsuru; KATO Hiroaki
     
    In this study, we examined the usefulness of induction of the phosphorylation of p53-Ser46 the next day after initiation of treatment as a biomarker of the prediction of treatment response of chemotherapy/chemoradiotherapy for esophageal squamous cell carcinoma. We confirmed the fact for the first time that the phosphorylation of p53-Ser-46 was induced by chemotherapy/chemoradiotherapy in the early stage of treatment. However, there was no significant correlation between the phosphorylation of p-53-Ser-46 and treatment response. Among cases obtained complete response to preoperative therapy, the cases with p-53 mutant and no induction of Ser-46 phosphorylation were involved, therefore, these results suggested that the effect on chemotherapy and chemoradiotherapy was caused not only by apoptosis thorough p53 pathway, but also by another pathway associating with other factors.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 2009 -2011 
    Author : YASUDA Takushi; SHIOZAKI Hitoshi; IMAMOTO Haruhiko; IMANO Motohiro; SHINKAI Masayuki; PENG Ying-feng; YASUDA Atsushi; SHIRAISHI Osamu; NISHIKI Kouhei; KATO Hiroaki
     
    Aspiration of elderly patients is caused by decreased secretion of substance P(SP) that regulates cough and swallowing reflexes. We prospectively investigated the change of perioperative plasma SP concentration in patients with esophageal cancer undergoing esophagectomy and examined the association with development of aspiration. The plasma SP concentration did not show a significant change in the perioperative period. However, decreased preoperative SP concentration had a strong association with postoperative aspiration(p=0.004), suggesting that patients with decreased preoperative plasma SP concentration(60 pg/ml or less) might carry a higher risk of development of postoperative aspiration in patients after esophagectomy.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 1998 -1999 
    Author : YONEKURA Takeo; IMANO Motohiro; KUBOTA Akio; OOYANAGI Harumasa; HOKI Masanori; HIROOKA Shinji
     
    Research 1 : Interaction of nitric oxide (NO) and free radical is suspected the cause of multiple organ failure in ischemia reperfusion injury. In this research, we evaluated effect of nitric oxide on oxidant stress to estimate mechanism of cellular injury in ischemia reperfusion using partial hepatic ischemia-reperfusion model. Rats were subjected to ischemia and reperfusion in the lateral lobe of the liver. After continuous administration of NG-nitro-L-arginine methyl ester (L-NAME), L-arginine (L-Arg) or saline, we evaluated tissue blood flow and concentrations of oxidized and reduced glutathione in the I/R-lobe and the non-I/R-lobe in each group. Inhibition of NO production deteriorated tissue blood flow, hepatic injury and oxidant stress in both the I/R-lobe and the non-I/R-lobe. Administration of L-Arg had only transient increase of tissue blood flow in the I/R-lobe, moreover deteriorated hepatic injury and oxidant stress. Research 2 : Sepsis often causes multiple organ failure. To reveal the mechanism of septic organ failure, we developed a novel reproducible septic animal model applying drug delivery system (DDS). Rats implanted with DDS contained with lipopolysaccharide maintained high blood levels of endotoxin for 72 hours, and also exhibited septic condition.
  • Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
    Date (from‐to) : 1996 -1997 
    Author : YONEKURA Takeo; IMANO Motohiro; MIYAMOTO Masaaki; HOKI Masanori; KUBOTA Akio; OHYANAGI Habumasa
     
    PURPOSE.To evaluate the role of nitric oxide in ischemia/reperfusion injury. METHODS.Experiment 1) Male Wistar rats (250-350 gin) were underwent intestinal ischemia for 30 minutes and reperfusion for 60 minutes. The NO synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg), the substrate for NO generation, L-arginine (L-Arg, 300 mg/kg) or saline (5 ml/kg) were administered intravenously 10 minutes before ischemia. Arterial blood pressure, portal blood flow, hepatic- and intestinal-tissue blood flow were monitored as hemodynamic parameters during the procedure. Plasma reduced glutathione (GSH) and oxidized glutathione (GSSG) were investigated to evaluate oxidant stress at the end of the procedure. The damage of the resected specimen of the ileum was examined microscopically. Experiment 2) Ischmeia/reperfusion of the partial lobe of the liver in Male Wistar rats (250-350 gm) were perfumed. The L-NAME (20 mg/kg/h), the L-arginine (600 mg/kg/h) or saline (5 ml/kg/h) were contineously administered intravenously 10 minutes before ischemia. Hepatic microvascular blood flow in the I/R non-I/R lobes were monitored as hemodynamic parameters during the procedure. GSH and GSSG in the I/R and non-I/R lobes were investigated to evaluate oxidant stress at the end of the procedure. The damage of the I/R lobe and non-I/R lobes was examined microscopically. RESULTS.The experiment 1 and 2 reveals that inhibition of NO production deteriorated organ blood flow exacerbated tissue destruction in IRI with increased oxidant stress. L-NAME treatment deteriorates microvascular circulation, increases mucosal damage. Moreover, inhibition of NO production aggravates oxidant stress in both acute intestinal ischemia/reperfusion model and partial hepatic ischemia/reperfusion model. In experiment 1, L-NAME-treated rats showed significant mucosal necrosis, surface epithelial disruption, lamina propria congestion and hemorrhage and submucosal necrosis, while L-Arg-treated rats had low histopathologic grading of terminal ileal samples. The protective effect of L-arginine treatment on intestinal and partial hepatic ischemia/reperfusion injury may be related its ability to prevent microvascular constriction by the stimulation of endogenous NO production.

Other link

researchmap



Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.